<SEC-DOCUMENT>0001193125-22-220066.txt : 20220812
<SEC-HEADER>0001193125-22-220066.hdr.sgml : 20220812
<ACCEPTANCE-DATETIME>20220812170205
ACCESSION NUMBER:		0001193125-22-220066
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		14
FILED AS OF DATE:		20220812
DATE AS OF CHANGE:		20220812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266841
		FILM NUMBER:		221161066

	BUSINESS ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		8030 EL RIO STREET
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d286456ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on August 12, 2022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">84-1475642</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices and
principal place of business) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Kevin S. Boyle, Sr. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Chief
Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Houston, TX 77054 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT
STYLE="white-space:nowrap">355-4099</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address and telephone number of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Melinda Lackey</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Senior Vice President, Legal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>8030 El Rio Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Houston,
TX 77054</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(346) <FONT STYLE="white-space:nowrap">355-4099</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Brian K. Rosenzweig</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Lilit Kazangyan</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Covington&nbsp;&amp; Burling LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>620 Eighth Avenue</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>New York,
NY 10018</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">841-1000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>Approximate date of proposed sale to the public: </B>From time to time after the effective date of this registration statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the
following&nbsp;box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant
to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following&nbsp;box:&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this
form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall
become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If this form
is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, or a smaller reporting company. See definition of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD>
<TD HEIGHT="1" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This registration statement contains two prospectuses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus which covers the offering, issuance and sale by the registrant of up to a maximum aggregate
offering price of $200,000,000 of the registrant&#146;s common stock, preferred stock, debt securities, and/or warrants; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an equity distribution agreement prospectus covering the offering, issuance and sale by the registrant of up to a
maximum aggregate offering price of $50,000,000 of the registrant&#146;s common stock that may be issued and sold under an equity distribution agreement with Piper Sandler&nbsp;&amp; Co., or Piper Sandler. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any other securities to be offered pursuant to the base prospectus will
be specified in one or more prospectus supplements to the base prospectus. The equity distribution agreement prospectus immediately follows the base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $50,000,000 of shares of common stock that may be offered, issued and sold under the equity distribution agreement prospectus is included in the
$200,000,000 of securities that may be offered, issued and sold by the registrant under the base prospectus. Upon termination of the equity distribution agreement, any portion of the $50,000,000 included in the equity distribution agreement
prospectus that is not sold pursuant to the equity distribution agreement will be available for sale in other offerings pursuant to the base prospectus and an accompanying prospectus supplement, and if no shares are sold under the equity
distribution agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and an accompanying prospectus supplement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#ff4338"><B>Subject to completion, dated August 12, 2022 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286456g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may offer
and sell up to $200,000,000 in the aggregate of the securities identified above, either individually or in combination, at prices and on terms described in one or more supplements to this prospectus. We may also offer securities as may be issuable
upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable anti-dilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. Each time we offer and sell
securities, we will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The
prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing
prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to
consummate a sale of any securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market
under the symbol &#147;TCRT.&#148; On August 10, 2022, the closing price of our common stock, as reported on the Nasdaq Global Select Market, was $1.86. The applicable prospectus supplement will contain information, where applicable, as to other
listings, if any, on the Nasdaq Global Select Market or other securities exchange of the securities covered by the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities may
be sold to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information on the methods of sale, you should refer to the section titled &#147;<I>Plan of Distribution</I>&#148;
in this prospectus and in the applicable prospectus supplement. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or
commissions and options to purchase additional securities will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;</B><B><I><A HREF="#toc286456_4">Risk Factors</A></I></B><B>&#148; on page 4 of this prospectus and any similar section contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use
in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this
prospectus is truthful or complete. A representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_1">ABOUT THIS PROSPECTUS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_2">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_8">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_9">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_10">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_11">CERTAIN PROVISIONS OF DELAWARE LAW, THE CERTIFICATE OF INCORPORATION AND BYLAWS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_12">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_15">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_16">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc286456_17">INCORPORATION OF INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or SEC, using a &#147;shelf&#148; registration process under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we may sell common stock, preferred stock, various series of debt
securities, or warrants to purchase any of such securities, either individually or in combination with other securities described in this prospectus, in one or more offerings from time to time up to an aggregate dollar amount of $200,000,000. This
prospectus provides you with a general description of the securities we may offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we sell any type or series of securities under this
prospectus, we will provide a prospectus supplement that will include more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information
relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have
incorporated by reference into this prospectus. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus
supplement, will include all material information relating to the applicable offering. Before buying any of the securities being offered, we urge you to carefully read this prospectus, the applicable prospectus supplement and any related free
writing prospectuses we have authorized for use in connection with a specific offering, together with the additional information incorporated herein by reference as described under the heading &#147;<I>Incorporation of Information by
Reference</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus and the applicable prospectus supplement, along with
the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different or additional information. We take no responsibility for, and
can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement and any related free writing prospectus is accurate only as of the
date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus, the prospectus supplement or
any related free writing prospectus, or the time of any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus includes summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents
for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the
registration statement of which this prospectus is a part, and you may obtain copies of those documents as described under the heading &#147;<I>Where You Can Find More Information</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to &#147;Alaunos,&#148; or the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our&#148; and similar terms refer to Alaunos Therapeutics, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, any applicable prospectus supplement, and the information incorporated by reference herein and therein, contains estimates, projections and
other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is
inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data
from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. Although we believe these sources are reliable, we do not guarantee the accuracy or
completeness of this information and we have not independently verified this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of
data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus, and does not contain
all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in
our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into
this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company
Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered
<FONT STYLE="white-space:nowrap">T-cell</FONT> therapies, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our novel
cancer mutation hotspot TCR library and our proprietary, <FONT STYLE="white-space:nowrap">non-viral</FONT> <I>Sleeping Beauty</I> genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens
arising from common tumor-related mutations in key oncogenic genes, including <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#147;EasyWeb, Inc.&#148; in February
1999. We <FONT STYLE="white-space:nowrap">re-incorporated</FONT> in Delaware on May&nbsp;16, 2005 under the same name. On September&nbsp;13, 2005, we completed a &#147;reverse&#148; acquisition of privately held Ziopharm, Inc., a Delaware
corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we caused Ziopharm,
Inc. to merge with and into us and we changed our name to &#147;ZIOPHARM Oncology, Inc.&#148; As a result, Ziopharm, Inc. became the registrant with the SEC and the historical financial statements of Ziopharm, Inc. became our historical financial
statements. On January&nbsp;25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, or (as amended) our certificate of incorporation, with the Delaware Secretary of State to change our name to Alaunos
Therapeutics, Inc. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Office Location </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal
executive offices are located at 8030 El Rio Street, Houston, Texas 77054, and our telephone number is (346) <FONT STYLE="white-space:nowrap">355-4099.</FONT> Our internet site is www.alaunos.com. Information found on, or accessible through, our
website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#147;<I>Risk
Factors</I>&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2021 and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended March 31, 2022, as updated by our subsequent filings with the SEC, which are incorporated by reference into this prospectus,
before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations, financial
condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that
we currently believe are immaterial may also significantly impair our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are all statements contained in, or incorporate by reference, herein that are not historical fact, and in some cases can be identified by terms such as: &#147;anticipate,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;target,&#148; &#147;will&#148; and other words and terms of similar meaning. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These statements are based on management&#146;s current beliefs and assumptions and on information currently available to management. These statements involve
risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that
the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be
certain. Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise substantial additional capital to fund our planned operations and repay our existing
indebtedness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of our product candidates, including statements regarding the initiation, timing, progress and
results of our preclinical studies, clinical trials and research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our product candidates through various stages of development, especially through pivotal
safety and efficacy trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that final trial data may not support interim analysis of the viability of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation regarding the safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and Drug Administration,
or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to license additional intellectual property relating to our product candidates from third parties and
to comply with our existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the
results and potential benefits contemplated from relationships with collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations and licenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectation of developments and projections relating to competition from other pharmaceutical and
biotechnology companies or our industry; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the potential market opportunity for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated rate and degree of commercial scope and potential, as well as market acceptance of our product
candidates for any indication, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated amount, timing and accounting of contract liability, milestones and other payments under
licensing, collaboration or acquisition agreements, research and development costs and other expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position, including the strength and enforceability of our intellectual property
rights; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified employees and key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
the expected duration of disruption to key clinical trial activities, limitations on travel, quarantine and social distancing protocols, diversion of healthcare resources away from the conduct of or clinical trials, and other immediate and long-term
impact and effect on our business and operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this prospectus reflect our current views with
respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by these forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should refer to the &#147;<I>Risk Factors</I>&#148; section
contained in this prospectus and any related prospectus supplement and free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may
cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking
statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of
the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to
reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of our securities offered by this prospectus. Unless we indicate otherwise in
the applicable prospectus supplement or in any related free writing prospectus we have authorized for use in connection with a specific offering, we anticipate that any net proceeds will be used for working capital and general corporate purposes. We
will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending these
uses, we intend to invest the net proceeds in short-term U.S. treasury money market mutual funds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of investors purchasing
securities in an offering under this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the net tangible book value per share of our equity securities before and after the offering;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the increase in such net tangible book value per share attributable to the cash payments made by
purchasers in the offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_8"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our capital stock and provisions of our certificate of incorporation, and amended and restated bylaws, or bylaws, are
summaries. You should also refer to our certificate of incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our
authorized capital stock consists of 450,000,000 shares, comprised of 420,000,000 shares of common stock, par value $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.001 per share. As of August 10, 2022, there were 216,174,542
shares of common stock and no shares of preferred stock issued and outstanding. Our common stock is traded on the Nasdaq Global Select Market under the symbol &#147;TCRT&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights.</I> The holders of our
common stock are entitled to one vote for each outstanding share of common stock owned by such stockholder on every matter properly submitted to the stockholders for their vote. Stockholders are not entitled to vote cumulatively for the election of
directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. At any meeting of the stockholders, a
quorum as to any matter shall consist of the holders of a majority of the votes entitled to be cast on the matter, except where a larger quorum is required by law, by our certificate of incorporation or by our bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights.</I> Holders of our common stock are entitled to receive ratably dividends and other distributions of cash or any other right or property
as may be declared by our board of directors out of our assets or funds legally available for such dividends or distributions. The dividend rights of holders of common stock are subject to the dividend rights of the holders of any series of
preferred stock that may be issued and outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights.</I> In the event of any voluntary or involuntary
liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of liabilities. If we have any preferred
stock outstanding at such time, the holders of such preferred stock may be entitled to distribution and/or liquidation preferences that require us to pay the applicable distribution to the holders of preferred stock before paying distributions to
the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences.</I> Holders of our common stock have no preemptive, conversion or subscription rights, and there
are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of
our preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock
Transfer&nbsp;&amp; Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See &#147;<I>Certain Provisions of Delaware Law, the Certificate of Incorporation and Bylaws</I>&#148; for a
description of provisions in our certificate of incorporation and bylaws which may have the effect of delaying, deferring or preventing changes in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of
incorporation, our board of directors has the authority, without stockholder approval, subject to limitations prescribed by law, to provide for the issuance of up to 30,000,000 shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the number of shares to be included in
each such series, and to fix the designation, powers, preferences and rights of the shares of each series and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not below
the number of shares of such series then outstanding. We have designated 250,000 shares of our preferred stock as our Series 1 Preferred Stock, none of which are outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or
restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC,
the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if cumulative,
the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock,
including the conversion price (or manner of calculation) and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material and/or special U.S. federal income tax considerations applicable to the preferred
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the
liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors could authorize the issuance of shares of preferred stock with terms and conditions
that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could adversely
affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to vote separately as a
class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any series of preferred stock will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_9"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt.
While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus
supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental
indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the indenture that we will enter
into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which
this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be
incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary of material provisions of the debt securities and the indenture
is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing
prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture does not limit the amount of debt
securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and
sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any negative covenants or other provisions designed to give holders of any debt securities protection against changes in our
operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture as &#147;discount
securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue discount,&#148; or
OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more
detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of debt securities being
offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the
applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether
conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive
would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that
restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, upon any such consolidation or merger (in each case, if Alaunos is not the survivor
of such transaction) or any such sale, conveyance, transfer or other disposition (other than a subsidiary of ours) the successor or acquiror must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is continuing, other than an
event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given
by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and
accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect
to the series and its consequences if we have paid or deposited with the trustee a sum sufficient to pay all matured installments of principal and interest upon all the debt securities of that series that shall have become due otherwise than by
acceleration, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of
default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no
obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of
a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred
on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of
any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest
on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may
change an indenture without the consent of any holders with respect to specific matters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;<I>Description of Debt Securities &#151; Consolidation,
Merger or Sale</I>;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;<I>Description of Debt Securities &#151; General</I>&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add
to the rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the
trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to
a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified
obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agent agreements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government
obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will issue the debt
securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue
debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable
prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the
debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security
registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer
or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement the security
registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a
change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of less than all outstanding debt securities of the same series that may be selected for redemption and ending at the close of business on the day of the mailing; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are
specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this
provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities
that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date
to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us,
except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable
prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents
that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed
at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities will
be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_10"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related free writing
prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt
securities and be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply
generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the
warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the
registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or
the warrant agreement and warrant certificate, as applicable, that describe the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following summaries of material
terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements
applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any
related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus
supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon
such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe
in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any
time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the
warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants
represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the
applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent
for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or
otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities
purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_11"></A>CERTAIN PROVISIONS OF DELAWARE LAW, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE CERTIFICATE OF INCORPORATION AND BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Directors&#146; Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate
of incorporation and our bylaws contain provisions indemnifying our directors and officers to the fullest extent permitted by law. In addition, as permitted by Delaware law, our certificate of incorporation provides that no director will be liable
to us or our stockholders for monetary damages for breach of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a
director for breach of certain fiduciary duties as a director, except that a director will be personally liable for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the benefits to be derived from relationships with our collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of his or her duty of loyalty to the registrant or its stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith which involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the payment of dividends or the redemption or purchase of stock in violation of Delaware law; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This provision does not affect a director&#146;s liability under the federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that our directors, officers and controlling persons are indemnified under the provisions contained in our certificate of incorporation,
Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is therefore
unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions that May Have an Anti-Takeover Effect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions set forth in our certificate of incorporation, bylaws and in Delaware law, which are summarized below, are intended to enhance the
likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control.
In that regard, these provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have
the effect of discouraging others from making tender offers for shares of our common stock and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover attempts.
Such provisions also may have the effect of preventing changes in our management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Blank Check Preferred Stock.</I> Our certificate of incorporation
contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, up to 30,000,000 shares of preferred stock in one or more series and, with respect to each such series, to fix the number of
shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other special rights, if any, and any qualifications, limitations
or restrictions, of the shares of such series. As a result, our board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of delaying, deferring or preventing a transaction or a
change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Special Meetings of
Stockholders.</I> Our bylaws provide that special meetings of stockholders may be called only by the board of directors. Stockholders are not permitted to call a special meeting of stockholders or to require that the board of directors call such a
special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Takeover Statute. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which regulates acquisitions of some Delaware corporations. In general,
Section&nbsp;203 prohibits, with some exceptions, a Delaware corporation that is a public company from engaging in any &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years following the date that
such stockholder became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to such date, the board of directors of the corporation approved either the business combination or the
transaction that resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned (x)&nbsp;by persons who are
directors and also officers and (y)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to such date, the business combination is approved by the board of directors and authorized at
an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines &#147;business combination&#148; to include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the
interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any
stock of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock
of any class or series of the corporation beneficially owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested shareholder&#148;
as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such entity or person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_12"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to
those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary, warrant agent, unit agent or similar intermediary maintain for this purpose as the &#147;holders&#148; of those securities.
These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities.
As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry
form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other
financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their
customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be
registered in the name of the depositary or its nominee. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary.
The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one
another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not
own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant.
As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors may
choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For securities held in
street name, we or any applicable trustee, depositary or agent will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any
applicable trustee, depositary or agent will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their
customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the
obligations of any applicable trustee, depositary or agent and of any third parties employed by us or any such trustee, depositary or agent run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial
interests in global securities, in street name or by any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal
holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the legal holders to amend an indenture or other
governing instrument, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the legal holders, and not the
indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders subject to any contractual or legal obligation they may have. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold
securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued
in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor
depositary, unless special termination situations arise. We describe those situations below under &#147;<I>Special Situations When a Global Security Will Be Terminated</I>.&#148; As a result of these arrangements, the depositary, or its nominee,
will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account
with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the
security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates
that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another
book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial institution and of the
depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain certificates for
his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank, broker or other financial
institution for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your bank, broker or other financial institution may require you to do so as well; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any
of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing
those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to have their
interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global security
that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the
institutions that will be the initial legal holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_13"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these
methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the times of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule 415 under the Securities
Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of The Nasdaq Stock Market LLC, or Nasdaq, or any other securities exchange or
quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other than on Nasdaq or such other securities exchanges or quotation or trading services. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus we will provide a prospectus supplement or supplements (and any related free writing prospectus
that we may authorize to be provided to you) that will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any options under which underwriters may purchase additional securities from us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more
transactions at a fixed public offering price or at varying prices determined at the time of sale. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or
commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting
agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Any public offering price and any discounts or concessions allowed or reallowed or paid
to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent
involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of
its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities. We may also authorize agents or underwriters to solicit offers from certain types
of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will
describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may
provide agents and underwriters with indemnification against civil liabilities related to offerings, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to
these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All
securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at
any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment,
stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as
the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim
a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would
otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT>
market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on
Nasdaq in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price
limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive
market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise
prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_14"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities
offered by this prospectus, and any supplement thereto, will be passed upon by Covington&nbsp;&amp; Burling LLP, New York, New York. Any underwriters will also be advised about the validity of the securities and other legal matters by their own
counsel, which will be named in the prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_15"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Alaunos Therapeutics, Inc. as of December 31, 2021 and 2020 and the years then ended incorporated in this prospectus by reference
from the Alaunos Therapeutics, Inc. Annual Report on Form&nbsp;10-K for the year ended December 31, 2021 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report, incorporated herein by reference,
and have been incorporated in&nbsp;this prospectus and the registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_16"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities Act. This
prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer
you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized anyone else to
provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date of
this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual,
quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including us. The
address of the SEC website is www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.alaunos.com. Information found on, or accessible through, our website is not a
part of, and is not incorporated into, this prospectus, and you should not consider it part of this prospectus or part of any prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc286456_17"></A>INCORPORATION OF INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by
referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">001-33038.</FONT> The documents incorporated by reference into
this prospectus contain important information that you should read about us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following documents are incorporated by reference into this document:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022009942/tcrt-20220331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the fiscal quarter ended March&nbsp;31, 2022, filed with the SEC on May&nbsp;16, 2022; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522001682/d263245d8k.htm">January&nbsp;4,
 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522017681/d173910d8k.htm">January&nbsp;26, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522077889/d332571d8k.htm">March&nbsp;
17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522079589/d332630d8k.htm">March&nbsp;18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522135461/d219505d8k.htm">May&nbsp;2, 2022</A> (first
filed only), <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522176544/d251784d8k.htm">June&nbsp;17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522182171/d383158d8k.htm">June&nbsp;
27, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522192331/d219766d8k.htm">July&nbsp;13, 2022</A> to the extent the information in such reports is filed and not furnished; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021, which was filed with the SEC on March&nbsp;30, 2022, including any amendments or reports filed for the purpose of updating
such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities
Act and the Exchange Act of 1934, as amended, prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part
of this prospectus from the date of the filing of such reports and documents. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any
or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You may request a copy of such documents
at no cost, by writing or telephoning us at the following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8030 El Rio St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Houston, TX 77054
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Senior Vice President, Legal </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(346) <FONT STYLE="white-space:nowrap">355-4099</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286456g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$200,000,000 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><FONT COLOR="#a03245"><B>The information in this prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#a03245"><B>Subject to completion, dated August 12, 2022 </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>PROSPECTUS </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286456g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Up to $50,000,000
</B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We have entered into an equity distribution agreement, or the Equity Distribution Agreement, with Piper Sandler&nbsp;&amp; Co., or Piper
Sandler, relating to shares of our common stock offered by this prospectus. In accordance with the terms of the Equity Distribution Agreement, pursuant to this prospectus, we may offer and sell shares of our common stock, $0.001 par value, having an
aggregate offering price of up to $50,000,000 from time to time through Piper Sandler acting as our agent. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our common stock
is listed on the Nasdaq Global Select Market under the symbol &#147;TCRT.&#148; On August&nbsp;10, 2022, the last reported sale price of our common stock was $1.86 per share. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Sales of our common stock, if any, under this prospectus will be made in sales deemed to be &#147;at the market offerings&#148; as
defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Piper Sandler will act as our agent on a best efforts basis and will use commercially reasonable efforts to sell on our behalf all of the
shares of common stock requested to be sold by us, consistent with its normal trading and sales practices, on mutually agreed terms between Piper Sandler and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Piper Sandler will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds of any
shares of common stock sold pursuant to the Equity Distribution Agreement. See &#147;<I>Plan of Distribution</I>&#148; for additional information regarding compensation to be paid to Piper Sandler. In connection with the sale of the common stock on
our behalf, Piper Sandler will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Piper Sandler will be deemed to be underwriting commissions or discounts. We have also agreed to provide
indemnification and contribution to Piper Sandler with respect to certain liabilities, including liabilities under the Securities Act and the Exchange Act of 1934, as amended, or the Exchange Act. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under
the heading &#147;</B><B><I><A HREF="#toc2286456_5">Risk Factors</A></I></B><B>&#148; on page&nbsp;6 of this prospectus and any similar section contained in any free writing prospectuses and under similar headings in the documents that are
incorporated by reference into this prospectus. </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Neither the Securities and Exchange Commission nor any state
securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. A representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:-3%; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Piper Sandler </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022 </B></FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Prospectus </B></FONT></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #465361"><FONT COLOR="#465361"><B>Page</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_1">ABOUT THIS PROSPECTUS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_2">MARKET, INDUSTRY AND OTHER
DATA</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_3">PROSPECTUS SUMMARY</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_4">THE OFFERING</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_5">RISK FACTORS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_6">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_7">USE OF PROCEEDS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_8">DILUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_9">DESCRIPTION OF CAPITAL STOCK</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_10">CERTAIN PROVISIONS OF DELAWARE LAW, THE CERTIFICATE
 OF INCORPORATION AND BYLAWS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_11">PLAN OF DISTRIBUTION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_12">LEGAL MATTERS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_13">EXPERTS</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_14">WHERE YOU CAN FIND MORE
INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><A HREF="#toc2286456_15">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
</A></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_1"></A>ABOUT THIS PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus relates to the registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the
Securities and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell shares of our common stock. Under this prospectus, we may from time to time sell
shares of our common stock having an aggregate offering price of up to $50,000,000, at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the common stock that we are offering, we urge you to
carefully read this prospectus, any prospectus supplement, and the information incorporated by reference as described under the headings &#147;<I>Where You Can Find More Information</I>&#148; and &#147;<I>Incorporation of Certain Information by
Reference</I>&#148; herein and therein. These documents contain important information that you should consider when making your investment decision. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents
incorporated by reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus
that was filed with the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later
date (for example, a document incorporated by reference into this prospectus) the statement in the document having the later date modifies or supersedes the earlier statement. The information contained in this prospectus or any free writing
prospectus, or incorporated by reference herein or therein, is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus or of any sale of our shares of common stock. Our business, financial condition,
results of operations and prospects may have changed since those dates. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating
risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We have not, and Piper Sandler has not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus, any prospectus supplement or in any free writing prospectus prepared by
or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus does not constitute an offer to sell, or a
solicitation of an offer to purchase, the securities offered by this prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Unless the context indicates otherwise, references in this prospectus to &#147;Alaunos,&#148; or the &#147;Company,&#148;
&#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar terms refer to Alaunos Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We own or have rights
to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks
Alaunos<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, Ziopharm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and hunTR<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> as well as the graphic trademark found on our
website. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this prospectus are
listed without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks,
service marks and trade names. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">1
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_2"></A>MARKET, INDUSTRY AND OTHER DATA
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus and the information incorporated by reference herein contains estimates, projections and other
information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections or similar methodologies is inherently
subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from
reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. Although we believe these sources are reliable, we do not guarantee the accuracy or
completeness of this information and we have not independently verified this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of
data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">2
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_3"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated
by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this
offering, we encourage you to read and consider carefully the more detailed information in this prospectus, including the information incorporated by reference in this prospectus and the information included in any free writing prospectus that we
have authorized for use in connection with this offering, including the information under the heading &#147;Risk Factors&#148; in this prospectus on page 6 of this prospectus and in the documents incorporated by reference into this prospectus.
</I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Company Overview </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We are a clinical-stage oncology-focused cell therapy company developing adoptive TCR engineered
<FONT STYLE="white-space:nowrap">T-cell</FONT> therapies, or <FONT STYLE="white-space:nowrap">TCR-T,</FONT> designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We are leveraging our novel
cancer mutation hotspot TCR library and our proprietary, <FONT STYLE="white-space:nowrap">non-viral</FONT> <I>Sleeping Beauty</I> genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens
arising from common tumor-related mutations in key oncogenic genes, including <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. In collaboration with The University of Texas MD Anderson Cancer Center, or MD Anderson, we are currently enrolling patients for
a Phase 1/2 clinical trial evaluating ten TCRs reactive to mutated <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I> from our TCR library for the investigational treatment of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung, colorectal,
endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our <FONT STYLE="white-space:nowrap">TCR-T</FONT> Library Phase 1/2 Trial. We announced the dosing of the first patient in this trial in May 2022 and expect to report
interim data in the second half of 2022. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In the United States, solid tumors represent approximately 90% of new cancer
diagnoses. Approximately 1.9&nbsp;million people are expected to be diagnosed with cancer in the United States in 2022 and approximately 609,000 people are expected to die from cancer in the United States in 2022. Some of the cancers we are
targeting in our <FONT STYLE="white-space:nowrap">TCR-T</FONT> Library Phase 1/2 Trial are expected to be among the most prevalent cancers diagnosed in the United States in 2022. In 2022, it is estimated that 236,740 people will be diagnosed with
lung and bronchus cancer, 151,030 will be diagnosed with colorectal cancer, 65,950 people will be diagnosed with endometrial cancer, 62,210 people will be diagnosed with pancreatic cancer, 19,880 people will be diagnosed with ovarian cancer and
approximately 7,400 people will be diagnosed with bile duct cancer. Mutations of the <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I> genes are commonly expressed across a wide variety of cancers. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The table below sets forth our multiple solid tumor pipeline programs. </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286456g01a03.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">3
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program targeting solid tumors consists of: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>TCR Library</I>: We have built a TCR library that targets shared hotspot mutations known
to be one of the key causes of cancer. These are <FONT STYLE="white-space:nowrap">non-inherited</FONT> mutations. We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the National Cancer Institute, or the NCI, multiple TCRs derived from
third parties that are reactive to mutated <I>KRAS</I>, <I>TP53</I> and <I>EGFR</I>. Our TCR library currently consists of ten TCRs targeting six solid tumor indications. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>Sleeping Beauty Genetic Engineering Technology</I>: Our proprietary <FONT
STYLE="white-space:nowrap">non-viral</FONT> genetic engineering technology utilizes a particular enzyme referred to as a transposase to cut and paste donor DNA referred to as a transposon into chromosomes of a T cell using a process called
transposition. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
<P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361"><I>hunTR</I><SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP><I></I>&nbsp;(<B><U>hu</U></B>man
<B><U>n</U></B>eoantigen <B><U>T</U></B> cell <B><U>R</U></B>eceptor) <I>Discovery Engine</I>: Our robust and innovative TCR discovery engine enables us to rapidly identify new TCRs to add to our ever-expanding TCR library. Using our <I>hunTR
</I>discovery engine, we are able to analyze thousands of single T cells simultaneously using <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics and
next generation sequencing. We aim to maximize the breadth of our TCR library by evaluating both helper and killer T cells. The ability to continue discovering new TCRs has the potential to expand the applicable patient population for our ongoing
and future clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We believe our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program has
several potential advantages over other cell therapy approaches for solid tumors, including <FONT STYLE="white-space:nowrap">CAR-T</FONT> and tumor-infiltrating lymphocytes, or TIL. As compared to <FONT STYLE="white-space:nowrap">CAR-T,</FONT> these
potential advantages include that our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program targets intracellular and extracellular neoantigens whereas <FONT STYLE="white-space:nowrap">CAR-T</FONT> only targets extracellular antigens. As compared to
TIL, these potential advantages include that our <FONT STYLE="white-space:nowrap">TCR-T</FONT> program has defined target specificity from the genetic engineering employed in manufacturing whereas in TIL there is no further genetic engineering
employed.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We originally incorporated in Colorado in September 1998 (under the name Net Escapes, Inc.) and later changed our name to &#147;EasyWeb,
Inc.&#148; in February 1999. We <FONT STYLE="white-space:nowrap">re-incorporated</FONT> in Delaware on May&nbsp;16, 2005 under the same name. On September&nbsp;13, 2005, we completed a &#147;reverse&#148; acquisition of privately held Ziopharm,
Inc., a Delaware corporation. To effect this transaction, we caused ZIO Acquisition Corp., our wholly-owned subsidiary, to merge with and into Ziopharm, Inc., with Ziopharm, Inc. surviving as our wholly owned subsidiary. Following the merger, we
caused Ziopharm, Inc. to merge with and into us and we changed our name to &#147;ZIOPHARM Oncology, Inc.&#148; As a result, Ziopharm, Inc. became the registrant with the SEC and the historical financial statements of Ziopharm, Inc. became our
historical financial statements. On January&nbsp;25, 2022, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation, or (as amended) our certificate of incorporation, with the Delaware Secretary of State to change
our name to Alaunos Therapeutics, Inc. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Office Location </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our principal executive offices are located at 8030 El Rio Street, Houston, Texas 77054, and our telephone number is (346) <FONT
STYLE="white-space:nowrap">355-4099.</FONT> Our internet site is www.alaunos.com. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this prospectus, and you should not consider it part of this
prospectus. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">4
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_4"></A>THE OFFERING </B></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Common Stock Offered By Us </FONT></P></TD>
<TD><FONT COLOR="#465361">Shares of our common stock having an aggregate offering price of up to $50,000,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Common Stock Outstanding After This Offering </FONT></P></TD>
<TD><FONT COLOR="#465361">Up to 242,832,281 shares, assuming the sale of up to 26,881,720 shares of our common stock at a price of $1.86 per share, which was the closing price of our common stock on the Nasdaq Global Select Market on August 10,
2022. The actual number of shares issued will vary depending on the sales price under this offering. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Plan of Distribution </FONT></P></TD>
<TD><FONT COLOR="#465361">&#147;At the market&#148; offering that may be made from time to time through our agent, Piper Sandler. See &#147;<I>Plan of Distribution</I>&#148; on page 18 of this prospectus. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Use of Proceeds </FONT></P></TD>
<TD><FONT COLOR="#465361">We currently intend to use the net proceeds from the sale of the securities offered hereby to fund the continued development of the product candidates in our pipeline, and for working capital, capital expenditures and
general corporate purposes. See &#147;<I>Use of Proceeds</I>&#148; on page 10 of this prospectus. </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Risk Factors </FONT></P></TD>
<TD><FONT COLOR="#465361">Investing in our common stock involves significant risks. See &#147;<I>Risk Factors</I>&#148; on page 6 of this prospectus, and under similar headings in other documents incorporated by reference into this prospectus.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Symbol on the Nasdaq Global Select Market </FONT></P></TD>
<TD><FONT COLOR="#465361">&#147;TCRT&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">The number of shares of common stock to be outstanding after this offering is based on 215,950,561 shares of common stock outstanding as of March 31, 2022 and excludes in each case as of March 31, 2022: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">10,969,653 shares of common stock issuable upon the exercise of outstanding stock options
having a weighted-average exercise price of approximately $2.16 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">22,922,342 shares of common stock issuable upon the exercise of outstanding warrants with a
weighted-average exercise price of $5.62 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">15,242,103 shares of common stock reserved for issuance pursuant to future awards under our
2020 Equity Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In addition, unless we specifically state otherwise, all information in this
prospectus assumes no exercise of outstanding stock options subsequent to March 31, 2022. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">5
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_5"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below
and under the section titled &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2021 and in our most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the period ended March 31, 2022, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus, before deciding whether to purchase any of
the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value
of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair
our business operations. Please also read carefully the section below titled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361"><B>ADDITIONAL RISKS RELATED TO THIS OFFERING </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>You may experience dilution. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to
this offering. Assuming that an aggregate of 26,881,720 shares of our common stock are sold at a price of $1.86 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on August 10, 2022, for aggregate gross
proceeds of $50&nbsp;million, and after deducting commissions and estimated offering expenses payable by us, you would experience immediate dilution of $1.46 per share, representing the difference between our as adjusted net tangible book value per
share as of March 31, 2022 after giving effect to this offering and the assumed offering price. The exercise of outstanding stock options would result in further dilution of your investment. See the section entitled &#147;<I>Dilution</I>&#148; below
for a more detailed illustration of the dilution you would incur if you participate in this offering. Because the sales of the shares offered hereby will be made directly into the market or in negotiated transactions, the prices at which we sell
these shares will vary and these variations may be significant. Purchasers of the shares we sell, as well as our existing shareholders, will experience significant dilution if we sell shares at prices significantly below the price at which they
invested. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible
into or exchangeable for our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or
exchangeable for our common stock in future transactions may be higher or lower than the price per share in this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>Our management might apply the net proceeds from this offering in ways with which you do not agree and in ways that may impair the
value of your investment. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We currently intend to use the net proceeds from this offering primarily to fund the
continued development of the product candidates in our pipeline, and for working capital, capital expenditures and general corporate purposes. Pending these uses, we expect to invest the net proceeds in short-term U.S. treasury money market mutual
funds. Our management has broad discretion as to the use of these proceeds and you will be relying on the judgment of our management regarding the application of these proceeds. We might apply these proceeds in ways with which you do not agree, or
in ways that do not yield a favorable return. If our management applies these proceeds in a manner that does not yield a </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">6
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">
significant return, if any, on our investment of these net proceeds, it could compromise our ability to pursue our growth strategy and adversely affect the market price of our common stock.
</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>It is not possible to predict the actual number of shares we will sell under the Equity Distribution Agreement or the
gross proceeds resulting from those sales. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Subject to certain limitations in the Equity Distribution Agreement and
compliance with applicable law, we have the discretion to deliver instruction to Piper Sandler to sell shares of our common stock at any time throughout the term of the Equity Distribution Agreement. The number of shares that are sold through Piper
Sandler after our instruction will fluctuate based on a number of factors, including the market price of our common stock during the sales period, the limits we set with Piper Sandler in any instruction to sell shares, and the demand for our common
stock during the sales period. Because the price per share of each share sold will fluctuate during this offering, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with
those sales. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who
buy shares at different times will likely pay different prices. </I></B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Investors who purchase shares in this offering at
different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of
shares sold in this offering. In addition, subject to the final determination by our board of directors, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares
they purchase in this offering as a result of sales made at prices lower than the prices they paid. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">7
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus and the documents incorporated by reference herein contain forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in, or incorporate by reference, herein that are not historical fact, and in some cases can be identified by terms
such as: &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;forecast,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;target,&#148; &#147;will&#148; and other words
and terms of similar meaning. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">These statements are based on management&#146;s current beliefs and assumptions and on
information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed
or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently
known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this prospectus and the documents incorporated by reference herein include, but are not limited to, statements about: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to raise substantial additional capital to fund our planned operations and
repay our existing indebtedness; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated
capital requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the development of our product candidates, including statements regarding the initiation,
timing, progress and results of our preclinical studies, clinical trials and research and development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to advance our product candidates through various stages of development,
especially through pivotal safety and efficacy trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the risk that final trial data may not support interim analysis of the viability of our
product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectation regarding the safety and efficacy of our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the timing, scope or likelihood of regulatory filings and approvals from the U.S. Food and
Drug Administration, or FDA, or equivalent foreign regulatory agencies for our product candidates and for which indications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to license additional intellectual property relating to our product candidates
from third parties and to comply with our existing license agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to enter into partnerships or strategic collaboration agreements and our
ability to achieve the results and potential benefits contemplated from relationships with collaborators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to maintain and establish collaborations and licenses;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectation of developments and projections relating to competition from other
pharmaceutical and biotechnology companies or our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our estimates regarding the potential market opportunity for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the anticipated rate and degree of commercial scope and potential, as well as market
acceptance of our product candidates for any indication, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the anticipated amount, timing and accounting of contract liability, milestones and other
payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">8
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our intellectual property position, including the strength and enforceability of our
intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our ability to attract and retain qualified employees and key personnel;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our expectations regarding the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including the expected duration of disruption to key clinical trial activities, limitations on travel, quarantine and social distancing protocols, diversion of healthcare resources away from
the conduct of or clinical trials, and other immediate and long-term impact and effect on our business and operations. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">Any forward-looking statements in this prospectus reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from
current expectations include, among other things, those described the section titled &#147;<I>Risk Factors</I>.&#148; Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we
assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">You should refer to the &#147;<I>Risk Factors</I>&#148; section contained in this prospectus, any related free writing prospectus, and
under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our
forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place
undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not
regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking
statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">9
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_7"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50&nbsp;million from time to time. Because
there is no minimum offering price for the shares that we may offer from time to time, the actual total public offering amount, commissions to Piper Sandler and proceeds to us, if any, are not determinable at this time. There can be no assurance
that we will sell any shares under or fully utilize the Equity Distribution Agreement with Piper Sandler as a source of financing. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We currently intend to use the net proceeds from the sale of the securities offered hereby to fund the continued development of the product candidates in our pipeline, and for working capital, capital expenditures and general
corporate purposes. Pending these uses, we expect to invest the net proceeds in short-term U.S. treasury money market mutual funds. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under &#147;<I>Risk Factors</I>&#148; in this
prospectus and the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the
application of the net proceeds. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">10
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the
public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our net tangible book value as of March 31, 2022 was approximately $49,122,000 or $0.23 per share. Net tangible book value per share is
determined by dividing our total tangible assets (including our right-of-use lease assets), less total liabilities, by the number of shares of our common stock outstanding as of March 31, 2022. Dilution with respect to net tangible book value per
share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">After giving effect to the sale of 26,881,720 shares of our common stock in this offering at an assumed offering price of $1.86 per
share, the last reported sale price of our common stock on the Nasdaq Global Select Market on August 10, 2022, for aggregate gross proceeds of $50&nbsp;million, and after deducting commissions and offering expenses payable by us, our as adjusted net
tangible book value as of March 31, 2022 would have been approximately $97,272,000, or $0.40 per share. This represents an immediate increase in net tangible book value of $0.17 per share to existing stockholders and immediate dilution of $1.46 per
share to investors purchasing our common stock in this offering at the assumed public offering price. The following table illustrates this dilution on a per share basis: </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Assumed public offering price per share</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">1.86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Net tangible book value per share of as of March 31, 2022</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Increase in net tangible book value per share attributable to this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">As adjusted net tangible book value per share as of March 31, 2022, after
giving effect to this offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">0.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Dilution per share to investors purchasing our common stock in this
offering</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT COLOR="#465361">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT COLOR="#465361">1.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT COLOR="#465361">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The above discussion and table are based on 215,950,561 shares of common stock outstanding as of March
31, 2022 and exclude in each case as of March 31, 2022: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">10,969,653 shares of common stock issuable upon the exercise of outstanding stock options
having a weighted-average exercise price of approximately $2.16 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">22,922,342 shares of common stock issuable upon the exercise of outstanding warrants with a
weighted-average exercise price of $5.62 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">15,242,103 shares of common stock reserved for issuance pursuant to future awards under our
2020 Equity Incentive Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In addition, unless we specifically state otherwise, all information in this
prospectus assumes no exercise of outstanding stock options subsequent to March 31, 2022. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The table above assumes for
illustrative purposes that an aggregate of 26,881,720 shares of our common stock are offered during the term of the Equity Distribution Agreement with Piper Sandler at a price of $1.86 per share, the last reported sale price of our common stock on
the Nasdaq Global Select Market on August 10, 2022, for aggregate gross proceeds of $50&nbsp;million. The shares subject to the Equity Distribution Agreement with Piper Sandler are being sold from time to time at various prices. An increase of $1.00
per share in the price at which the shares are sold from the assumed offering price of $1.86 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50&nbsp;million during the term of the Equity Distribution
Agreement with Piper Sandler is sold at that price, would increase our as adjusted net tangible book value per share after the offering to $0.42 per share and would increase the dilution in net tangible book value per share to new investors in this
offering to </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">11
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">
$2.44 per share, after deducting commissions and estimated aggregate offering expenses payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed
offering price of $1.86 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50&nbsp;million during the term of the Equity Distribution Agreement with Piper Sandler is sold at that price, would decrease
our as adjusted net tangible book value per share after the offering to $0.35 per share and would decrease the dilution in net tangible book value per share to new investors in this offering to $0.51 per share, after deducting commissions and
estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">To the
extent that outstanding stock options outstanding as of March 31, 2022 have been or may be exercised or other shares issued, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise
additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity, convertible
debt securities or other securities exchangeable for common stock, the issuance of these securities could result in further dilution to our stockholders. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">12
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_9"></A>DESCRIPTION OF CAPITAL STOCK
</B></FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>The following description of our capital stock and provisions of our certificate of incorporation, and amended and
restated bylaws, or bylaws, are summaries. You should also refer to our certificate of incorporation and the bylaws, which are filed as exhibits to the registration statement of which this prospectus is part. </I></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>General </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">As of the date of this prospectus, our authorized capital stock consists of 450,000,000 shares, comprised of 420,000,000 shares of common stock, par value $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.001
per share. As of August 10, 2022, there were 216,174,542 shares of common stock and no shares of preferred stock issued and outstanding. Our common stock is traded on the Nasdaq Global Select Market under the symbol &#147;TCRT&#148;. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361"><I>Voting Rights.</I> The holders of our common stock are entitled to one vote for each outstanding share of common stock owned by such stockholder on every matter properly submitted to the stockholders for their vote. Stockholders
are not entitled to vote cumulatively for the election of directors. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they
should so choose. At any meeting of the stockholders, a quorum as to any matter shall consist of the holders of a majority of the votes entitled to be cast on the matter, except where a larger quorum is required by law, by our certificate of
incorporation or by our bylaws. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Dividend Rights.</I> Holders of our common stock are entitled to receive ratably
dividends and other distributions of cash or any other right or property as may be declared by our board of directors out of our assets or funds legally available for such dividends or distributions. The dividend rights of holders of common stock
are subject to the dividend rights of the holders of any series of preferred stock that may be issued and outstanding from time to time. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361"><I>Liquidation Rights.</I> In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available
for distribution to stockholders after payment of liabilities. If we have any preferred stock outstanding at such time, the holders of such preferred stock may be entitled to distribution and/or liquidation preferences that require us to pay the
applicable distribution to the holders of preferred stock before paying distributions to the holders of common stock. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Rights and Preferences.</I> Holders of our common stock have no preemptive, conversion or subscription rights, and there are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our
preferred stock that we may designate and issue in the future. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The transfer agent and registrar for our common stock is
American Stock Transfer&nbsp;&amp; Trust Company. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">See &#147;<I>Certain Provisions of Delaware Law, the Certificate of
Incorporation and Bylaws</I>&#148; for a description of provisions in our certificate of incorporation and bylaws which may have the effect of delaying, deferring or preventing changes in control. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">13
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Preferred Stock </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Pursuant to our certificate of incorporation, our board of directors has the authority, without stockholder approval, subject to
limitations prescribed by law, to provide for the issuance of up to 30,000,000 shares of preferred stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware, to establish from time to time the
number of shares to be included in each such series, and to fix the designation, powers, preferences and rights of the shares of each series and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of
shares of any such series, but not below the number of shares of such series then outstanding. We have designated 250,000 shares of our preferred stock as our Series 1 Preferred Stock, none of which are outstanding. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series, as well as the
qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from
reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the title and stated value; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the number of shares offered; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the liquidation preference per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the purchase price per share; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation for
dividends; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
and, if cumulative, the date from which dividends will accumulate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our right, if any, to defer payment of dividends and the maximum length of any such
deferral period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the procedures for any auction and remarketing, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the provisions for a sinking fund, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the provision for redemption or repurchase, if applicable, and any restrictions on our
ability to exercise those redemption and repurchase rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any listing of the preferred stock on any securities exchange or market;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the terms and conditions, if applicable, upon which the preferred stock will be convertible
into common stock, including the conversion price (or manner of calculation) and conversion period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether the preferred stock will be exchangeable into debt securities, and, if applicable,
the exchange price, or how it will be calculated, and the exchange period; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">voting rights, if any, of the preferred stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">preemptive rights, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">restrictions on transfer, sale or other assignment, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">whether interests in the preferred stock will be represented by depositary shares;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">a discussion of any material and/or special U.S. federal income tax considerations
applicable to the preferred stock; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">14
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the relative ranking and preferences of the preferred stock as to dividend rights and
rights upon the liquidation, dissolution or winding up of our affairs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any limitations on issuance of any class or series of preferred stock ranking senior to or
on a parity with the class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any other specific terms, preferences, rights, limitations or restrictions of the preferred
stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our board of directors could authorize the issuance of shares of preferred stock with terms and
conditions that could have the effect of discouraging a takeover or other transaction that might involve a premium price for holders of the shares or which holders might believe to be in their best interests. The issuance of preferred stock could
adversely affect the voting power, conversion or other rights of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The laws of the state of Delaware, the state of our incorporation, provide that the holders of preferred stock will have the right to
vote separately as a class on any proposal involving fundamental changes in the rights of holders of such preferred stock. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">15
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_10"></A>CERTAIN PROVISIONS OF DELAWARE LAW,
</B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>THE CERTIFICATE OF INCORPORATION AND BYLAWS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Limitations on Directors&#146; Liability </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Our certificate of incorporation and our bylaws contain provisions indemnifying our directors and officers to the fullest extent
permitted by law. In addition, as permitted by Delaware law, our certificate of incorporation provides that no director will be liable to us or our stockholders for monetary damages for breach of certain fiduciary duties as a director. The effect of
this provision is to restrict our rights and the rights of our stockholders in derivative suits to recover monetary damages against a director for breach of certain fiduciary duties as a director, except that a director will be personally liable
for: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the benefits to be derived from relationships with our collaborators;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any breach of his or her duty of loyalty to the registrant or its stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">acts or omissions not in good faith which involve intentional misconduct or a knowing
violation of law; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the payment of dividends or the redemption or purchase of stock in violation of Delaware
law; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any transaction from which the director derived an improper personal benefit.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This provision does not affect a director&#146;s liability under the federal securities laws. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">To the extent that our directors, officers and controlling persons are indemnified under the provisions contained in our certificate of
incorporation, Delaware law or contractual arrangements against liabilities arising under the Securities Act, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and
is therefore unenforceable. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><B>Provisions that May Have an Anti-Takeover Effect </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Certain provisions set forth in our certificate of incorporation, bylaws and in Delaware law, which are summarized below, are intended to
enhance the likelihood of continuity and stability in the composition of our board of directors and in the policies formulated by our board of directors and to discourage certain types of transactions that may involve an actual or threatened change
of control. In that regard, these provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions
could have the effect of discouraging others from making tender offers for shares of our common stock and, as a consequence, they also may inhibit fluctuations in the market price of our common stock that could result from actual or rumored takeover
attempts. Such provisions also may have the effect of preventing changes in our management. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Blank Check Preferred
Stock.</I> Our certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, up to 30,000,000 shares of preferred stock in one or more series and, with respect
to each such series, to fix the number of shares constituting the series and the designation of the series, the voting powers (if any) of the shares of the series, and the preferences and relative, participating, optional and other special rights,
if any, and any qualifications, limitations or restrictions, of the shares of such series. As a result, our board of directors could authorize the issuance of shares of preferred stock with terms and conditions that could have the effect of
delaying, deferring or preventing a transaction or a change in control that might involve a premium price for holders of our common stock or otherwise be in their best interest. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">16
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Special Meetings of Stockholders.</I> Our bylaws provide that special meetings of
stockholders may be called only by the board of directors. Stockholders are not permitted to call a special meeting of stockholders or to require that the board of directors call such a special meeting. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361"><I>Delaware Takeover Statute. </I></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which regulates acquisitions of some Delaware corporations. In general, Section&nbsp;203 prohibits, with some exceptions, a Delaware corporation
that is a public company from engaging in any &#147;business combination&#148; with any &#147;interested stockholder&#148; for a period of three years following the date that such stockholder became an interested stockholder, unless: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">prior to such date, the board of directors of the corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">on consummation of the transaction that resulted in the stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned
(x)&nbsp;by persons who are directors and also officers and (y)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or
exchange offer; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">on or subsequent to such date, the business combination is approved by the board of
directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Section&nbsp;203 of the DGCL defines &#147;business combination&#148; to include: </FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any merger or consolidation involving the corporation and the interested stockholder;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any sale, transfer, pledge or other disposition of 10% or more of the assets of the
corporation involving the interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">subject to certain exceptions, any transaction that results in the issuance or transfer by
the corporation of any stock of the corporation to the interested stockholder; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the receipt by the interested stockholder of the benefit of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the corporation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In general,
Section&nbsp;203 defines an &#147;interested shareholder&#148; as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with such entity or person. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">17
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_11"></A>PLAN OF DISTRIBUTION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We have entered into the Equity Distribution Agreement with Piper Sandler, as our sales agent, pursuant to which we may issue and sell
from time to time shares of our common stock having an aggregate offering price of up to $50,000,000 through Piper Sandler. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus only relates to up to $50,000,000 of shares of our common stock that we may issue and sell from time to time under the
Equity Distribution Agreement. We will be required to file another prospectus or prospectus supplement in the event we want to offer more than $50,000,000 in shares of our common stock in accordance with the terms of the Equity Distribution
Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Piper Sandler will use commercially reasonable efforts to sell on our behalf all shares of our common stock
requested to be sold by us, consistent with its normal trading and sales practices, under the terms and subject to the conditions set forth in the Equity Distribution Agreement. We may instruct Piper Sandler not to sell our common stock if the sales
cannot be effected at or above the price designated by us in any instruction. We or Piper Sandler may suspend the offering of our common stock upon proper notice and subject to other conditions, as further described in the Equity Distribution
Agreement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Upon delivery of a placement notice, and subject to our instructions in that notice and the terms and conditions
of the Equity Distribution Agreement generally, Piper Sandler may sell our common stock by any method permitted by law that is deemed to be an &#147;at the market offering&#148; as defined in Rule&nbsp;415(a)(4)&nbsp;promulgated under
the&nbsp;Securities Act, including sales made directly on or through the Nasdaq Global Select Market or on any other existing trading market for our common stock. Piper Sandler will provide written confirmation to us no later than the opening of
trading on the Nasdaq Global Select Market on the day following each day in which our common stock is sold under the Equity Distribution Agreement. Each such confirmation will include the number of shares of our common stock sold on such day, the
volume-weighted average price of the shares sold, the net proceeds to us and the compensation payable by us to Piper Sandler in connection with such sales. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will pay Piper Sandler commissions for its services in acting as sales agent in the sale of our common stock. Piper Sandler will be
entitled to compensation in an amount equal to 3.0% of the gross sales price of all common stock sold through it as sales agent under the Equity Distribution Agreement. We have also agreed to reimburse Piper Sandler for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;out-of-pocket&nbsp;reasonable</FONT></FONT> fees and disbursements of its legal counsel, in an amount not to exceed $75,000, in connection with the establishment of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">this&nbsp;at-the-market&nbsp;offering</FONT></FONT> program. In accordance with Financial Industry Regulatory Authority, Inc. Rule&nbsp;5110, these reimbursed fees and expenses are deemed
sales compensation in connection with this offering.&nbsp;We estimate that the total expenses for this offering, excluding compensation and reimbursements payable to Piper Sandler under the terms of the Equity Distribution Agreement, will be
approximately $350,000. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Settlement for sales of our common stock will occur on the second business day following the date on
which any such sales are made, or on some other date that is agreed upon by us and Piper Sandler in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an
escrow, trust or similar arrangement. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will report at least quarterly the number of shares of our common stock sold
through Piper Sandler, as sales agent, under the Equity Distribution Agreement, and the net proceeds to us in connection with such sales. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#465361">Piper Sandler and its affiliates may in the future provide various investment banking, commercial banking, fiduciary and advisory services for us for which they may receive, customary fees and expenses. Piper Sandler and its
affiliates may from time to time engage in other transactions with and perform services for us in the ordinary course of their business. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">18
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">In connection with the sale of our common stock on our behalf, Piper Sandler will be
deemed to be an underwriter within the meaning of the&nbsp;Securities Act, and the compensation paid by us to Piper Sandler will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Piper Sandler against specified
liabilities, including liabilities under the&nbsp;Securities Act, or to contribute to payments that Piper Sandler may be required to make because of such liabilities. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The offering of our common stock pursuant to the Equity Distribution Agreement will terminate upon the termination of the Equity
Distribution Agreement. The Equity Distribution Agreement may be terminated by Piper Sandler or us at any time upon specified prior written notice. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Any summary of provisions of the Equity Distribution Agreement above does not purport to be a complete statement of the Equity
Distribution Agreement terms and conditions. A copy of the Equity Distribution Agreement is filed as an exhibit to the registration statement of which this prospectus forms a part. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">19
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_12"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The validity of the common stock offered by this prospectus will be passed upon by Covington&nbsp;&amp; Burling LLP, New York, New York.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., New York, New York, is counsel for Piper Sandler in connection with this offering. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_13"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The financial statements of Alaunos Therapeutics, Inc. as of December 31, 2021 and 2020 and the years then ended incorporated in this
prospectus by reference from the Alaunos Therapeutics, Inc. Annual Report on Form 10-K for the year ended December 31, 2021 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report, incorporated
herein by reference, and have been incorporated in&nbsp;this prospectus and the registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set
forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. You should rely only on the information contained in this prospectus or incorporated by reference herein. We have not authorized anyone else to provide you with different information. We are
not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus, regardless of the time of
delivery of this prospectus or any sale of the securities offered by this prospectus. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We file annual, quarterly and current
reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Copies of certain information filed by us with the SEC are also available on our website at www.alaunos.com. Information contained in or
accessible through our website does not constitute a part of this prospectus and is not incorporated by reference in this prospectus. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B><A NAME="toc2286456_15"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The SEC allows us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important
information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038.</FONT> The documents
incorporated by reference into this prospectus contain important information that you should read about us. </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">The following
documents are incorporated by reference into this document: </FONT></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;30, 2022; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022009942/tcrt-20220331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the fiscal quarter ended March&nbsp;31, 2022, filed with the SEC on May&nbsp;16, 2022; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC
on <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522001682/d263245d8k.htm">January&nbsp;4, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522017681/d173910d8k.htm">January&nbsp;
26, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522077889/d332571d8k.htm">March&nbsp;17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522079589/d332630d8k.htm">March&nbsp;
18, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522135461/d219505d8k.htm">May&nbsp;2, 2022</A> (first filed only), <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522176544/d251784d8k.htm">June&nbsp;
17, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522182171/d383158d8k.htm">June&nbsp;27, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312522192331/d219766d8k.htm">July&nbsp;13, 2022</A> to
the extent the information in such reports is filed and not furnished; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">20
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT COLOR="#465361">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT COLOR="#465361">the description of our common stock set forth in <A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex4_7.htm">Exhibit
 4.7</A> to our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2021, which was filed with the SEC on March&nbsp;30, 2022, including any amendments or reports filed for the purpose of
updating such description. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">All reports and other documents we subsequently file pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part
of this prospectus from the date of the filing of such reports and documents. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral
request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits that are specifically incorporated by reference into such documents. You may request a
copy of such documents at no cost, by writing or telephoning us at the following address or telephone number: </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Alaunos Therapeutics, Inc. </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">8030 El Rio St. </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Houston, TX 77054 </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">Attention: Senior Vice President, Legal </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">(346) <FONT STYLE="white-space:nowrap">355-4099</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#465361">Any statement contained in this prospectus or contained in a document incorporated or deemed to be incorporated by reference into this
prospectus will be deemed to be modified or superseded to the extent that a statement contained in this prospectus or any subsequently filed supplement to this prospectus, or document deemed to be incorporated by reference into this prospectus,
modifies or supersedes such statement. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361">21
</FONT></P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Up to $50,000,000 </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>ALAUNOS THERAPEUTICS, INC. </B></FONT></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g286456g01a04.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>PROSPECTUS </B></FONT></P><center>
<P STYLE="line-height:5.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #465361;width:20%">&nbsp;</P></center> <P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#465361"><B>Piper Sandler </B></FONT></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#465361"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022
</B></FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the fees and expenses, other than underwriting compensation, payable in connection with the registration of securities
hereunder. All amounts are estimates except for the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blue sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents registration fee applicable to amount included in prospectus for $200 million in shares of common
stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated expenses are not presently known. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the State of Delaware. Subsection (a)&nbsp;of Section&nbsp;145 of the General Corporation Law of the State of Delaware,
or the DGCL, empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in
connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or
proceeding, had no reasonable cause to believe the person&#146;s conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsection (b)&nbsp;of Section&nbsp;145 of the DGCL empowers a
corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that
the person acted in any of the capacities set forth above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in
good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all
the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the
defense of any action, suit or proceeding referred to in subsections (a)&nbsp;and (b) of Section&nbsp;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#146; fees)
actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&nbsp;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification
provided for by Section&nbsp;145 shall, unless </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#146;s heirs,
executors and administrators. Section&nbsp;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising
out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&nbsp;145. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102(b)(7) of the DGCL provides that a corporation&#146;s certificate of incorporation may contain a provision eliminating or limiting the
personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&nbsp;for any breach of
the director&#146;s duty of loyalty to the corporation or its stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of the DGCL or
(iv)&nbsp;for any transaction from which the director derived an improper personal benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the
indemnification of our directors and officers to the maximum extent permitted by applicable law, and our bylaws, as amended, provide for the indemnification of our directors, officers, employees and other agents to the maximum extent permitted by
law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our directors, whereby we have agreed to indemnify our directors to the fullest extent
permitted by the DGCL, including advancement of expenses incurred in legal proceedings to which the director was, or is threatened to be made, a party by reason of the fact that (i)&nbsp;such director is or was a director of the Company,
(ii)&nbsp;such director acted while a director, officer, employee or agent of the Company, or (iii)&nbsp;such director was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust,
employee benefit plan or other enterprise. At present, there is no pending litigation or proceeding involving a director of the Company regarding which indemnification is sought, nor are we aware of any threatened litigation that may result in
claims for indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a directors&#146; and officers&#146; liability insurance policy that indemnifies the our directors and officers
against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his capacity as such. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Description of Document</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;1.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex12.htm">Equity Distribution Agreement dated August 12, 2022 by and between the Registrant and Piper Sandler&nbsp;&amp; Co. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, and all amendments thereto. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm">Amended and Restated Bylaws of the Registrant, dated as of September&nbsp;
21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> SEC File <FONT STYLE="white-space:nowrap">No.&nbsp;001-33038,</FONT> filed September&nbsp;22, 2020).
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Certificate and Certificate of Designations of Preferred Stock.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex42.htm">Form of Indenture between the Registrant and one or more trustees to be named therein. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3**</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Debt Securities.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.4*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex44.htm">Form of Common Stock Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.5*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex45.htm">Form of Preferred Stock Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.6*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex46.htm">Form of Debt Securities Warrant Agreement and Warrant Certificate. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex51.htm">Opinion of Covington&nbsp;&amp; Burling LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;5.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex52.htm">Opinion of Covington&nbsp;&amp; Burling LLP. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex231.htm">Consent of Independent Registered Public Accounting Firm. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.2*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex51.htm">Consent of Covington&nbsp;&amp; Burling LLP (included as part of Exhibit 5.1). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.3*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dex52.htm">Consent of Covington&nbsp;&amp; Burling LLP (included as part of Exhibit 5.2). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;24.1*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page). </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;25.1***</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility of Trustee under the Debt Indenture.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;107*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d286456dexfilingfees.htm">Filing Fee Table. </A></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment or by a report filed under the Securities Exchange Act of 1934, as amended, and
incorporated herein by reference, if applicable. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed pursuant to Section&nbsp;305(b)(2) of the Trust Indenture Act of 1939 at the time of an offering of
debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)&nbsp;(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus
required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts
or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective registration
statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in this registration statement
or any material change to such information in this registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, <I>however</I>, that paragraphs (a)(1)(i), (a)(1)(ii) and
(a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&nbsp;13 or
Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is
part of this registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) That, for the purposes of determining any liability under the Securities Act, each such post-effective amendment
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
prospectus was deemed part of and included in the registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) each prospectus required to be filed pursuant to Rule 424(b)(2),
(b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities
Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in
the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
effective date; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of such undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, such undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) any preliminary prospectus or prospectus of such undersigned registrant relating to the offering required to be filed pursuant to Rule
424; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) any free writing prospectus relating to the offering prepared by or on behalf of such undersigned registrant or used or referred to by such
undersigned registrant; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii) the portion of any other free writing prospectus relating to the offering containing material
information about such undersigned registrant or its securities provided by or on behalf of such undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iv) any other communication
that is an offer in the offering made by such undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) The undersigned registrant hereby undertakes that, for
purposes of determining any liability under the Securities Act, each filing of the registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s
annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) The undersigned registrant hereby undertakes that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of the registration
statement in reliance upon Rule 430A and contained in the form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of the registration statement as of the time it
was declared effective; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) for purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection
(a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act of 1939 (the &#147;Trust Indenture Act&#148;) in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section&nbsp;305(b)(2) of the Trust
Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on this
12th day of August, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ALAUNOS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer<B> </B></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin S. Boyle, Sr. and Michael Wong, jointly and
severally, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and resubstitution, for him or her, and in his or her name, place
and stead, in any and all capacities, to sign any and all amendments to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting
unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith,
as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or his or her
substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended,
this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Signature</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Title</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Date</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Director <I>(Principal Executive Officer and Principal Financial Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Wong</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Wong</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Vice President, Finance <I>(Principal Accounting Officer)</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Bowden</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher Bowden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Huang</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Huang</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert W. Postma</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert W. Postma</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mary Thistle</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mary Thistle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaime Vieser</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jaime Vieser</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Holger Weis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Holger Weis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">August 12, 2022</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>2
<FILENAME>d286456dex12.htm
<DESCRIPTION>EX-1.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EQUITY DISTRIBUTION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">August&nbsp;12, 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PIPER SANDLER&nbsp;&amp;
CO. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota 55402 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As further set forth in this agreement (this <B><I>&#147;Agreement&#148;</I></B>), Alaunos Therapeutics, Inc., a Delaware corporation (the
<B><I>&#147;Company&#148;</I></B>), proposes to issue and sell from time to time through Piper Sandler&nbsp;&amp; Co. (the <B><I>&#147;Agent&#148;</I></B>), as sales agent, the Company&#146;s common stock, par value $0.001 per share (the
<B><I>&#147;Common Stock&#148;</I></B>) (such shares of Common Stock to be sold pursuant to this Agreement, the <B><I>&#147;Shares&#148;</I></B>) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties
hereto agree that compliance with the limitation set forth in Section&nbsp;2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in
connection with such compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the Agent with respect to the sale of the Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>1.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Representations and Warranties of the Company</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; The Company represents and warrants to, and agrees with, the Agent that, unless otherwise specified below, and except as may be
disclosed in the Prospectus (including any documents incorporated by reference therein and any supplements thereto) on or before each date of delivery, as of the date of this Agreement, each Representation Date (as defined in Section&nbsp;3(o)
below), each date on which a Placement Notice (as defined in Section&nbsp;2(a)(i) below) is given (each, a <B><I>&#147;Notice Date&#148;</I></B>), each date on which Shares are sold hereunder (each, an <B><I>&#147;Applicable Time&#148;</I></B>), and
each Settlement Date (as defined in Section&nbsp;2(a)(vii) below) as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration
Statement and Prospectus</I>. The Company will file, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the <B><I>&#147;Securities Act&#148;</I></B>), with the
Securities and Exchange Commission (the <B><I>&#147;Commission&#148;</I></B>) a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including a base prospectus, relating to certain securities, including the Common Stock, to
be issued from time to time by the Company, as well as a prospectus relating to the Shares (the <B><I>&#147;EDA Prospectus&#148;</I></B>), both of which incorporate by reference documents that the Company has filed or will file in accordance with
the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the <B><I>&#147;Exchange Act&#148;</I></B>). The Company will furnish to the Agent, for use by the Agent, copies of
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the EDA Prospectus. Except where the context otherwise requires, such registration statement, as amended when it becomes effective, including all documents filed as part thereof or incorporated
by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant
to Rule 430B or 462(b) of the Securities Act, is herein called the <B><I>&#147;Registration Statement.&#148;</I></B> The EDA Prospectus, including all documents incorporated therein by reference, included in the Registration Statement, in the form
in which the EDA Prospectus has most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any <B><I>&#147;issuer free writing prospectus,&#148;</I></B> as defined in Rule 433 of the
Securities Act (<B><I>&#147;Rule 433&#148;</I></B>), relating to the Shares, if any, that (i)&nbsp;is required to be filed with the Commission by the Company or (ii)&nbsp;is exempt from filing pursuant to Rule 433(d)(5)(i), in each case in the form
filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#146;s records pursuant to Rule 433(g), is herein called the <B><I>&#147;Prospectus.&#148;</I></B> Any reference herein to the
Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or
&#147;supplement&#148; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein. For
purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant the Electronic Data Gathering Analysis and
Retrieval System (<B><I>&#147;EDGAR&#148;</I></B>). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Continuing Effectiveness of
Registration Statement</I>. As of each Representation Date, Notice Date, Applicable Time and Settlement Date: The Registration Statement and any Rule&nbsp;462(b) Registration Statement will have been declared effective by the Commission under the
Securities Act. The Company will have complied, to the Commission&#146;s satisfaction, with all requests of the Commission for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any
Rule&nbsp;462(b) Registration Statement shall be in effect and, to the knowledge of the Company, no proceedings for such purpose shall have been instituted, be pending or be contemplated or threatened by the Commission. The Company meets the
requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The sale of the Shares hereunder meets the requirements of General Instruction I.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Material Misstatements or Omissions</I>. The Prospectus when filed, and as amended or
supplemented, if applicable, will comply in all material respects with the Securities Act. Each of the Registration Statement, any Rule&nbsp;462(b) Registration Statement, the Prospectus and any post-effective amendments or supplements thereto, at
the time it becomes effective or its date, as applicable, and as of each Settlement Date, will comply in all material respects with the Securities Act, and as of each effective date and each Settlement Date, will not contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date and as of each
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Settlement Date, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule&nbsp;462(b) Registration
Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to the Agent furnished to the Company in writing by the Agent
expressly for use therein. There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Eligible Issuer</I>. The Company is not an &#147;ineligible issuer&#148; (as defined in Rule
405 under the Securities Act) as of the eligibility determination date for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the Shares contemplated by the Registration Statement; the parties hereto agree and
understand that the content of any and all &#147;road shows&#148; (as defined in Rule 433 under the Securities Act) related to the offering of the Shares contemplated hereby is solely the property of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp; <I>Financial Statements</I>. The historical financial statements (including the related notes and
supporting schedules) to be included or incorporated by reference in the Registration Statement and the Prospectus comply as to form in all material respects with the requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the
Securities Act (<B><I>&#147;Regulation <FONT STYLE="white-space:nowrap">S-X&#148;</FONT></I></B>) and present fairly in all material respects the financial condition, results of operations and cash flows of the entities purported to be shown thereby
at the dates and for the periods indicated and have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis throughout the periods involved. There are no financial statements
(historical or pro forma) that are required to be included in the Registration Statement or the Prospectus that are not so included as required. The interactive data in eXtensible Business Reporting Language (<B><I>&#147;XBRL&#148;</I></B>) included
or incorporated by reference in the Registration Statement and the Prospectus fairly present the information called for in all material respects and have been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp; <I>No <FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Transactions</I>. There are
no transactions, arrangements and other relationships between and/or among the Company, and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structural finance, special
purpose or limited purpose entity (each, an <B><I><FONT STYLE="white-space:nowrap">&#147;Off-Balance</FONT> Sheet Transaction&#148;</I></B>) that could reasonably be expected to affect materially the Company&#146;s liquidity or the availability of
or requirements for its capital resources, including those <FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Transactions described in the Commission&#146;s Statement about Management&#146;s Discussion and Analysis of Financial Conditions
and Results of Operations (Release Nos. <FONT STYLE="white-space:nowrap">33-8056;</FONT> <FONT STYLE="white-space:nowrap">34-45321;</FONT> <FONT STYLE="white-space:nowrap">FR-61),</FONT> and are required to be described in the Prospectus, which have
not been described as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Auditor Independence.</I> RSM US LLP, who
have certified certain financial statements of the Company, whose report appears in the Registration Statement and the Prospectus, are independent public accountants as required by the Securities Act and the Public Accounting Oversight Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Organization and Good Standing</I>. The Company has no &#147;significant subsidiaries&#148; as
defined in Rule 405 under the Securities Act. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company&#146;s most recent Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K.</FONT> The Company has been duly organized and is validly existing and in good standing under the laws of their respective jurisdictions of organization. The Company is, and will be, duly
licensed or qualified as a foreign entity for transaction of business and in good standing under the laws of each other jurisdiction in which its ownership or lease of property or the conduct of its business requires such license or qualification,
and has all corporate power and authority necessary to own or hold its properties and to conduct its business as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such
power or authority would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. <B><I>&#147;Material Adverse Effect&#148;</I></B> shall mean any material adverse effect, or any development involving a
prospective material adverse change or effect, on (i)&nbsp;the business, earnings, assets, liabilities, prospects, condition (financial or otherwise), operations, general affairs, management, financial position, stockholders&#146; equity or results
of operations of the Company, or (ii)&nbsp;the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp; <I>Capitalization</I>. The Company has an authorized capitalization as set forth in each of the
Registration Statement and the Prospectus (other than for subsequent issuances, if any, pursuant to a Specified Equity Plan (as defined in Section&nbsp;1(a)(xviii) below) or upon the exercise of outstanding options or warrants), and all of the
issued shares of the Company have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> conform in all material respects to the description thereof contained in the Registration Statement
and the Prospectus and were not issued in violation of any preemptive right, resale right, right of first refusal or similar right. All of the Company&#146;s options, warrants and other rights to purchase or exchange any securities for shares of the
Company&#146;s capital stock have been duly authorized and validly issued, and conform in all material respects to the description thereof contained in the Registration Statement and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp; <I>Due Authorization, Valid Issuance and <FONT STYLE="white-space:nowrap">Non-Assessiblity</FONT>
of Shares</I>. The Shares to be issued and sold by the Company to the Agent hereunder have been duly authorized and, upon payment and delivery in accordance with this Agreement, will be validly issued, fully paid and
<FONT STYLE="white-space:nowrap">non-assessable,</FONT> will conform in all material respects to the description thereof contained in the Registration Statement and the Prospectus, will be issued in compliance with federal and state securities laws
and will be free of statutory and contractual preemptive rights, rights of first refusal and similar rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp; <I>Authority to Enter into this Agreement</I>.
The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. This Agreement has been duly and validly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp; <I><FONT STYLE="white-space:nowrap">Non-Contravention</FONT></I>. The issue and sale of the
Shares, the execution, delivery and performance of this Agreement by the Company, the consummation of the transactions contemplated hereby and the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148;
in the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, impose any lien, charge or encumbrance upon any property or assets of the Company, or constitute a default under, any
indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company is subject;
(ii)&nbsp;result in any violation of the provisions of the certificate of incorporation or bylaws of the Company, as currently in effect; or (iii)&nbsp;result in any violation of any statute or any judgment, order, decree, rule or regulation of any
court or governmental agency or body having jurisdiction over the Company or any of its properties or assets, except, with respect to clauses (i)&nbsp;and (iii), for such conflicts, breaches, violations, liens, charges, encumbrances or defaults that
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Consent or Approval Required</I>. No consent, approval, authorization or order of, or
filing, registration or qualification with, any court or governmental agency or body having jurisdiction over the Company or any of its properties or assets is required for the issue and sale of the Shares, the execution, delivery and performance of
this Agreement by the Company, the consummation of the transactions contemplated hereby or the application of the proceeds from the sale of the Shares as described under &#147;Use of Proceeds&#148; in the Prospectus, except for (i)&nbsp;the
registration of the Shares under the Securities Act; (ii)&nbsp;such consents, approvals, authorizations, orders, filings, registrations or qualifications as may be required under the Exchange Act, and applicable state or foreign securities laws
and/or the bylaws and rules of the Financial Industry Regulatory Authority (<B><I>&#147;FINRA&#148;</I></B>) in connection with the sale of the Shares by the Agent; and (iii)&nbsp;the inclusion of the Shares on the Exchange.
<B><I>&#147;Exchange&#148;</I></B> shall mean the Nasdaq Global Select Market or, if then the principal market on which the Common Stock is listed or quoted, the Nasdaq Global Market or Nasdaq Capital Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Internal Controls</I>. The Company maintains a system of &#147;internal control over financial
reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles in the United States, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in
accordance with management&#146;s general or specific authorization, (ii)&nbsp;transactions are recorded as necessary to permit preparation of the Company&#146;s financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for its assets, (iii)&nbsp;access to the Company&#146;s assets is
permitted only in accordance with management&#146;s general or specific authorization, (iv)&nbsp;the recorded accountability for the Company&#146;s assets is compared with existing assets at reasonable intervals and appropriate action is taken with
respect to any differences, and (v)&nbsp;the interactive data in XBRL included or incorporated by reference in the Registration Statement and the Prospectus fairly present the information called for in all material respects and are prepared in
accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement or the Prospectus, as of the date of the most recent balance sheet of the Company audited by RSM US LLP, there were no
&#147;significant deficiencies&#148; or &#147;material weaknesses&#148; (each as defined by the Public Company Accounting Oversight Board) in the Company&#146;s internal controls over financial reporting, or any fraud, whether or not material, that
involves management or other employees of the Company who have a significant role in the Company&#146;s internal controls; and since the end of the latest audited fiscal year, there has been no change in the Company&#146;s internal control over
financial reporting (whether or not remediated) that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company&#146;s internal control over financial reporting. The Company&#146;s board of
directors has, subject to the exceptions, cure periods and the phase in periods specified in the Nasdaq listing rules (<B><I>&#147;Exchange Rules&#148;</I></B>), validly appointed an audit committee to oversee internal accounting controls whose
composition satisfies the applicable requirements of the Exchange Rules and the Company&#146;s board of directors and/or the audit committee has adopted a charter that satisfies the requirements of the Exchange Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Disclosure Controls</I>. The Company maintains an effective system of &#147;disclosure controls
and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by
the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure
that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of its disclosure controls
and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp; <I>Critical Accounting Policies</I>. The section entitled &#147;Critical Accounting Policies and
Significant Estimates&#148; incorporated by reference in the Registration Statement and the Prospectus accurately describes in all material respects (i)&nbsp;the accounting policies that the Company believes are the most important in the portrayal
of the Company&#146;s financial condition and results of operations and that require management&#146;s most difficult, subjective or complex judgments (<B><I>&#147;Critical Accounting Policies&#148;</I></B>); (ii) the judgments and uncertainties
affecting the application of Critical Accounting Policies; and (iii)&nbsp;the likelihood that materially different amounts would be reported under different conditions or using different assumptions, and an explanation thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Sarbanes-Oxley Compliance</I>. There is
and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of
2002 and the rules and regulations promulgated in connection therewith that are applicable to the Company or its directors or officers in their capacities as directors or officers of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Exceptions</I>. Except as would not, in the aggregate, reasonably be expected to have a
Material Adverse Effect, since the date of the latest audited financial statements included in the Registration Statement and the Prospectus, and, except as disclosed in the Registration Statement and the Prospectus, the Company has not
(i)&nbsp;sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, (ii)&nbsp;issued or granted
any securities (other than pursuant to inducement awards under the Exchange Rules or employee benefit plans, qualified stock option plans or other equity compensation plans or arrangements disclosed in the Registration Statement and the Prospectus
(collectively, the <B><I>&#147;Specified Equity Plans&#148;</I></B>)), (iii) incurred any material liability or obligation, direct or contingent, other than liabilities and obligations that were incurred in the ordinary course of business,
(iv)&nbsp;entered into any material transaction not in the ordinary course of business, or (v)&nbsp;declared or paid any dividend on its share capital; and since such date, except as disclosed in the Registration Statement and the Prospectus, there
has not been any change in the share capital, long-term debt, net current assets or short-term debt of the Company or any adverse change, or any development involving a prospective adverse change, in or affecting the condition (financial or
otherwise), results of operations, stockholders&#146; equity, properties, management, business or prospects of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp; <I>Valid Title</I>. The Company has good and marketable title in fee simple to all real property
and good and marketable title to all personal property owned by it, that is material to the business of the Company, in each case free and clear of all liens, encumbrances and defects, except such liens, encumbrances and defects as do not materially
affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company. All assets held under lease by the Company, that are material to the business of the Company, are held by it
under valid, subsisting and enforceable leases, with such exceptions as do not materially interfere with the use made and proposed to be made of such assets by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp; <I>Intellectual Property</I>. The Company owns, possesses, has rights to or can acquire on
reasonable terms, all Intellectual Property (as defined below) necessary for the conduct of the Company&#146;s business as now conducted or as proposed to be conducted, as described in the Registration Statement and the Prospectus, except where the
failure to own, possess, have rights to or such ability to acquire would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Furthermore, except as would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect, (A)&nbsp;to the knowledge of the Company, there is no infringement, misappropriation or violation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by third parties of any such Intellectual Property; (B)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the
Company&#146;s rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C)&nbsp;the Intellectual Property owned by the Company and, to the knowledge of the
Company, the Intellectual Property licensed to the Company, has not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (D)&nbsp;there is no pending or, to the
knowledge of the Company, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, the Company has not received any
written notice of such claim and the Company is unaware of any other fact which would form a reasonable basis for any such claim; (E)&nbsp;to the Company&#146;s knowledge, no employee of the Company is in or has ever been in violation of any term of
any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure agreement or
any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company or actions undertaken by the employee while employed with the Company; (F)&nbsp;there is no prior art
or public or commercial activity of which the Company is aware that may render any patent included in the Intellectual Property invalid or that would preclude the issuance of any patent on any patent application included in the Intellectual
Property, which has not been disclosed to the U.S. Patent and Trademark Office or the relevant foreign patent authority, as the case may be; and (G)&nbsp;to the Company&#146;s knowledge, the issued patents included in the Intellectual Property are
valid and enforceable and the Company is unaware of any facts that would preclude the issuance of a valid and enforceable patent on any pending patent application included in the Intellectual Property; (H)&nbsp;the Company has taken steps reasonably
designed to secure the interests of the Company in the Intellectual Property purported to be owned by the Company from all employees, consultants, agents or contractors that developed (in whole or in part) such Intellectual Property; (I)&nbsp;no
government funding, facilities or resources of a university, college, other educational institution or research center was used in the development of any Intellectual Property that is owned or purported to be owned by the Company that would confer
upon any governmental agency or body, university, college, other educational institution or research center any claim or right in or to any such Intellectual Property; and (J)&nbsp;to the Company&#146;s knowledge, none of the technology employed by
the Company has been obtained or is being used by the Company in violation of the rights of any entity. <B><I>&#147;Intellectual Property&#148;</I></B> shall mean all patents, patent applications, trade and service marks, trade and service mark
registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property in the United States and foreign jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxi)&nbsp;&nbsp;&nbsp;&nbsp; <I>Health Care Authorizations</I>. The Company
has submitted and possesses, or qualifies for applicable exemptions to, such valid and current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments thereto issued or required
by the appropriate state, federal or foreign regulatory agencies or bodies necessary to conduct its business as described in the Registration Statement and the Prospectus (<B><I>&#147;Permits&#148;</I></B>), including, without limitation, all such
Permits required by the U.S. Food and Drug Administration (the <B><I>&#147;FDA&#148;</I></B>), the U.S. Department of Health and Human Services (<B><I>&#147;HHS&#148;</I></B>), the U.S. Centers for Medicare&nbsp;&amp; Medicaid Services
(<B><I>&#147;CMS&#148;</I></B>), the European Medicines Agency (<B><I>&#147;EMA&#148;</I></B>), Health Canada or any other comparable state, federal or foreign agencies or bodies to which it is subject, except for such Permits, the lack of which
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and the Company has not received any written notice of proceedings relating to the revocation or modification of, or <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with, any such Permit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with
Health Care Laws</I>. The Company is in material compliance with all health care laws applicable to the Company, or any of its products or activities, including, but not limited to, any state, federal or foreign law, rule or regulation which imposes
requirements on manufacturing, development, testing, labeling, advertising, marketing, promotion, distribution, reporting, kickbacks, patient or program charges, recordkeeping, claims process, documentation requirements, medical necessity,
referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health
care, clinical laboratory or diagnostics products or services (collectively, <B><I>&#147;Health Care Laws&#148;</I></B>). Since January&nbsp;1, 2019, the Company has not received any notification, including notification of any pending or threatened
claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority, including, without limitation, the FDA, the EMA, Health Canada, the U.S. Federal Trade Commission, the U.S. Drug Enforcement
Administration (<B><I>&#147;DEA&#148;</I></B>), CMS, HHS&#146;s Office of Inspector General, the U.S. Department of Justice and state Attorneys General or similar agencies of <FONT STYLE="white-space:nowrap">non-compliance</FONT> by, or liability
of, the Company under any Health Care Laws, except, with respect to any of the foregoing, such as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The statements with respect to Health Care Laws
and the Company&#146;s compliance therewith included in the Registration Statement and in the Prospectus fairly summarize in all material respects the matters therein described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Clinical Trials</I>. The studies, tests and preclinical and clinical trials conducted by or
on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were
and, if still pending, are, to the Company&#146;s knowledge, being conducted in all material respects in accordance with protocols, procedures and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable
statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject; the descriptions of the results of such studies, tests and trials contained in the
Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading, except where the failure to be in such accordance would not reasonably be expected
to have a Material Adverse Effect; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which the Company believes reasonably call into question in any material
respect the results of the studies, tests and trials described in the Registration Statement or Prospectus, when viewed in the context in which such results are described and the clinical state of development; and the Company has not received any
notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the
termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company&#146;s knowledge, there
are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports
to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Absence of Settlement Agreements or Undertakings</I>. Except as disclosed in the Registration
Statement and the Prospectus, the Company is not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxv)&nbsp;&nbsp;&nbsp;&nbsp; <I>Absence of Legal or Governmental Proceedings</I>. Except as disclosed in the Registration
Statement and the Prospectus, there are no legal or governmental proceedings pending to which the Company is a party or of which any property or assets of the Company is the subject that, if determined adversely to the Company, would, in the
aggregate, reasonably be expected to have a Material Adverse Effect; and to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp; <I>Material Contracts</I>. There are no contracts or other documents required to be described in
the Registration Statement or filed as exhibits to the Registration Statement that are not described and filed as required. The statements made in the Registration Statement and Prospectus, insofar as they purport to constitute summaries of the
terms of the contracts and other documents described and filed, constitute accurate summaries of the terms of such contracts and documents in all material respects. Except as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
disclosed in the Registration Statement and the Prospectus, the Company has no knowledge that any other party to any such contract or other document has any intention not to render full
performance as contemplated by the terms thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Insurance</I>. The Company maintains
insurance from nationally recognized insurers in such amounts and covering such risks as is commercially reasonable in accordance with customary practices for companies engaged in similar businesses and similar industries for the conduct of its
business and the value of its properties. All policies of insurance of the Company are in full force and effect; the Company is in compliance with the terms of such policies in all material respects; and the Company has not received notice from any
insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance; there are no material claims by the Company under any such policy or instrument as to which
any insurance company is denying liability or defending under a reservation of rights clause; and the Company does not have any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or
to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Related Party Disclosure</I>. No relationship, direct or indirect, exists between or among
the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the Registration Statement or the Prospectus which is not so described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Labor Dispute</I>. No labor disturbance by or dispute with the employees of the Company
exists or, to the knowledge of the Company, is imminent that would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxx)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Violation or Default</I>. Except as disclosed in the Registration Statement and the
Prospectus, the Company is not (i)&nbsp;in violation of its certificate of incorporation or bylaws, as currently in effect, (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant, condition or other obligation contained in any indenture, mortgage, deed of trust, loan agreement, license or other agreement or instrument to which it is a party or by which it is bound or
to which any of its properties or assets is subject, or (iii)&nbsp;in violation of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over it or its property or assets or has failed to obtain
any license, permit, certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business, except in the case of clauses (ii)&nbsp;and (iii), to the extent any such
conflict, breach, violation or default would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;<I>Environmental Laws</I>. Except as disclosed in the Registration Statement and the Prospectus,
the Company (i)&nbsp;is, and at all times prior hereto was, in compliance with all applicable laws, regulations, ordinances, rules, orders, judgments, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
decrees, permits or other legal requirements of any governmental authority, including without limitation any international, foreign, national, state, provincial, regional, or local authority,
relating to pollution, the protection of human health or safety, the environment, or natural resources, or to use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release of hazardous or toxic substances or
wastes, pollutants or contaminants (<B><I>&#147;Environmental Laws&#148;</I></B>), which compliance includes, without limitation, obtaining, maintaining and complying with all permits and authorizations and approvals required by Environmental Laws
to conduct its business, except for such <FONT STYLE="white-space:nowrap">non-compliance</FONT> as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and (ii)&nbsp;has not received notice of any
actual or alleged violation of Environmental Laws, or of any actual or potential liability for or other obligation concerning the presence, disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants and has no
knowledge of any event or condition that would reasonably be expected to result in any such notice. Except as described in the Registration Statement and the Prospectus, (x)&nbsp;there are no proceedings that are pending or, to the Company&#146;s
knowledge, threatened, against the Company under Environmental Laws in which a governmental authority is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed,
(y)&nbsp;the Company is not aware of any issues regarding compliance with Environmental Laws or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would
reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;the Company does not anticipate material capital expenditures relating to Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes</I>. The Company has filed all federal, state, local and foreign tax returns required
to be filed through the date hereof, subject to permitted extensions, and have paid all taxes due (except where the failure to so file or pay would not, in the aggregate, reasonably be expected to have a Material Adverse Effect, and except as
currently being contested in good faith and for which reserves have been created), and no tax deficiency has been determined adversely to the Company, nor does the Company have any knowledge of any tax deficiencies that have been, or would
reasonably be expected to be, asserted against the Company that would, in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiii)&nbsp;&nbsp;&nbsp;&nbsp;<I>ERISA Compliance</I>. Except as would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect, (i)&nbsp;each &#147;employee benefit plan&#148; (within the meaning of Section&nbsp;3(3) of the Employee Retirement Security Act of 1974, as amended
(<B><I>&#147;</I></B><B><I>ERISA</I></B><B><I>&#148;</I></B>)) for which the Company or any member of its &#147;Controlled Group&#148; (defined as any organization which is a member of a controlled group of corporations within the meaning of
Section&nbsp;414 of the Internal Revenue Code of 1986, as amended (the <B><I>&#147;</I></B><B><I>Code</I></B><B><I>&#148;</I></B>)) would have any liability (each a <B><I>&#147;</I></B><B><I>Plan</I></B><B><I>&#148;</I></B>) has been maintained in
compliance in all material respects with its terms and with the requirements of all applicable statutes, rules and regulations including ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or
Section&nbsp;4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
administrative exemption; (iii)&nbsp;with respect to each Plan subject to Title IV of ERISA (A)&nbsp;no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA) has
occurred or is reasonably expected to occur that would result in a material loss to the Company, (B)&nbsp;no &#147;accumulated funding deficiency&#148; (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code), whether or not
waived, has occurred or is reasonably expected to occur, (C)&nbsp;the fair market value of the assets under each Plan that is required to be funded exceeds the present value of all benefits accrued under such Plan (determined based on those
assumptions used to fund such Plan), and (D)&nbsp;neither the Company or any member of its Controlled Group has incurred, or reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the
Pension Benefit Guaranty Corporation in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148;, within the meaning of Section&nbsp;4001(c)(3) of ERISA); and (iv)&nbsp;each Plan that is intended to
be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, to the Company&#146;s knowledge, whether by action or by failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxiv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accuracy of Statistical and Market Data</I>. The statistical and market-related data included
in the Registration Statement and the Prospectus are based on or derived from sources that the Company believes to be reliable in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxv)&nbsp;&nbsp;&nbsp;&nbsp;<I>Not an Investment Company</I>. The Company is not, nor, after giving effect to the offer and
sale of the Shares and the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Prospectus, will be, (i)&nbsp;an &#147;investment company&#148; or a company &#147;controlled&#148; by an &#147;investment
company&#148; within the meaning of the Investment Company Act of 1940, as amended (the <B><I>&#147;Investment Company Act&#148;</I></B>), and the rules and regulations of the Commission thereunder, or (ii)&nbsp;a &#147;business development
company&#148; (as defined in Section&nbsp;2(a)(48) of the Investment Company Act). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvi)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accuracy of Certain Summaries and Statements</I>. The statements set forth or incorporated by
reference, as applicable, in each of the Registration Statement and the Prospectus under the captions &#147;Description of Capital Stock,&#148; and in the Company&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
under the captions &#147;Legal Proceedings&#148; and &#147;Certain Relationships and Related Transactions, and Director Independence&#148;, insofar as they purport to summarize the provisions of the laws and documents referred to therein, are
accurate summaries in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxvii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Registration Rights</I>. Except as
disclosed in the Registration Statement and the Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the
Securities Act with respect to any securities of the Company owned or to be owned by such person. There are no contracts, agreements or understandings to require the Company to include any such securities in the securities proposed to be offered
pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxviii)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Other Brokers</I>. The Company is
not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against it or the Agent for a brokerage commission, finder&#146;s fee or like payment in connection with the
offering and sale of the Shares, except for such contracts, agreements or understandings as have been waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xxxix)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Integration</I>. The Company has not sold or issued any securities that would be
integrated with the offering of the Shares contemplated by this Agreement pursuant to the Securities Act or the interpretations thereof by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xl)&nbsp;&nbsp;&nbsp;&nbsp; <I>Absence of Stabilization or Manipulation</I>. The Company has not taken, directly or
indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company in connection with the offering of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xli)&nbsp;&nbsp;&nbsp;&nbsp; <I>Exchange Act Registration and Listing of the Common Stock</I>. The shares of Common Stock are
registered pursuant to Section&nbsp;12(b) of the Exchange Act and listed on the Exchange; the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange
Act or delisting the Common Stock from the Exchange, nor has the Company received any notification that the Commission or the Exchange is contemplating terminating such registration or listing, except as disclosed in the Registration Statement and
the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Offering Material</I>. The Company has not distributed and prior to any
Settlement Date, will not distribute any offering material in connection with any Placement (as defined in Section&nbsp;2(a)(i) below), other than any preliminary prospectus, the Prospectus, and any Permitted Free Writing Prospectus (as defined in
Section&nbsp;3(n) below) to which the Agent has consented. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xliii)&nbsp;&nbsp;&nbsp;&nbsp; <I>Compliance with Labor
Laws</I>. The Company is not in violation of and has not received notice of any violation with respect to any federal or state law relating to discrimination in the hiring, promotion or pay of employees, nor any applicable federal or state wage and
hour laws, nor any state law precluding the denial of credit due to the neighborhood in which a property is situated, the violation of any of which would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xliv)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Unlawful Payments</I>. The Company has not, nor, to the knowledge of the Company, has any
director, officer, agent, employee or other person acting on behalf of the Company (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made any
direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, the Organization for
Economic <FONT STYLE="white-space:nowrap">Co-operation</FONT> and Development Convention on Bribery of Foreign Public Officials in International Business Transactions, and the rules and regulations thereunder and any other similar foreign or
domestic law or regulation applicable to the Company; or (iv)&nbsp;made any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment. The Company has instituted and maintains policies and procedures reasonably designed to ensure continued
compliance with the laws and regulations referenced in clause (iii)&nbsp;of this paragraph. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlv)&nbsp;&nbsp;&nbsp;&nbsp;
<I>Anti-Money Laundering Compliance</I>. The operations of the Company are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act
of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any applicable related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental
agency (collectively, the <B><I>&#147;Money Laundering Laws&#148;</I></B>) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company, threatened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlvi)&nbsp;&nbsp;&nbsp;&nbsp; <I>OFAC</I>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its directors, officers or employees, nor, to the Company&#146;s
knowledge, any agent, affiliate or representative of the Company, is an individual or entity that is, or is owned or controlled by an individual or entity that is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s
Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, <B><I>&#147;Sanctions&#148;</I></B>), nor </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;located, organized or resident in a country or territory that is the subject of Sanctions
(including, without limitation, Crimea, Cuba, Iran, North Korea and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;The Company will
not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other individual or entity: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;to fund or facilitate any activities or business of or with any individual or entity or in any
country or territory that, at the time of such funding or facilitation, is the subject of Sanctions; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;in any other manner that will result in a violation of Sanctions by any individual or entity
(including any individual or entity participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;For the past five years, the Company has not
knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlvii)&nbsp;&nbsp;&nbsp;&nbsp; <I>[Reserved].</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlviii)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Taxes or Fees Due Upon Issuance</I>. No stamp, issue, registration, documentary,
transfer or other similar taxes and duties, including interest and penalties, are payable by the Agent on or in connection with the issuance and sale of the Shares by the Company or the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xlix)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Immunity</I>. Neither the Company, nor any of its owned properties or assets, has any
immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment to prior judgment, attachment in aid of execution or otherwise) under the laws of any jurisdiction in which it is organized,
headquartered or doing business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Legal, Accounting or Tax Advice</I>. The Company has not
relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice in connection with the offering and sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(li)&nbsp;&nbsp;&nbsp;&nbsp;<I>Certificate as Representation and Warranty</I>. Any certificate signed by any officer of the
Company and delivered to the Agent or the Agent&#146;s counsel in connection with the offering of the Shares shall be deemed a representation and warranty by the Company to the Agent as to the matters covered thereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(lii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Cybersecurity. </I>The Company&#146;s information technology assets and equipment, computers,
systems, networks, hardware, software, websites, applications, and databases (collectively, <B><I>&#147;IT Systems&#148;</I></B>) are adequate for, and operate and perform in all material respects as required in connection with the operation of the
business of the Company as currently conducted, free and clear, to the knowledge of the Company, of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has implemented and maintained commercially
reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and
data, including &#147;Personal Data,&#148; used in connection with their businesses. <B><I>&#147;Personal Data&#148;</I></B> means (i)&nbsp;a natural person&#146;s name, street address, telephone number,
<FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or customer or account number;
(ii)&nbsp;any information which would qualify as &#147;personally identifying information&#148; under the Federal Trade Commission Act, as amended; (iii) &#147;personal data&#148; as defined by GDPR (as defined in Section&nbsp;1(a)(liii) below);
(iv) any information which would qualify as &#147;protected health information&#148; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act
(collectively, <B><I>&#147;HIPAA&#148;</I></B>); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and (v)&nbsp;any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified
person&#146;s health or sexual orientation. There have been no material breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any
other person, nor any incidents under internal review or investigations relating to the same. The Company is presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or
arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use,
access, misappropriation or modification. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(liii)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Data Privacy Laws. </I>The
Company is, and at all prior times was, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company has, since May&nbsp;25, 2018, been and currently
is in material compliance with, the European Union General Data Protection Regulation (<B><I>&#147;GDPR&#148;</I></B>) (EU 2016/679) (collectively, the <B><I>&#147;Privacy Laws&#148;</I></B>). To promote compliance with the Privacy Laws, the Company
has taken appropriate steps reasonably designed to ensure compliance in all material respects with such Privacy Laws. The Company has at all times made all disclosures to users or customers required by applicable laws and regulatory rules or
requirements, and none of such disclosures made have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company (i)&nbsp;has not received notice
of any actual or potential material liability under or relating to, or actual or potential material violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice;
(ii)&nbsp;is not currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; and (iii)&nbsp;is not a party to any order, decree, or agreement that imposes any
obligation or liability under any Privacy Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(liv)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Shutdowns or Prohibitions</I>. The
Company has not had any product, clinical laboratory or manufacturing site (whether Company-owned or that of a third party manufacturer for the Company&#146;s products) subject to a governmental authority (including FDA) shutdown or import or export
prohibition, nor received any FDA Form 483 or other governmental authority notice of adverse finding, &#147;warning letters,&#148; &#147;untitled letters,&#148; requests to make changes to the Company&#146;s products, processes or operations, or
similar correspondence or notice from the FDA or other governmental authority alleging or asserting material noncompliance with any applicable Health Care Laws. To the Company&#146;s knowledge, neither the FDA nor any other governmental authority is
considering such action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>2.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Purchase, Sale and Delivery of Shares</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I> </I><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">At-the-Market</FONT></FONT> Sales.
</I>On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agrees to issue and sell through the Agent as sales agent, and the Agent agrees to use its commercially reasonable efforts to sell for and on behalf of the Company, the Shares on the following
terms and conditions; <I>provided</I>, <I>however</I>, that any obligation of the Agent to use such commercially reasonable efforts shall be subject to the continuing accuracy of the representations and warranties of the Company herein, the
performance by the Company of its covenants and obligations hereunder and the continuing satisfaction of the additional conditions specified in Section&nbsp;4 of this Agreement. The Company acknowledges and agrees that (i)&nbsp;there can be no
assurance that the Agent will be successful in selling Shares, and (ii)&nbsp;the Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for any reason other than a failure by the Agent to
use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Shares as required under this Section&nbsp;2. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp; Each time that the Company wishes to issue and sell the Shares hereunder (each, a
<B><I>&#147;Placement&#148;</I></B>), it will notify the Agent by email notice (or other method mutually agreed to in writing by the parties) (a <B><I>&#147;Placement Notice&#148;</I></B>) containing the parameters in accordance with which it
desires the Shares to be sold, which shall at a minimum include the number of Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Shares that may be sold in any one Trading Day (as
defined below) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters necessary is attached hereto as <U>Schedule 1</U>.&nbsp;The Placement Notice shall originate from any of the individuals
from the Company set forth on <U>Schedule 2</U> (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from the Agent set forth on <U>Schedule 2</U>. <U>Schedule
2</U> may be amended from time to time upon notice by the amending party to the other. The Placement Notice shall be effective upon receipt by the Agent unless and until (i)&nbsp;in accordance with the notice requirements set forth in
Section&nbsp;2(a)(iii) of this Agreement, the Agent declines to accept the terms contained therein for any reason, in its sole discretion, (ii)&nbsp;the entire amount of the Shares have been sold, (iii)&nbsp;the Company suspends or terminates the
Placement Notice in accordance with the notice requirements set forth in Section&nbsp;2(a)(iii) below, (iv)&nbsp;the Company issues a subsequent Placement Notice with parameters superseding those on the earlier dated Placement Notice, or
(v)&nbsp;this Agreement has been terminated under the provisions of Section&nbsp;7.&nbsp;The amount of any commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Shares shall be calculated in
accordance with the terms set forth in Section&nbsp;2(a)(v) below. It is expressly acknowledged and agreed that neither the Company nor the Agent will have any obligation whatsoever with respect to a Placement or any Shares unless and until the
Company delivers a Placement Notice to the Agent, and then only upon the terms specified therein and herein and unless and until such time as the Agent declines such Placement Notice pursuant to the terms set forth above.&nbsp;It is expressly
acknowledged and agreed that the Agent may delay sales following delivery of a Placement Notice to the extent necessary to avoid a violation of the provisions of Rule 101(a) of Regulation M applicable to the Shares to be sold pursuant to such
Placement Notice. In the event of a conflict between the terms of this Agreement and the terms of the Placement Notice, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the terms of the Placement Notice will control. For the purposes hereof, <B><I>&#147;Trading Day&#148;</I></B> means any day on which the Company&#146;s Common Stock is purchased and sold on the
Exchange. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Shares are to be sold by the Agent on a daily basis or otherwise as shall be
agreed to by the Company and the Agent on any day that is a Trading Day (other than a day on which the Exchange is scheduled to close prior to its regular weekday closing time). The gross sales price of the Shares sold under this Section&nbsp;2(a)
shall be the market price for the Company&#146;s Common Stock sold by the Agent under this Section&nbsp;2(a) at the time of such sale. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; Notwithstanding the foregoing, the Company may instruct the Agent by telephone (confirmed
promptly by email) not to sell the Shares if such sales cannot be effected at or above the price designated by the Company in any such instruction. Furthermore, the Company shall not authorize the issuance and sale of, and the Agent shall not be
obligated to use its commercially reasonable efforts to sell, any Share at a price lower than the minimum price therefor designated from time to time by the Company&#146;s Board of Directors and notified to the Agent in writing. In addition, the
Company or the Agent may, upon notice to the other party hereto by telephone (confirmed promptly by email), suspend the offering of the Shares, whereupon the Agent shall so suspend the offering of Shares until further notice is provided to the other
party to the contrary; <I>provided</I>, <I>however</I>, that such suspension or termination shall not affect or impair the parties&#146; respective obligations with respect to the Shares sold hereunder prior to the giving of such notice.
Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company and the Agent agree that (i)&nbsp;no sale of
Shares will take place, (ii)&nbsp;the Company shall not request the sale of any Shares, and (iii)&nbsp;the Agent shall not be obligated to sell or offer to sell any Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; Subject to the terms of the Placement Notice, the Agent may sell the Shares by any method
permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on or through the Exchange. Subject to the terms of any Placement Notice, the Agent may also
sell Shares in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices and/or any other method permitted by law, subject to the prior written consent of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp; The compensation to the Agent for sales of the Shares, as an agent of the Company, shall be 3.0% of
the gross sales price of the Shares sold pursuant to this Section&nbsp;2(a), payable in cash (the <B><I>&#147;Sales Commission&#148;</I></B>); <I>provided that</I> the combined Sales Commission and reimbursement of the Agent for its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses pursuant to Section&nbsp;3(g), including reasonable fees and disbursements of the Agent&#146;s counsel, shall not exceed 8.0% of the gross sales price
of the Shares. The remaining proceeds, after further deduction for any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales, and reimbursement of expenses that the Agent may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
be entitled to pursuant to Section&nbsp;3(g), shall constitute the net proceeds to the Company for such Shares (the <B><I>&#147;Net Proceeds&#148;</I></B>). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp; The Agent will provide written confirmation to the Company (including by email correspondence to
each of the individuals of the Company set forth on <U>Schedule 2</U>), no later than the opening of the Trading Day immediately following the Trading Day on which it has made sales of Shares hereunder, setting forth the number of Shares sold on
such day, the volume-weighted average price of the Shares sold, and the Net Proceeds payable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp; All Shares sold pursuant to this Section&nbsp;2(a) will be delivered by the Company to the Agent
for the account of the Agent, against payment of the Net Proceeds therefor, by wire transfer of <FONT STYLE="white-space:nowrap">same-day</FONT> funds payable to the order of the Company at the offices of Piper Sandler&nbsp;&amp; Co., U.S. Bancorp
Center, 800 Nicollet Mall, Minneapolis, Minnesota, or such other location as may be mutually acceptable, at 9:00&nbsp;a.m. Central Time on the second full business day following the date on which such Shares are sold, or at such other time and date
as the Agent and the Company determine pursuant to Rule <FONT STYLE="white-space:nowrap">15c6-1(a)</FONT> under the Exchange Act, each such time and date of delivery being herein referred to as a <B><I>&#147;Settlement Date.&#148;</I></B> If the
Agent so elects, delivery of the Shares may be made by credit through full fast transfer to an account or accounts at The Depository Trust Company designated by the Agent. On each Settlement Date, the Agent will deliver the Net Proceeds in same day
funds to an account designated by the Company on, or prior to, such Settlement Date.&nbsp;The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to timely deliver duly authorized Shares on a
Settlement Date, in addition to and in no way limiting the rights and obligations set forth in Section&nbsp;5&nbsp;hereof, it will (i)&nbsp;hold the Agent harmless against any loss, claim, damage, or expense (including reasonable legal fees and
expenses), as incurred, arising out of or in connection with such default by the Company, (ii)&nbsp;reimburse the Agent for any losses incurred by the Agent attributable, directly or indirectly, to such default and (iii)&nbsp;pay to the Agent any
commission or other compensation to which the Agent would otherwise have been entitled absent such default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;
<I>Maximum Amount</I>. Under no circumstances shall the aggregate number or aggregate value of the Shares sold pursuant to this Agreement exceed: (i)&nbsp;the aggregate number and aggregate dollar amount of shares of Common Stock available for
issuance and sale under the currently effective Registration Statement (including any limit set forth in General Instruction I.B.6 thereof, if applicable), (ii) the aggregate number of authorized but unissued shares of Common Stock that are
available for issuance under the Company&#146;s certificate of incorporation or (iii)&nbsp;the aggregate number or aggregate dollar amount of shares of Common Stock for which the Company has filed the Prospectus in connection with the Shares (the
lesser of (i), (ii) and (iii), the <B><I>&#147;Maximum Amount&#148;</I></B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Association or
Partnership</I>. Nothing herein contained shall constitute the Agent as an unincorporated association or partner with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp; <I>Duration</I>. Under no circumstances shall any Shares be sold
pursuant to this Agreement after the date which is three years after the Registration Statement is first declared effective by the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I> Market Transactions by Agent</I>. The Company acknowledges and agrees that the Agent has informed the Company
that the Agent may, to the extent permitted under the Securities Act, the Exchange Act and this Agreement, purchase and sell shares of Common Stock for its own account while this Agreement is in effect, <I>provided, that</I> (i)&nbsp;no sale for its
own account shall take place while a Placement Notice is in effect (except to the extent the Agent may engage in sales of Shares purchased or deemed purchased from the Company as a &#147;riskless principal&#148; or in a similar capacity) and
(ii)&nbsp;the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent. The Company consents to the Agent trading in the Common Stock for the account of any of its clients at the same time as sales of
the Shares occur pursuant to this Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>3.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Covenants of the Company</I></B>. The Company
covenants and agrees with the Agent as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; <I>Amendments to Registration Statement and Prospectus</I>.
After the date of this Agreement and during any period in which a prospectus relating to any Shares is required to be delivered by the Agent under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to
Rule&nbsp;172 under the Securities Act), the Company agrees that it will: (i)&nbsp;notify the Agent promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference or amendments not
related to the Shares, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus related to the Shares has been filed and of any request by the Commission for any amendment or supplement to the
Registration Statement (insofar as it relates to the transactions contemplated hereby) or Prospectus or for additional information; (ii)&nbsp;prepare and file with the Commission, promptly upon the Agent&#146;s written request, any amendments or
supplements to the Registration Statement or Prospectus that, in the Agent&#146;s reasonable opinion, may be necessary or advisable in connection with the sale of the Shares by the Agent (<I>provided, however</I>, that the failure of the Agent to
make such written request shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#146;s right to rely on the representations and warranties made by the Company in this Agreement); (iii)&nbsp;not file any
amendment or supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Shares unless a copy thereof has been submitted to the Agent within a reasonable period of time before the filing
and the Agent has not reasonably objected thereto (<I>provided, however</I>, that (A)&nbsp;the failure of the Agent to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&#146;s right to
rely on the representations and warranties made by the Company in this Agreement, (B)&nbsp;the Company has no obligation to provide the Agent any advance copy of such filing or to provide the Agent an opportunity to object to such filing if the
filing does not name the Agent or does not relate to a Placement or other transaction contemplated hereunder, and (C)&nbsp;the only remedy that the Agent shall have with respect to the failure by the Company to provide the Agent with such copy or
the filing of such amendment or supplement despite the Agent&#146;s objection shall be to cease making sales under this Agreement); (iv) furnish to the Agent at the time of filing thereof a copy of any
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (v)&nbsp;cause each
amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; <I>Stop Order</I>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge
thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, or of the
initiation or threatening of any proceeding for any such purpose, and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; <I>Continuing Amendments</I>. During any period in which a prospectus relating to the Shares is required to be
delivered by the Agent under the Securities Act with respect to any Placement or pending sale of the Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will comply
with all requirements imposed upon it by the Securities Act, as from time to time in force, and file on or before their respective due dates all reports (taking into account any extensions available under the Exchange Act) and any definitive proxy
or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. If during such period any event occurs as a result of which the
Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during
such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Shares during such period and the Company will
promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp; <I>Qualification of the Shares</I>. The Company shall take or cause to be taken all necessary action to qualify
the Shares for sale under the securities laws of such jurisdictions as the Agent reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Shares, except that the Company shall not be
required in connection therewith to qualify as a foreign corporation or to execute a general consent to service of process in any jurisdiction. The Company shall promptly advise the Agent of the receipt by the Company of any notification with
respect to the suspension of the qualification of the Shares for offer or sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp; <I>Copies of Registration Statement and Prospectus</I>. The Company will furnish to the Agent and counsel for the
Agent copies of the Registration Statement (which will include three complete manually signed copies of the Registration Statement and all consents and exhibits filed therewith), the Prospectus and all amendments and supplements to such documents,
in each case as soon as available and in such quantities as the Agent may from time to time reasonably request; <I>provided, however</I>, that the Company shall not be required to furnish any document to the extent such document is available on
EDGAR. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp; <I>Section</I><I></I><I>&nbsp;11(a)</I>. The Company will make
generally available to its security holders as soon as practicable an earnings statement (which need not be audited) covering a <FONT STYLE="white-space:nowrap">12-month</FONT> period that shall satisfy the provisions of Section&nbsp;11(a) of the
Securities Act and Rule&nbsp;158 promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp; <I>Expenses</I>. The Company, whether or not the
transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid (i)&nbsp;all expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred
in connection with the registration, issue, sale and delivery of the Shares, (ii)&nbsp;all expenses and fees (including, without limitation, fees and expenses of the Company&#146;s accountants and counsel) in connection with the preparation,
printing, filing, delivery, and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto), the Shares, the Prospectus and any amendment thereof or supplement thereto, and
the producing, word-processing, printing, delivery, and shipping of this Agreement and other transaction documents or closing documents, including Blue Sky Memoranda (covering the states and other applicable jurisdictions) and including the cost to
furnish copies of each thereof to the Agent, (iii)&nbsp;all filing fees, (iv)&nbsp;all reasonable fees and disbursements of the Agent&#146;s counsel incurred in connection with the qualification of the Shares for offering and sale by the Agent or by
dealers under the securities or blue sky laws of the states and other jurisdictions which the Agent shall designate, (v)&nbsp;the fees and expenses of any transfer agent or registrar, (vi)&nbsp;the filing fees and reasonable fees and disbursements
of the Agent&#146;s counsel incident to any required review and approval by FINRA of the terms of the sale of the Shares, (vii)&nbsp;listing fees, if any, (viii)&nbsp;the cost and expenses of the Company relating to investor presentations or any
&#147;roadshow&#148; undertaken in connection with marketing of the Shares, and (ix)&nbsp;all other reasonable costs and expenses incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein. In
addition to (iv)&nbsp;and (vi) above, the Company shall reimburse the Agent for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including reasonable fees and disbursements of the
Agent&#146;s counsel in connection with this Agreement, the Registration Statement and the Prospectus; provided that such fees and disbursements shall not exceed: (A) $75,000 in connection with the execution of this Agreement and the filing of the
Registration Statement and Prospectus (which shall include any fees and disbursements of Agent&#146;s counsel pursuant to Sections 3(g)(iv) and 3(g)(vi) hereof), and (B) $15,000 in connection with each Representation Date on which a Representation
Certificate is delivered pursuant to Section&nbsp;3(q) below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp; <I>Use of Proceeds</I>. The Company will apply
the net proceeds from the sale of the Shares in the manner described in the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp; <I>Restrictions on
Future Sales</I>. Without the written consent of the Agent, the Company will not offer for sale, sell, contract to sell, pledge, grant any option for the sale of, enter into any transaction which is designed to, or might reasonably be expected to,
result in the disposition of Common Stock (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the Company or any affiliate, or otherwise issue or dispose of, directly or indirectly (or publicly
disclose the intention to make any such offer, sale, pledge, grant, issuance or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other disposition), any Common Stock or any securities convertible into or exchangeable for, or any options or rights to purchase or acquire, Common Stock, or permit the registration under the
Securities Act of any Common Stock, such securities, options or rights during the period beginning on the Trading Day immediately prior to the date on which any Placement Notice is delivered to the Agent hereunder and ending on the Trading Day
immediately following the Settlement Date with respect to Shares sold pursuant to such Placement Notice; <I>provided, however</I>, that such restrictions shall not apply to: (i)&nbsp;the registration of the Shares and the sales through the Agent
pursuant to this Agreement, (ii)&nbsp;any transaction in which the Agent is a participant or acting as an advisor to or agent of the Company or in some similar capacity, (iii)&nbsp;sales of Common Stock through any dividend reinvestment and stock
purchase plan of the Company, (iv)&nbsp;restricted stock, restricted stock units, options and other awards granted pursuant to Specified Equity Plans, the Common Stock issuable upon the exercise of such options, the vesting of such restricted stock
or restricted stock units or the exercise or vesting of any such other awards, (v)&nbsp;the filing of registration statements on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> (vi) the issuance or sale of Common Stock issuable upon exchange,
conversion or redemption of securities or the exercise or vesting of warrants or options, in each case described in the Registration Statement and Prospectus; (vii)&nbsp;modification of any such securities, options or warrants, (viii)&nbsp;issuances
or sales of Common Stock in connection with any research and development collaborations or similar transactions, provided that number of shares of Common Stock issued in such transactions is equal to or less than 5% of the Company&#146;s outstanding
capital stock as of the date of such issuance, or (ix)&nbsp;the issuance of securities in connection with an acquisition, merger or sale or purchase of assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Stabilization or Manipulation</I>. The Company has not taken and will not take, directly or indirectly, any
action designed to, or which might reasonably be expected to cause or result in, or which constitutes: (i)&nbsp;the stabilization or manipulation of the price of the Common Stock or any other security of the Company to facilitate the sale or resale
of the Shares, (ii)&nbsp;a violation of Regulation M. The Company shall notify the Agent of any violation of Regulation M by the Company or any of its officers or directors promptly after the Company has received notice or obtained knowledge of any
such violation. The Company shall not invest in futures contracts, options on futures contracts or options on commodities, unless the Company is exempt from the registration requirements of the Commodity Exchange Act, as amended (the
<B><I>&#147;Commodity Act&#148;</I></B>), or otherwise complies with the Commodity Act. The Company will not engage in any activities bearing on the Commodity Act, unless such activities are exempt from the Commodity Act or otherwise comply with the
Commodity Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Other Broker</I>. Except as contemplated by this Agreement, the Company will not incur
any liability for any finder&#146;s or broker&#146;s fee or agent&#146;s commission in connection with the execution and delivery of this Agreement, or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp; <I>Timely Securities Act and Exchange Act Reports</I>. During any prospectus delivery period with respect to the
Shares, the Company will use its commercially reasonable efforts to file on a timely basis with the Commission such periodic and special reports as required by the Securities Act and the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp; <I>Internal Controls</I>. The Company will maintain controls and
other procedures, including without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 and the applicable regulations thereunder, that are designed to ensure that information required to be disclosed by the Company
in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including without limitation, controls and procedures designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#146;s management, including its principal executive officer and its
principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that material information relating to the Company is made known to them by others within those
entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp; <I>Permitted Free Writing Prospectus</I>. The Company represents and agrees that it has not made
and, unless it obtains the prior written consent of the Agent, will not make, and the Agent represents that it has not made and agrees that, unless it obtains the prior written consent of the Company, it will not make any offer relating to the
Shares that would constitute an &#147;issuer free writing prospectus,&#148; as defined in Rule 433 under the Securities Act, or that would otherwise constitute a &#147;free writing prospectus,&#148; as defined in Rule 405 under the Securities Act,
required to be filed with the Commission. Any such free writing prospectus consented to by the Company and the Agent is hereinafter referred to as a <B><I>&#147;</I></B><B><I>Permitted Free Writing Prospectus.</I></B><B><I>&#148;</I></B> The Company
represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an &#147;issuer free writing prospectus,&#148; as defined in Rule 433, and has complied and will comply with the requirements of Rule 433
applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record keeping. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp; <I>Representation Date and Opinions of Counsel</I>. On or prior to the date of the first Placement Notice, and
thereafter during the term of this Agreement, each time the Company (A)&nbsp;files an amendment to the Registration Statement or Prospectus (other than relating solely to the offering of securities other than the Shares), (B) files an Annual Report
on Form <FONT STYLE="white-space:nowrap">10-K</FONT> under the Exchange Act or files its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> under the Exchange Act; and (C)&nbsp;files a report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> containing amended financial statements (other than an earnings release) under the Exchange Act (each of the dates in (A), (B) and (C)&nbsp;are referred to herein as a <B><I>&#147;Representation
Date&#148;</I></B>), the Company shall cause Covington&nbsp;&amp; Burling LLP, counsel for the Company, to furnish to the Agent the opinion and negative assurance statement of such counsel, dated as of such date and addressed to the Agent, in form
and substance reasonably satisfactory to the Agent; <I>provided, however</I>, only a negative assurance statement of such counsel shall be required for each subsequent Representation Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the requirement to provide counsel opinions under this Section&nbsp;3(o)&nbsp;shall be waived for any
Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the date the Company delivers a Placement Notice to the Agent.&nbsp;Notwithstanding the foregoing, if the Company subsequently decides
to sell Shares following a Representation Date when the Company relied on such waiver and did not provide the Agent with opinions under this Section&nbsp;3(o), then before the Agent sells any Shares pursuant to Section&nbsp;2(a), the Company shall
cause the opinions (including the opinion pursuant to Section&nbsp;3(o) if not delivered on the date of the prior Form <FONT STYLE="white-space:nowrap">10-K),</FONT> comfort letter, certificates and documents that would be delivered on a
Representation Date to be delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp; <I>Representation Date and</I> <I>Comfort Letter</I>. On or
prior to the date of the first Placement Notice and thereafter during the term of this Agreement, on each Representation Date to which a waiver does not apply, the Company shall cause RSM US LLP, or other independent accountants reasonably
satisfactory to the Agent (the <B><I>&#147;</I></B><B><I>Accountants</I></B><B><I>&#148;</I></B>), to deliver to the Agent a letter, dated as of such date and addressed to the Agent, confirming that they are independent public accountants within the
meaning of the Securities Act and are in compliance with the applicable requirements relating to the qualifications of accountants under <FONT STYLE="white-space:nowrap">Rule&nbsp;2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT>
of the Commission, and stating the conclusions and findings of said firm with respect to the financial information and other matters covered by its letter in form and substance satisfactory to the Agent of the same tenor as the first such letter
received hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp; <I>Representation Date and Representation Certificate</I>. On or prior to the date of the
first Placement Notice and thereafter during the term of this Agreement, on each Representation Date to which a waiver does not apply, the Company shall furnish to the Agent a certificate (the <B><I>&#147;</I></B><B><I>Representation
Certificate</I></B><B><I>&#148;</I></B>), substantially in the form of <U>Schedule 3</U> hereto and dated as of such date, addressed to the Agent and signed by the chief executive officer and the principal financial officer or principal accounting
officer of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp; <I>Disclosure of Shares Sold</I>. The Company shall disclose in its Quarterly Reports
on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> the number of the Shares sold through the Agent under this Agreement, the net proceeds to the Company and the
compensation paid by the Company with respect to sales of the Shares pursuant to this Agreement during the relevant quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp; <I>Continued Listing of Shares</I>. The Company shall use its commercially reasonable efforts to maintain the
listing of the Common Stock on the Exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp; <I>Notice of Changes</I>. At any time during the term of this
Agreement, as supplemented from time to time, the Company shall advise the Agent as soon as practicable after it shall have received notice or obtained knowledge of any information or fact that would alter or affect any opinion, certificate, letter
or other document provided to the Agent pursuant to this Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp; <I>Maximum Amount</I>. The Company
will not instruct the Agent to sell or otherwise attempt to sell Shares pursuant to this Agreement in excess of the Maximum Amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp; <I>Principal Accounting Officer Certificate.</I> Prior to the date of the first Placement Notice and thereafter
during the term of this Agreement, on each Representation Date to which a waiver does not apply, the Company shall furnish to the Agent a certificate, dated the date of such Representation Date and addressed to the Agent, of its principal financial
officer or principal accounting officer with respect to certain portions of such information contained in the Prospectus, providing &#147;management comfort&#148; with respect to such information, in form and substance reasonably satisfactory to the
Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>4.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Conditions of Agent&#146;s
Obligations</I></B>. The obligations of the Agent hereunder are subject to (i)&nbsp;the accuracy, as of the date of this Agreement, each Representation Date, each Notice Date, each Applicable Time, and each Settlement Date (in each case, as if made
at such date) of and compliance with all representations, warranties and agreements of the Company contained herein, (ii)&nbsp;the performance by the Company of its obligations hereunder and (iii)&nbsp;the following additional conditions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; <I>Continuing Amendments; No Stop Order</I>. If filing of the Prospectus, or any amendment or supplement thereto,
or any Permitted Free Writing Prospectus, is required under the Securities Act, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted Free Writing Prospectus with the Commission in the manner and within the
time period so required (without reliance on Rule 424(b)(8) or Rule 164(b) under the Securities Act); the Registration Statement shall be effective; no stop order suspending the effectiveness of the Registration Statement or any part thereof, any
registration statement filed pursuant to Rule 462(b) under the Securities Act, or any amendment thereof, nor suspending or preventing the use of the Prospectus shall have been issued; no proceedings for the issuance of such an order shall have been
initiated or, to the knowledge of the Company, threatened; and any request of the Commission for additional information (to be included in the Registration Statement, the Prospectus or otherwise) shall have been complied with to the Agent&#146;s
satisfaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Absence of Certain Events</I>. None of the following events shall have occurred and be
continuing: (i)&nbsp;receipt by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which
would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii)&nbsp;the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness
of the Registration Statement or the initiation of any proceedings for that purpose; (iii)&nbsp;receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Shares for
sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv)&nbsp;the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material document
incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related Prospectus or such documents so that, in the case of the Registration
Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus, it will
not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Misstatement or Omission</I>. The Agent shall not have advised the Company in
writing that the Registration Statement or the Prospectus contains an untrue statement of fact which, in the Agent&#146;s opinion, is material, or omits to state a fact which, in the Agent&#146;s opinion, is material and is required to be stated
therein or necessary to make the statements therein not misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Adverse Changes</I>. Except as contemplated in the
Prospectus, subsequent to the respective dates as of which information is given in the Prospectus, the Company shall not have incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions, or
declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there shall not have been any change in the capital stock (other than a change in the number of outstanding shares of Common Stock due to the
issuance of shares of Common Stock upon the exercise or vesting of outstanding options or warrants or awards granted pursuant to any Specified Equity Plan), or any material change in the <FONT STYLE="white-space:nowrap">short-term</FONT> or <FONT
STYLE="white-space:nowrap">long-term</FONT> debt of the Company, or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company (other than pursuant to a Specified Equity Plan), or any
Material Adverse Effect (whether or not arising in the ordinary course of business, or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company, the effect of which, in any
such case described above, in the Agent&#146;s reasonable judgment, makes it impractical or inadvisable to offer or deliver the Shares on the terms and in the manner contemplated in the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp; <I>No Rated Securities</I>. There are no debt securities or preferred shares issued, or guaranteed, by the Company
that are rated by a &#147;nationally recognized statistical rating organization,&#148; as such term is defined in Section&nbsp;3(a)(62) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp; <I>Compliance with Certain Obligations</I>. The Company shall have performed each of its obligations under
Sections 3(o) &#150; 3(q) and Section&nbsp;3(v). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp; <I>Opinion of Agent Counsel</I>. On each Representation Date
to which a waiver does not apply, there shall have been furnished to the Agent the opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Agent, dated as of such Representation Date and
addressed to the Agent, in a form reasonably satisfactory to the Agent, and such counsel shall have received such papers and information as they request to enable them to pass upon such matters; <I>provided, however</I>, the opinion of Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C. shall only be required prior to the first Placement Notice, and thereafter, only a negative assurance letter of such counsel shall be required for each subsequent Representation Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representation Certificate</I>. On or prior to the first Placement Notice, the Agent shall have received the
Representation Certificate in form and substance satisfactory to the Agent and its counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Objection by
FINRA</I>. FINRA shall have raised no objection to the fairness and reasonableness of the compensation terms and arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp; <I>Timely Filing of Prospectus and Prospectus Supplement</I>. All filings with the Commission required by Rule 424
under the Securities Act to have been filed by the Settlement Date, as the case may be, shall have been made within the applicable time period prescribed for such filing by Rule 424 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp; <I>Additional Documents and Certificates</I>. The Company shall
have furnished to the Agent and the Agent&#146;s counsel such additional documents, certificates and evidence as they may have reasonably requested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All opinions, certificates, letters and other documents described in this Section&nbsp;4 will be in compliance with the provisions hereof only
if they are reasonably satisfactory in form and substance to the Agent and the Agent&#146;s counsel. The Company will furnish the Agent with such conformed copies of such opinions, certificates, letters and other documents as the Agent shall
reasonably request. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>5.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Indemnification and Contribution</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Company Indemnification</I>. The Company agrees to indemnify and hold harmless the Agent, its affiliates,
directors, officers and employees, and each person, if any, who controls the Agent within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act against any losses, claims, damages or liabilities, joint or
several, to which the Agent may become subject, under the Securities Act or otherwise (including in settlement of any litigation), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon,
in whole or in part: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;an untrue statement or alleged untrue statement of a material fact contained in the
Registration Statement, including the Rule 430B Information (as defined below) and at any subsequent time pursuant to Rules&nbsp;430A and 430B promulgated under the Securities Act, and any other information deemed to be part of the Registration
Statement at the time of effectiveness, and at any subsequent time pursuant to the Securities Act or the Exchange Act, and the Prospectus, or any amendment or supplement thereto (including any documents filed under the Exchange Act and deemed to be
incorporated by reference into the Prospectus), any Permitted Free Writing Prospectus, or any roadshow as defined in Rule 433(h) under the Securities Act (a <B><I>&#147;road show&#148;</I></B>), or an omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements therein not misleading, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;any
inaccuracy in the representations and warranties of the Company contained herein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp; any investigation or
proceeding by any governmental authority, commenced or threatened (whether or not the Agent is a target of or party to such investigation or proceeding); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp; any failure of the Company to perform its respective obligations hereunder or under law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and will reimburse the Agent for any legal or other expenses reasonably incurred and documented by it in connection with investigating or defending against
such loss, claim, damage, liability or action; <I>provided, however,</I> that the Company shall not be liable in any such case of (i)&nbsp;through (iv) to the extent that any such loss, claim, damage, liability or action arises out of or is based
upon an untrue statement or alleged untrue statement or omission or alleged omission made in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration Statement, the Prospectus, or any such amendment or supplement, in reliance upon and in conformity with written information furnished to the Company by the Agent specifically for use
in the preparation thereof. <B><I>&#147;Rule 430B Information,&#148;</I></B> as used herein, means information with respect to the Shares and the offering thereof permitted to be omitted from the Registration Statement when it becomes effective
pursuant to Rule 430B. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In addition to its other obligations under this Section&nbsp;5(a), the Company agrees that, as an interim measure
during the pendency of any claim, action, investigation, inquiry or other proceeding arising out of or based upon any statement or omission, or any alleged statement or omission, described in this Section&nbsp;5(a), it will reimburse the Agent on a
monthly basis for all reasonable and documented legal fees or other expenses incurred in connection with investigating or defending any such claim, action, investigation, inquiry or other proceeding, notwithstanding the absence of a judicial
determination as to the propriety and enforceability of the Company&#146;s obligation to reimburse the Agent for such expenses and the possibility that such payments might later be held to have been improper by a court of competent jurisdiction. Any
such interim reimbursement payments which are not made to the Agent within 30 days of a request for reimbursement shall bear interest at the WSJ Prime Rate (as published from time to time by the Wall Street Journal). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; <I>Agent Indemnification</I>. The Agent will indemnify and hold harmless the Company, its directors, its officers
who sign the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act against any losses, claims, damages or liabilities to which the
Company may become subject, under the Securities Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Agent), but only insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Prospectus, any amendment or supplement thereto, or arise out of or are based
upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or
alleged untrue statement or omission or alleged omission was made in conformity with written information furnished to the Company by the Agent specifically for use in the preparation thereof, it being understood and agreed that the only information
furnished by the Agent for use in the Registration Statement or the Prospectus consists of the statements set forth in the eighth paragraph under the caption &#147;Plan of Distribution&#148; in the Prospectus, and will reimburse the Company for any
legal or other expenses reasonably incurred by the Company in connection with investigating or defending against any such loss, claim, damage, liability or action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; <I>Notice and Procedures</I>. Promptly after receipt by an indemnified party under subsection (a)&nbsp;or (b)
above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof;
but the omission so to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure.
In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in, and, to the extent that it shall wish,
jointly with any other indemnifying party similarly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified party of the indemnifying
party&#146;s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection with the
defense thereof other than reasonable costs of investigation; <I>provided</I>, <I>however</I>, that if, in the sole judgment of the Agent, it is advisable for the Agent to be represented by separate counsel, the Agent shall have the right to employ
a single counsel to represent the Agent, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the Agent as incurred (in accordance with the provisions of the
second paragraph in subsection (a)&nbsp;above). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The indemnifying party under this Section&nbsp;5 shall not be liable for any settlement
of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability
or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by this Section&nbsp;5, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by such
indemnifying party of the aforesaid request, (ii)&nbsp;such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement being entered into, and (iii)&nbsp;such indemnifying party shall not
have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the
entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such
settlement, compromise or consent (a)&nbsp;includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and (b)&nbsp;does not include a statement as to or an
admission of fault, culpability or a failure to act by or on behalf of any indemnified party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;
<I>Contribution; Limitations on Liability; <FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedy</I>. If the indemnification provided for in this Section&nbsp;5 is unavailable or insufficient to hold harmless an indemnified party under
subsection&nbsp;(a) or (b)&nbsp;above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection&nbsp;(a) or
(b)&nbsp;above, (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Agent on the other from the offering of the Shares, or (ii)&nbsp;if the allocation provided by
clause&nbsp;(i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company on the one hand and the Agent on
the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the
Agent on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total commissions received by the Agent (before deducting expenses) from the
sale of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the
Agent agree that it would not be just and equitable if contributions pursuant to this subsection&nbsp;(d) were to be determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations
referred to in this subsection&nbsp;(d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities referred to in this subsection&nbsp;(d) shall be deemed to include any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating or defending against any action or claim which is the subject of this subsection&nbsp;(d). Notwithstanding the provisions of this subsection&nbsp;(d), the Agent shall not
be required to contribute any amount in excess of the commissions received by it under this Agreement. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>6.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;
<B><I>Representations and Agreements to Survive Delivery</I></B>. All representations, warranties, and agreements of the Company herein or in certificates delivered pursuant hereto, including but not limited to the agreements of the Agent and the
Company contained in Section&nbsp;5 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the Agent or any controlling person thereof, or the Company or any of its officers, directors, or
controlling persons, and shall survive delivery of, and payment for, the Shares to and by the Agent hereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>7.&nbsp;&nbsp;&nbsp;&nbsp; Termination of this Agreement. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; The Company shall have the right, by giving three (3)&nbsp;days&#146; written notice as hereinafter specified, to
terminate the provisions of this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party except that (i)&nbsp;with
respect to any pending sale, through the Agent for the Company, the obligations of the Company, including in respect of compensation of the Agent, shall remain in full force and effect notwithstanding the termination and (ii)&nbsp;the provisions of
Section&nbsp;3(g), Section&nbsp;5 and Section&nbsp;6 of this Agreement shall remain in full force and effect notwithstanding such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; The Agent shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of
this Agreement relating to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability of any party to any other party except that the provisions of Section&nbsp;3(g),
Section&nbsp;5 and Section&nbsp;6 of this Agreement shall remain in full force and effect notwithstanding such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; Unless earlier terminated pursuant to this Section&nbsp;7, this Agreement shall automatically terminate upon the
earlier to occur of the issuance and sale of all of the Shares through the Agent on the terms and subject to the conditions set forth herein, except that the provisions of Section&nbsp;3(g), Section&nbsp;5 and Section&nbsp;6 of this Agreement shall
remain in full force and effect notwithstanding such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp; This Agreement shall remain in full force and effect unless
terminated pursuant to Sections 7(a), (b) or (c)&nbsp;above or otherwise by mutual agreement of the parties; provided that any such termination by mutual agreement shall in all cases be deemed to provide that Section&nbsp;3(g), Section&nbsp;5 and
Section&nbsp;6 shall remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp; Any termination of this Agreement shall be effective on
the date specified in such notice of termination; provided that such termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as the case may be. If such termination shall
occur prior to the Settlement Date for any sale of the Shares, such sale shall settle in accordance with the provisions of Section&nbsp;2(a)(vii) of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>8.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Default by the Company</I></B>. If the Company shall fail at any Settlement Date to sell and
deliver the number of Shares which it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of the Agent or, except as provided in Section&nbsp;3(g) hereof, any
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> party. No action taken pursuant to this Section shall relieve the Company from liability, if any, in respect of such default, and the Company shall (A)&nbsp;hold the Agent harmless against any
loss, claim or damage arising from or as a result of such default by the Company and (B)&nbsp;pay the Agent any commission to which it would otherwise be entitled absent such default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>9.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> Notices</I></B>. Except as otherwise provided herein, all communications under this Agreement
shall be in writing and, if to the Agent, shall be delivered via overnight delivery services to (i)&nbsp;Piper Sandler&nbsp;&amp; Co., U.S. Bancorp Center, 800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, with a
copy to Piper Sandler General Counsel at 800 Nicollet Mall, Minneapolis, MN 55402 and [***]; and (ii)&nbsp;the Company at Alaunos Therapeutics, Inc., 8030 El Rio Street, Houston, TX 77054, Attention: Legal Counsel and [***], with a copy to
Covington&nbsp;&amp; Burling LLP, 620 Eighth Avenue, New York, NY 10018, Attention: Brian K. Rosenzweig and [***]; or in each case to such other address as the person to be notified may have requested in writing. Any party to this Agreement may
change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>10.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Persons Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section&nbsp;5. Nothing in this Agreement is intended or shall be construed to give to any other
person, firm or corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained. The term &#147;successors and assigns&#148; as herein used shall not include any purchaser, as such
purchaser, of any of the Shares from the Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>11.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Absence of Fiduciary
Relationship</I></B>. The Company, having been advised by counsel, acknowledges and agrees that: (a)&nbsp;the Agent has been retained solely to act as a sales agent in connection with the sale of the Shares and that no fiduciary, advisory or agency
relationship between the Company (including any of the Company&#146;s affiliates (including directors), equity holders, creditors, employees or agents, hereafter, <B><I>&#147;Company Representatives&#148;</I></B>), on the one hand, and the Agent on
the other, has been created or will be created in respect of any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the transactions contemplated by this Agreement, irrespective of whether the Agent has advised or is advising the Company on other matters and irrespective of the use of the defined term
&#147;Agent;&#148; (b) neither the Agent nor any of its affiliates (including directors), equity holders, creditors, employees or agents (hereafter, <B><I>&#147;Agent Representatives&#148;</I></B>) shall have any duty or obligation to the Company or
any Company Representative except as set forth in this Agreement; (c)&nbsp;the price and other terms of any Placement executed pursuant to this Agreement, as well as the terms of this Agreement, are deemed acceptable to the Company and its counsel,
following discussions and <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations with the Agent; (d)&nbsp;the Company is capable of evaluating and understanding, and in fact has evaluated, understands and accepts the terms, risks and
conditions of any Placement Notice to be executed pursuant to this Agreement, and any other transactions contemplated by this Agreement; (e)&nbsp;the Company has been advised that the Agent and the Agent Representatives are engaged in a broad range
of transactions which may involve interests that differ from those of the Company and that the Agent and the Agent Representatives have no obligation to disclose any such interests and transactions to the Company by virtue of any fiduciary, advisory
or agency relationship, or otherwise; (f)&nbsp;the Company has been advised that the Agent is acting, in respect of any Placement and the transactions contemplated by this Agreement, solely for the benefit of the Agent, and not on behalf of the
Company; and (g)&nbsp;the Company and the Company Representatives waive, to the fullest extent permitted by law, any claims that they may have against the Agent or any of the Agent Representatives for breach of fiduciary duty or alleged breach of
fiduciary duty in respect of any Placement or any of the transactions contemplated by this Agreement and agree that the Agent and the Agent Representatives shall have no liability (whether direct or indirect, in contract, tort or otherwise) to the
Company or any of the Company Representatives in respect of any person asserting any claim of breach of any fiduciary duty on behalf of or in right of the Company or any of the Company Representatives. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>12.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Recognition of the U.S. Special Resolution Regimes</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp; In the event that the Agent qualifies as a Covered Entity and becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from the Agent of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; In the event that the Agent qualifies as a Covered Entity and becomes subject, or a BHC Act Affiliate of the Agent
becomes subject, to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Agent are permitted to be exercised to no greater extent than such Default Rights could be exercised under
the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp; As used in this section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;BHC Act Affiliate&#148;</I></B> has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in
accordance with, 12 U.S.C. &#167; 1841(k); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Covered Entity&#148;</I></B> means any of the following: (i)&nbsp;a
&#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or
(iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Default Right&#148;</I></B> has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;U.S. Special Resolution Regime&#148;</I></B> means each of
(i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>13.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> Governing Law and Waiver of Jury Trial</I></B>. This Agreement and any transaction
contemplated by this Agreement and any claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would
results in the application of any other law than the laws of the State of New York. THE COMPANY (ON ITS OWN BEHALF AND ON BEHALF OF ITS STOCKHOLDERS AND AFFILIATES) HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>14.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> Submission to Jurisdiction, Etc.</I></B> Each party hereby submits to the exclusive
jurisdiction of the U.S. federal and New York state courts sitting in the Borough of Manhattan, City of New York, in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The parties hereby
irrevocably and unconditionally waive any objection to the laying of venue of any lawsuit, action or other proceeding in such courts, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any
such lawsuit, action or other proceeding brought in any such court has been brought in an inconvenient forum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>15.</I></B>&nbsp;&nbsp;&nbsp;&nbsp; <B><I>Counterparts</I></B>. This Agreement may be executed in counterparts, each of which shall be
deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile or electronic mail (including, without limitation, &#147;pdf&#148;, &#147;tif&#148; or &#147;jpg&#148;) and any
counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>16.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;<B><I> Construction.</I></B> The section and exhibit&nbsp;headings herein are for convenience only
and shall not affect the construction hereof. References herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed to refer to such law, statute, ordinance, code, regulation,
rule or other requirement of any governmental authority as amended, reenacted, supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated thereunder. This Agreement constitutes
the entire agreement of the parties to this Agreement and supersedes all prior written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may not be amended or modified unless in writing by all
of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Pages Follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Please sign and return to the Company the enclosed duplicates of this letter whereupon this
letter will become a binding agreement between the Company and the Agent in accordance with its terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>ALAUNOS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kevin S. Boyle, Sr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confirmed as of the date first</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">above mentioned.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>PIPER SANDLER&nbsp;&amp; CO.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Bassett</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Bassett</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;OF PLACEMENT NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>No Facsimile and No Voicemail </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">From:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Alaunos Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention:</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil A. Riley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael W. Bassett</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Connor N. Anderson</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tom Wright</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***]</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay A. Hershey</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">[***]</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[&#9679;], 20[&#9679;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Subject:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Equity Distribution Agreement &#150; Placement Notice</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gentlemen:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms and subject to the conditions contained in the Equity Distribution Agreement between Alaunos
Therapeutics, Inc. ( &#147;<B>Company</B>&#148;), and Piper Sandler&nbsp;&amp; Co. ( &#147;<B>Agent</B>&#148;) dated August&nbsp;12, 2022 (the &#147;<B>Agreement</B>&#148;),&nbsp;the Company hereby requests that Agent sell up to [&#9679;] shares of
the Company&#146;s common stock, par value $0.001 per share, at a minimum market price of $[&#9679;] per share.&nbsp;Sales should begin on the date of this Placement Notice and shall continue until [&#9679;] /[all shares are sold]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE PARTIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alaunos Therapeutics,
Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kevin S. Boyle, Sr. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael Wong </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Piper Sandler&nbsp;&amp; Co. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neil A. Riley </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael W. Bassett </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Connor N. Anderson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tom Wright </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay A. Hershey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF REPRESENTATION CERTIFICATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 3(q) OF THE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Date] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper Sandler&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, MN 55402 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sir: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned, the duly qualified and elected [&#9679;]
and [&#9679;], of Alaunos Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), do hereby certify in such capacities and on behalf of the Company, pursuant to <U>Section</U><U></U><U>&nbsp;3(q)</U> of the Equity Distribution
Agreement, dated August&nbsp;12, 2022 (the &#147;<B>Equity Distribution Agreement</B>&#148;), between the Company and Piper Sandler&nbsp;&amp; Co., that to the best of their respective knowledge: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the representations and warranties of the Company in the Equity Distribution Agreement are true and correct, in all material
respects, as if made at and as of the date of the certificate, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the date of the certificate; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;no stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment
thereof or the qualification of the Shares for Registration Statement, nor suspending or preventing the use of the Prospectus or any Permitted Free Writing Prospectus, has been issued, and, to the Company&#146;s knowledge, no proceeding for that
purpose has been instituted or is contemplated by the Commission or any state or regulatory body; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;the Shares have been duly
and validly authorized by the Company and all corporate action required to be taken for the authorization, issuance and sale of the Shares has been validly and sufficiently taken; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;the Registration Statement, the Prospectus and any Permitted Free Writing Prospectus, and any amendments thereof or supplements
thereto (including any documents filed under the Exchange Act and deemed to be incorporated by reference therein), comply in all material respects with the requirements of the Securities Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;each part of the Registration Statement and the Prospectus, or any amendment thereof or supplements thereto (including any
documents filed under the Exchange Act and deemed to be incorporated by reference therein) does not contain as of the date hereof, and did not contain, when such part of the Registration Statement (or such amendment) became effective, any untrue
statement of a material fact or omit to state, as of the date hereof, and did not omit to state, when such part of the Registration Statement (or such amendment) became effective, any material fact required to be stated therein or necessary to make
the statements therein not misleading; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;the Prospectus, as amended or supplemented, does not include as of the date
hereof, and did not include as of its date, or the time of first use within the meaning of the Securities Act, any untrue statement of a material fact or omit to state, as of the date hereof, and did not omit to state, as of its date, or the time of
first use within the meaning of the Securities Act, a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;except as stated in the Prospectus or any Permitted Free Writing Prospectus, the Company has not incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions, not in the ordinary course of business, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock, and except
as disclosed in the Prospectus and any Permitted Free Writing Prospectus, there has not been any material change in the capital stock (other than a change in the number of outstanding Common Stock due to sales of Shares pursuant to the Equity
Distribution Agreement and the issuance of shares of Common Stock upon the exercise or vesting of outstanding options or warrants or awards granted pursuant to any Specified Equity Plan), or any material change in the short-term or long-term debt of
the Company, any Material Adverse Effect (whether or not arising in the ordinary course of business) or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;except as stated in the base prospectus, the Prospectus, and any Permitted Free Writing Prospectus, there is not pending, or, to
the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company is a party before or by any court or governmental agency, authority or body, or any arbitrator, which, if determined adversely to the
Company, would reasonably be expected to result in a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Capitalized terms used herein without definition shall have
the meanings given to such terms in the Equity Distribution Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>d286456dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION OF ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Pursuant to Section&nbsp;242 of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>General Corporation Law of the State of Delaware) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the General
Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law proposing this
Amendment of the Amended and Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Amended and Restated Certificate of Incorporation, and authorizing the appropriate officers of the Corporation to solicit the
approval of the stockholders therefor, which resolution setting forth the proposed amendment is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESOLVED: </B>that the first paragraph of
section four of the Amended and Restated Certificate of Incorporation of the Corporation, as amended, be and it hereby is, deleted in its entirety and the following paragraph is inserted in lieu thereof: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;4. Number of Shares. The total number of shares of all classes of stock that the Corporation shall have authority to issue is Four Hundred Fifty Million
(450,000,000) shares consisting of: Four Hundred Twenty Million (420,000,000) shares of common stock, $0.001 par value per share (&#147;Common Stock&#148;); and Thirty Million (30,000,000) shares of preferred stock, $0.001 par value per share
(&#147;Preferred Stock&#148;).&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. This Certificate of Amendment of the Amended and Restated Certificate of Incorporation has been duly adopted by
the stockholders of the Corporation in accordance with the provisions of Section&nbsp;242 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of
page intentionally blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF, </B>this Corporation has caused this Certificate of Amendment of the Amended and
Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 16th day of June, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin S. Boyle, Sr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND
RESTATED CERTIFICATE OF INCORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZIOPHARM ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZIOPHARM Oncology, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the
General Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The name of the Corporation is ZIOPHARM Oncology, Inc., formerly known as EasyWeb, Inc. The date of filing of its original Certificate of
Incorporation with the Secretary of State was May&nbsp;16, 2005. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. This Certificate of Amendment amends the provisions of the
Corporation&#146;s Amended and Restated Certificate of Incorporation filed with the Secretary of State on April&nbsp;26, 2006, as amended (the &#147;Certificate of Incorporation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.<B> </B>Article 1 of the Certificate of Incorporation is hereby amended and restated to read as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#147;1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Name.</I> The name of the corporation is Alaunos Therapeutics, Inc. (the &#147;Corporation&#148;).&#148;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.<B> </B>This Certificate of Amendment has been duly adopted in accordance with the provisions of Section&nbsp;242 of
the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. All other provisions of the Certificate of Incorporation shall remain in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Certificate of Amendment to be
signed by its Chief Executive Officer this 25th day of January, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin S. Boyle, Sr.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kevin S. Boyle, Sr.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF AMENDMENT OF THE RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION OF ZIOPHARM ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Section&nbsp;242 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ziopharm Oncology, Inc. (the &#147;Corporation&#148;), a corporation organized and existing under and by virtue of the provisions of the
General Corporation Law of the State of Delaware (the &#147;General Corporation Law&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section&nbsp;242 of the General Corporation Law
proposing this Amendment of the Restated Certificate of Incorporation and declaring the advisability of this Amendment of the Restated Certificate of Incorporation, and authorizing the appropriate officers of the Corporation to solicit the consent
of the shareholders therefor, which resolution setting forth the proposed amendment is as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RESOLVED, that the first paragraph of
section four of the Restated Certificate of Incorporation of the Corporation, as amended, be and it hereby is, deleted in its entirety and the following paragraph is inserted in lieu thereof: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;4.<I></I><I>&nbsp;Number of Shares.</I>&nbsp;The total number of shares of all classes of stock that the Corporation shall have
authority to issue is Three Hundred Eighty Million (380,000,000) shares consisting of: Three Hundred Fifty Million (350,000,000) shares of common stock, $.001 par value per share (&#147;Common Stock&#148;); and Thirty Million (30,000,000) shares of
preferred stock, $.001 par value per share (&#147;Preferred Stock&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">shareholders of the Corporation in accordance with the
provisions of Section&nbsp;242 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Corporation has caused this Certificate of Amendment of the
Restated Certificate of Incorporation to be signed by its Chief Executive Officer this 19<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>&nbsp;day of May, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heidi Hagen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heidi Hagen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interim Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">of
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ZIOPHARM Oncology, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZIOPHARM Oncology, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. The name of the corporation is ZIOPHARM Oncology, Inc., formerly known as EasyWeb, Inc. The date of filing of its original Certificate of Incorporation
with the Secretary of State was May&nbsp;16, 2005. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. That the Board of Directors of the corporation adopted resolutions, in accordance with Sections 242
and 245 of the General Corporation Law of the State of Delaware, setting forth a proposed Amended and Restated Certificate of Incorporation (the &#147;Amended and Restated Certificate&#148;), declaring the Amended and Restated Certificate to be
advisable. The resolution setting forth the proposed Amended and Restated Certificate is as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that, subject to the
approval of the holders of a majority of the outstanding shares of the Corporation&#146;s common stock, par value $.001 per share (the &#147;Common Stock&#148;), the Corporation&#146;s Amended Certificate of Incorporation shall be amended and
restated in the manner set forth on the attached Exhibit A.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Please see Exhibit A attached hereto.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. This Amended and Restated Certificate was duly adopted by vote of the stockholders of the Corporation in accordance with the provisions of Sections 222,
242 and 245 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. That the Amended and Restated Certificate was duly adopted in accordance with the
applicable provisions of Sections 222, 242 and 245 of the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the
Corporation has caused this document to be executed in its corporate name as of this 26<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day of April, 2006. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ZIOPHARM Oncology, Inc.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jonathan Lewis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jonathan Lewis, <I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Name.</I> The name of the corporation is ZIOPHARM Oncology, Inc. (the &#147;Corporation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Address; Registered Office and Agent.</I> The address of the Corporation&#146;s registered office is 2711 Centerville Road Suite 400,
Wilmington, Delaware 19808. The Corporation may from time to time, in the manner provided by law, change the registered agent and the registered office within the State of Delaware. The Corporation may also maintain offices for the conduct of its
business, either within or without the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Purposes. </I>The purpose of the Corporation is to engage in any lawful
act or activity for which corporations may be organized under the Delaware General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Number of Shares.</I> The total
number of shares of all classes of stock that the Corporation shall have authority to issue is Two Hundred Eighty Million (280,000,000) shares consisting of: Two Hundred Fifty Million (250,000,000) shares of common stock, $.001 par value per share
(&#147;Common Stock&#148;); and Thirty Million (30,000,000) shares of preferred stock, $.001 par value per share (&#147;Preferred Stock&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Stock may be divided into, and may be issued from time to time in one or more series. The Board of Directors of the Corporation
(the &#147;Board&#148;) is authorized from time to time to establish and designate any such series of Preferred Stock, to fix and determine the variations in the relative rights, preferences, privileges and restrictions as between and among such
series and any other class of capital stock of the Corporation and any series thereof, and to fix or alter the number of shares comprising any such series and the designation thereof. The authority of the Board from time to time with respect to each
such series shall include, but not be limited to, determination of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. The designation of the series; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. The number of shares of the series and (except where otherwise provided in the creation of the series) any subsequent
increase or decrease therein; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. The dividends, if any, for shares of the series and the rates, conditions, times and
relative preferences thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. The redemption rights, if any, and price or prices for shares of the series; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e. The terms and amounts of any sinking fund provided for the purchase or redemption of the series; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f. The relative rights of shares of the series in the event of any voluntary or involuntary liquidation, dissolution or winding
up of the affairs of the Corporation; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g. Whether the shares of the series shall be convertible into shares of any
other class or series of shares of the Corporation, and, if so, the specification of such other class or series, the conversion prices or rate or rates, any adjustments thereof, the date or dates as of which such shares shall be convertible and all
other terms and conditions upon which such conversion may be made; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h. The voting rights, if any, of the holders of such
series; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. Such other designations, powers, preference and relative, participating, optional or other special rights
and qualifications, limitations or restrictions thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Election of Directors.</I> Unless and except to the extent that the <FONT
STYLE="white-space:nowrap">by-laws</FONT> of the Corporation (the <FONT STYLE="white-space:nowrap">&#147;By-laws&#148;)</FONT> shall so require, the election of directors of the Corporation need not be by written ballot. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Limitation of Liability.</I> To the fullest extent permitted under the General Corporation Law, as amended from time to time, no
director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of the foregoing provision shall not adversely
affect any right or protection of a director of the Corporation hereunder in respect of any act or omission occurring prior to the time of such amendment, repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Indemnification.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1
<I>Right to Indemnification.</I> The Corporation shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended, any person (a &#147;Covered Person&#148;) who was or is made or
is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#147;Proceeding&#148;), by reason of the fact that he or she, or a person for whom he or she is
the legal representative, is or was a director or officer of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or
of a partnership, joint venture, trust, enterprise or nonprofit entity (an &#147;Other Entity&#148;), including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&#146; fees)
reasonably incurred by such Covered Person. Notwithstanding the preceding sentence, except as otherwise provided in Section&nbsp;7.3, the Corporation shall be required to indemnify a Covered Person in connection with a Proceeding (or part thereof)
commenced by such Covered Person only if the commencement of such Proceeding (or part thereof) by the Covered Person was authorized by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <I>Prepayment of Expenses.</I> The Corporation shall pay the expenses (including attorneys&#146; fees) incurred by a Covered Person in
defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by applicable law, such payment of expenses in advance of the final disposition of the Proceeding shall be made only upon receipt of an
undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified under this Article 7 or otherwise. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <I>Claims.</I> If a claim for indemnification or advancement of expenses under this
Article 7 is not paid in full within 30 days after a written claim therefor by the Covered Person has been received by the Corporation, the Covered Person may file suit to recover the unpaid amount of such claim and, if successful in whole or in
part, shall be entitled to be paid the expense of prosecuting such claim. In any such action the Corporation shall have the burden of proving that the Covered Person is not entitled to the requested indemnification or advancement of expenses under
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <I>Nonexclusivity of Rights.</I> The rights conferred on any Covered Person by this Article 7 shall not be exclusive
of any other rights that such Covered Person may have or hereafter acquire under any statute, provision of this Certificate of Incorporation, the <FONT STYLE="white-space:nowrap">By-laws,</FONT> agreement, vote of stockholders or disinterested
directors or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <I>Other Sources.</I> The Corporation&#146;s obligation, if any, to indemnify or to advance expenses to any
Covered Person who was or is serving at its request as a director, officer, employee or agent of an Other Entity shall be reduced by any amount such Covered Person may collect as indemnification or advancement of expenses from such Other Entity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <I>Amendment or Repeal.</I> Any repeal or modification of the foregoing provisions of this Article 7 shall not adversely affect any
right or protection hereunder of any Covered Person in respect of any act or omission occurring prior to the time of such repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7 <I>Other Indemnification and Prepayment of Expenses.</I> This Article 7 shall not limit the right of the Corporation, to the extent and in
the manner permitted by applicable law, to indemnify and to advance expenses to persons other than Covered Persons when and as authorized by appropriate corporate action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Adoption, Amendment and/or Repeal of <FONT STYLE="white-space:nowrap">By-Laws.</FONT></I> In furtherance and not in limitation of the
powers conferred by the laws of the State of Delaware, the Board is expressly authorized to make, alter and repeal the <FONT STYLE="white-space:nowrap">By-laws,</FONT> subject to the power of the stockholders of the Corporation to alter or repeal
any <FONT STYLE="white-space:nowrap">By-law</FONT> whether adopted by them or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certificate Amendments.</I> The
Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, and other provisions authorized by the laws of the State of
Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by applicable law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons
whomsoever by and pursuant to this Amended and Restated Certificate of Incorporation in its present form or as hereafter amended are granted subject to the rights reserved in this article. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZIOPHARM ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF DESIGNATION, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PREFERENCES AND RIGHTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SERIES 1 PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Caesar J. Belbel, Chief Operating Officer, Executive Vice President and Chief Legal Officer of ZIOPHARM Oncology, Inc. (the
&#147;<B><I>Corporation</I></B>&#148;), organized and existing under the General Corporation Law of the State of Delaware, hereby certify that the following recitals and resolution were adopted by the Board of Directors of the Corporation as
required by Section&nbsp;151 of the General Corporation Law by unanimous written consent on July&nbsp;1, 2016: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>WHEREAS</B>,
pursuant to the Certificate of Incorporation (which authorizes 30,000,000 shares of preferred stock, $.001 par value per share (&#147;<B><I>Preferred Stock</I></B>&#148;)), the Board of Directors fixed the voting powers, preferences and relative,
participating, optional and other special rights of the Corporation&#146;s Series 1 Preferred Stock; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, no shares of
Series 1 Preferred Stock have been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that, pursuant to the authority vested in the Board of Directors of this
Corporation and in accordance with the provisions of the Certificate of Incorporation of this Corporation, the Certificate of Designations, Preferences and Rights of the Series 1 Preferred Stock filed with the office of the Secretary of State of
Delaware on June&nbsp;29, 2016, creating a class of authorized Preferred Stock of this Corporation designated as Series 1 Preferred Stock is hereby amended and restated in its entirety and that the designation and number of shares thereof and the
relative rights, powers and preferences, and qualifications, limitations and restrictions thereof, as amended and restated, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">250,000 of the authorized shares of the Corporation&#146;s preferred stock, par value $0.001 per share (the
&#147;<B><I>Preferred Stock</I></B>&#148;) are hereby designated &#147;Series 1 Preferred Stock&#148; (the &#147;<B><I>Series 1 Preferred</I></B>&#148;). Each share of Series 1 Preferred shall have a stated value equal to $1,200 (subject to
appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the Series 1 Preferred) (the &#147;<B><I>Stated Value</I></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The rights, preferences, privileges, restrictions and other matters relating to the Series 1 Preferred are as
follows: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dividend Rights. </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From and after the date of the issuance of any shares of Series 1 Preferred, dividends at the rate per month of
the Series 1 Dividend Rate (as defined below) shall accrue on such shares of Series 1 Preferred (the &#147;<B><I>Series 1 PIK Dividends</I></B>&#148;). The Series 1 PIK Dividends shall accrue on each share of Series 1 Preferred from day to day and
shall be paid monthly in the form of a number of additional shares of Series 1 Preferred equal to the cash value of the Series 1 PIK Dividend on such share that accrued during the preceding month, divided by the Stated Value of such share of Series
1 Preferred, within 10 days following the end of the preceding calendar month; provided, however, that the Series 1 PIK Dividend on any shares of Series 1 Preferred issued on or about July&nbsp;1, 2016 shall commence accruing on June&nbsp;30, 2016
(but for the purposes of clarity, shall be due and paid on July&nbsp;31, 2016). The payment of the Series 1 PIK Dividend each calendar month shall be mandatory for so long as the Corporation has funds legally available therefor. The &#147;Series 1
Dividend Rate&#148; for each share of Series 1 Preferred shall equal: (i)&nbsp;in the event that such share is not Unconverted Series 1 Preferred (as defined below), (A) $12.00 per month (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination, adjustment in the Stated Value or other recapitalization with respect to the Series 1 Preferred) or (ii)&nbsp;in the event that such share is Unconverted Series 1 Preferred, (A) $24.00 per month (subject to
appropriate adjustment in the event of any stock dividend, stock split, combination, adjustment in the Stated Value or other recapitalization with respect to the Series 1 Preferred). For the avoidance of doubt, Series 1 PIK Dividends shall be paid
only in the form of shares of Series 1 Preferred and not in the form of cash. No fractional shares of Series 1 Preferred shall be issued as a Series 1 PIK Dividend. Whether or not fractional shares would be issuable as Series 1 PIK Dividends shall
be determined on the basis of the total number of shares of Series 1 Preferred to be issued as a Series 1 PIK Dividend to any single holder of Series 1 Preferred based on the total shares of Series 1 Preferred held by such holder immediately prior
to the payment of such Series 1 PIK Dividend. Any fractional shares not paid pursuant to this Section&nbsp;1(a) shall be forfeited. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Voting Rights. </B>The holders of Series 1 Preferred have no voting power whatsoever, other than as set
forth in Section&nbsp;2(a) below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">At any time when shares of Series 1 Preferred are outstanding, the Corporation shall not, either directly or
indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders of at least a
majority of the then outstanding shares of Series 1 Preferred (the &#147;<B>Requisite Holders</B>&#148;), given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such act or transaction
entered into without such consent or vote shall be null and void ab initio, and of no force or effect: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amend, alter or repeal any provision of the Certificate of Incorporation in a manner that adversely affects the
powers, preferences or rights of the Series 1 Preferred in a manner that is more adverse than the effect on any other class or series of the Corporation&#146;s capital stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or
series of capital stock unless the same ranks junior or pari passu to the Series 1 Preferred with respect to the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends and rights of
redemption, or (B)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior or pari passu to the Series 1 Preferred with respect to the distribution of assets on the liquidation, dissolution or winding up of the
Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 Preferred in respect of any such right, preference or privilege; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">enter into any transaction (or series of related transactions) the effect of which would adversely affect the
holders of the Series 1 Preferred in a manner that is more adverse than the effect on any other class or series of the Corporation&#146;s capital stock; <I>provided; however</I>, that any issuances of the Corporation&#146;s capital stock in
connection with any transaction (or series of related transactions) would not require approval of the Requisite Holders, unless the special rights, preferences, privileges and obligations of the Series 1 Preferred are adversely affected.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conversion Of Series 1 Preferred Shares Into Common Stock. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;3(f) and 3(g), upon the close of business on the second (2nd) business day following
the Conversion Event Date (as defined below) (the &#147;<B><I>Mandatory Conversion Time</I></B>&#148;), each outstanding share of Series 1 Preferred shall automatically be converted into shares of Common Stock, without the payment of additional
consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the Stated Value of such share of Series 1 Preferred by the Series 1
Conversion Price (as defined below). The &#147;<B><I>Series 1 Conversion Price</I></B>&#148; shall be equal to the greater of: (x)&nbsp;the volume weighted average closing price of the Corporation&#146;s Common Stock as reported by the Nasdaq Stock
Market, LLC over the 20 trading days ending on the Conversion Event Date or (y) $1.00 per share. The &#147;<B><I>Conversion Event Date</I></B>&#148; shall be the date that the first approval in the United States of (i)&nbsp;a ZIOPHARM Product, as
defined in and developed under the Exclusive Channel Partner Agreement dated as of January&nbsp;6, 2011 and as amended from time to time, by and between the Corporation and Intrexon Corporation, or (ii)&nbsp;a Product, as defined in and developed
under the Exclusive Channel Collaboration Agreement dated September&nbsp;28, 2015 and as amended from time to time, by and between the Corporation and Intrexon Corporation, or (iii)&nbsp;a Product, as defined in and developed under the License and
Collaboration Agreement dated March&nbsp;27, 2015 and as amended from time to time, by and among Intrexon Corporation, ARES TRADING Trading, S.A. and the Corporation, is publicly announced. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fractional shares of Common Stock shall be issued upon conversion of the Series 1 Preferred. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not
fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Series 1 Preferred the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock
issuable upon such conversion. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All holders of record of shares of Series 1 Preferred shall be sent written notice of the Mandatory Conversion
Time and the place designated for mandatory conversion of all such shares of Series 1 Preferred pursuant to this Section&nbsp;3. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice,
each holder of shares of Series 1 Preferred in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate
affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at
the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly
executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series 1 Preferred converted pursuant to Section&nbsp;3(a), including the rights, if any, to receive the Series 1 PIK
Dividends, notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only
the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Section&nbsp;3(c) (though for
the avoidance of doubt this sentence shall not apply to Unconverted Series 1 Preferred unless and until such Unconverted Series 1 Preferred is converted). As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender
of any certificate or certificates (or lost certificate affidavit and agreement) for Series 1 Preferred, the Corporation shall (i)&nbsp;deliver, or cause to be delivered, to the converting holder a certificate or book-entry statement representing
the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (ii)&nbsp;pay cash as provided in Section&nbsp;3(b) in lieu of any fraction of a share of Common Stock otherwise issuable upon such
conversion. Such converted Series 1 Preferred shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be
necessary to reduce the authorized number of shares of Series 1 Preferred accordingly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation shall at all times when the Series 1 Preferred shall be outstanding, reserve and keep available
out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Series 1 Preferred, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of
all outstanding Series 1 Preferred; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Series 1 Preferred, the Corporation shall take
such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in commercially reasonable efforts to
obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any
issuance or delivery of shares of Common Stock upon conversion of shares of Series 1 Preferred pursuant to this Section&nbsp;3. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved
in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Series 1 Preferred so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting
such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation shall not effect any conversion of the Series 1 Preferred into Common Stock to the extent that
the number of shares of Common Stock issued in such conversion would represent a number of shares in excess of the Conversion Limitation (as defined below), unless prior to such conversion, stockholder approval for such issuances have been obtained
in accordance with and to the extent required by the NASDAQ Stock Market Listing Rules (such approval, the &#147;<B><I>Conversion Approval</I></B>&#148;). In the event that the limitation provided in the preceding sentence applies, then on the
Mandatory Conversion Date, the Corporation shall convert the maximum number of shares of Series 1 Preferred into Common Stock as is possible without exceeding the Conversion Limitation. Any shares of Series 1 Preferred that are not converted on the
Mandatory Conversion Date (such shares of Series 1 Preferred remaining outstanding after the Mandatory Conversion Time are referred to as &#147;<B><I>Unconverted Series 1 Preferred</I></B>&#148;) shall remain outstanding until the Conversion
Approval is obtained, at which point all Unconverted Series 1 Preferred shall be converted into Common Stock at the Series 1 Conversion Price as provided in this Section&nbsp;3. The &#147;<B><I>Conversion Limitation</I></B>&#148; shall be 19.9% of
the lesser of (i)&nbsp;the number of outstanding shares of the Corporation&#146;s Common Stock immediately prior to the closing of the transactions contemplated by that certain Share Issuance Agreement by and between the Corporation and Intrexon
corporation dated on or about the date hereof or (ii)&nbsp;the number of outstanding shares of Corporation&#146;s Common Stock at the time of conversion. The provisions of this paragraph shall be construed and implemented in a manner otherwise than
in strict conformity with the terms of this Section&nbsp;3(f) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Conversion Limitation contained herein or to make changes or supplements
necessary or desirable to properly give effect to such limitation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding any provision to the contrary in this Section&nbsp;3, without stockholder approval in
accordance with the NASDAQ Stock Market Listing Rules, the Corporation shall not effect any conversion of the Series 1 Preferred into Common Stock to the extent that the number of shares of Common Stock issued in such conversion should constitute a
change of control under the NASDAQ Stock Market Listing Rules, taking into account for these purposes, the NASDAQ Stock Market&#146;s policy of calculating of beneficial ownership in accordance with Section&nbsp;13 of the Securities Exchange Act of
1934, as amended, and the rules and regulations promulgated thereunder. Any shares of Series 1 Preferred that are not converted into Common Stock on or after the Mandatory Conversion Date as a result of the limitation in this Section&nbsp;3(g) shall
be Unconverted Series 1 Preferred, and shall remain outstanding until such time as stockholder approval in accordance with the NASDAQ Stock Market Listing Rules is obtained such that such shares of Series 1 Preferred may be converted into Common
Stock in accordance with the NASDAQ Stock Market Listing Rules, at which point such shares of Series 1 Preferred shall be converted into Common Stock at the Series 1 Conversion Price as provided in this Section&nbsp;3. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;3(g) to correct this paragraph (or any portion hereof) to the extent necessary to ensure compliance with the NASDAQ
Stock Market Listing Rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4)</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Liquidation. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each of the following events shall be considered a &#147;<B><I>Deemed Liquidation Event</I></B>&#148;:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation in which (A)&nbsp;the Corporation is a constituent party or (B)&nbsp;a subsidiary of
the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital
stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least
a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting entity; or (2)&nbsp;if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or consolidation, the
parent entity of such surviving or resulting entity; or </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related
transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one
or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other
disposition is to a wholly owned subsidiary of the Corporation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the closing of the transfer of this Corporation&#146;s capital stock (whether by merger, consolidation or
otherwise), in one transaction or a series of related transactions, to a person or group of affiliated persons (other than an underwriter of this Corporation&#146;s securities), if, after such closing, such person or group of affiliated persons
would hold at least a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting entity; or (2)&nbsp;if the surviving or resulting entity is a wholly owned subsidiary of another entity immediately following such merger or
consolidation, the parent entity of such surviving or resulting entity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or
Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be distributed among the holders of the shares of Series 1 Preferred and Common Stock, pro rata based on the number of shares held by each
such holder, treating for this purpose all shares of Series 1 Preferred as if they had been converted into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock as is determined by dividing the
Stated Value of such share of Series 1 Preferred by the Series 1 Liquidation Assumed Conversion Price (as defined below), rounded down to the nearest whole share. The amount per share payable to the Series 1 Preferred pursuant to the preceding
sentence is referred to as the &#147;<B><I>Series 1 Liquidation Amount</I></B>.&#148; The &#147;<B><I>Series 1 Liquidation Assumed Conversion Price</I></B>&#148; shall be equal to either (i)&nbsp;if such shares of Series 1 Preferred are <U>not</U>
Unconverted Series 1 Preferred, the volume weighted average closing price of the Corporation&#146;s Common Stock as reported by the Nasdaq Stock Market, LLC over the 20 trading days ending on the public announcement of such voluntary or involuntary
liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event or (ii)&nbsp;if such shares of Series 1 Preferred are Unconverted Series 1 Preferred, the Series 1 Conversion Price. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In connection with or following a Deemed Liquidation Event, the Corporation may, in lieu of distributing the
proceeds of such Deemed Liquidation Event pro rata among the holders of Series 1 Preferred and Common Stock as contemplated by Section&nbsp;4(b), elect to redeem all, but not less than all of the Series 1 Preferred then outstanding at a price per
share of Series 1 Preferred equal to the Series 1 Liquidation Amount. A redemption of the Series 1 Preferred pursuant to this Section&nbsp;4(c) shall occur upon the closing of such Deemed Liquidation Event or on such other date determined by the
Corporation during the period commencing on the date of the closing of such Deemed Liquidation Event and ending on the 20th day following such Deemed Liquidation Event (such date, the &#147;<B><I>Redemption Date</I></B>&#148;) and shall be effected
in accordance with Subsections 4(c)(i) through 4(c)(iii): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Corporation shall send written notice of the redemption (the &#147;<B><I>Redemption Notice</I></B>&#148;)
to each holder of record of Series 1 Preferred not less than 5 days prior to the Redemption Date. Each Redemption Notice shall state: (A)&nbsp;the number of shares of Series 1 Preferred held by such holder that the Corporation shall redeem on the
Redemption Date specified in the Redemption Notice; (B)&nbsp;the Redemption Date and the Series 1 Liquidation Amount payable for such holder&#146;s shares of Series 1 Preferred; and (C)&nbsp;that the holder is to surrender to the Corporation, in the
manner and at the place designated in the Redemption Notice, his, her or its certificate or certificates, if any, representing the shares of Series 1 Preferred to be redeemed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On or before the Redemption Date, each holder of shares of Series 1 Preferred to be redeemed on the Redemption
Date shall surrender the certificate or certificates, if any, representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable
to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the
Redemption Notice, and thereupon the Series 1 Liquidation Amount, for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Redemption Notice shall have been duly given, and if on the Redemption Date the Series 1 Liquidation
Amount, payable upon redemption of the shares of Series 1 Preferred to be redeemed on the Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then
notwithstanding that the certificates, if any, evidencing any of the shares of Series 1 Preferred so called for redemption shall not have been surrendered, all rights with respect to such shares of Series 1 Preferred shall forthwith after the
Redemption Date terminate, except only the right of the holders to receive the Series 1 Liquidation Amount, without interest, upon surrender of their certificate or certificates therefor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Redeemed Or Otherwise Acquired Shares</B>. Any shares of Series 1 Preferred that are redeemed or otherwise
acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other
rights granted to the holders of Series 1 Preferred following redemption. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver</B>. Any of the rights, powers, preferences and other terms of the Series 1 Preferred set forth
herein may be waived on behalf of all holders of Series 1 Preferred by the affirmative written consent or vote of the Requisite Holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Next Business Day</B>. Whenever any payment or other obligation hereunder shall be due on a day other than a
business day, such payment shall be made on the next succeeding business day. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, ZIOPHARM Oncology, Inc. has caused this Amended and Restated
Certificate of Designation, Preferences and Rights of the Terms of the Series 1 Preferred Stock to be executed by its Chief Operating Officer, Executive Vice President and Chief Legal Officer this 1st day of July, 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Caesar J. Belbel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Caesar J. Belbel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Operating Officer, Executive Vice President and Chief</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Legal Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZIOPHARM ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE PAGE TO CERTIFICATE OF DESIGNATION </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>d286456dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Alaunos Therapeutics, Inc., </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Issuer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[TRUSTEE], </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trustee
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDENTURE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of
[&#149;], 20 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ABLE</SMALL> O<SMALL>F</SMALL> C<SMALL>ONTENTS</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>P<SMALL>AGE</SMALL></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 1 DEFINITIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;1.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Definitions of Terms</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF
SECURITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Designation and Terms of Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Form of Securities and Trustee&#146;s Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Denominations: Provisions for Payment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution and Authentications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Registration of Transfer and Exchange</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Temporary Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Mutilated, Destroyed, Lost or Stolen Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Cancellation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Benefits of Indenture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Authenticating Agent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Global Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;2.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>CUSIP Numbers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 3 REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Redemption</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Redemption</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment Upon Redemption</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Sinking Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Satisfaction of Sinking Fund Payments with Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Redemption of Securities for Sinking Fund</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 4 COVENANTS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Principal, Premium and Interest</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Maintenance of Office or Agency</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Paying Agents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;4.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Appointment to Fill Vacancy in Office of Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 5 SECURITYHOLDERS&#146; LISTS AND REPORTS BY THE COMPANY AND THE
TRUSTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company to Furnish Trustee Names and Addresses of Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preservation Of Information; Communications With Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports by the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;5.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reports by the Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 6 REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Events of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Collection of Indebtedness and Suits for Enforcement by Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Application of Moneys Collected</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Limitation on Suits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Rights and Remedies Cumulative; Delay or Omission Not Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Control by Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;6.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Undertaking to Pay Costs</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 7 CONCERNING THE TRUSTEE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Duties and Responsibilities of Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Rights of Trustee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Trustee Not Responsible for Recitals or Issuance or Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>May Hold Securities</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Moneys Held in Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compensation and Reimbursement</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Reliance on Officer&#146;s Certificate</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Disqualification; Conflicting Interests</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Corporate Trustee Required; Eligibility</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Resignation and Removal; Appointment of Successor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Acceptance of Appointment By Successor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Merger, Conversion, Consolidation or Succession to Business</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Preferential Collection of Claims Against the Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;7.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notice of Default</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 8 CONCERNING THE SECURITYHOLDERS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Evidence of Action by Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Proof of Execution by Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Who May be Deemed Owners</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certain Securities Owned by Company Disregarded</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;8.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Actions Binding on Future Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 9 SUPPLEMENTAL INDENTURES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supplemental Indentures Without the Consent of Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Supplemental Indentures With Consent of Securityholders</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect of Supplemental Indentures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Securities Affected by Supplemental Indentures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;9.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Execution of Supplemental Indentures</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 10 SUCCESSOR ENTITY</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Company May Consolidate, Etc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;10.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Successor Entity Substituted</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 11 SATISFACTION AND DISCHARGE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Satisfaction and Discharge of Indenture</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Discharge of Obligations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Deposited Moneys to be Held in Trust</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payment of Moneys Held by Paying Agents</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;11.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Repayment to Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 12 IMMUNITY OF INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;12.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>No Recourse</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARTICLE 13 MISCELLANEOUS PROVISIONS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.01</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Effect on Successors and Assigns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.02</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Actions by Successor</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.03</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Surrender of Company Powers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.04</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Notices</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.05</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Governing Law; Jury Trial Waiver</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.06</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Treatment of Securities as Debt</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.07</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Certificates and Opinions as to Conditions Precedent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.08</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Payments on Business Days</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.09</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Conflict with Trust Indenture Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.10</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Counterparts</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Separability</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.12</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Compliance Certificates</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.13</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>U.S.A Patriot Act</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.14</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Force Majeure</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Section&nbsp;13.15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Table of Contents; Headings</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDENTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NDENTURE</SMALL></B><SMALL></SMALL>, dated as of [&#149;], 20 , among <B>Alaunos Therapeutics, Inc.</B>, a Delaware corporation
(the &#147;Company&#148;), and [<B>T<SMALL>RUSTEE</SMALL></B><SMALL></SMALL>], as trustee (the &#147;Trustee&#148;): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of
this Indenture to provide for the issuance of debt securities (hereinafter referred to as the &#147;Securities&#148;), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as
registered Securities without coupons, to be authenticated by the certificate of the Trustee; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, to provide the terms and conditions upon which the Securities are to be authenticated, issued
and delivered, the Company has duly authorized the execution of this Indenture; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, all
things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the premises and the purchase of the Securities by the
holders thereof, it is mutually covenanted and agreed as follows for the equal and ratable benefit of the holders of Securities: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1.01 Definitions of Terms. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms defined in this Section (except as in this Indenture or any indenture supplemental hereto otherwise expressly provided or unless the
context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section and shall include the plural as well as the singular. All other terms used in this
Indenture that are defined in the Trust Indenture Act of 1939, as amended, or that are by reference in such Act defined in the Securities Act of 1933, as amended (except as herein or any indenture supplemental hereto otherwise expressly provided or
unless the context otherwise requires), shall have the meanings assigned to such terms in said Trust Indenture Act and in said Securities Act as in force at the date of the execution of this instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Authenticating Agent</I></B>&#148; means the Trustee or an authenticating agent with respect to all or any of the series of
Securities appointed by the Trustee pursuant to Section&nbsp;2.10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Bankruptcy Law</I></B>&#148; means Title 11, U.S. Code, or
any similar federal or state law for the relief of debtors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board of Directors</I></B>&#148; means the Board of Directors (or
the functional equivalent thereof) of the Company or any duly authorized committee of such Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Board Resolution</I></B>&#148; means a copy of a resolution certified by the
Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors (or duly authorized committee thereof) and to be in full force and effect on the date of such certification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Business Day</I></B>&#148; means, with respect to any series of Securities, any day other than a day on which federal or state
banking institutions in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of the Trustee, are authorized or obligated by law, executive order or regulation to close. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Commission</I></B>&#148; means the Securities and Exchange Commission, as from time to time constituted, created under the
Exchange Act, or, if at any time after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture Act, then the body performing such duties at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Company</I></B>&#148; means <B>Alaunos Therapeutics</B><B>, I</B><B>nc.</B>, a corporation duly organized and existing under the
laws of the State of Delaware, and, subject to the provisions of Article Ten, shall also include its successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Corporate Trust Office</I></B>&#148; means the office of the Trustee at which, at any particular time, its corporate trust
business shall be principally administered, which office at the date hereof is located at . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Custodian</I></B>&#148; means any
receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Defaulted Interest</I></B>&#148; has
the meaning set forth in Section&nbsp;2.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Depositary</I></B>&#148; means, with respect to Securities of any series for
which the Company shall determine that such Securities will be issued as a Global Security, The Depository Trust Company, another clearing agency, or any successor registered as a clearing agency under the Exchange Act, or other applicable statute
or regulation, which, in each case, shall be designated by the Company pursuant to either Section&nbsp;2.01 or 2.11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Event of
Default</I></B>&#148; means, with respect to Securities of a particular series, any event specified in Section&nbsp;6.01, continued for the period of time, if any, therein designated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Exchange Act</I></B>&#148; means the United States Securities and Exchange Act of 1934, as amended, and the rules and regulations
promulgated by the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>given</I></B>&#148;, &#147;<B><I>mailed</I></B>&#148;,
&#147;<B><I>notify</I></B>&#148; or &#147;<B><I>sent</I></B>&#148; with respect to any notice to be given to a Securityholder pursuant to this Indenture, shall mean notice (x)&nbsp;given to the Depositary (or its designee) pursuant to the standing
instructions from the Depositary or its designee, including by electronic mail in accordance with accepted practices or procedures at the Depositary (in the case of a Global Security) or (y)&nbsp;mailed to such Holder by first class mail, postage
prepaid, at its address as it appears on the Security Register (in the case of a definitive Security). Notice so &#147;given&#148; shall be deemed to include any notice to be &#147;mailed&#148; or &#147;delivered,&#148; as applicable, under this
Indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Global Security</I></B>&#148; means a Security issued to evidence all or a part
of any series of Securities which is executed by the Company and authenticated and delivered by the Trustee to the Depositary or pursuant to the Depositary&#146;s instruction, all in accordance with the Indenture, which shall be registered in the
name of the Depositary or its nominee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Governmental Obligations</I></B>&#148; means securities that are (a)&nbsp;direct
obligations of the United States of America for the payment of which its full faith and credit is pledged or (b)&nbsp;obligations of a Person controlled or supervised by and acting as an agency or instrumentality of the United States of America, the
payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States of America that, in either case, are not callable or redeemable at the option of the issuer thereof at any time prior to the stated maturity of
the Securities, and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such Governmental Obligation or a specific payment of principal of or interest on any such Governmental Obligation held by
such custodian for the account of the holder of such depositary receipt; provided, however, that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from
any amount received by the custodian in respect of the Governmental Obligation or the specific payment of principal of or interest on the Governmental Obligation evidenced by such depositary receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>herein</I></B>&#148;, &#147;<B><I>hereof</I></B>&#148; and &#147;<B><I>hereunder</I></B>&#148;, and other words of similar import,
refer to this Indenture as a whole and not to any particular Article, Section or other subdivision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Indenture</I></B>&#148;
means this instrument as originally executed or as it may from time to time be supplemented or amended by one or more indentures supplemental hereto entered into in accordance with the terms hereof and shall include the terms of particular series of
Securities established as contemplated by Section&nbsp;2.01. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Interest Payment Date</I></B>&#148;, when used with respect to
any installment of interest on a Security of a particular series, means the date specified in such Security or in a Board Resolution or in an indenture supplemental hereto with respect to such series as the fixed date on which an installment of
interest with respect to Securities of that series is due and payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Officer</I></B>&#148; means, with respect to the
Company, the chairman of the Board of Directors, a chief executive officer, a president, a chief financial officer, a chief operating officer, any executive vice president, any senior vice president, any vice president, the treasurer or any
assistant treasurer, the controller or any assistant controller or the secretary or any assistant secretary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Officer&#146;s
Certificate</I></B>&#148; means a certificate signed by any Officer. Each such certificate shall include the statements provided for in Section&nbsp;13.07, if and to the extent required by the provisions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Opinion of Counsel</I></B>&#148; means an opinion in writing subject to customary exceptions of legal counsel, who may be an
employee of or counsel for the Company, that is delivered to the Trustee in accordance with the terms hereof. Each such opinion shall include the statements provided for in Section&nbsp;13.07, if and to the extent required by the provisions thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Outstanding</I></B>&#148;, when used with reference to Securities of any series,
means, subject to the provisions of Section&nbsp;8.04, as of any particular time, all Securities of that series theretofore authenticated and delivered by the Trustee under this Indenture, except (a)&nbsp;Securities theretofore canceled by the
Trustee or any paying agent, or delivered to the Trustee or any paying agent for cancellation or that have previously been canceled; (b)&nbsp;Securities or portions thereof for the payment or redemption of which moneys or Governmental Obligations in
the necessary amount shall have been deposited in trust with the Trustee or with any paying agent (other than the Company) or shall have been set aside and segregated in trust by the Company (if the Company shall act as its own paying agent);
provided, however, that if such Securities or portions of such Securities are to be redeemed prior to the maturity thereof, notice of such redemption shall have been given as provided in Article Three, or provision satisfactory to the Trustee shall
have been made for giving such notice; and (c)&nbsp;Securities in lieu of or in substitution for which other Securities shall have been authenticated and delivered pursuant to the terms of Section&nbsp;2.07. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Person</I></B>&#148; means any individual, corporation, partnership, joint venture, joint-stock company, limited liability
company, association, trust, unincorporated organization, any other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Predecessor Security</I></B>&#148; of any particular Security means every previous Security evidencing all or a portion of the
same debt as that evidenced by such particular Security; and, for the purposes of this definition, any Security authenticated and delivered under Section&nbsp;2.07 in lieu of a lost, destroyed or stolen Security shall be deemed to evidence the same
debt as the lost, destroyed or stolen Security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Responsible Officer</I></B>&#148; when used with respect to the Trustee means
any officer within the Corporate Trust Office of the Trustee (or any successor group of the Trustee) or any other officer of the Trustee customarily performing functions similar to those performed by any of the above designated officers and also
means, with respect to a particular corporate trust matter, any other officer to whom such matter is referred because of his or her knowledge of and familiarity with the particular subject and in each case who shall have direct responsibility for
the administration of this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities</I></B>&#148; has the meaning stated in the first recital of this Indenture
and more particularly means any Securities authenticated and delivered under this Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securities Act</I></B>&#148;
means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Securityholder</I></B>&#148;, &#147;<B><I>holder of Securities</I></B>&#148;,
&#147;<B><I>registered holder</I></B>&#148;, or other similar term, means the Person or Persons in whose name or names a particular Security is registered on the Security Register kept for that purpose in accordance with the terms of this Indenture.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Security Register</I></B>&#148; and &#147;<B><I>Security Registrar</I></B>&#148; shall have the meanings as set forth in
Section&nbsp;2.05. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Subsidiary</I></B>&#148; means, with respect to any Person, any corporation,
association, partnership or other business entity of which more than 50% of the total voting power of shares of capital stock or other interests (including partnership interests) entitled (without regard to the occurrence of any contingency) to vote
in the election of directors, managers, general partners or trustees thereof is at the time owned or controlled, directly or indirectly, by (i)&nbsp;such Person; (ii)&nbsp;such Person and one or more Subsidiaries of such Person; or (iii)&nbsp;one or
more Subsidiaries of such Person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trustee</I></B>&#148; means , and, subject to the provisions of Article Seven, shall also
include its successors and assigns, and, if at any time there is more than one Person acting in such capacity hereunder, &#147;Trustee&#148; shall mean each such Person. The term &#147;Trustee&#148; as used with respect to a particular series of the
Securities shall mean the trustee with respect to that series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>Trust Indenture Act</I></B>&#148; means the Trust Indenture
Act of 1939, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><I>U.S.A. Patriot Act</I></B>&#148; means the Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. <FONT STYLE="white-space:nowrap">107-56,</FONT> as amended and signed into law October&nbsp;26, 2001. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISSUE,
DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.01 Designation and Terms of Securities.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The
Securities may be issued in one or more series up to the aggregate principal amount of Securities of that series from time to time authorized by or pursuant to a Board Resolution or pursuant to one or more indentures supplemental hereto. Prior to
the initial issuance of Securities of any series, there shall be established in or pursuant to a Board Resolution, and set forth in an Officer&#146;s Certificate, or established in one or more indentures supplemental hereto: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) the title of the Securities of the series (which shall distinguish the Securities of that series from all other Securities); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) any limit upon the aggregate principal amount of the Securities of that series that may be authenticated and delivered under this
Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of that series); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) the maturity date or dates on which the principal of the Securities of the series is payable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) the form of the Securities of the series including the form of the certificate of authentication for such series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(5) the applicability of any guarantees; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(6) whether or not the Securities will be secured or unsecured, and the terms of any
secured debt; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(7) whether the Securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof,
and the terms of any subordination; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(8) if the price (expressed as a percentage of the aggregate principal amount thereof) at which such
Securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such
Securities that is convertible into another security or the method by which any such portion shall be determined; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(9) the interest rate
or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining
such dates; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(10) the Company&#146;s right, if any, to defer the payment of interest and the maximum length of any such deferral period;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(11) if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, the Company
may at its option, redeem the series of Securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(12) the date or dates, if any, on which, and the price or prices at which the Company is obligated, pursuant to any mandatory sinking fund
or analogous fund provisions or otherwise, to redeem, or at the Securityholder&#146;s option to purchase, the series of Securities and the currency or currency unit in which the Securities are payable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(13) the denominations in which the Securities of the series shall be issuable, if other than denominations of one thousand U.S. dollars
($1,000) or any integral multiple thereof; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(14) any and all terms, if applicable, relating to any auction or remarketing of the
Securities of that series and any security for the obligations of the Company with respect to such Securities and any other terms which may be advisable in connection with the marketing of Securities of that series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(15) whether the Securities of the series shall be issued in whole or in part in the form of a Global Security or Securities; the terms and
conditions, if any, upon which such Global Security or Securities may be exchanged in whole or in part for other individual Securities; and the Depositary for such Global Security or Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(16) if applicable, the provisions relating to conversion or exchange of any Securities of the series and the terms and conditions upon which
such Securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at the Company&#146;s option or the holders&#146; option)
conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange, which may, without limitation, include the payment of cash as well as the delivery of securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(17) if other than the full principal amount thereof, the portion of the principal amount
of Securities of the series which shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section&nbsp;6.01; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(18) additions to or changes in the covenants applicable to the series of Securities being issued, including, among others, the
consolidation, merger or sale covenant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(19) additions to or changes in the Events of Default with respect to the Securities and any
change in the right of the Trustee or the Securityholders to declare the principal, premium, if any, and interest, if any, with respect to such Securities to be due and payable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(20) additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(21) additions to or changes in the provisions relating to satisfaction and discharge of this Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(22) additions to or changes in the provisions relating to the modification of this Indenture both with and without the consent of
Securityholders of Securities issued under this Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(23) the currency of payment of Securities if other than U.S. dollars and the
manner of determining the equivalent amount in U.S. dollars; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(24) whether interest will be payable in cash or additional Securities at
the Company&#146;s or the Securityholders&#146; option and the terms and conditions upon which the election may be made; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(25) the terms
and conditions, if any, upon which the Company shall pay amounts in addition to the stated interest, premium, if any and principal amounts of the Securities of the series to any Securityholder that is not a &#147;United States person&#148; for
federal tax purposes; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(26) any restrictions on transfer, sale or assignment of the Securities of the series; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(27) any other specific terms, preferences, rights or limitations of, or restrictions on, the Securities, any other additions or changes in
the provisions of this Indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
Securities of any one series shall be substantially identical except as may otherwise be provided in or pursuant to any such Board Resolution or in any indentures supplemental hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the terms of the series are established by action taken pursuant to a Board
Resolution of the Company, a copy of an appropriate record of such action shall be certified by the secretary or an assistant secretary of the Company and delivered to the Trustee at or prior to the delivery of the Officer&#146;s Certificate of the
Company setting forth the terms of the series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities of any particular series may be issued at various times, with different dates
on which the principal or any installment of principal is payable, with different rates of interest, if any, or different methods by which rates of interest may be determined, with different dates on which such interest may be payable and with
different redemption dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.02 Form of Securities and Trustee&#146;s Certificate. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities of any series and the Trustee&#146;s certificate of authentication to be borne by such Securities shall be substantially of the
tenor and purport as set forth in one or more indentures supplemental hereto or as provided in a Board Resolution, and set forth in an Officer&#146;s Certificate, and they may have such letters, numbers or other marks of identification or
designation and such legends or endorsements printed, lithographed or engraved thereon as the Company may deem appropriate and as are not inconsistent with the provisions of this Indenture, or as may be required to comply with any law or with any
rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which Securities of that series may be listed, or to conform to usage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.03 Denominations: Provisions for Payment. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities shall be issuable as registered Securities and in the denominations of one thousand U.S. dollars ($1,000) or any integral
multiple thereof, subject to Section&nbsp;2.01(a)(13). The Securities of a particular series shall bear interest payable on the dates and at the rate specified with respect to that series. Subject to Section&nbsp;2.01(a)(23), the principal of and
the interest on the Securities of any series, as well as any premium thereon in case of redemption or repurchase thereof prior to maturity, and any cash amount due upon conversion or exchange thereof, shall be payable in the coin or currency of the
United States of America that at the time is legal tender for public and private debt, at the office or agency of the Company maintained for that purpose. Each Security shall be dated the date of its authentication. Interest on the Securities shall
be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year composed of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The interest installment on any Security that is payable, and is punctually paid or duly provided for, on any Interest Payment Date for
Securities of that series shall be paid to the Person in whose name said Security (or one or more Predecessor Securities) is registered at the close of business on the regular record date for such interest installment. In the event that any Security
of a particular series or portion thereof is called for redemption and the redemption date is subsequent to a regular record date with respect to any Interest Payment Date and prior to such Interest Payment Date, interest on such Security will be
paid upon presentation and surrender of such Security as provided in Section&nbsp;3.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any interest on any Security that is payable, but
is not punctually paid or duly provided for, on any Interest Payment Date for Securities of the same series (herein called &#147;Defaulted Interest&#148;) shall forthwith cease to be payable to the registered holder on the relevant regular record
date by virtue of having been such holder; and such Defaulted Interest shall be paid by the Company, at its election, as provided in clause (1)&nbsp;or clause (2)&nbsp;below: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The Company may make payment of any Defaulted Interest on Securities to the Persons in
whose names such Securities (or their respective Predecessor Securities) are registered in the Security Register at the close of business on a special record date for the payment of such Defaulted Interest, which shall be fixed in the following
manner: the Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each such Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of
money equal to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in
trust for the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a special record date for the payment of such Defaulted Interest which shall not be more than 15 nor less than 10
days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such special record date and, in the name and at the
expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the special record date therefor to be sent, to each Securityholder not less than 10 days prior to such special record date. Notice of the proposed
payment of such Defaulted Interest and the special record date therefor having been sent as aforesaid, such Defaulted Interest shall be paid to the Persons in whose names such Securities (or their respective Predecessor Securities) are registered in
the Security Register on such special record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) The Company may make payment of any Defaulted Interest on any Securities in any
other lawful manner not inconsistent with the requirements of any securities exchange on which such Securities may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the
proposed payment pursuant to this clause, such manner of payment shall be deemed practicable by the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise set forth
in a Board Resolution or one or more indentures supplemental hereto establishing the terms of any series of Securities pursuant to Section&nbsp;2.01 hereof, the term &#147;regular record date&#148; as used in this Section with respect to a series of
Securities and any Interest Payment Date for such series shall mean either the fifteenth day of the month immediately preceding the month in which an Interest Payment Date established for such series pursuant to Section&nbsp;2.01 hereof shall occur,
if such Interest Payment Date is the first day of a month, or the first day of the month in which an Interest Payment Date established for such series pursuant to Section&nbsp;2.01 hereof shall occur, if such Interest Payment Date is the fifteenth
day of a month, whether or not such date is a Business Day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing provisions of this Section, each Security of a
series delivered under this Indenture upon transfer of or in exchange for or in lieu of any other Security of such series shall carry the rights to interest accrued and unpaid, and to accrue, that were carried by such other Security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.04 Execution and Authentications. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities shall be signed on behalf of the Company by one of its Officers. Signatures may be in the form of a manual or facsimile
signature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may use the facsimile signature of any Person who shall have been an Officer (at the time of execution),
notwithstanding the fact that at the time the Securities shall be authenticated and delivered or disposed of such Person shall have ceased to be such an officer of the Company. The Securities may contain such notations, legends or endorsements
required by law, stock exchange rule or usage. Each Security shall be dated the date of its authentication by the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Security
shall not be valid until authenticated manually by an authorized signatory of the Trustee, or by an Authenticating Agent. Such signature shall be conclusive evidence that the Security so authenticated has been duly authenticated and delivered
hereunder and that the holder is entitled to the benefits of this Indenture. At any time and from time to time after the execution and delivery of this Indenture, the Company may deliver Securities of any series executed by the Company to the
Trustee for authentication, together with a written order of the Company for the authentication and delivery of such Securities, signed by an Officer, and the Trustee in accordance with such written order shall authenticate and deliver such
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Company&#146;s delivery of any such authentication order to the Trustee at any time after the initial issuance of
Securities under this Indenture, the Trustee shall be provided with, and (subject to Sections 315(a) through 315(d) of the Trust Indenture Act) shall be fully protected in relying upon, (1)&nbsp;an Opinion of Counsel or reliance letter and
(2)&nbsp;an Officer&#146;s Certificate stating that all conditions precedent to the execution, authentication and delivery of such Securities are in conformity with the provisions of this Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee shall not be required to authenticate such Securities if the issue of such Securities pursuant to this Indenture will affect the
Trustee&#146;s </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">own rights, duties or immunities under the Securities and this Indenture or otherwise in a manner that is not reasonably
acceptable to the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.05 Registration of Transfer and Exchange. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Securities of any series may be exchanged upon presentation thereof at the office or agency of the Company designated for such purpose,
for other Securities of such series of authorized denominations, and for a like aggregate principal amount, upon payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, all as provided in this Section. In
respect of any Securities so surrendered for exchange, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in exchange therefor the Security or Securities of the same series that the Securityholder
making the exchange shall be entitled to receive, bearing numbers not contemporaneously outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall keep, or cause
to be kept, at its office or agency designated for such purpose a register or registers (herein referred to as the &#147;Security Register&#148;) in which, subject to such reasonable regulations as it may prescribe, the Company shall register the
Securities and the transfers of Securities as in this Article provided and which at all reasonable times shall be open for inspection by the Trustee. The registrar for the purpose of registering Securities and transfer of Securities as herein
provided shall be appointed as authorized by Board Resolution or Supplemental Indenture (the &#147;Security Registrar&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender for transfer of any Security at the office or agency of the Company
designated for such purpose, the Company shall execute, the Trustee shall authenticate and such office or agency shall deliver in the name of the transferee or transferees a new Security or Securities of the same series as the Security presented for
a like aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company initially appoints the Trustee as initial Security Registrar for each series of Securities
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Securities presented or surrendered for exchange or registration of transfer, as provided in this Section, shall be accompanied (if
so required by the Company or the Security Registrar) by a written instrument or instruments of transfer, in form satisfactory to the Company or the Security Registrar, duly executed by the registered holder or by such holder&#146;s duly authorized
attorney in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Except as provided pursuant to Section&nbsp;2.01 pursuant to a Board Resolution, and set forth in an
Officer&#146;s Certificate, or established in one or more indentures supplemental to this Indenture, no service charge shall be made for any exchange or registration of transfer of Securities, or issue of new Securities in case of partial redemption
of any series or repurchase, conversion or exchange of less than the entire principal amount of a Security, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge in relation thereto, other than
exchanges pursuant to Section&nbsp;2.06, Section&nbsp;3.03(b) and Section&nbsp;9.04 not involving any transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company and the
Security Registrar shall not be required (i)&nbsp;to issue, exchange or register the transfer of any Securities during a period beginning at the opening of business 15 days before the day of the sending of a notice of redemption of less than all the
Outstanding Securities of the same series and ending at the close of business on the day of such sending, nor (ii)&nbsp;to register the transfer of or exchange any Securities of any series or portions thereof called for redemption or surrendered for
repurchase, but not validly withdrawn, other than the unredeemed portion of any such Securities being redeemed in part or not surrendered for repurchase, as the case may be. The provisions of this Section&nbsp;2.05 are, with respect to any Global
Security, subject to Section&nbsp;2.11 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee shall have no obligation or duty to monitor, determine or inquire as to
compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Security (including any transfers between or among Depositary participants or beneficial owners of
interests in any Global Security) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the
same to determine substantial compliance as to form with the express requirements hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.06 Temporary Securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the preparation of definitive Securities of any series, the Company may execute, and the Trustee shall authenticate and deliver,
temporary Securities (printed, lithographed or typewritten) of any authorized denomination. Such temporary Securities shall be substantially in the form of the definitive Securities in lieu of which they are issued, but with such omissions,
insertions and variations as may be appropriate for temporary Securities, all as may be determined by the Company. Every temporary Security of any series shall be executed by the Company and be authenticated by the Trustee upon the same conditions
and in substantially the same manner, and with like effect, as the definitive Securities of such series. Without unnecessary delay the Company will execute and will furnish definitive Securities of such series and thereupon any or all temporary
Securities of such series may be surrendered in exchange therefor (without charge to the Securityholders), at the office or agency of the Company designated for the purpose, and the Trustee shall authenticate and such office or agency shall deliver
in exchange for such temporary Securities an equal aggregate principal amount of definitive Securities of such series, unless the Company advises the Trustee to the effect that definitive Securities need not be executed and furnished until further
notice from the Company. Until so exchanged, the temporary Securities of such series shall be entitled to the same benefits under this Indenture as definitive Securities of such series authenticated and delivered hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.07 Mutilated, Destroyed, Lost or Stolen Securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any temporary or definitive Security shall become mutilated or be destroyed, lost or stolen, the Company (subject to the next
succeeding sentence) shall execute, and upon the Company&#146;s request the Trustee (subject as aforesaid) shall authenticate and deliver, a new Security of the same series, bearing a number not contemporaneously outstanding, in exchange and
substitution for the mutilated Security, or in lieu of and in substitution for the Security so destroyed, lost or stolen. In every case the applicant for a substituted Security shall furnish to the Company and the Trustee such security or indemnity
as may be required by them to save each of them harmless, and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company and the Trustee evidence to their satisfaction of the destruction, loss or theft of the
applicant&#146;s Security and of the ownership thereof. The Trustee may authenticate any such substituted Security and deliver the same upon the written request or authorization of any officer of the Company. Upon the issuance of any substituted
Security, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any Security that has matured or is about to mature shall become mutilated or be destroyed, lost or stolen, the Company may, instead
of issuing a substitute Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Security) if the applicant for such payment shall furnish to the Company and the Trustee such security or
indemnity as they may require to save them harmless, and, in case of destruction, loss or theft, evidence to the satisfaction of the Company and the Trustee of the destruction, loss or theft of such Security and of the ownership thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every replacement Security issued pursuant to the provisions of this Section shall
constitute an additional contractual obligation of the Company whether or not the mutilated, destroyed, lost or stolen Security shall be found at any time, or be enforceable by anyone, and shall be entitled to all the benefits of this Indenture
equally and proportionately with any and all other Securities of the same series duly issued hereunder. All Securities shall be held and owned upon the express condition that the foregoing provisions are exclusive with respect to the replacement or
payment of mutilated, destroyed, lost or stolen Securities, and shall preclude (to the extent lawful) any and all other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the contrary with respect to the
replacement or payment of negotiable instruments or other securities without their surrender. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.08 Cancellation. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Securities surrendered for the purpose of payment, redemption, repurchase, exchange, registration of transfer or conversion shall, if
surrendered to the Company or any paying agent (or any other applicable agent), be delivered to the Trustee for cancellation, or, if surrendered to the Trustee, shall be cancelled by it, and no Securities shall be issued in lieu thereof except as
expressly required or permitted by any of the provisions of this Indenture. On request of the Company at the time of such surrender, the Trustee shall deliver to the Company canceled Securities held by the Trustee. In the absence of such request the
Trustee may dispose of canceled Securities in accordance with its standard procedures and deliver a certificate of disposition to the Company. If the Company shall otherwise acquire any of the Securities, however, such acquisition shall not operate
as a redemption or satisfaction of the indebtedness represented by such Securities unless and until the same are delivered to the Trustee for cancellation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.09 Benefits of Indenture. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing in this Indenture or in the Securities, express or implied, shall give or be construed to give to any Person, other than the parties
hereto and the holders of the Securities any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained; all such covenants, conditions and provisions being for the
sole benefit of the parties hereto and of the holders of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.10 Authenticating Agent. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as any of the Securities of any series remain Outstanding there may be an Authenticating Agent for any or all such series of
Securities which the Trustee shall have the right to appoint. Said Authenticating Agent shall be authorized to act on behalf of the Trustee to authenticate Securities of such series issued upon exchange, transfer or partial redemption, repurchase or
conversion thereof, and Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and obligatory for all purposes as if authenticated by the Trustee hereunder. All references in this Indenture to the
authentication of Securities by the Trustee shall be deemed to include authentication by an Authenticating Agent for such series. Each Authenticating Agent shall be acceptable to the Company and shall be a corporation that has a combined capital and
surplus, as most recently reported or determined by it, sufficient under the laws of any jurisdiction under which it is organized or in which it is doing business to conduct a trust business, and that is otherwise authorized under such laws to
conduct such business and is subject to supervision or examination by federal or state authorities. If at any time any Authenticating Agent shall cease to be eligible in accordance with these provisions, it shall resign immediately. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Authenticating Agent may at any time resign by giving written notice of resignation to
the Trustee and to the Company. The Trustee may at any time (and upon request by the Company shall) terminate the agency of any Authenticating Agent by giving written notice of termination to such Authenticating Agent and to the Company. Upon
resignation, termination or cessation of eligibility of any Authenticating Agent, the Trustee may appoint an eligible successor Authenticating Agent acceptable to the Company. Any successor Authenticating Agent, upon acceptance of its appointment
hereunder, shall become vested with all the rights, powers and duties of its predecessor hereunder as if originally named as an Authenticating Agent pursuant hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.11 Global Securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Company shall establish pursuant to Section&nbsp;2.01 that the Securities of a particular series are to be issued as a Global
Security, then the Company shall execute and the Trustee shall, in accordance with Section&nbsp;2.04, authenticate and deliver, a Global Security that (i)&nbsp;shall represent, and shall be denominated in an amount equal to the aggregate principal
amount of, all of the Outstanding Securities of such series, (ii)&nbsp;shall be registered in the name of the Depositary or its nominee, (iii)&nbsp;shall be delivered by the Trustee to the Depositary or pursuant to the Depositary&#146;s instruction
(or if the Depositary names the Trustee as its custodian, retained by the Trustee), and (iv)&nbsp;shall bear a legend substantially to the following effect: &#147;Except as otherwise provided in Section&nbsp;2.11 of the Indenture, this Security may
be transferred, in whole but not in part, only to another nominee of the Depositary or to a successor Depositary or to a nominee of such successor Depositary.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Notwithstanding the provisions of Section&nbsp;2.05, the Global Security of a series may be transferred, in whole but not in part and in
the manner provided in Section&nbsp;2.05, only to another nominee of the Depositary for such series, or to a successor Depositary for such series selected or approved by the Company or to a nominee of such successor Depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) If at any time the Depositary for a series of the Securities notifies the Company that it is unwilling or unable to continue as Depositary
for such series or if at any time the Depositary for such series shall no longer be registered or in good standing under the Exchange Act, or other applicable statute or regulation, and a successor Depositary for such series is not appointed by the
Company within 90 days after the Company receives such notice or becomes aware of such condition, as the case may be, or if an Event of Default has occurred and is continuing and the Company has received a request from the Depositary or from the
Trustee, this Section&nbsp;2.11 shall no longer be applicable to the Securities of such series and the Company will execute, and subject to Section&nbsp;2.04, the Trustee will authenticate and deliver the Securities of such series in definitive
registered form without coupons, in authorized denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. In addition, the Company may at any time
determine that the Securities of any series shall no longer be represented by a Global Security and that the provisions of this Section&nbsp;2.11 shall no longer apply to the Securities of such series. In such event the Company will execute and,
subject to Section&nbsp;2.04, the Trustee, upon receipt of an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Officer&#146;s Certificate evidencing such determination by the Company, will authenticate and deliver the Securities of such series in definitive registered form without coupons, in authorized
denominations, and in an aggregate principal amount equal to the principal amount of the Global Security of such series in exchange for such Global Security. Upon the exchange of the Global Security for such Securities in definitive registered form
without coupons, in authorized denominations, the Global Security shall be canceled by the Trustee. Such Securities in definitive registered form issued in exchange for the Global Security pursuant to this Section&nbsp;2.11(c) shall be registered in
such names and in such authorized denominations as the Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall instruct the Trustee. The Trustee shall deliver such Securities to the Depositary for delivery
to the Persons in whose names such Securities are so registered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2.12 CUSIP Numbers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company in issuing the Securities may use &#147;CUSIP&#148; numbers (if then generally in use), and, if so, the Trustee shall use
&#147;CUSIP&#148; numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any
notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers. The Company will promptly
notify the Trustee of any change in the &#147;CUSIP&#148; numbers. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REDEMPTION OF SECURITIES AND SINKING FUND PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.01 Redemption. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may redeem the Securities of any series issued hereunder on and after the dates and in accordance with the terms established for
such series pursuant to Section&nbsp;2.01 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.02 Notice of Redemption. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In case the Company shall desire to exercise such right to redeem all or, as the case may be, a portion of the Securities of any series in
accordance with any right the Company reserved for itself to do so pursuant to Section&nbsp;2.01 hereof, the Company shall, or shall cause the Trustee to, give notice of such redemption to holders of the Securities of such series to be redeemed by
mailing, first class postage prepaid (or with regard to any Global Security held in book entry form, by electronic mail in accordance with the applicable procedures of the Depositary), a notice of such redemption not less than 30 days and not more
than 90 days before the date fixed for redemption of that series to such Securityholders, unless a shorter period is specified in the Securities to be redeemed. Any notice that is mailed in the manner herein provided shall be conclusively presumed
to have been duly given, whether or not the registered holder receives the notice. In any case, failure duly to give such notice to the holder of any Security of any series designated for redemption in whole or in part, or any defect in the notice,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall not affect the validity of the proceedings for the redemption of any other Securities of such series or any other series. In the case of any redemption of Securities prior to the expiration
of any restriction on such redemption provided in the terms of such Securities or elsewhere in this Indenture, the Company shall furnish the Trustee with an Officer&#146;s Certificate evidencing compliance with any such restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each such notice of redemption shall identify the Securities to be redeemed (including CUSIP numbers, if any), specify the date fixed for
redemption and the redemption price at which Securities of that series are to be redeemed, and shall state that payment of the redemption price of such Securities to be redeemed will be made at the office or agency of the Company, upon presentation
and surrender of such Securities, that interest accrued to the date fixed for redemption will be paid as specified in said notice, that from and after said date interest will cease to accrue and that the redemption is from a sinking fund, if such is
the case. If less than all the Securities of a series are to be redeemed, the notice to the holders of Securities of that series to be redeemed in part shall specify the particular Securities to be so redeemed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any Security is to be redeemed in part only, the notice that relates to such Security shall state the portion of the principal amount
thereof to be redeemed, and shall state that on and after the redemption date, upon surrender of such Security, a new Security or Securities of such series in principal amount equal to the unredeemed portion thereof will be issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If less than all the Securities of a series are to be redeemed, the Company shall give the Trustee at least 45 days&#146; notice (unless a
shorter notice shall be satisfactory to the Trustee) in advance of the date fixed for redemption as to the aggregate principal amount of Securities of the series to be redeemed, and thereupon the Securities to be redeemed shall be selected, by lot,
on a pro rata basis, or in such other manner as the Company shall deem appropriate and fair in its discretion and that may provide for the selection of a portion or portions (equal to one thousand U.S. dollars ($1,000) or any integral multiple
thereof) of the principal amount of such Securities of a denomination larger than $1,000, the Securities to be redeemed and shall thereafter promptly notify the Company in writing of the numbers of the Securities to be redeemed, in whole or in part.
The Company may, if and whenever it shall so elect, by delivery of instructions signed on its behalf by an Officer, instruct the Trustee or any paying agent to call all or any part of the Securities of a particular series for redemption and to give
notice of redemption in the manner set forth in this Section, such notice to be in the name of the Company or its own name as the Trustee or such paying agent may deem advisable. In any case in which notice of redemption is to be given by the
Trustee or any such paying agent, the Company shall deliver or cause to be delivered to, or permit to remain with, the Trustee or such paying agent, as the case may be, such Security Register, transfer books or other records, or suitable copies or
extracts therefrom, sufficient to enable the Trustee or such paying agent to give any notice by mail that may be required under the provisions of this Section. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.03 Payment Upon Redemption. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the giving of notice of redemption shall have been completed as above provided, the Securities or portions of Securities of the series
to be redeemed specified in such notice shall become due and payable on the date and at the place stated in such notice at the applicable redemption price, together with interest accrued to, but excluding, the date fixed for redemption and interest
on such Securities or portions of Securities shall cease to accrue on and after the date fixed for redemption, unless the Company shall default in the payment of such redemption price and accrued interest with respect to any such Security or portion
thereof. On presentation and surrender of such Securities on or after the date fixed for redemption at the place of payment specified in the notice, said Securities shall be paid and redeemed at the applicable redemption price for such series,
together with interest accrued thereon to, but excluding, the date fixed for redemption (but if the date fixed for redemption is an Interest Payment Date, the interest installment payable on such date shall be payable to the registered holder at the
close of business on the applicable record date pursuant to Section&nbsp;2.03). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Upon presentation of any Security of such series that
is to be redeemed in part only, the Company shall execute and the Trustee shall authenticate and the office or agency where the Security is presented shall deliver to the Securityholder thereof, at the expense of the Company, a new Security of the
same series of authorized denominations in principal amount equal to the unredeemed portion of the Security so presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.04 Sinking Fund. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of Sections 3.04, 3.05 and 3.06 shall be applicable to any sinking fund for the retirement of Securities of a series, except as
otherwise specified as contemplated by Section&nbsp;2.01 for Securities of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The minimum amount of any sinking fund payment
provided for by the terms of Securities of any series is herein referred to as a &#147;mandatory sinking fund payment,&#148; and any payment in excess of such minimum amount provided for by the terms of Securities of any series is herein referred to
as an &#147;optional sinking fund payment&#148;. If provided for by the terms of Securities of any series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section&nbsp;3.05. Each sinking fund payment shall be
applied to the redemption of Securities of any series as provided for by the terms of Securities of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.05
Satisfaction of Sinking Fund Payments with Securities. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company (i)&nbsp;may deliver Outstanding Securities of a series and
(ii)&nbsp;may apply as a credit Securities of a series that have been redeemed either at the election of the Company pursuant to the terms of such Securities or through the application of permitted optional sinking fund payments pursuant to the
terms of such Securities, in each case in satisfaction of all or any part of any sinking fund payment with respect to the Securities of such series required to be made pursuant to the terms of such Securities as provided for by the terms of such
series, provided that such Securities have not been previously so credited. Such Securities shall be received and credited for such purpose by the Trustee at the redemption price specified in such Securities for redemption through operation of the
sinking fund and the amount of such sinking fund payment shall be reduced accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3.06 Redemption of Securities for Sinking Fund. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not less than 45 days prior to each sinking fund payment date for any series of Securities (unless a shorter period shall be satisfactory to
the Trustee), the Company will deliver to the Trustee an Officer&#146;s Certificate specifying the amount of the next ensuing sinking fund payment for that series pursuant to the terms of the series, the portion thereof, if any, that is to be
satisfied by delivering and crediting Securities of that series pursuant to Section&nbsp;3.05 and the basis for such credit and will, together with such Officer&#146;s Certificate, deliver to the Trustee any Securities to be so delivered. Not less
than 30 days before each such sinking fund payment date the Securities to be redeemed upon such sinking fund payment date shall be selected in the manner specified in Section&nbsp;3.02 and the Company Shall cause notice of the redemption thereof to
be given in the name of and at the expense of the Company in the manner provided in Section&nbsp;3.02. Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Section&nbsp;3.03.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.01 Payment of Principal, Premium and Interest. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will duly and punctually pay or cause to be paid the principal of (and premium, if any) and interest on the Securities of that
series at the time and place and in the manner provided herein and established with respect to such Securities. Payments of principal on the Securities may be made at the time provided herein and established with respect to such Securities by U.S.
dollar check drawn on and mailed to the address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account if such Securityholder shall have furnished wire
instructions to the Trustee no later than 15 days prior to the relevant payment date. Payments of interest on the Securities may be made at the time provided herein and established with respect to such Securities by U.S. dollar check mailed to the
address of the Securityholder entitled thereto as such address shall appear in the Security Register, or U.S. dollar wire transfer to, a U.S. dollar account if such Securityholder shall have furnished wire instructions in writing to the Security
Registrar and the Trustee no later than 15 days prior to the relevant payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.02 Maintenance of Office or Agency.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as any series of the Securities remain Outstanding, the Company agrees to maintain an office or agency with respect to each
such series and at such other location or locations as may be designated as provided in this Section&nbsp;4.02, where (i)&nbsp;Securities of that series may be presented for payment, (ii)&nbsp;Securities of that series may be presented as herein
above authorized for registration of transfer and exchange, and (iii)&nbsp;notices and demands to or upon the Company in respect of the Securities of that series and this Indenture may be given or served, such designation to continue with respect to
such office or agency until the Company shall, by written notice signed by any officer authorized to sign an Officer&#146;s Certificate and delivered to the Trustee, designate some other office or agency for such purposes or any of them. If at any
time the Company shall fail to maintain any such required office or agency or shall fail to furnish the Trustee with the address thereof, such presentations, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and
the Company hereby appoints the Trustee as its agent to receive all such presentations, notices and demands. The Company initially appoints the Corporate Trust Office of the Trustee as its paying agent with respect to the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.03 Paying Agents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If the Company shall appoint one or more paying agents for all or any series of the Securities, other than the Trustee, the Company will
cause each such paying agent to execute and deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to the provisions of this Section: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) that it will hold all sums held by it as such agent for the payment of the principal of (and premium, if any) or interest on the
Securities of that series (whether such sums have been paid to it by the Company or by any other obligor of such Securities) in trust for the benefit of the Persons entitled thereto; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) that it will give the Trustee notice of any failure by the Company (or by any other obligor of such Securities) to make any payment of
the principal of (and premium, if any) or interest on the Securities of that series when the same shall be due and payable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) that it
will, at any time during the continuance of any failure referred to in the preceding paragraph (a)(2) above, upon the written request of the Trustee, forthwith pay to the Trustee all sums so held in trust by such paying agent; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) that it will perform all other duties of paying agent as set forth in this Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Company shall act as its own paying agent with respect to any series of the Securities, it will on or before each due date of the
principal of (and premium, if any) or interest on Securities of that series, set aside, segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay such principal (and premium, if any) or interest so becoming
due on Securities of that series until such sums shall be paid to such Persons or otherwise disposed of as herein provided and will promptly notify the Trustee of such action, or any failure (by it or any other obligor on such Securities) to take
such action. Whenever the Company shall have one or more paying agents for any series of Securities, it will, prior to each due date of the principal of (and premium, if any) or interest on any Securities of that series, deposit with the paying
agent a sum sufficient to pay the principal (and premium, if any) or interest so becoming due, such sum to be held in trust for the benefit of the Persons entitled to such principal, premium or interest, and (unless such paying agent is the Trustee)
the Company will promptly notify the Trustee of this action or failure so to act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything in this Section to the
contrary, (i)&nbsp;the agreement to hold sums in trust as provided in this Section is subject to the provisions of Section&nbsp;11.05, and (ii)&nbsp;the Company may at any time, for the purpose of obtaining the satisfaction and discharge of this
Indenture or for any other purpose, pay, or direct any paying agent to pay, to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by the Trustee upon the same terms and conditions as those upon which such
sums were held by the Company or such paying agent; and, upon such payment by the Company or any paying agent to the Trustee, the Company or such paying agent shall be released from all further liability with respect to such money. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4.04 Appointment to Fill Vacancy in Office of Trustee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in
Section&nbsp;7.10, a Trustee, so that there shall at all times be a Trustee hereunder. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITYHOLDERS&#146; LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.01 Company to Furnish Trustee Names and Addresses of Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will furnish or cause to be furnished to the Trustee (a)&nbsp;within 15 days after each regular record date (as defined in
Section&nbsp;2.03) a list, in such form as the Trustee may reasonably require, of the names and addresses of the holders of each series of Securities as of such regular record date, provided that the Company shall not be obligated to furnish or
cause to furnish such list at any time that the list shall not differ in any respect from the most recent list furnished to the Trustee by the Company and (b)&nbsp;at such other times as the Trustee may request in writing within 30 days after the
receipt by the Company of any such request, a list of similar form and content as of a date not more than 15 days prior to the time such list is furnished; provided, however, that, in either case, no such list need be furnished for any series for
which the Trustee shall be the Security Registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.02 Preservation Of Information; Communications With Securityholders.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of
the holders of Securities contained in the most recent list furnished to it as provided in Section&nbsp;5.01 and as to the names and addresses of holders of Securities received by the Trustee in its capacity as Security Registrar (if acting in such
capacity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Trustee may destroy any list furnished to it as provided in Section&nbsp;5.01 upon receipt of a new list so furnished.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Securityholders may communicate as provided in Section&nbsp;312(b) of the Trust Indenture Act with other Securityholders with respect
to their rights under this Indenture or under the Securities, and, in connection with any such communications, the Trustee shall satisfy its obligations under Section&nbsp;312(b) of the Trust Indenture Act in accordance with the provisions of
Section&nbsp;312(b) of the Trust Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.03 Reports by the Company. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company will at all times comply with Section&nbsp;314(a) of the Trust Indenture Act. The Company covenants and agrees to provide
(which delivery may be via electronic mail) to the Trustee within 30 days, after the Company files the same with the Commission, copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of
the foregoing as the Commission may from time to time by rules and regulations prescribe) that the Company is required to file with the Commission pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act; provided, however, the Company
shall not be required to deliver to the Trustee any correspondence filed with the Commission or any materials for which the Company has sought and received confidential treatment by the Commission; and provided further, that so long as such filings
by the Company are available on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval System (EDGAR), or any successor system, such filings shall be deemed to have been filed with the Trustee for purposes hereof without any further
action required by the Company. For the avoidance of doubt, a failure by the Company to file annual reports, information and other reports with the Commission within the time period prescribed thereof by the Commission shall not be deemed a breach
of this Section&nbsp;5.03. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Delivery of reports, information and documents to the Trustee under Section&nbsp;5.03 is for informational
purposes only and the information and the Trustee&#146;s receipt of the foregoing shall not constitute constructive notice of any information contained therein, or determinable from information contained therein including the Company&#146;s
compliance with any of their covenants thereunder (as to which the Trustee is entitled to rely exclusively on an Officer&#146;s Certificate). The Trustee is under no duty to examine any such reports, information or documents delivered to the Trustee
or filed with the Commission via EDGAR to ensure compliance with the provision of this Indenture or to ascertain the correctness or otherwise of the information or the statements contained therein. The Trustee shall have no responsibility or duty
whatsoever to ascertain or determine whether the above referenced filings with the Commission on EDGAR (or any successor system) has occurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5.04 Reports by the Trustee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) If required by Section&nbsp;313(a) of the Trust Indenture Act, the Trustee, within sixty (60)&nbsp;days after each May&nbsp;1, shall mail
to the Securityholders a brief report dated as of such May&nbsp;1, which complies with Section&nbsp;313(a) of the Trust Indenture Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Trustee shall comply with Section&nbsp;313(b) and 313(c) of the Trust Indenture Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) A copy of each such report shall, at the time of such transmission to Securityholders, be filed by the Trustee with the Company, with each
securities exchange upon which any Securities are listed (if so listed) and also with the Commission. The Company agrees to notify the Trustee when any Securities become listed on any securities exchange. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REMEDIES OF THE TRUSTEE AND SECURITYHOLDERS ON EVENT OF DEFAULT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.01 Events of Default. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Whenever used herein with respect to Securities of a particular series, &#147;Event of Default&#148; means any one or more of the
following events that has occurred and is continuing: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) the Company defaults in the payment of any installment of interest upon any of
the Securities of that series, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by the Company in accordance with the terms
of any indenture supplemental hereto shall not constitute a default in the payment of interest for this purpose; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) the Company
defaults in the payment of the principal of (or premium, if any, on) any of the Securities of that series as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required
by any sinking or analogous fund established with respect to that series; provided, however, that a valid extension of the maturity of such Securities in accordance with the terms of any indenture supplemental hereto shall not constitute a default
in the payment of principal or premium, if any; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) the Company fails to observe or perform any other of its covenants or agreements
with respect to that series contained in this Indenture or otherwise established with respect to that series of Securities pursuant to Section&nbsp;2.01 hereof (other than a covenant or agreement that has been expressly included in this Indenture
solely for the benefit of one or more series of Securities other than such series) for a period of 90 days after the date on which written notice of such failure, requiring the same to be remedied and stating that such notice is a &#147;Notice of
Default&#148; hereunder, shall have been given to the Company by the Trustee, by registered or certified mail, or to the Company and the Trustee by the holders of at least 25% in principal amount of the Securities of that series at the time
Outstanding; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) the Company pursuant to or within the meaning of any Bankruptcy Law (i)&nbsp;commences a voluntary case,
(ii)&nbsp;consents to the entry of an order for relief against it in an involuntary case, (iii)&nbsp;consents to the appointment of a Custodian of it or for all or substantially all of its property or (iv)&nbsp;makes a general assignment for the
benefit of its creditors; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(5) a court of competent jurisdiction enters an order under any Bankruptcy Law that (i)&nbsp;is for relief
against the Company in an involuntary case, (ii)&nbsp;appoints a Custodian of the Company for all or substantially all of its property or (iii)&nbsp;orders the liquidation of the Company, and the order or decree remains unstayed and in effect for 90
days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In each and every such case (other than an Event of Default specified in clause (4)&nbsp;or clause (5)&nbsp;above), unless the
principal of all the Securities of that series shall have already become due and payable, either the Trustee or the holders of not less than 25% in aggregate principal amount of the Securities of that series then Outstanding hereunder, by notice in
writing to the Company (and to the Trustee if given by such Securityholders), may declare the principal of (and premium, if any, on) and accrued and unpaid interest on all the Securities of that series to be due and payable immediately, and upon any
such declaration the same shall become and shall be immediately due and payable. If an Event of Default specified in clause (4)&nbsp;or clause (5)&nbsp;above occurs, the principal of and accrued and unpaid interest on all the Securities of that
series shall automatically be immediately due and payable without any declaration or other act on the part of the Trustee or the holders of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) At any time after the principal of (and premium, if any, on) and accrued and unpaid
interest on the Securities of that series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the holders of a majority in
aggregate principal amount of the Securities of that series then Outstanding hereunder, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if: (i)&nbsp;the Company has paid or deposited with
the Trustee a sum sufficient to pay all matured installments of interest upon all the Securities of that series and the principal of (and premium, if any, on) any and all Securities of that series that shall have become due otherwise than by
acceleration (with interest upon such principal and premium, if any, and, to the extent that such payment is enforceable under applicable law, upon overdue installments of interest, at the rate per annum expressed in the Securities of that series to
the date of such payment or deposit) and the amount payable to the Trustee under Section&nbsp;7.06, and (ii)&nbsp;any and all Events of Default under the Indenture with respect to such series, other than the nonpayment of principal on (and premium,
if any, on) and accrued and unpaid interest on Securities of that series that shall not have become due by their terms, shall have been remedied or waived as provided in Section&nbsp;6.06. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No such rescission and annulment shall extend to or shall affect any subsequent default or impair any right consequent thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) In case the Trustee shall have proceeded to enforce any right with respect to Securities of that series under this Indenture and such
proceedings shall have been discontinued or abandoned because of such rescission or annulment or for any other reason or shall have been determined adversely to the Trustee, then and in every such case, subject to any determination in such
proceedings, the Company and the Trustee shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company and the Trustee shall continue as though no such proceedings had been taken.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.02 Collection of Indebtedness and Suits for Enforcement by Trustee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company covenants that (i)&nbsp;in case it shall default in the payment of any installment of interest on any of the Securities of a
series, or in any payment required by any sinking or analogous fund established with respect to that series as and when the same shall have become due and payable, and such default shall have continued for a period of 90 days, or (ii)&nbsp;in case
it shall default in the payment of the principal of (or premium, if any, on) any of the Securities of a series when the same shall have become due and payable, whether upon maturity of the Securities of a series or upon redemption or upon
declaration or otherwise then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the holders of the Securities of that series, the whole amount that then shall have been become due and payable on all such Securities
for principal (and premium, if any) or interest, or both, as the case may be, with interest upon the overdue principal (and premium, if any) and (to the extent that payment of such interest is enforceable under applicable law) upon overdue
installments of interest at the rate per annum expressed in the Securities of that series; and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, and the amount payable to the Trustee
under Section&nbsp;7.06. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If the Company shall fail to pay such amounts forthwith upon such demand, the Trustee,
in its own name and as trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to
judgment or final decree, and may enforce any such judgment or final decree against the Company or other obligor upon the Securities of that series and collect the moneys adjudged or decreed to be payable in the manner provided by law or equity out
of the property of the Company or other obligor upon the Securities of that series, wherever situated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In case of any receivership,
insolvency, liquidation, bankruptcy, reorganization, readjustment, arrangement, composition or judicial proceedings affecting the Company, or its creditors or property, the Trustee shall have power to intervene in such proceedings and take any
action therein that may be permitted by the court and shall (except as may be otherwise provided by law) be entitled to file such proofs of claim and other papers and documents as may be necessary or advisable in order to have the claims of the
Trustee and of the holders of Securities of such series allowed for the entire amount due and payable by the Company under the Indenture at the date of institution of such proceedings and for any additional amount that may become due and payable by
the Company after such date, and to collect and receive any moneys or other property payable or deliverable on any such claim, and to distribute the same after the deduction of the amount payable to the Trustee under Section&nbsp;7.06; and any
receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the holders of Securities of such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such
payments directly to such Securityholders, to pay to the Trustee any amount due it under Section&nbsp;7.06. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) All rights of action and
of asserting claims under this Indenture, or under any of the terms established with respect to Securities of that series, may be enforced by the Trustee without the possession of any of such Securities, or the production thereof at any trial or
other proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for payment to the Trustee of any
amounts due under Section&nbsp;7.06, be for the ratable benefit of the holders of the Securities of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of an Event of
Default hereunder, the Trustee may in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such
rights, either at law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in the Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other
legal or equitable right vested in the Trustee by this Indenture or by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained herein shall be deemed to authorize the
Trustee to authorize or consent to or accept or adopt on behalf of any Securityholder any plan of reorganization, arrangement, adjustment or composition affecting the Securities of that series or the rights of any Securityholder thereof or to
authorize the Trustee to vote in respect of the claim of any Securityholder in any such proceeding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.03 Application of Moneys Collected. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any moneys collected by the Trustee pursuant to this Article with respect to a particular series of Securities shall be applied in the
following order, at the date or dates fixed by the Trustee and, in case of the distribution of such moneys on account of principal (or premium, if any) or interest, upon presentation of the Securities of that series, and notation thereon of the
payment, if only partially paid, and upon surrender thereof if fully paid: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FIRST: To the payment of costs and expenses of collection and
of all amounts payable to the Trustee under Section&nbsp;7.06; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SECOND: To the payment of the amounts then due and unpaid upon Securities
of such series for principal (and premium, if any) and interest, in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such
Securities for principal (and premium, if any) and interest, respectively; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIRD: To the payment of the remainder, if any, to the
Company or any other Person lawfully entitled thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.04 Limitation on Suits. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No holder of any Security of any series shall have any right by virtue or by availing of any provision of this Indenture to institute any
suit, action or proceeding in equity or at law upon or under or with respect to this Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless (i)&nbsp;such Securityholder previously shall have given to the
Trustee written notice of an Event of Default and of the continuance thereof with respect to the Securities of such series specifying such Event of Default, as hereinbefore provided; (ii)&nbsp;the holders of not less than 25% in aggregate principal
amount of the Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as Trustee hereunder; (iii)&nbsp;such Securityholder or Securityholders shall have
offered to the Trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred in compliance with such request; (iv)&nbsp;the Trustee for 90 days after its receipt of such notice, request and offer of indemnity, shall
have failed to institute any such action, suit or proceeding and (v)&nbsp;during such 90 day period, the holders of a majority in principal amount of the Securities of that series do not give the Trustee a direction inconsistent with the request.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything contained herein to the contrary or any other provisions of this Indenture, the right of any holder of any
Security to receive payment of the principal of (and premium, if any) and interest on such Security, as therein provided, on or after the respective due dates expressed in such Security (or in the case of redemption, on the redemption date), or to
institute suit for the enforcement of any such payment on or after such respective dates or redemption date, shall not be impaired or affected without the consent of such holder and by accepting a Security hereunder it is expressly understood,
intended and covenanted by the taker </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and holder of every Security of such series with every other such taker and holder and the Trustee, that no one or more holders of Securities of such series shall have any right in any manner
whatsoever by virtue or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of the holders of any other of such Securities, or to obtain or seek to obtain priority over or preference to any other such holder, or
to enforce any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all holders of Securities of such series. For the protection and enforcement of the provisions of this Section, each and
every Securityholder and the Trustee shall be entitled to such relief as can be given either at law or in equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.05
Rights and Remedies Cumulative; Delay or Omission Not Waiver. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Except as otherwise provided in Section&nbsp;2.07, all powers and
remedies given by this Article to the Trustee or to the Securityholders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any other powers and remedies available to the Trustee or the holders of the Securities, by
judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture or otherwise established with respect to such Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No delay or omission of the Trustee or of any holder of any of the Securities to exercise any right or power accruing upon any Event of
Default occurring and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to the provisions of Section&nbsp;6.04, every power and remedy
given by this Article or by law to the Trustee or the Securityholders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.06 Control by Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding, determined in accordance with
Section&nbsp;8.04, shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect to such series; provided,
however, that such direction shall not be in conflict with any rule of law or with this Indenture or subject the Trustee in its sole discretion to personal liability. Subject to the provisions of Section&nbsp;7.01, the Trustee shall have the right
to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer or officers of the Trustee, determine that the proceeding so directed, subject to the Trustee&#146;s duties under the Trust Indenture Act, would
involve the Trustee in personal liability or might be unduly prejudicial to the Securityholders not involved in the proceeding. The holders of a majority in aggregate principal amount of the Securities of any series at the time Outstanding affected
thereby, determined in accordance with Section&nbsp;8.04, may on behalf of the holders of all of the Securities of such series waive any past default in the performance of any of the covenants contained herein or established pursuant to
Section&nbsp;2.01 with respect to such series and its consequences, except a default in the payment of the principal of, or premium, if any, or interest on, any of the Securities of that series as and when the same shall become due by the terms of
such Securities otherwise than by acceleration (unless such default has been cured and a sum sufficient to pay all matured </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
installments of interest and principal and any premium has been deposited with the Trustee (in accordance with Section&nbsp;6.01(c)). Upon any such waiver, the default covered thereby shall be
deemed to be cured for all purposes of this Indenture and the Company, the Trustee and the holders of the Securities of such series shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to
any subsequent or other default or impair any right consequent thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6.07 Undertaking to Pay Costs. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All parties to this Indenture agree, and each holder of any Securities by such holder&#146;s acceptance thereof shall be deemed to have
agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken or omitted by it as Trustee, the filing by any party litigant
in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#146; fees and expenses, against any party litigant in such suit, having due regard to
the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Trustee, to any suit instituted by any Securityholder, or group of Securityholders,
holding more than 10% in aggregate principal amount of the Outstanding Securities of any series, or to any suit instituted by any Securityholder for the enforcement of the payment of the principal of (or premium, if any) or interest on any Security
of such series, on or after the respective due dates expressed in such Security or established pursuant to this Indenture. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING THE TRUSTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.01 Certain Duties and Responsibilities of Trustee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Trustee, prior to the occurrence of an Event of Default with respect to the Securities of a series and after the curing of all Events
of Default with respect to the Securities of that series that may have occurred, shall undertake to perform with respect to the Securities of such series such duties and only such duties as are specifically set forth in this Indenture, and no
implied covenants shall be read into this Indenture against the Trustee. In case an Event of Default with respect to the Securities of a series has occurred (that has not been cured or waived), the Trustee shall exercise with respect to Securities
of that series such of the rights and powers vested in it by this Indenture, and use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the circumstances in the conduct of his or her own affairs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No provision of this Indenture shall be construed to relieve the Trustee from liability
for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) prior to the occurrence
of an Event of Default with respect to the Securities of a series and after the curing or waiving of all such Events of Default with respect to that series that may have occurred: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(A) the duties and obligations of the Trustee shall with respect to the Securities of such series be determined solely by the express
provisions of this Indenture, and the Trustee shall not be liable with respect to the Securities of such series except for the performance of such duties and obligations as are specifically set forth in this Indenture, and no implied covenants or
obligations shall be read into this Indenture against the Trustee; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(B) in the absence of bad faith on the part of the Trustee, the
Trustee may with respect to the Securities of such series conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon any certificates or opinions furnished to the Trustee and conforming to the
requirements of this Indenture; but in the case of any such certificates or opinions that by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or
not they conform to the requirements of this Indenture; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Trustee shall not be liable to any Securityholder or to any other
Person for any error of judgment made in good faith by a Responsible Officer or Responsible Officers of the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the
direction of the holders of not less than a majority in principal amount of the Securities of any series at the time Outstanding relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or
exercising any trust or power conferred upon the Trustee under this Indenture with respect to the Securities of that series; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) none
of the provisions contained in this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur personal financial liability in the performance of any of its duties or in the exercise of any of its rights or powers if
there is reasonable ground for believing that the repayment of such funds or liability is not reasonably assured to it under the terms of this Indenture or adequate indemnity against such risk is not reasonably assured to it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) The Trustee shall not be required to give any bond or surety in respect of the performance of its powers or duties hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) The permissive right of the Trustee to do things enumerated in this Indenture shall not be construed as a duty of the Trustee; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) No Trustee shall have any duty or responsibility for any act or omission of any other Trustee appointed with respect to a series of
Securities hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.02 Certain Rights of Trustee. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in Section&nbsp;7.01: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Trustee may conclusively rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, approval, bond, security or other paper or document believed by it to be genuine and to have been signed or presented by the proper party or parties; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by a Board Resolution or an
instrument signed in the name of the Company by any authorized Officer of the Company (unless other evidence in respect thereof is specifically prescribed herein); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Trustee may consult with counsel and the opinion or written advice of such counsel or, if requested, any Opinion of Counsel shall be
full and complete authorization and protection in respect of any action taken or suffered or omitted hereunder in good faith and in reliance thereon; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order or
direction of any of the Securityholders pursuant to the provisions of this Indenture, unless such Securityholders shall have offered to the Trustee security or indemnity reasonably acceptable to the Trustee against the costs, expenses and
liabilities that may be incurred therein or thereby; nothing contained herein shall, however, relieve the Trustee of the obligation, upon the occurrence of an Event of Default with respect to a series of the Securities (that has not been cured or
waived), to exercise with respect to Securities of that series such of the rights and powers vested in it by this Indenture, and to use the same degree of care and skill in their exercise, as a prudent man would exercise or use under the
circumstances in the conduct of his or her own affairs; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Trustee shall not be liable for any action taken or omitted to be taken
by it in good faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, approval, bond, security, or other papers or documents or inquire as to the performance by the Company of one of its covenants under this Indenture, unless requested in writing so to do
by the holders of not less than a majority in principal amount of the Outstanding Securities of the particular series affected thereby (determined as provided in Section&nbsp;8.04); provided, however, that if the payment within a reasonable time to
the Trustee of the costs, expenses or liabilities likely to be incurred by it in the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the Trustee by the security afforded to it by the terms of this Indenture,
the Trustee may require security or indemnity reasonably acceptable to the Trustee against such costs, expenses or liabilities as a condition to so proceeding. The reasonable expense of every such examination shall be paid by the Company or, if paid
by the Trustee, shall be repaid by the Company upon demand; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) The Trustee may execute any of the trusts or powers hereunder or perform any duties
hereunder either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising
out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and
interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to
resume performance as soon as practicable under the circumstances; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) In no event shall the Trustee be responsible or liable for
special, indirect, punitive or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the
form of action; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) The Trustee agrees to accept and act upon instructions or directions pursuant to this Indenture sent by unsecured
<FONT STYLE="white-space:nowrap">e-mail,</FONT> facsimile transmission or other similar unsecured electronic methods; provided, however, that such instructions or directions shall be signed by an authorized representative of the party providing such
instructions or directions. If the party elects to give the Trustee <FONT STYLE="white-space:nowrap">e-mail</FONT> or facsimile instructions (or instructions by a similar electronic method) and the Trustee in its discretion elects to act upon such
instructions, the Trustee&#146;s understanding of such instructions shall be deemed controlling. The Trustee shall not be liable for any losses, costs or expenses arising directly or indirectly from the Trustee&#146;s reliance upon and compliance
with such instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The party providing electronic instructions agrees to assume all risks arising out of the use of such electronic methods to
submit instructions and directions to the Trustee, including without limitation the risk of the Trustee acting on unauthorized instructions, and the risk or interception and misuse by third parties. The Trustee may request that the Company deliver
an Officer&#146;s Certificate setting forth the names of individuals and/or titles of officers authorized at such time to furnish the Trustee with Officer&#146;s Certificates, Company Orders and any other matters or directions pursuant to this
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its
right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder and under the Securities, and each agent, custodian or other person employed to act under this Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Trustee shall not be deemed to have knowledge of any Default or Event of Default (other than an Event of Default constituting the
failure to pay the interest on, or the principal of, the Securities if the Trustee also serves the paying agent for such Securities) until the Trustee shall have received written notification in the manner set forth in this Indenture or a
Responsible Officer of the Trustee shall have obtained actual knowledge. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.03 Trustee Not Responsible for Recitals or Issuance or Securities.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The recitals contained herein and in the Securities shall be taken as the statements of the Company, and the Trustee assumes no
responsibility for the correctness of the same. The Trustee shall not be responsible for any statement in any registration statement, prospectus, or any other document in connection with the sale of Securities. The Trustee shall not be responsible
for any rating on the Securities or any action or omission of any rating agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Trustee makes no representations as to the
validity or sufficiency of this Indenture or of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Trustee shall not be accountable for the use or application by
the Company of any of the Securities or of the proceeds of such Securities, or for the use or application of any moneys paid over by the Trustee in accordance with any provision of this Indenture or established pursuant to Section&nbsp;2.01, or for
the use or application of any moneys received by any paying agent other than the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.04 May Hold Securities.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee or any paying agent or Security Registrar, in its individual or any other capacity, may become the owner or pledgee of
Securities with the same rights it would have if it were not Trustee, paying agent or Security Registrar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.05 Moneys
Held in Trust. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;11.05, all moneys received by the Trustee shall, until used or applied as
herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required by law. The Trustee shall be under no liability for interest on any moneys received by it
hereunder except such as it may agree with the Company to pay thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.06 Compensation and Reimbursement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company shall pay to the Trustee for each of its capacities hereunder from time to time compensation for its services as the Company
and the Trustee shall from time to time agree upon in writing. The Trustee&#146;s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Company shall reimburse the Trustee upon request for all reasonable <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee&#146;s agents and counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall indemnify each of the Trustee in each of its capacities hereunder against any loss, liability or expense (including the
cost of defending itself and including the reasonable compensation and expenses of the Trustee&#146;s agents and counsel) incurred by it except as set forth in Section&nbsp;7.06(c) in the exercise or performance of its powers, rights or duties under
this Indenture as Trustee or Agent. The Trustee shall notify the Company promptly of any claim for which it may seek indemnity. The Company shall defend the claim and the Trustee shall cooperate in the defense. The Trustee may have one separate
counsel and the Company shall pay the reasonable fees and expenses of such counsel. The Company need not pay for any settlement made without its consent, which consent shall not be unreasonably withheld. This indemnification shall apply to officers,
directors, employees, shareholders and agents of the Trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company need not reimburse any expense or indemnify against any loss or liability
incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through negligence or bad faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
To ensure the Company&#146;s payment obligations in this Section, the Trustee shall have a lien prior to the Securities on all funds or property held or collected by the Trustee, except that held in trust to pay principal of or interest on
particular Securities. When the Trustee incurs expenses or renders services in connection with an Event of Default specified in Section&nbsp;6.01(4) or (5), the expenses (including the reasonable fees and expenses of its counsel) and the
compensation for services in connection therewith are to constitute expenses of administration under any bankruptcy law. The provisions of this Section&nbsp;7.06 shall survive the termination of this Indenture and the resignation or removal of the
Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.07 Reliance on Officer&#146;s Certificate. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in Section&nbsp;7.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem
it reasonably necessary or desirable that a matter be proved or established prior to taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the
absence of negligence or bad faith on the part of the Trustee, be deemed to be conclusively proved and established by an Officer&#146;s Certificate delivered to the Trustee and such certificate, in the absence of negligence or bad faith on the part
of the Trustee, shall be full warrant to the Trustee for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture upon the faith thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.08 Disqualification; Conflicting Interests. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Trustee has or shall acquire any &#147;conflicting interest&#148; within the meaning of Section&nbsp;310(b) of the Trust Indenture Act,
the Trustee and the Company shall in all respects comply with the provisions of Section&nbsp;310(b) of the Trust Indenture Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.09 Corporate Trustee Required; Eligibility. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There shall at all times be a Trustee with respect to the Securities issued hereunder which shall at all times be a corporation organized and
doing business under the laws of the United States of America or any state or territory thereof or of the District of Columbia, or a corporation or other Person permitted to act as trustee by the Commission, authorized under such laws to exercise
corporate trust powers, having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and subject to supervision or examination by federal, state, territorial, or District of Columbia authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If such corporation or other Person publishes reports of condition at least annually,
pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section, the combined capital and surplus of such corporation or other Person shall be deemed to be its combined capital and
surplus as set forth in its most recent report of condition so published. The Company may not, nor may any Person directly or indirectly controlling, controlled by, or under common control with the Company, serve as Trustee. In case at any time the
Trustee shall cease to be eligible in accordance with the provisions of this Section, the Trustee shall resign immediately in the manner and with the effect specified in Section&nbsp;7.10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.10 Resignation and Removal; Appointment of Successor. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Trustee or any successor hereafter appointed may at any time resign with respect to the Securities of one or more series by giving
written notice thereof to the Company and Securityholders of such series. Upon receiving such notice of resignation, the Company shall promptly appoint a successor trustee with respect to Securities of such series by written instrument, in
duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the resigning Trustee and one copy to the successor trustee. If no successor trustee shall have been so appointed and have accepted
appointment within 30 days after the sending of such notice of resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor trustee with respect to Securities of such series, or any
Securityholder of that series who has been a bona fide holder of a Security or Securities for at least six months may on behalf of himself and all others similarly situated, petition any such court for the appointment of a successor trustee. Such
court may thereupon after such notice, if any, as it may deem proper and prescribe, appoint a successor trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In case at any time
any one of the following shall occur: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Trustee shall fail to comply with the provisions of Section&nbsp;7.08 after written
request therefor by the Company or by any Securityholder who has been a bona fide holder of a Security or Securities for at least six months; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) the Trustee shall cease to be eligible in accordance with the provisions of Section&nbsp;7.09 and shall fail to resign after written
request therefor by the Company or by any such Securityholder; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the Trustee shall become incapable of acting, or shall be
adjudged a bankrupt or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee or of its property shall be appointed or consented to, or any public officer shall take charge or control of the Trustee or of its property
or affairs for the purpose of rehabilitation, conservation or liquidation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">then, in any such case, the Company may remove the Trustee
with respect to all Securities and appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor
trustee, or any Securityholder who has been a bona fide holder of a Security or Securities for at least six months may, on behalf of that holder and all others similarly situated, petition any court of competent jurisdiction for the removal of the
Trustee and the appointment of a successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the Trustee and appoint a successor trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The holders of a majority in aggregate principal amount of the Securities of any series
at the time Outstanding may at any time remove the Trustee with respect to such series by so notifying the Trustee and the Company and may appoint a successor Trustee for such series with the consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any resignation or removal of the Trustee and appointment of a successor trustee with respect to the Securities of a series pursuant to
any of the provisions of this Section shall become effective upon acceptance of appointment by the successor trustee as provided in Section&nbsp;7.11. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any successor trustee appointed pursuant to this Section may be appointed with respect to the Securities of one or more series or all of
such series, and at any time there shall be only one Trustee with respect to the Securities of any particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.11 Acceptance of Appointment By Successor. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In case of the appointment hereunder of a successor trustee with respect to all Securities, every such successor trustee so appointed
shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor trustee, without
any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring Trustee shall, upon payment of any amounts
due to it pursuant to the provisions of Section&nbsp;7.06, execute and deliver an instrument transferring to such successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign, transfer and deliver to such
successor trustee all property and money held by such retiring Trustee hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In case of the appointment hereunder of a successor
trustee with respect to the Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor trustee with respect to the Securities of one or more series shall execute and deliver an indenture supplemental hereto
wherein each successor trustee shall accept such appointment and which (i)&nbsp;shall contain such provisions as shall be necessary or desirable to transfer and confirm to, and to vest in, each successor trustee all the rights, powers, trusts and
duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee relates, (ii)&nbsp;shall contain such provisions as shall be deemed necessary or desirable to confirm that all
the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and (iii)&nbsp;shall add to or
change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall
constitute such Trustees <FONT STYLE="white-space:nowrap">co-trustees</FONT> of the same trust, that each such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other
such Trustee and that no Trustee shall be responsible for any act or failure to act on the part of any other Trustee hereunder; and upon the execution and delivery of such supplemental indenture the resignation or removal of the retiring Trustee
shall become effective to the extent provided therein, such retiring Trustee shall with respect to the Securities of that or those series to which the appointment of such successor trustee relates have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
no further responsibility for the exercise of rights and powers or for the performance of the duties and obligations vested in the Trustee under this Indenture, and each such successor trustee,
without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties of the retiring Trustee with respect to the Securities of that or those series to which the appointment of such successor trustee
relates; but, on request of the Company or any successor trustee, such retiring Trustee shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by such supplemental indenture, the property and money held by such
retiring Trustee hereunder with respect to the Securities of that or those series to which the appointment of such successor trustee relates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Upon request of any such successor trustee, the Company shall execute any and all instruments for more fully and certainly vesting in and
confirming to such successor trustee all such rights, powers and trusts referred to in paragraph (a)&nbsp;or (b) of this Section, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No successor trustee shall accept its appointment unless at the time of such acceptance such successor trustee shall be qualified and
eligible under this Article. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Upon acceptance of appointment by a successor trustee as provided in this Section, the Company shall
send notice of the succession of such trustee hereunder to the Securityholders. If the Company fails to transmit such notice within ten days after acceptance of appointment by the successor trustee, the successor trustee shall cause such notice to
be transmitted at the expense of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.12 Merger, Conversion, Consolidation or Succession to Business. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any corporation into which the Trustee may be merged or converted or with which it may be consolidated, or any corporation resulting from any
merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all the corporate trust business of the Trustee, including the administration of the trust created by this Indenture,
shall be the successor of the Trustee hereunder, provided that such corporation shall be qualified under the provisions of Section&nbsp;7.08 and eligible under the provisions of Section&nbsp;7.09, without the execution or filing of any paper or any
further act on the part of any of the parties hereto, anything herein to the contrary notwithstanding. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion or
consolidation to such authenticating Trustee may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.13 Preferential Collection of Claims Against the Company. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee shall comply with Section&nbsp;311(a) of the Trust Indenture Act, excluding any creditor relationship described in
Section&nbsp;311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed shall be subject to Section&nbsp;311(a) of the Trust Indenture Act to the extent included therein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7.14 Notice of Default. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Event of Default occurs and is continuing and if such Event of Default is known to a Responsible Officer of the Trustee, the Trustee
shall send to each Securityholder in the manner and to the extent provided in Section&nbsp;313(c) of the Trust Indenture Act notice of the Event of Default within the earlier of 90 days after it occurs and 30 days after it is known to a Responsible
Officer of the Trustee or written notice of it is received by the Trustee, unless such Event of Default has been cured; provided, however, that, except in the case of a default in the payment of the principal of (or premium, if any) or interest on
any Security, the Trustee shall be protected in withholding such notice if and so long as the Responsible Officers of the Trustee in good faith determine that the withholding of such notice is in the interest of the Securityholders. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING
THE SECURITYHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.01 Evidence of Action by Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever in this Indenture it is provided that the holders of a majority or specified percentage in aggregate principal amount of the
Securities of a particular series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action), the fact that at the time of taking any such action the holders of
such majority or specified percentage of that series have joined therein may be evidenced by any instrument or any number of instruments of similar tenor executed by such holders of Securities of that series in person or by agent or proxy appointed
in writing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company shall solicit from the Securityholders of any series any request, demand, authorization, direction, notice,
consent, waiver or other action, the Company may, at its option, as evidenced by an Officer&#146;s Certificate, fix in advance a record date for such series for the determination of Securityholders entitled to give such request, demand,
authorization, direction, notice, consent, waiver or other action, but the Company shall have no obligation to do so. If such a record date is fixed, such request, demand, authorization, direction, notice, consent, waiver or other action may be
given before or after the record date, but only the Securityholders of record at the close of business on the record date shall be deemed to be Securityholders for the purposes of determining whether Securityholders of the requisite proportion of
Outstanding Securities of that series have authorized or agreed or consented to such request, demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the Outstanding Securities of that series shall be computed
as of the record date; provided, however, that no such authorization, agreement or consent by such Securityholders on the record date shall be deemed effective unless it shall become effective pursuant to the provisions of this Indenture not later
than six months after the record date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.02 Proof of Execution by Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of Section&nbsp;7.01, proof of the execution of any instrument by a Securityholder (such proof will not require
notarization) or his or her agent or proxy and proof of the holding by any Person of any of the Securities shall be sufficient if made in the following manner: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The fact and date of the execution by any such Person of any instrument may be proved in any reasonable manner acceptable to the Trustee.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The ownership of Securities shall be proved by the Security Register of such Securities
or by a certificate of the Security Registrar thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee may require such additional proof of any matter referred to in this
Section as it shall deem necessary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.03 Who May be Deemed Owners. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the due presentment for registration of transfer of any Security, the Company, the Trustee, any paying agent and any Security
Registrar may deem and treat the Person in whose name such Security shall be registered upon the books of the Security Registrar as the absolute owner of such Security (whether or not such Security shall be overdue and notwithstanding any notice of
ownership or writing thereon made by anyone other than the Security Registrar) for the purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to Section&nbsp;2.03) interest on such Security and for all other
purposes; and neither the Company nor the Trustee nor any paying agent nor any Security Registrar shall be affected by any notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.04 Certain Securities Owned by Company Disregarded. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether the holders of the requisite aggregate principal amount of Securities of a particular series have concurred in any
direction, consent or waiver under this Indenture, the Securities of that series that are owned by the Company or any other obligor on the Securities of that series or by any Person directly or indirectly controlling or controlled by or under common
control with the Company or any other obligor on the Securities of that series shall be disregarded and deemed not to be Outstanding for the purpose of any such determination, except that for the purpose of determining whether the Trustee shall be
protected in relying on any such direction, consent or waiver, only Securities of such series that the Trustee actually knows are so owned shall be so disregarded. The Securities so owned that have been pledged in good faith may be regarded as
Outstanding for the purposes of this Section, if the pledgee shall establish to the satisfaction of the Trustee the pledgee&#146;s right so to act with respect to such Securities and that the pledgee is not a Person directly or indirectly
controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection to the
Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8.05 Actions Binding on Future Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time prior to (but not after) the evidencing to the Trustee, as provided in Section&nbsp;8.01, of the taking of any action by the
holders of the majority or percentage in aggregate principal amount of the Securities of a particular series specified in this Indenture in connection with such action, any holder of a Security of that series that is shown by the evidence to be
included in the Securities the holders of which have consented to such action may, by filing written notice with the Trustee, and upon proof of holding as provided in Section&nbsp;8.02, revoke such action so far as concerns such Security. Except as
aforesaid any such action taken by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder of any Security shall be conclusive and binding upon such holder and upon all future holders and owners of such Security, and of any Security issued in exchange therefor, on registration
of transfer thereof or in place thereof, irrespective of whether or not any notation in regard thereto is made upon such Security. Any action taken by the holders of the majority or percentage in aggregate principal amount of the Securities of a
particular series specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the holders of all the Securities of that series. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENTAL
INDENTURES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.01 Supplemental Indentures Without the Consent of Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to any supplemental indenture otherwise authorized by this Indenture, the Company and the Trustee may from time to time and at any
time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect), without the consent of the Securityholders, for one or more of the following purposes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) to cure any ambiguity, defect, or inconsistency herein or in the Securities of any series; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) to comply with Article Ten; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) to provide for uncertificated Securities in addition to or in place of certificated Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) to add to the covenants, restrictions, conditions or provisions relating to the Company for the benefit of the holders of all or any
series of Securities (and if such covenants, restrictions, conditions or provisions are to be for the benefit of less than all series of Securities, stating that such covenants, restrictions, conditions or provisions are expressly being included
solely for the benefit of such series), to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an Event of Default, or to surrender any right or power
herein conferred upon the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) to add to, delete from, or revise the conditions, limitations, and restrictions on the authorized
amount, terms, or purposes of issue, authentication, and delivery of Securities, as herein set forth; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) to make any change that does
not adversely affect the rights of any Securityholder in any material respect; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) to provide for the issuance of and establish the form
and terms and conditions of the Securities of any series as provided in Section&nbsp;2.01, to establish the form of any certifications required to be furnished pursuant to the terms of this Indenture or any series of Securities, or to add to the
rights of the holders of any series of Securities; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) to evidence and provide for the acceptance of appointment hereunder by a successor
trustee; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to comply with any requirements of the Commission or any successor in connection with the qualification of this Indenture
under the Trust Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Trustee is hereby authorized to join with the Company in the execution of any such supplemental
indenture, and to make any further appropriate agreements and stipulations that may be therein contained, but the Trustee shall not be obligated to enter into any such supplemental indenture that affects the Trustee&#146;s own rights, duties or
immunities under this Indenture or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any supplemental indenture authorized by the provisions of this Section may be executed by
the Company and the Trustee without the consent of the holders of any of the Securities at the time Outstanding, notwithstanding any of the provisions of Section&nbsp;9.02. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.02 Supplemental Indentures With Consent of Securityholders. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the consent (evidenced as provided in Section&nbsp;8.01) of the holders of not less than a majority in aggregate principal amount of the
Securities of each series affected by such supplemental indenture or indentures at the time Outstanding, the Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures
supplemental hereto (which shall conform to the provisions of the Trust Indenture Act as then in effect) for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any
supplemental indenture or of modifying in any manner not covered by Section&nbsp;9.01 the rights of the holders of the Securities of such series under this Indenture; provided, however, that no such supplemental indenture shall, without the consent
of the holders of each Security then Outstanding and affected thereby, (a)&nbsp;extend the fixed maturity of any Securities of any series, or reduce the principal amount thereof, or reduce the rate or extend the time of payment of interest thereon,
or reduce any premium payable upon the redemption thereof or (b)&nbsp;reduce the aforesaid percentage of Securities, the holders of which are required to consent to any such supplemental indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It shall not be necessary for the consent of the Securityholders of any series affected thereby under this Section to approve the particular
form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.03 Effect of Supplemental Indentures. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the execution of any supplemental indenture pursuant to the provisions of this Article or of Section&nbsp;10.01, this Indenture shall,
with respect to such series, be and be deemed to be modified and amended in accordance therewith and the respective rights, limitations of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and the holders of
Securities of the series affected thereby shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments, and all the terms and conditions of any such supplemental indenture shall be and
be deemed to be part of the terms and conditions of this Indenture for any and all purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.04 Securities Affected by Supplemental Indentures. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities of any series affected by a supplemental indenture, authenticated and delivered after the execution of such supplemental indenture
pursuant to the provisions of this Article or of Section&nbsp;10.01, may bear a notation in form approved by the Company, provided such form meets the requirements of any securities exchange upon which such series may be listed, as to any matter
provided for in such supplemental indenture. If the Company shall so determine, new Securities of that series so modified as to conform, in the opinion of the Board of Directors, to any modification of this Indenture contained in any such
supplemental indenture may be prepared by the Company, authenticated by the Trustee and delivered in exchange for the Securities of that series then Outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9.05 Execution of Supplemental Indentures. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the request of the Company, accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture, and upon
the filing with the Trustee of evidence of the consent of Securityholders required to consent thereto as aforesaid, the Trustee shall join with the Company in the execution of such supplemental indenture unless such supplemental indenture affects
the Trustee&#146;s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion but shall not be obligated to enter into such supplemental indenture. The Trustee, subject to the provisions of
Section&nbsp;7.01, shall receive an Officer&#146;s Certificate or an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant to this Article is authorized or permitted by the terms of this Article and that all
conditions precedent to the execution of the supplemental indenture have been complied with; provided, however, that such Officer&#146;s Certificate or Opinion of Counsel need not be provided in connection with the execution of a supplemental
indenture that establishes the terms of a series of Securities pursuant to Section&nbsp;2.01 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly after the execution by the
Company and the Trustee of any supplemental indenture pursuant to the provisions of this Section, the Company shall (or shall direct the Trustee to) send a notice, setting forth in general terms the substance of such supplemental indenture, to the
Securityholders of all series affected thereby .as their names and addresses appear upon the Security Register. Any failure of the Company to send, or cause the sending of, such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any such supplemental indenture. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUCCESSOR ENTITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10.01 Company May Consolidate, Etc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nothing contained in this Indenture shall prevent any consolidation or merger of the Company with or into any other Person (whether or not
affiliated with the Company) or successive consolidations or mergers in which the Company or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or other disposition of the property of the Company
or its successor or successors as an entirety, or substantially as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entirety, to any other Person (whether or not affiliated with the Company or its successor or successors); provided, however, the Company hereby covenants and agrees that, upon any such
consolidation or merger (in each case, if the Company is not the survivor of such transaction) or any such sale, conveyance, transfer or other disposition (other than a sale, conveyance, transfer or other disposition to a Subsidiary of the Company),
the due and punctual payment of the principal of (premium, if any) and interest on all of the Securities of all series in accordance with the terms of each series, according to their tenor, and the due and punctual performance and observance of all
the covenants and conditions of this Indenture with respect to each series or established with respect to such series pursuant to Section&nbsp;2.01 to be kept or performed by the Company shall be expressly assumed, by supplemental indenture (which
shall conform to the provisions of the Trust Indenture Act, as then in effect) reasonably satisfactory in form to the Trustee executed and delivered to the Trustee by the entity formed by such consolidation, or into which the Company shall have been
merged, or by the entity which shall have acquired such property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10.02 Successor Entity Substituted. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition and upon the assumption by the successor entity
by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the obligations set forth under Section&nbsp;10.01 on all of the Securities of all series Outstanding, such successor entity shall succeed
to and be substituted for the Company with the same effect as if it had been named as the Company herein, and thereupon the predecessor corporation shall be relieved of all obligations and covenants under this Indenture and the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) In case of any such consolidation, merger, sale, conveyance, transfer or other disposition, such changes in phraseology and form (but not
in substance) may be made in the Securities thereafter to be issued as may be appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Nothing contained in this Article shall
require any action by the Company in the case of a consolidation or merger of any Person into the Company where the Company is the survivor of such transaction, or the acquisition by the Company, by purchase or otherwise, of all or any part of the
property of any other Person (whether or not affiliated with the Company). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SATISFACTION AND DISCHARGE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.01 Satisfaction and Discharge of Indenture. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time: (a)&nbsp;the Company shall have delivered to the Trustee for cancellation all Securities of a series theretofore authenticated
and not delivered to the Trustee for cancellation (other than any Securities that shall have been destroyed, lost or stolen and that shall have been replaced or paid as provided in Section&nbsp;2.07 and Securities for whose payment money or
Governmental Obligations have theretofore been deposited in trust or segregated and held in trust by the Company and thereupon repaid to the Company or discharged from such trust, as provided in Section&nbsp;11.05); or (b)&nbsp;all such Securities
of a particular series not theretofore </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
delivered to the Trustee for cancellation shall have become due and payable, or are by their terms to become due and payable within one year or are to be called for redemption within one year
under arrangements satisfactory to the Trustee for the giving of notice of redemption, and the Company shall deposit or cause to be deposited with the Trustee as trust funds the entire amount in moneys or Governmental Obligations or a combination
thereof, sufficient in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay at maturity or upon redemption all Securities of that series not
theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the Company shall also pay or cause
to be paid all other sums payable hereunder with respect to such series by the Company then this Indenture shall thereupon cease to be of further effect with respect to such series except for the provisions of Sections 2.03, 2.05, 2.07, 4.01, 4.02,
4.03 and 7.10, 11.05 and 13.04 that shall survive until the date of maturity or redemption date, as the case may be, and Sections 7.06 and 11.05, that shall survive to such date and thereafter, and the Trustee, on demand of the Company and at the
cost and expense of the Company shall execute proper instruments acknowledging satisfaction of and discharging this Indenture with respect to such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.02 Discharge of Obligations. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time all such Securities of a particular series not heretofore delivered to the Trustee for cancellation or that have not become due
and payable as described in Section&nbsp;11.01 shall have been paid by the Company by depositing irrevocably with the Trustee as trust funds moneys or an amount of Governmental Obligations sufficient to pay at maturity or upon redemption all such
Securities of that series not theretofore delivered to the Trustee for cancellation, including principal (and premium, if any) and interest due or to become due to such date of maturity or date fixed for redemption, as the case may be, and if the
Company shall also pay or cause to be paid all other sums payable hereunder by the Company with respect to such series, then after the date such moneys or Governmental Obligations, as the case may be, are deposited with the Trustee the obligations
of the Company under this Indenture with respect to such series shall cease to be of further effect except for the provisions of Sections 2.03, 2.05, 2.07, 4,01, 4.02, 4,03, 7.06, 7.10 and 11.05 and 13.04 hereof that shall survive until such
Securities shall mature and be paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thereafter, Sections 7.06 and 11.05 shall survive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.03 Deposited Moneys to be Held in Trust. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All moneys or Governmental Obligations deposited with the Trustee pursuant to Sections 11.01 or 11.02 shall be held in trust and shall be
available for payment as due, either directly or through any paying agent (including the Company acting as its own paying agent), to the holders of the particular series of Securities for the payment or redemption of which such moneys or
Governmental Obligations have been deposited with the Trustee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.04 Payment of Moneys Held by Paying Agents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the satisfaction and discharge of this Indenture all moneys or Governmental Obligations then held by any paying agent under
the provisions of this Indenture shall, upon demand of the Company, be paid to the Trustee and thereupon such paying agent shall be released from all further liability with respect to such moneys or Governmental Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11.05 Repayment to Company. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any moneys or Governmental Obligations deposited with any paying agent or the Trustee, or then held by the Company, in trust for payment of
principal of or premium, if any, or interest on the Securities of a particular series that are not applied but remain unclaimed by the holders of such Securities for at least two years after the date upon which the principal of (and premium, if any)
or interest on such Securities shall have respectively become due and payable, or such other shorter period set forth in applicable escheat or abandoned or unclaimed property law, shall be repaid to the Company on May&nbsp;31 of each year or upon
the Company&#146;s request or (if then held by the Company) shall be discharged from such trust; and thereupon the paying agent and the Trustee shall be released from all further liability with respect to such moneys or Governmental Obligations, and
the holder of any of the Securities entitled to receive such payment shall thereafter, as a general creditor, look only to the Company for the payment thereof. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUNITY OF
INCORPORATORS, STOCKHOLDERS, OFFICERS AND DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12.01 No Recourse. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No recourse under or upon any obligation, covenant or agreement of this Indenture, or of any Security, or for any claim based thereon or
otherwise in respect thereof, shall be had against any incorporator, stockholder, officer or director, past, present or future as such, of the Company or of any predecessor or successor corporation, either directly or through the Company or any such
predecessor or successor corporation, whether by virtue of any constitution, statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being expressly understood that this Indenture and the obligations issued
hereunder are solely corporate obligations, and that no such personal liability whatever shall attach to, or is or shall be incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of any predecessor or
successor corporation, or any of them, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom; and
that any and all such personal liability of every name and nature, either at common law or in equity or by constitution or statute, of, and any and all such rights and claims against, every such incorporator, stockholder, officer or director as
such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture or in any of the Securities or implied therefrom, are hereby expressly waived and
released as a condition of, and as a consideration for, the execution of this Indenture and the issuance of such Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.01 Effect on Successors and Assigns. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All the covenants, stipulations, promises and agreements in this Indenture made by or on behalf of the Company shall bind its successors and
assigns, whether so expressed or not. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.02 Actions by Successor. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any act or proceeding by any provision of this Indenture authorized or required to be done or performed by any board, committee or officer of
the Company shall and may be done and performed with like force and effect by the corresponding board, committee or officer of any corporation that shall at the time be the lawful successor of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.03 Surrender of Company Powers. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company by instrument in writing executed by authority of its Board of Directors and delivered to the Trustee may surrender any of the
powers reserved to the Company, and thereupon such power so surrendered shall terminate both as to the Company and as to any successor corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.04 Notices. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise expressly provided herein, any notice, request or demand that by any provision of this Indenture is required or permitted
to be given, made or served by the Trustee, the Security Registrar, any paying or other agent under this Indenture or by the holders of Securities or by any other Person pursuant to this Indenture to or on the Company may be given or served by being
deposited in first class mail, postage prepaid, addressed (until another address is filed in writing by the Company with the Trustee), as follows: . Any notice, election, request or demand by the Company or any Securityholder or by any other Person
pursuant to this Indenture to or upon the Trustee shall be deemed to have been sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office of the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.05 Governing Law; Jury Trial Waiver. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indenture and each Security shall be governed by, and construed in accordance with, the internal laws of the State of New York, except to
the extent that the Trust Indenture Act is applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">EACH PARTY HERETO, AND EACH HOLDER OF A SECURITY BY ACCEPTANCE THEREOF, HEREBY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS INDENTURE. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.06 Treatment of Securities as Debt. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is intended that the Securities will be treated as indebtedness and not as equity for federal income tax purposes. The provisions of this
Indenture shall be interpreted to further this intention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.07 Certificates and Opinions as to Conditions Precedent.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon any application or demand by the Company to the Trustee to take any action under any of the provisions of this Indenture,
the Company shall furnish to the Trustee an Officer&#146;s Certificate stating that all conditions precedent provided for in this Indenture (other than the certificate to be delivered pursuant to Section&nbsp;13.12) relating to the proposed action
have been complied with and, if requested, an Opinion of Counsel stating that in the opinion of such counsel all such conditions precedent have been complied with, except that in the case of any such application or demand as to which the furnishing
of such documents is specifically required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion need be furnished. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance with a condition or
covenant in this Indenture (other than the certificate to be delivered pursuant to Section&nbsp;13.12 of this Indenture or Section&nbsp;314(a)(1) of the Trust Indenture Act) shall include (i)&nbsp;a statement that the Person making such certificate
or opinion has read such covenant or condition; (ii)&nbsp;a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; (iii)&nbsp;a
statement that, in the opinion of such Person, he has made such examination or investigation as is reasonably necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and
(iv)&nbsp;a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.08 Payments on Business Days. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided pursuant to Section&nbsp;2.01 pursuant to a Board Resolution, and set forth in an Officer&#146;s Certificate, or
established in one or more indentures supplemental to this Indenture, in any case where the date of maturity of interest or principal of any Security or the date of redemption of any Security shall not be a Business Day, then payment of interest or
principal (and premium, if any) may be made on the next succeeding Business Day with the same force and effect as if made on the nominal date of maturity or redemption, and no interest shall accrue for the period after such nominal date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.09 Conflict with Trust Indenture Act. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and to the extent that any provision of this Indenture limits, qualifies or conflicts with the duties imposed by Section&nbsp;318(c) of the
Trust Indenture Act, such imposed duties shall control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.10 Counterparts. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together
constitute but one and the same instrument. The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used
in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.11 Separability. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any one or more of the provisions contained in this Indenture or in the Securities of any series shall for any reason be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Indenture or of such Securities, but this Indenture and such Securities shall be construed as if such
invalid or illegal or unenforceable provision had never been contained herein or therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.12 Compliance Certificates.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall deliver to the Trustee, within 120 days after the end of each fiscal year during which any Securities of any series
were outstanding, an officer&#146;s certificate stating whether or not the signers know of any Event of Default that occurred during such fiscal year. Such certificate shall contain a certification from the principal executive officer, principal
financial officer or principal accounting officer of the Company that a review has been conducted of the activities of the Company and the Company&#146;s performance under this Indenture and that the Company has complied with all conditions and
covenants under this Indenture. For purposes of this Section&nbsp;13.12, such compliance shall be determined without regard to any period of grace or requirement of notice provided under this Indenture. If the officer of the Company signing such
certificate has knowledge of such an Event of Default, the certificate shall describe any such Event of Default and its status. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.13 U.S.A Patriot Act. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties hereto acknowledge that in accordance with Section&nbsp;326 of the U.S.A. Patriot Act, the Trustee, like all financial
institutions and in order to help fight the funding of terrorism and money laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the
Trustee. The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.14 Force Majeure. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no event shall the Trustee, the Security Registrar, any paying agent or any other agent under this Indenture be responsible or liable for
any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or
military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions or utilities, communications or computer (software and hardware) services; it being understood that the Trustee, the Security Registrar,
any paying agent or any other agent under this Indenture shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13.15 Table of Contents; Headings. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table of contents and headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are
not intended to be considered a part hereof, and will not modify or restrict any of the terms or provisions hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Indenture to be duly executed all as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Alaunos Therapeutics, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[<B>T<SMALL>RUSTEE</SMALL></B><SMALL></SMALL>], as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>CROSS-REFERENCE TABLE (1)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Section of Indenture</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Section of Trust Indenture Act of 1939, as Amended</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">310(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.09</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">310(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.08</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.10</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">310(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Inapplicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">311(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">311(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.13</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">311(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Inapplicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">312(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.02(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">312(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.02(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">312(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.02(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">313(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">313(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">313(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.04(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.04(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">313(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.04(c)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13.12</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Inapplicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13.07(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Inapplicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(e)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13.07(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">314(f)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Inapplicable</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">315(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.01(a)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">315(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.14</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">315(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">315(d)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7.01(b)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">315(e)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.07</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">316(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.06</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">316(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.04</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">316(c)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8.01</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">317(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6.02</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">317(b)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4.03</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">318(a)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">13.09</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Cross-Reference Table does not constitute part of the Indenture and shall not have any bearing on the
interpretation of any of its terms or provisions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>5
<FILENAME>d286456dex44.htm
<DESCRIPTION>EX-4.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.4 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>__________ , AS
WARRANT AGENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF COMMON STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED
AS OF </B>__________ </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>LAUNOS</SMALL> <SMALL>THERAPEUTICS</SMALL>, <SMALL>INC</SMALL>.
F<SMALL>ORM</SMALL> <SMALL>OF</SMALL> <SMALL>COMMON</SMALL> <SMALL>STOCK</SMALL> <SMALL>WARRANT</SMALL> <SMALL>AGREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this
&#147;<B><I>Agreemen</I></B>t&#148;), dated as of [&#149;], between <B>A<SMALL>LAUNOS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and [&#149;], a [corporation]
[national banking association] organized and existing under the laws of [&#149;] and having a corporate trust office in [&#149;], as warrant agent (the &#147;<B><I>Warrant Agent</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W</B><B><SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company proposes to sell [<B><I>If Warrants are sold with other securities</I></B>
&#151;[title of such other securities being offered] (the &#147;<B><I>Other Securities</I></B>&#148;) with] warrant certificates evidencing one or more warrants (the &#147;<B><I>Warrants</I></B>&#148; or, individually, a
&#147;<B><I>Warrant</I></B>&#148;) representing the right to purchase Common Stock of the Company, par value $0.001 per share (the &#147;<B><I>Warrant Securities</I></B>&#148;), such warrant certificates and other warrant certificates issued
pursuant to this Agreement being herein called the &#147;<B><I>Warrant Certificates</I></B>&#148;; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W</B><B><SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant
Agent is willing so to act, in connection with the issuance, registration, transfer, exchange, exercise and replacement of the Warrant Certificates, and in this Agreement wishes to set forth, among other things, the form and provisions of the
Warrant Certificates and the terms and conditions on which they may be issued, registered, transferred, exchanged, exercised and replaced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the premises and of the mutual agreements herein
contained, the parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISSUANCE OF WARRANTS AND EXECUTION AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELIVERY OF WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1 Issuance of Warrants</B>. [<B><I>If Warrants alone</I></B> &#151;Upon issuance, each Warrant Certificate shall evidence one or more
Warrants.] [<B><I>If Other Securities and Warrants</I></B> &#151;Warrant Certificates will be issued in connection with the issuance of the Other Securities but shall be separately transferable and each Warrant Certificate shall evidence one or more
Warrants.] Each Warrant evidenced thereby shall represent the right, subject to the provisions contained herein and therein, to purchase one Warrant Security. [<B><I>If Other Securities and Warrants</I></B> &#151;Warrant Certificates will be issued
with the Other Securities and each Warrant Certificate will evidence [&#149;] Warrants for each [$[&#149;] principal amount] [[&#149;] shares] of Other Securities issued.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 Execution and Delivery of Warrant Certificates</B>. Each Warrant Certificate, whenever issued, shall be in registered form substantially
in the form set forth in <B>Exhibit A</B> hereto, shall be dated the date of its countersignature by the Warrant Agent and may have such letters, numbers, or other marks of identification or designation and such legends or endorsements printed,
lithographed or engraved thereon as the officers of the Company executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Agreement, or as may be required to
comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which the Warrants may be listed, or to conform to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
usage. The Warrant Certificates shall be signed on behalf of the Company by any of its present or future chief executive officers, presidents, senior vice presidents, vice presidents, chief
financial officers, chief legal officers, treasurers, assistant treasurers, controllers, assistant controllers, secretaries or assistant secretaries under its corporate seal reproduced thereon. Such signatures may be manual or facsimile signatures
of such authorized officers and may be imprinted or otherwise reproduced on the Warrant Certificates. The seal of the Company may be in the form of a facsimile thereof and may be impressed, affixed, imprinted or otherwise reproduced on the Warrant
Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Warrant Certificate shall be valid for any purpose, and no Warrant evidenced thereby shall be exercisable, until such
Warrant Certificate has been countersigned by the manual signature of the Warrant Agent. Such signature by the Warrant Agent upon any Warrant Certificate executed by the Company shall be conclusive evidence that the Warrant Certificate so
countersigned has been duly issued hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any officer of the Company who shall have signed any of the Warrant Certificates
either manually or by facsimile signature shall cease to be such officer before the Warrant Certificates so signed shall have been countersigned and delivered by the Warrant Agent, such Warrant Certificates may be countersigned and delivered
notwithstanding that the person who signed such Warrant Certificates ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Warrant
Certificate, shall be the proper officers of the Company, although at the date of the execution of this Agreement any such person was not such officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>holder</I></B>&#148; or &#147;<B><I>holder of a Warrant Certificate</I></B>&#148; as used herein shall mean any person in
whose name at the time any Warrant Certificate shall be registered upon the books to be maintained by the Warrant Agent for that purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3 Issuance of Warrant Certificates</B>. Warrant Certificates evidencing the right to purchase Warrant Securities may be executed by the
Company and delivered to the Warrant Agent upon the execution of this Agreement or from time to time thereafter. The Warrant Agent shall, upon receipt of Warrant Certificates duly executed on behalf of the Company, countersign such Warrant
Certificates and shall deliver such Warrant Certificates to or upon the order of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT PRICE, DURATION AND EXERCISE OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 W</B><B><SMALL>HEREAS</SMALL></B><SMALL></SMALL>. During the period specified in Section&nbsp;2.2, each Warrant shall, subject to the
terms of this Agreement and the applicable Warrant Certificate, entitle the holder thereof to purchase the number of Warrant Securities specified in the applicable Warrant Certificate at an exercise price of $[&#149;] per Warrant Security, subject
to adjustment upon the occurrence of certain events, as hereinafter provided. Such purchase price per Warrant Security is referred to in this Agreement as the &#147;<B><I>Warrant Price</I></B>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Duration of Warrants</B>. Each Warrant may be exercised in whole or in part at any
time, as specified herein, on or after [the date thereof] [&#149;] and at or before [&#149;] p.m., [City] time, on [&#149;] or such later date as the Company may designate by notice to the Warrant Agent and the holders of Warrant Certificates mailed
to their addresses as set forth in the record books of the Warrant Agent (the &#147;<B><I>Expiration Date</I></B>&#148;). Each Warrant not exercised at or before [&#149;] p.m., [City] time, on the Expiration Date shall become void, and all rights of
the holder of the Warrant Certificate evidencing such Warrant under this Agreement shall cease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 </B><B><I>Exercise of
Warrants</I></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>During the period specified in Section&nbsp;2.2, the Warrants may be exercised to purchase a whole number of
Warrant Securities in registered form by providing certain information as set forth on the reverse side of the Warrant Certificate and by paying in full, in lawful money of the United States of America, [in cash or by certified check or official
bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds] the Warrant Price for each Warrant Security with respect to which a Warrant is being exercised to the Warrant Agent at its corporate trust office,
provided that such exercise is subject to receipt within five business days of such payment by the Warrant Agent of the Warrant Certificate with the form of election to purchase Warrant Securities set forth on the reverse side of the Warrant
Certificate properly completed and duly executed. The date on which payment in full of the Warrant Price is received by the Warrant Agent shall, subject to receipt of the Warrant Certificate as aforesaid, be deemed to be the date on which the
Warrant is exercised; provided, however, that if, at the date of receipt of such Warrant Certificates and payment in full of the Warrant Price, the transfer books for the Warrant Securities purchasable upon the exercise of such Warrants shall be
closed, no such receipt of such Warrant Certificates and no such payment of such Warrant Price shall be effective to constitute the person so designated to be named as the holder of record of such Warrant Securities on such date, but shall be
effective to constitute such person as the holder of record of such Warrant Securities for all purposes at the opening of business on the next succeeding day on which the transfer books for the Warrant Securities purchasable upon the exercise of
such Warrants shall be opened, and the certificates for the Warrant Securities in respect of which such Warrants are then exercised shall be issuable as of the date on such next succeeding day on which the transfer books shall next be opened, and
until such date the Company shall be under no duty to deliver any certificate for such Warrant Securities. The Warrant Agent shall deposit all funds received by it in payment of the Warrant Price in an account of the Company maintained with it and
shall advise the Company by telephone at the end of each day on which a payment for the exercise of Warrants is received of the amount so deposited to its account. The Warrant Agent shall promptly confirm such telephone advice to the Company in
writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Warrant Agent shall, from time to time, as promptly as practicable, advise the Company of (i)&nbsp;the number of
Warrant Securities with respect to which Warrants were exercised, (ii)&nbsp;the instructions of each holder of the Warrant Certificates evidencing such Warrants with respect to delivery of the Warrant Securities to which such holder is entitled upon
such exercise, (iii)&nbsp;delivery of Warrant Certificates evidencing the balance, if any, of the Warrants for the remaining Warrant Securities after such exercise, and (iv)&nbsp;such other information as the Company shall reasonably require. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>As soon as practicable after the exercise of any Warrant, the Company shall issue
to or upon the order of the holder of the Warrant Certificate evidencing such Warrant the Warrant Securities to which such holder is entitled, in fully registered form, registered in such name or names as may be directed by such holder. If fewer
than all of the Warrants evidenced by such Warrant Certificate are exercised, the Company shall execute, and an authorized officer of the Warrant Agent shall manually countersign and deliver, a new Warrant Certificate evidencing Warrants for the
number of Warrant Securities remaining unexercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>The Company shall not be required to pay any stamp or other tax or other
governmental charge required to be paid in connection with any transfer involved in the issue of the Warrant Securities, and in the event that any such transfer is involved, the Company shall not be required to issue or deliver any Warrant Security
until such tax or other charge shall have been paid or it has been established to the Company&#146;s satisfaction that no such tax or other charge is due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Prior to the issuance of any Warrants there shall have been reserved, and the Company shall at all times through the Expiration Date
keep reserved, out of its authorized but unissued Warrant Securities, a number of shares sufficient to provide for the exercise of the Warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
PROVISIONS RELATING TO RIGHTS OF HOLDERS OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 No Rights as Warrant Securityholder Conferred by Warrants or Warrant Certificates</B>. No Warrant Certificate or Warrant evidenced
thereby shall entitle the holder thereof to any of the rights of a holder of Warrant Securities, including, without limitation, the right to receive the payment of dividends or distributions, if any, on the Warrant Securities or to exercise any
voting rights, except to the extent expressly set forth in this Agreement or the applicable Warrant Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Lost, Stolen,
Mutilated or Destroyed Warrant Certificates</B>. Upon receipt by the Warrant Agent of evidence reasonably satisfactory to it and the Company of the ownership of and the loss, theft, destruction or mutilation of any Warrant Certificate and/or
indemnity reasonably satisfactory to the Warrant Agent and the Company and, in the case of mutilation, upon surrender of the mutilated Warrant Certificate to the Warrant Agent for cancellation, then, in the absence of notice to the Company or the
Warrant Agent that such Warrant Certificate has been acquired by a bona fide purchaser, the Company shall execute, and an authorized officer of the Warrant Agent shall manually countersign and deliver, in exchange for or in lieu of the lost, stolen,
destroyed or mutilated Warrant Certificate, a new Warrant Certificate of the same tenor and evidencing Warrants for a like number of Warrant Securities. Upon the issuance of any new Warrant Certificate under this Section&nbsp;3.2, the Company may
require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Warrant Agent) in connection therewith. Every substitute
Warrant Certificate executed and delivered pursuant to this Section&nbsp;3.2 in lieu of any lost, stolen or destroyed Warrant Certificate shall represent an additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual obligation of the Company, whether or not the lost, stolen or destroyed Warrant Certificate shall be at any time enforceable by anyone, and shall be entitled to the benefits of this
Agreement equally and proportionately with any and all other Warrant Certificates duly executed and delivered hereunder. The provisions of this Section&nbsp;3.2 are exclusive and shall preclude (to the extent lawful) all other rights and remedies
with respect to the replacement of mutilated, lost, stolen or destroyed Warrant Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Holder of Warrant Certificate May
Enforce Rights</B>. Notwithstanding any of the provisions of this Agreement, any holder of a Warrant Certificate, without the consent of the Warrant Agent, the holder of any Warrant Securities or the holder of any other Warrant Certificate, may, in
such holder&#146;s own behalf and for such holder&#146;s own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company suitable to enforce, or otherwise in respect of, such holder&#146;s right to exercise
the Warrants evidenced by such holder&#146;s Warrant Certificate in the manner provided in such holder&#146;s Warrant Certificate and in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Adjustments</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)
</B>In case the Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Warrant Price in effect immediately prior to such subdivision shall be proportionately reduced and the number of Warrant
Securities purchasable under the Warrants shall be proportionately increased. Conversely, in case the outstanding shares of Common Stock of the Company shall be combined into a smaller number of shares, the Warrant Price in effect immediately prior
to such combination shall be proportionately increased and the number of Warrant Securities purchasable under the Warrants shall be proportionately decreased. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>If at any time or from time to time the holders of Common Stock (or any shares of stock or other securities at the time receivable
upon the exercise of the Warrants) shall have received or become entitled to receive, without payment therefore, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(i) </B>Common Stock
or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of
dividend or other distribution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B>any cash paid or payable otherwise than as a cash dividend paid or payable out of the
Company&#146;s current or retained earnings; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iii) </B>any evidence of the Company&#146;s indebtedness or rights to subscribe for or
purchase the Company&#146;s indebtedness; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(iv) </B>Common Stock or additional stock or other securities or property (including
cash) by way of spinoff, <FONT STYLE="white-space:nowrap">split-up,</FONT> reclassification, combination of shares or similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section&nbsp;3.4(a) above), then and in each such case, the holder of each Warrant shall, upon the exercise of the Warrant, be entitled to receive, in addition to the number of Warrant Securities receivable thereupon, and
without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment of any additional consideration therefore, the amount of stock and other securities and property (including cash and indebtedness or rights to subscribe for or purchase indebtedness)
which such holder would hold on the date of such exercise had such holder been the holder of record of such Warrant Securities as of the date on which holders of Common Stock received or became entitled to receive such shares or all other additional
stock and other securities and property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>In case of (i)&nbsp;any reclassification, capital reorganization, or change in the
Common Stock of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section&nbsp;3.4(a) or Section&nbsp;3.4(b) above), (ii) share exchange, merger or similar transaction of the Company with or into
another person or entity (other than a share exchange, merger or similar transaction in which the Company is the acquiring or surviving corporation and which does not result in any change in the Common Stock other than the issuance of additional
shares of Common Stock) or (iii)&nbsp;the sale, exchange, lease, transfer or other disposition of all or substantially all of the properties and assets of the Company as an entirety (in any such case, a &#147;<B><I>Reorganization
Event</I></B>&#148;), then, as a condition of such Reorganization Event, lawful provisions shall be made, and duly executed documents evidencing the same from the Company or its successor shall be delivered to the holders of the Warrants, so that
the holders of the Warrants shall have the right at any time prior to the expiration of the Warrants to purchase, at a total price equal to that payable upon the exercise of the Warrants, the kind and amount of shares of stock and other securities
and property receivable in connection with such Reorganization Event by a holder of the same number of Warrant Securities as were purchasable by the holders of the Warrants immediately prior to such Reorganization Event. In any such case appropriate
provisions shall be made with respect to the rights and interests of the holders of the Warrants so that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon
exercise the Warrants, and appropriate adjustments shall be made to the Warrant Price payable hereunder provided the aggregate purchase price shall remain the same. In the case of any transaction described in clauses (ii)&nbsp;and (iii) above, the
Company shall thereupon be relieved of any further obligation hereunder or under the Warrants, and the Company as the predecessor corporation may thereupon or at any time thereafter be dissolved, wound up or liquidated. Such successor or assuming
entity thereupon may cause to be signed, and may issue either in its own name or in the name of the Company, any or all of the Warrants issuable hereunder which heretofore shall not have been signed by the Company, and may execute and deliver
securities in its own name, in fulfillment of its obligations to deliver Warrant Securities upon exercise of the Warrants. All the Warrants so issued shall in all respects have the same legal rank and benefit under this Agreement as the Warrants
theretofore or thereafter issued in accordance with the terms of this Agreement as though all of such Warrants had been issued at the date of the execution hereof. In any case of any such Reorganization Event, such changes in phraseology and form
(but not in substance) may be made in the Warrants thereafter to be issued as may be appropriate. The Warrant Agent may receive a written opinion of legal counsel as conclusive evidence that any such Reorganization Event complies with the provisions
of this Section&nbsp;3.4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>The Company may, at its option, at any time until the Expiration Date, reduce the then current
Warrant Price to any amount deemed appropriate by the Board of Directors of the Company for any period not exceeding twenty consecutive days (as evidenced in a resolution adopted by such Board of Directors), but only upon giving the notices required
by Section&nbsp;3.5 at least ten days prior to taking such action. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Except as herein otherwise expressly provided, no adjustment in the Warrant Price
shall be made by reason of the issuance of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, or securities carrying the right to purchase any of the foregoing or for any other reason whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) </B>No fractional Warrant Securities shall be issued upon the exercise of Warrants. If more than one Warrant shall be exercised at one
time by the same holder, the number of full Warrant Securities which shall be issuable upon such exercise shall be computed on the basis of the aggregate number of Warrant Securities purchased pursuant to the Warrants so exercised. Instead of any
fractional Warrant Security which would otherwise be issuable upon exercise of any Warrant, the Company shall pay a cash adjustment in respect of such fraction in an amount equal to the same fraction of the last reported sale price (or bid price if
there were no sales) per Warrant Security, in either case as reported on the principal registered national securities exchange on which the Warrant Securities are listed or admitted to trading on the business day that next precedes the day of
exercise or, if the Warrant Securities are not then listed or admitted to trading on any registered national securities exchange, the average of the closing high bid and low asked prices as reported on the OTC Bulletin Board Service (the
&#147;<B><I>OTC Bulletin Board</I></B>&#148;) operated by the Financial Industry Regulatory Authority, Inc. (&#147;<B><I>FINRA</I></B>&#148; ) or, if not available on the OTC Bulletin Board, then the average of the closing high bid and low asked
prices as reported on any other U.S. quotation medium or inter-dealer quotation system on such date, or if on any such date the Warrant Securities are not listed or admitted to trading on a registered national securities exchange, are not included
in the OTC Bulletin Board, and are not quoted on any other U.S. quotation medium or interdealer quotation system, an amount equal to the same fraction of the average of the closing bid and asked prices as furnished by any FINRA member firm selected
from time to time by the Company for that purpose at the close of business on the business day that next precedes the day of exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g) </B>Whenever the Warrant Price then in effect is adjusted as herein provided, the Company shall mail to each holder of the Warrants at
such holder&#146;s address as it shall appear on the books of the Company a statement setting forth the adjusted Warrant Price then and thereafter effective under the provisions hereof, together with the facts, in reasonable detail, upon which such
adjustment is based. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h) </B>Notwithstanding anything to the contrary herein, in no event shall the Warrant Price, as adjusted in
accordance with the terms hereof, be less than the par value per share of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5 Notice to Warrantholders</B>. In case the
Company shall (a)&nbsp;effect any dividend or distribution described in Section&nbsp;3.4(b), (b) effect any Reorganization Event, (c)&nbsp;make any distribution on or in respect of the Common Stock in connection with the dissolution, liquidation or
winding up of the Company, or (d)&nbsp;reduce the then current Warrant Price pursuant to Section&nbsp;3.4(d), then the Company shall mail to each holder of Warrants at such holder&#146;s address as it shall appear on the books of the Warrant Agent,
at least ten days prior to the applicable date hereinafter specified, a notice stating (x)&nbsp;the record date for such dividend or distribution, or, if a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
record is not to be taken, the date as of which the holders of record of Common Stock that will be entitled to such dividend or distribution are to be determined, (y)&nbsp;the date on which such
Reorganization Event, dissolution, liquidation or winding up is expected to become effective, and the date as of which it is expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities or
other property deliverable upon such Reorganization Event, dissolution, liquidation or winding up, or (z)&nbsp;the first date on which the then current Warrant Price shall be reduced pursuant to Section&nbsp;3.4(d). No failure to mail such notice
nor any defect therein or in the mailing thereof shall affect any such transaction or any adjustment in the Warrant Price required by Section&nbsp;3.4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6 </B>[<B><I>If the Warrants are Subject to Acceleration by the Company, Insert </I></B>&#151; Acceleration of Warrants by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>At any time on or after [&#149;], the Company shall have the right to accelerate any or all Warrants at any time by causing
them to expire at the close of business on the day next preceding a specified date (the &#147;<B><I>Acceleration Date</I></B>&#148;), if the Market Price (as hereinafter defined) of the Common Stock equals or exceeds [&#149;] percent ([&#149;]%) of
the then effective Warrant Price on any twenty Trading Days (as hereinafter defined) within a period of thirty consecutive Trading Days ending no more than five Trading Days prior to the date on which the Company gives notice to the Warrant Agent of
its election to accelerate the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) (b)</B> &#147;<B><I>Market Price</I></B>&#148; for each Trading Day shall be, if the
Common Stock is listed or admitted to trading on any registered national securities exchange, the last reported sale price, regular way (or, if no such price is reported, the average of the reported closing bid and asked prices, regular way) of
Common Stock, in either case as reported on the principal registered national securities exchange on which the Common Stock is listed or admitted to trading or, if not listed or admitted to trading on any registered national securities exchange, the
average of the closing high bid and low asked prices as reported on the OTC Bulletin Board operated by FINRA, or if not available on the OTC Bulletin Board, then the average of the closing high bid and low asked prices as reported on any other U.S.
quotation medium or inter-dealer quotation system, or if on any such date the shares of Common Stock are not listed or admitted to trading on a registered national securities exchange, are not included in the OTC Bulletin Board, and are not quoted
on any other U.S. quotation medium or inter-dealer quotation system, the average of the closing bid and asked prices as furnished by any FINRA member firm selected from time to time by the Company for that purpose. &#147;Trading Day&#148; shall be
each Monday through Friday, other than any day on which securities are not traded in the system or on the exchange that is the principal market for the Common Stock, as determined by the Board of Directors of the Company. In the event of an
acceleration of less than all of the Warrants, the Warrant Agent shall select the Warrants to be accelerated by lot, pro rata or in such other manner as it deems, in its discretion, to be fair and appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>Notice of an acceleration specifying the Acceleration Date shall be sent by mail first class, postage prepaid, to each registered
holder of a Warrant Certificate representing a Warrant accelerated at such holder&#146;s address appearing on the books of the Warrant Agent not more than sixty days nor less than thirty days before the Acceleration Date. Such notice of an
acceleration also shall be given no more than twenty days, and no less than ten days, prior to the mailing of notice to registered holders of Warrants pursuant to this Section&nbsp;3.6, by publication at least once in a newspaper of general
circulation in the City of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Any Warrant accelerated may be exercised until [&#149;] p.m., [City] time, on the
business day next preceding the Acceleration Date. The Warrant Price shall be payable as provided in Section&nbsp;2.] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AND TRANSFER OF WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Exchange and Transfer of Warrant Certificates</B>. Upon surrender at the corporate trust office of the Warrant Agent, Warrant
Certificates evidencing Warrants may be exchanged for Warrant Certificates in other denominations evidencing such Warrants or the transfer thereof may be registered in whole or in part; provided that such other Warrant Certificates evidence Warrants
for the same aggregate number of Warrant Securities as the Warrant Certificates so surrendered. The Warrant Agent shall keep, at its corporate trust office, books in which, subject to such reasonable regulations as it may prescribe, it shall
register Warrant Certificates and exchanges and transfers of outstanding Warrant Certificates, upon surrender of the Warrant Certificates to the Warrant Agent at its corporate trust office for exchange or registration of transfer, properly endorsed
or accompanied by appropriate instruments of registration of transfer and written instructions for transfer, all in form satisfactory to the Company and the Warrant Agent. No service charge shall be made for any exchange or registration of transfer
of Warrant Certificates, but the Company may require payment of a sum sufficient to cover any stamp or other tax or other governmental charge that may be imposed in connection with any such exchange or registration of transfer. Whenever any Warrant
Certificates are so surrendered for exchange or registration of transfer, an authorized officer of the Warrant Agent shall manually countersign and deliver to the person or persons entitled thereto a Warrant Certificate or Warrant Certificates duly
authorized and executed by the Company, as so requested. The Warrant Agent shall not be required to effect any exchange or registration of transfer which will result in the issuance of a Warrant Certificate evidencing a Warrant for a fraction of a
Warrant Security or a number of Warrants for a whole number of Warrant Securities and a fraction of a Warrant Security. All Warrant Certificates issued upon any exchange or registration of transfer of Warrant Certificates shall be the valid
obligations of the Company, evidencing the same obligations and entitled to the same benefits under this Agreement as the Warrant Certificate surrendered for such exchange or registration of transfer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 Treatment of Holders of Warrant Certificates</B>. The Company, the Warrant Agent and all other persons may treat the registered holder
of a Warrant Certificate as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the contrary notwithstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3 Cancellation of Warrant Certificates</B>. Any Warrant Certificate surrendered for exchange, registration of transfer or exercise of the
Warrants evidenced thereby shall, if surrendered to the Company, be delivered to the Warrant Agent and all Warrant Certificates surrendered or so delivered to the Warrant Agent shall be promptly canceled by the Warrant Agent and shall not be
reissued and, except as expressly permitted by this Agreement, no Warrant Certificate shall be issued hereunder in exchange therefor or in lieu thereof. The Warrant Agent shall deliver to the Company from time to time or otherwise dispose of
canceled Warrant Certificates in a manner satisfactory to the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING THE WARRANT AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Warrant Agent</B>. The Company hereby appoints [&#149;] as Warrant Agent of the Company in respect of the Warrants and the Warrant
Certificates upon the terms and subject to the conditions herein set forth, and [&#149;] hereby accepts such appointment. The Warrant Agent shall have the powers and authority granted to and conferred upon it in the Warrant Certificates and hereby
and such further powers and authority to act on behalf of the Company as the Company may hereafter grant to or confer upon it. All of the terms and provisions with respect to such powers and authority contained in the Warrant Certificates are
subject to and governed by the terms and provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Conditions of Warrant Agent&#146;s Obligations</B>. The Warrant Agent
accepts its obligations herein set forth upon the terms and conditions hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the holders from time to time of the Warrant Certificates shall be
subject: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) Compensation and Indemnification</B>. The Company agrees promptly to pay the Warrant Agent the compensation to be agreed
upon with the Company for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable
counsel fees) incurred without negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it
harmless against, any loss, liability or expense incurred without negligence, bad faith or willful misconduct on the part of the Warrant Agent, arising out of or in connection with its acting as Warrant Agent hereunder, including the reasonable
costs and expenses of defending against any claim of such liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) Agent for the Company</B>. In acting under this Agreement and
in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the holders of Warrant Certificates or beneficial
owners of Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) Counsel</B>. The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the
Company, and the written advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of such counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) Documents</B>. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action taken or omitted by it
in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) Certain Transactions</B>. The Warrant Agent, and its officers, directors and
employees, may become the owner of, or acquire any interest in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they may engage or be
interested in any financial or other transaction with the Company and may act on, or as depositary, trustee or agent for, any committee or body of holders of Warrant Securities or other obligations of the Company as freely as if it were not the
Warrant Agent hereunder. Nothing in this Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the Company is a party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f) No Liability for Interest</B>. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any
monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g) No Liability
for Invalidity</B>. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h) No Responsibility for Representations</B>. The Warrant Agent shall not be responsible for any of the recitals or representations herein
or in the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon), all of which are made solely by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i) No Implied Obligations</B>. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant
Certificates specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which
may tend to involve it in any expense or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under any duty or responsibility for the use by the
Company of any of the Warrant Certificates authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrant Certificates. The Warrant Agent shall
have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a holder of a Warrant
Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or, except as provided in Section&nbsp;6.2
hereof, to make any demand upon the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Resignation, Removal and Appointment of Successors</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a) </B>The Company agrees, for the benefit of the holders from time to time of the Warrant Certificates, that there shall at all times be a
Warrant Agent hereunder until all the Warrants have been exercised or are no longer exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b) </B>The Warrant Agent may at any time resign as agent by giving written notice to the
Company of such intention on its part, specifying the date on which its desired resignation shall become effective; provided that such date shall not be less than three months after the date on which such notice is given unless the Company otherwise
agrees. The Warrant Agent hereunder may be removed at any time by the filing with it of an instrument in writing signed by or on behalf of the Company and specifying such removal and the intended date when it shall become effective. Such resignation
or removal shall take effect upon the appointment by the Company, as hereinafter provided, of a successor Warrant Agent (which shall be a bank or trust company authorized under the laws of the jurisdiction of its organization to exercise corporate
trust powers) and the acceptance of such appointment by such successor Warrant Agent. The obligation of the Company under Section&nbsp;5.2(a) shall continue to the extent set forth therein notwithstanding the resignation or removal of the Warrant
Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c) </B>In case at any time the Warrant Agent shall resign, or shall be removed, or shall become incapable of acting, or shall
be adjudged a bankrupt or insolvent, or shall commence a voluntary case under the Federal bankruptcy laws, as now or hereafter constituted, or under any other applicable Federal or state bankruptcy, insolvency or similar law or shall consent to the
appointment of or taking possession by a receiver, custodian, liquidator, assignee, trustee, sequestrator (or other similar official) of the Warrant Agent or its property or affairs, or shall make an assignment for the benefit of creditors, or shall
admit in writing its inability to pay its debts generally as they become due, or shall take corporate action in furtherance of any such action, or a decree or order for relief by a court having jurisdiction in the premises shall have been entered in
respect of the Warrant Agent in an involuntary case under the Federal bankruptcy laws, as now or hereafter constituted, or any other applicable Federal or state bankruptcy, insolvency or similar law, or a decree or order by a court having
jurisdiction in the premises shall have been entered for the appointment of a receiver, custodian, liquidator, assignee, trustee, sequestrator (or similar official) of the Warrant Agent or of its property or affairs, or any public officer shall take
charge or control of the Warrant Agent or of its property or affairs for the purpose of rehabilitation, conservation, winding up or liquidation, a successor Warrant Agent, qualified as aforesaid, shall be appointed by the Company by an instrument in
writing, filed with the successor Warrant Agent. Upon the appointment as aforesaid of a successor Warrant Agent and acceptance by the successor Warrant Agent of such appointment, the Warrant Agent shall cease to be Warrant Agent hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d) </B>Any successor Warrant Agent appointed hereunder shall execute, acknowledge and deliver to its predecessor and to the Company an
instrument accepting such appointment hereunder, and thereupon such successor Warrant Agent, without any further act, deed or conveyance, shall become vested with all the authority, rights, powers, trusts, immunities, duties and obligations of such
predecessor with like effect as if originally named as Warrant Agent hereunder, and such predecessor, upon payment of its charges and disbursements then unpaid, shall thereupon become obligated to transfer, deliver and pay over, and such successor
Warrant Agent shall be entitled to receive, all monies, securities and other property on deposit with or held by such predecessor, as Warrant Agent hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e) </B>Any corporation into which the Warrant Agent hereunder may be merged or converted
or any corporation with which the Warrant Agent may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party, or any corporation to which the Warrant Agent shall sell or
otherwise transfer all or substantially all the assets and business of the Warrant Agent, provided that it shall be qualified as aforesaid, shall be the successor Warrant Agent under this Agreement without the execution or filing of any paper or any
further act on the part of any of the parties hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1
Amendment</B>. This Agreement may be amended by the parties hereto, without the consent of the holder of any Warrant Certificate, for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained
herein, or making any other provisions with respect to matters or questions arising under this Agreement as the Company and the Warrant Agent may deem necessary or desirable; provided that such action shall not materially adversely affect the
interests of the holders of the Warrant Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Notices and Demands to the Company and Warrant Agent</B>. If the Warrant
Agent shall receive any notice or demand addressed to the Company by the holder of a Warrant Certificate pursuant to the provisions of the Warrant Certificates, the Warrant Agent shall promptly forward such notice or demand to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Addresses</B>. Any communication from the Company to the Warrant Agent with respect to this Agreement shall be addressed to [&#149;],
Attention: [&#149;] and any communication from the Warrant Agent to the Company with respect to this Agreement shall be addressed to Alaunos Therapeutics, Inc., [&#149;], Attention: [&#149;] (or such other address as shall be specified in writing by
the Warrant Agent or by the Company). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 Governing Law</B>. This Agreement and each Warrant Certificate issued hereunder shall be
governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5 Delivery of Prospectus</B>. The Company shall
furnish to the Warrant Agent sufficient copies of a prospectus meeting the requirements of the Securities Act of 1933, as amended, relating to the Warrant Securities deliverable upon exercise of the Warrants (the
&#147;<B><I>Prospectus</I></B>&#148;), and the Warrant Agent agrees that upon the exercise of any Warrant, the Warrant Agent will deliver to the holder of the Warrant Certificate evidencing such Warrant, prior to or concurrently with the delivery of
the Warrant Securities issued upon such exercise, a Prospectus. The Warrant Agent shall not, by reason of any such delivery, assume any responsibility for the accuracy or adequacy of such Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6 Obtaining of Governmental Approvals</B>. The Company will from time to time take all action which may be necessary to obtain and keep
effective any and all permits, consents and approvals of governmental agencies and authorities and securities act filings under United States Federal and state laws (including without limitation a registration statement in respect of the Warrants
and Warrant Securities under the Securities Act of 1933, as amended), which may be or become requisite in connection with the issuance, sale, transfer, and delivery of the Warrant Securities issued upon exercise of the Warrants, the issuance, sale,
transfer and delivery of the Warrants or upon the expiration of the period during which the Warrants are exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7 Persons Having Rights Under the Agreement</B>. Nothing in this Agreement shall give
to any person other than the Company, the Warrant Agent and the holders of the Warrant Certificates any right, remedy or claim under or by reason of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8 Headings</B>. The descriptive headings of the several Articles and Sections of this Agreement are inserted for convenience only and
shall not control or affect the meaning or construction of any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9 Counterparts</B>. This Agreement may be
executed in any number of counterparts, each of which as so executed shall be deemed to be an original, but such counterparts shall together constitute but one and the same instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10 Inspection of Agreement</B>. A copy of this Agreement shall be available at all reasonable times at the principal corporate trust
office of the Warrant Agent for inspection by the holder of any Warrant Certificate. The Warrant Agent may require such holder to submit such holder&#146;s Warrant Certificate for inspection by it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Alaunos Therapeutics, Inc</B>., as Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: _________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: _______________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: ________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST: ____________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">COUNTERSIGNED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[</B><B>&#149;</B><B>]</B>, as Warrant Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: _________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: _______________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: ________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST: ____________________________</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> A<SMALL>LAUNOS</SMALL>
T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WARRANT CERTIFICATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FACE OF WARRANT CERTIFICATE] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">[<B><I>Form of Legend if Warrants are not immediately exercisable</I></B>.]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">[Prior to [&#149;], Warrants evidenced by this Warrant Certificate cannot be exercised.]</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISABLE ONLY IF COUNTERSIGNED BY THE WARRANT AGENT AS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROVIDED HEREIN </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOID AFTER
[&#149;] P.M., [City] time, ON [&#149;]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATE REPRESENTING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS TO PURCHASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK, PAR VALUE $0.001 PER SHARE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No. [&#149;]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [&#149;] Warrants </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certifies that [&#149;] or registered assigns is the registered owner of the above indicated number of Warrants, each Warrant entitling such owner to
purchase, at any time [after [&#149;] p.m., [City] time, [on [&#149;] and] on or before [&#149;] p.m., [City] time, on [&#149;], [&#149;] shares of Common Stock, par value $0.001 per share (the &#147;<B><I>Warrant Securities</I></B>&#148;), of
Alaunos Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;) on the following basis: during the period from [&#149;], through and including [&#149;], the exercise price per Warrant Security will be $[&#149;], subject to adjustment as provided
in the Warrant Agreement (as hereinafter defined) (the &#147;<B><I>Warrant Price&#148;</I></B>). The Holder may exercise the Warrants evidenced hereby by providing certain information set forth on the back hereof and by paying in full, in lawful
money of the United States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant Price for each Warrant Security with respect to which
this Warrant is exercised to the Warrant Agent (as hereinafter defined) and by surrendering this Warrant Certificate, with the purchase form on the back hereof duly executed, at the corporate trust office of [name of Warrant Agent], or its successor
as warrant agent (the &#147;<B><I>Warrant Agent</I></B>&#148;), which is, on the date hereof, at the address specified on the reverse hereof, and upon compliance with and subject to the conditions set forth herein and in the Warrant Agreement (as
hereinafter defined). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>Holder</I></B>&#148; as used herein shall mean the person in whose name at the time this Warrant Certificate
shall be registered upon the books to be maintained by the Warrant Agent for that purpose pursuant to Section&nbsp;4 of the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Warrants evidenced by this Warrant Certificate may be exercised to purchase a whole number of Warrant Securities in registered form. Upon any exercise of fewer than all of the Warrants evidenced by this Warrant Certificate, there shall be issued to
the Holder hereof a new Warrant Certificate evidencing Warrants for the number of Warrant Securities remaining unexercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate is
issued under and in accordance with the Warrant Agreement dated as of [&#149;] (the &#147;<B><I>Warrant Agreement</I></B>&#148;), between the Company and the Warrant Agent and is subject to the terms and provisions contained in the Warrant
Agreement, to all of which terms and provisions the Holder of this Warrant Certificate consents by acceptance hereof. Copies of the Warrant Agreement are on file at the above-mentioned office of the Warrant Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfer of this Warrant Certificate may be registered when this Warrant Certificate is surrendered at the corporate trust office of the Warrant Agent by the
registered owner or such owner&#146;s assigns, in the manner and subject to the limitations provided in the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After countersignature by
the Warrant Agent and prior to the expiration of this Warrant Certificate, this Warrant Certificate may be exchanged at the corporate trust office of the Warrant Agent for Warrant Certificates representing Warrants for the same aggregate number of
Warrant Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not entitle the Holder hereof to any of the rights of a holder of the Warrant
Securities, including, without limitation, the right to receive payments of dividends or distributions, if any, on the Warrant Securities (except to the extent set forth in the Warrant Agreement) or to exercise any voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not be valid or obligatory for any purpose until
countersigned by the Warrant Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the Company has caused this
Warrant to be executed in its name and on its behalf by the facsimile signatures of its duly authorized officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ALAUNOS THERAPEUTICS, INC</B>., as Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: _________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: _______________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: ________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ATTEST:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>COUNTERSIGNED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>[&#149;], as Warrant Agent</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By: _________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: _______________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: ________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>ATTEST:</B> ____________________________</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REVERSE OF WARRANT CERTIFICATE] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Instructions for Exercise of Warrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To exercise any Warrants evidenced hereby for Warrant Securities (as hereinafter defined), the Holder must pay, in lawful money of the United
States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant Price in full for Warrants exercised, to [&#149;] [address of Warrant
Agent], Attention: [&#149;], which payment must specify the name of the Holder and the number of Warrants exercised by such Holder. In addition, the Holder must complete the information required below and present this Warrant Certificate in person
or by mail (certified or registered mail is recommended) to the Warrant Agent at the appropriate address set forth above. This Warrant Certificate, completed and duly executed, must be received by the Warrant Agent within five business days of the
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed upon exercise of Warrants) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably elects to exercise Warrants, evidenced by this Warrant Certificate, to purchase shares of the Common Stock,
par value $0.001 per share (the &#147;<B><I>Warrant Securities</I></B>&#148;), of Alaunos Therapeutics, Inc. and represents that the undersigned has tendered payment for such Warrant Securities, in lawful money of the United States of America, [in
cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], to the order of Alaunos Therapeutics, Inc., c/o [insert name and address of Warrant Agent], in the amount of
$ in accordance with the terms hereof. The undersigned requests that said Warrant Securities be in fully registered form in the authorized denominations, registered in such names and delivered all as specified in accordance with the instructions set
forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of Warrants exercised is less than all of the Warrants evidenced hereby, the undersigned requests that a new
Warrant Certificate evidencing the Warrants for the number of Warrant Securities remaining unexercised be issued and delivered to the undersigned unless otherwise specified in the instructions below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: _______________________________</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:_____________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Please Print</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">_______________________________ _____</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="7">(Insert Social Security or Other Identifying Number of Holder)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature Guaranteed:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signature</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of holder as specified on the face of this Warrant Certificate and must bear a
signature guarantee by a FINRA member firm). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant may be exercised at the following addresses: By hand at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By mail at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Instructions as to form and delivery of Warrant Securities and, if applicable, Warrant Certificates evidencing Warrants for the number of Warrant Securities
remaining unexercised&#151;complete as appropriate.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Form of assignment to be executed if Warrant Holder desires to transfer Warrant] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>F<SMALL>OR</SMALL>&nbsp;V<SMALL>ALUE</SMALL>&nbsp;R<SMALL>ECEIVED</SMALL></B><SMALL></SMALL>,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">hereby sells, assigns and transfers unto:</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="56%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">______________________________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">__________________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Please&nbsp;print&nbsp;name&nbsp;and&nbsp;address&nbsp;including&nbsp;zip&nbsp;code)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Please print Social Security or other identifying number</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the right represented by the within Warrant to purchase shares of [Title of Warrant Securities] of Alaunos Therapeutics, Inc.
to which the within Warrant relates and appoints attorney to transfer such right on the books of the Warrant Agent with full power of substitution in the premises. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:&nbsp;________________________________</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Name:______________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Signature</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of holder as specified on the face of the Warrant) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Signature
Guaranteed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>6
<FILENAME>d286456dex45.htm
<DESCRIPTION>EX-4.5
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><B>, AS WARRANT AGENT</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DATED
AS OF</B> <U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>LAUNOS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.
F<SMALL>ORM</SMALL> O<SMALL>F</SMALL> P<SMALL>REFERRED</SMALL> S<SMALL>TOCK</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PREFERRED STOCK WARRANT AGREEMENT</B> (this &#147;<B><I>Agreement</I></B>&#148;), dated as of [&#149;], between
<B>A<SMALL>LAUNOS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL></B><SMALL></SMALL>., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and [&#149;], a [corporation] [national banking association] organized and existing under
the laws of [&#149;] and having a corporate trust office in [&#149;], as warrant agent (the &#147;<B><I>Warrant</I></B> <B><I>Agent</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company proposes to sell <B><I>[If Warrants are sold with other securities</I></B> &#151; [title of such other securities
being offered] (the &#147;<B><I>Other Securities</I></B>&#148;) with] warrant certificates evidencing one or more warrants (the &#147;<B><I>Warrants</I></B>&#148; or, individually, a &#147;<B><I>Warrant</I></B>&#148;) representing the right to
purchase [title of Preferred Stock purchasable through exercise of Warrants] of the Company, par value $0.001 per share (the &#147;<B><I>Warrant Securities</I></B>&#148;), such warrant certificates and other warrant certificates issued pursuant to
this Agreement being herein called the &#147;Warrant Certificates&#148;; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company desires the Warrant Agent to act
on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration, transfer, exchange, exercise and replacement of the Warrant Certificates, and in this Agreement wishes to set forth, among other
things, the form and provisions of the Warrant Certificates and the terms and conditions on which they may be issued, registered, transferred, exchanged, exercised and replaced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW THEREFORE</B>, in consideration of the premises and of the mutual agreements herein contained, the parties hereto agree as follows:
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ISSUANCE
OF WARRANTS AND EXECUTION AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELIVERY OF WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B>Issuance of Warrants.</B> <B><I>[If Warrants alone</I></B> &#151;Upon issuance, each Warrant Certificate shall evidence one or
more Warrants.] [<B><I>If Other Securities and Warrants</I></B> &#151;Warrant Certificates will be issued in connection with the issuance of the Other Securities but shall be separately transferable and each Warrant Certificate shall evidence one or
more Warrants.] Each Warrant evidenced thereby shall represent the right, subject to the provisions contained herein and therein, to purchase one Warrant Security. [<B><I>If Other Securities and Warrants</I></B> &#151;Warrant Certificates will be
issued with the Other Securities and each Warrant Certificate will evidence [&#149;] Warrants for each [$[&#149;] principal amount] [[&#149;] shares] of Other Securities issued.] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B>Execution and Delivery of Warrant Certificates</B>. Each Warrant Certificate, whenever issued, shall be in registered form
substantially in the form set forth in <B>Exhibit A</B> hereto, shall be dated the date of its countersignature by the Warrant Agent and may have such letters, numbers, or other marks of identification or designation and such legends or endorsements
printed, lithographed or engraved thereon as the officers of the Company executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Agreement, or as may be
required to comply with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which the Warrants may be listed, or to conform to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
usage. The Warrant Certificates shall be signed on behalf of the Company by any of its present or future chief executive officers, presidents, senior vice presidents, vice presidents, chief
financial officers, chief legal officers, treasurers, assistant treasurers, controllers, assistant controllers, secretaries or assistant secretaries under its corporate seal reproduced thereon. Such signatures may be manual or facsimile signatures
of such authorized officers and may be imprinted or otherwise reproduced on the Warrant Certificates. The seal of the Company may be in the form of a facsimile thereof and may be impressed, affixed, imprinted or otherwise reproduced on the Warrant
Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Warrant Certificate shall be valid for any purpose, and no Warrant evidenced thereby shall be exercisable, until such
Warrant Certificate has been countersigned by the manual signature of the Warrant Agent. Such signature by the Warrant Agent upon any Warrant Certificate executed by the Company shall be conclusive evidence that the Warrant Certificate so
countersigned has been duly issued hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any officer of the Company who shall have signed any of the Warrant Certificates
either manually or by facsimile signature shall cease to be such officer before the Warrant Certificates so signed shall have been countersigned and delivered by the Warrant Agent, such Warrant Certificates may be countersigned and delivered
notwithstanding that the person who signed such Warrant Certificates ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Warrant
Certificate, shall be the proper officers of the Company, although at the date of the execution of this Agreement any such person was not such officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>holder</I></B>&#148; or &#147;<B><I>holder of a Warrant Certificate</I></B>&#148; as used herein shall mean any person in
whose name at the time any Warrant Certificate shall be registered upon the books to be maintained by the Warrant Agent for that purpose. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B>Issuance of Warrant Certificates</B>. Warrant Certificates evidencing the right to purchase Warrant Securities may be executed by
the Company and delivered to the Warrant Agent upon the execution of this Agreement or from time to time thereafter. The Warrant Agent shall, upon receipt of Warrant Certificates duly executed on behalf of the Company, countersign such Warrant
Certificates and shall deliver such Warrant Certificates to or upon the order of the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT PRICE, DURATION AND EXERCISE OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B>Warrant Price</B>. During the period specified in Section&nbsp;2.2, each Warrant shall, subject to the terms of this Agreement
and the applicable Warrant Certificate, entitle the holder thereof to purchase the number of Warrant Securities specified in the applicable Warrant Certificate at an exercise price of $[&#149;] per Warrant Security, subject to adjustment upon the
occurrence of certain events, as hereinafter provided. Such purchase price per Warrant Security is referred to in this Agreement as the &#147;<B><I>Warrant Price</I></B>.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B>Duration of Warrants</B>. Each Warrant may be exercised in whole or in part at
any time, as specified herein, on or after [the date thereof] [&#149;] and at or before [&#149;] p.m., [City] time, on [&#149;] or such later date as the Company may designate by notice to the Warrant Agent and the holders of Warrant Certificates
mailed to their addresses as set forth in the record books of the Warrant Agent (the &#147;<B><I>Expiration Date</I></B>&#148;). Each Warrant not exercised at or before [&#149;] p.m., [City] time, on the Expiration Date shall become void, and all
rights of the holder of the Warrant Certificate evidencing such Warrant under this Agreement shall cease. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B>Exercise of
Warrants</B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period specified in Section&nbsp;2.2, the Warrants may be exercised to purchase a whole number of Warrant
Securities in registered form by providing certain information as set forth on the reverse side of the Warrant Certificate and by paying in full, in lawful money of the United States of America, [in cash or by certified check or official bank check
in New York Clearing House funds] [by bank wire transfer in immediately available funds] the Warrant Price for each Warrant Security with respect to which a Warrant is being exercised to the Warrant Agent at its corporate trust office, provided that
such exercise is subject to receipt within five business days of such payment by the Warrant Agent of the Warrant Certificate with the form of election to purchase Warrant Securities set forth on the reverse side of the Warrant Certificate properly
completed and duly executed. The date on which payment in full of the Warrant Price is received by the Warrant Agent shall, subject to receipt of the Warrant Certificate as aforesaid, be deemed to be the date on which the Warrant is exercised;
provided, however, that if, at the date of receipt of such Warrant Certificates and payment in full of the Warrant Price, the transfer books for the Warrant Securities purchasable upon the exercise of such Warrants shall be closed, no such receipt
of such Warrant Certificates and no such payment of such Warrant Price shall be effective to constitute the person so designated to be named as the holder of record of such Warrant Securities on such date, but shall be effective to constitute such
person as the holder of record of such Warrant Securities for all purposes at the opening of business on the next succeeding day on which the transfer books for the Warrant Securities purchasable upon the exercise of such Warrants shall be opened,
and the certificates for the Warrant Securities in respect of which such Warrants are then exercised shall be issuable as of the date on such next succeeding day on which the transfer books shall next be opened, and until such date the Company shall
be under no duty to deliver any certificate for such Warrant Securities. The Warrant Agent shall deposit all funds received by it in payment of the Warrant Price in an account of the Company maintained with it and shall advise the Company by
telephone at the end of each day on which a payment for the exercise of Warrants is received of the amount so deposited to its account. The Warrant Agent shall promptly confirm such telephone advice to the Company in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Warrant Agent shall, from time to time, as promptly as practicable, advise the Company of (i)&nbsp;the number of Warrant Securities
with respect to which Warrants were exercised, (ii)&nbsp;the instructions of each holder of the Warrant Certificates evidencing such Warrants with respect to delivery of the Warrant Securities to which such holder is entitled upon such exercise,
(iii)&nbsp;delivery of Warrant Certificates evidencing the balance, if any, of the Warrants for the remaining Warrant Securities after such exercise, and (iv)&nbsp;such other information as the Company shall reasonably require. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As soon as practicable after the exercise of any Warrant, the Company shall issue to or
upon the order of the holder of the Warrant Certificate evidencing such Warrant the Warrant Securities to which such holder is entitled, in fully registered form, registered in such name or names as may be directed by such holder. If fewer than all
of the Warrants evidenced by such Warrant Certificate are exercised, the Company shall execute, and an authorized officer of the Warrant Agent shall manually countersign and deliver, a new Warrant Certificate evidencing Warrants for the number of
Warrant Securities remaining unexercised. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be required to pay any stamp or other tax or other governmental charge
required to be paid in connection with any transfer involved in the issue of the Warrant Securities, and in the event that any such transfer is involved, the Company shall not be required to issue or deliver any Warrant Security until such tax or
other charge shall have been paid or it has been established to the Company&#146;s satisfaction that no such tax or other charge is due. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Prior to the issuance of any Warrants there shall have been reserved, and the Company shall at all times through the Expiration Date keep
reserved, out of its authorized but unissued Warrant Securities, a number of shares sufficient to provide for the exercise of the Warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER
PROVISIONS RELATING TO RIGHTS OF HOLDERS OF </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>No Rights as Warrant Securityholder Conferred by Warrants or Warrant Certificates</B>. No Warrant Certificate or Warrant
evidenced thereby shall entitle the holder thereof to any of the rights of a holder of Warrant Securities, including, without limitation, the right to receive the payment of dividends or distributions, if any, on the Warrant Securities or to
exercise any voting rights, except to the extent expressly set forth in this Agreement or the applicable Warrant Certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B>
<B>Lost, Stolen, Mutilated or Destroyed Warrant Certificates</B>. Upon receipt by the Warrant Agent of evidence reasonably satisfactory to it and the Company of the ownership of and the loss, theft, destruction or mutilation of any Warrant
Certificate and/or indemnity reasonably satisfactory to the Warrant Agent and the Company and, in the case of mutilation, upon surrender of the mutilated Warrant Certificate to the Warrant Agent for cancellation, then, in the absence of notice to
the Company or the Warrant Agent that such Warrant Certificate has been acquired by a bona fide purchaser, the Company shall execute, and an authorized officer of the Warrant Agent shall manually countersign and deliver, in exchange for or in lieu
of the lost, stolen, destroyed or mutilated Warrant Certificate, a new Warrant Certificate of the same tenor and evidencing Warrants for a like number of Warrant Securities. Upon the issuance of any new Warrant Certificate under this
Section&nbsp;3.2, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Warrant Agent) in
connection therewith. Every substitute Warrant Certificate executed and delivered pursuant to this Section&nbsp;3.2 in lieu of any lost, stolen or destroyed Warrant Certificate shall represent an additional
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual obligation of the Company, whether or not the lost, stolen or destroyed Warrant Certificate shall be at any time enforceable by anyone, and shall be entitled to the benefits of this
Agreement equally and proportionately with any and all other Warrant Certificates duly executed and delivered hereunder. The provisions of this Section&nbsp;3.2 are exclusive and shall preclude (to the extent lawful) all other rights and remedies
with respect to the replacement of mutilated, lost, stolen or destroyed Warrant Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Holder of Warrant Certificate
May Enforce Rights.</B> Notwithstanding any of the provisions of this Agreement, any holder of a Warrant Certificate, without the consent of the Warrant Agent, the holder of any Warrant Securities or the holder of any other Warrant Certificate, may,
in such holder&#146;s own behalf and for such holder&#146;s own benefit, enforce, and may institute and maintain any suit, action or proceeding against the Company suitable to enforce, or otherwise in respect of, such holder&#146;s right to exercise
the Warrants evidenced by such holder&#146;s Warrant Certificate in the manner provided in such holder&#146;s Warrant Certificate and in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Adjustments</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) In case the Company shall at any time subdivide its outstanding shares of [title of Preferred Stock purchasable through exercise of
Warrants] into a greater number of shares, the Warrant Price in effect immediately prior to such subdivision shall be proportionately reduced and the number of Warrant Securities purchasable under the Warrants shall be proportionately increased.
Conversely, in case the outstanding shares of [title of Preferred Stock purchasable through exercise of Warrants] shall be combined into a smaller number of shares, the Warrant Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Securities purchasable under the Warrants shall be proportionately decreased. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) If
at any time or from time to time the holders of [title of Preferred Stock purchasable through exercise of Warrants] (or any shares of stock or other securities at the time receivable upon the exercise of the Warrants) shall have received or become
entitled to receive, without payment therefore, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) [title of Preferred Stock purchasable through exercise of Warrants] or any shares of
stock or other securities which are at any time directly or indirectly convertible into or exchangeable for [title of Preferred Stock purchasable through exercise of Warrants], or any rights or options to subscribe for, purchase or otherwise acquire
any of the foregoing by way of dividend or other distribution; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any cash paid or payable otherwise than in accordance with the terms
of [title of Preferred Stock purchasable through exercise of Warrants] or as a cash dividend paid or payable out of the Company&#146;s current or retained earnings; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any evidence of the Company&#146;s indebtedness or rights to subscribe for or purchase the Company&#146;s indebtedness; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) [title of Preferred Stock purchasable through exercise of Warrants] or additional
stock or other securities or property (including cash) by way of spinoff, <FONT STYLE="white-space:nowrap">split-up,</FONT> reclassification, combination of shares or similar corporate rearrangement (other than shares of [title of Preferred Stock
purchasable through exercise of Warrants] issued as a stock split or adjustments in respect of which shall be covered by the terms of Section&nbsp;3.4(a) above), then and in each such case, the holder of each Warrant shall, upon the exercise of the
Warrant, be entitled to receive, in addition to the number of Warrant Securities receivable thereupon, and without payment of any additional consideration therefore, the amount of stock and other securities and property (including cash and
indebtedness or rights to subscribe for or purchase indebtedness) which such holder would hold on the date of such exercise had such holder been the holder of record of such Warrant Securities as of the date on which holders of [title of Preferred
Stock purchasable through exercise of Warrants] received or became entitled to receive such shares or all other additional stock and other securities and property. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In case of (i)&nbsp;any reclassification, capital reorganization, or change in the [title of Preferred Stock purchasable through exercise
of Warrants] of the Company (other than as a result of a subdivision, combination, or stock dividend provided for in Section&nbsp;3.4(a) or Section&nbsp;3.4(b) above), (ii) share exchange, merger or similar transaction of the Company with or into
another person or entity (other than a share exchange, merger or similar transaction in which the Company is the acquiring or surviving corporation and which does not result in any change in the [title of Preferred Stock purchasable through exercise
of Warrants] other than the issuance of additional shares of [title of Preferred Stock purchasable through exercise of Warrants]) or (iii)&nbsp;the sale, exchange, lease, transfer or other disposition of all or substantially all of the properties
and assets of the Company as an entirety (in any such case, a &#147;<B><I>Reorganization Event</I></B>&#148;), then, as a condition of such Reorganization Event, lawful provisions shall be made, and duly executed documents evidencing the same from
the Company or its successor shall be delivered to the holders of the Warrants, so that the holders of the Warrants shall have the right at any time prior to the expiration of the Warrants to purchase, at a total price equal to that payable upon the
exercise of the Warrants, the kind and amount of shares of stock and other securities and property receivable in connection with such Reorganization Event by a holder of the same number of shares of [title of Preferred Stock purchasable through
exercise of Warrants] as were purchasable by the holders of the Warrants immediately prior to such Reorganization Event. In any such case appropriate provisions shall be made with respect to the rights and interests of the holders of the Warrants so
that the provisions hereof shall thereafter be applicable with respect to any shares of stock or other securities and property deliverable upon exercise the Warrants, and appropriate adjustments shall be made to the Warrant Price payable hereunder
provided the aggregate purchase price shall remain the same. In the case of any transaction described in clauses (ii)&nbsp;and (iii) above, the Company shall thereupon be relieved of any further obligation hereunder or under the Warrants, and the
Company as the predecessor corporation may thereupon or at any time thereafter be dissolved, wound up or liquidated. Such successor or assuming entity thereupon may cause to be signed, and may issue either in its own name or in the name of the
Company, any or all of the Warrants issuable hereunder which heretofore shall not have been signed by the Company, and may execute and deliver securities in its own name, in fulfillment of its obligations to deliver Warrant Securities upon exercise
of the Warrants. All the Warrants so issued shall in all respects have the same legal rank and benefit under this Agreement as the Warrants theretofore or thereafter issued in accordance with the terms of this Agreement as though all of such
Warrants had been issued at the date of the execution hereof. In any case of any such Reorganization Event, such changes in phraseology and form (but not in substance) may be made in the Warrants thereafter to be issued as may be appropriate. The
Warrant Agent may receive a written opinion of legal counsel as conclusive evidence that any such Reorganization Event complies with the provisions of this Section&nbsp;3.4. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company may, at its option, at any time until the Expiration Date, reduce the then
current Warrant Price to any amount deemed appropriate by the Board of Directors of the Company for any period not exceeding twenty consecutive days (as evidenced in a resolution adopted by such Board of Directors), but only upon giving the notices
required by Section&nbsp;3.5 at least ten days prior to taking such action. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Except as herein otherwise expressly provided, no
adjustment in the Warrant Price shall be made by reason of the issuance of any securities of the Company or for any other reason whatsoever. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) No fractional Warrant Securities shall be issued upon the exercise of Warrants. If more than one Warrant shall be exercised at one time by
the same holder, the number of full Warrant Securities which shall be issuable upon such exercise shall be computed on the basis of the aggregate number of Warrant Securities purchased pursuant to the Warrants so exercised. Instead of any fractional
Warrant Security which would otherwise be issuable upon exercise of any Warrant, the Company shall pay a cash adjustment in respect of such fraction in an amount equal to the same fraction of the last reported sale price (or bid price if there were
no sales) per Warrant Security, in either case as reported on the principal registered national securities exchange on which the Warrant Securities are listed or admitted to trading on the business day that next precedes the day of exercise or, if
the Warrant Securities are not then listed or admitted to trading on any registered national securities exchange, the average of the closing high bid and low asked prices as reported on the OTC Bulletin Board Service (the &#147;<B><I>OTC Bulletin
Board</I></B>&#148;) operated by the Financial Industry Regulatory Authority, Inc. (&#147;<B><I>FINRA</I></B>&#148; ) or, if not available on the OTC Bulletin Board, then the average of the closing high bid and low asked prices as reported on any
other U.S. quotation medium or inter-dealer quotation system on such date, or if on any such date the Warrant Securities are not listed or admitted to trading on a registered national securities exchange, are not included in the OTC Bulletin Board,
and are not quoted on any other U.S. quotation medium or inter-dealer quotation system, an amount equal to the same fraction of the average of the closing bid and asked prices as furnished by any FINRA member firm selected from time to time by the
Company for that purpose at the close of business on the business day that next precedes the day of exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) Whenever the Warrant
Price then in effect is adjusted as herein provided, the Company shall mail to each holder of the Warrants at such holder&#146;s address as it shall appear on the books of the Company a statement setting forth the adjusted Warrant Price then and
thereafter effective under the provisions hereof, together with the facts, in reasonable detail, upon which such adjustment is based. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
Notwithstanding anything to the contrary herein, in no event shall the Warrant Price, as adjusted in accordance with the terms hereof, be less than the par value per share of [title of Preferred Stock purchasable through exercise of Warrants]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Notice to Warrantholders</B>. In case the Company shall (a)&nbsp;effect any
dividend or distribution described in Section&nbsp;3.4(b), (b) effect any Reorganization Event, (c)&nbsp;make any distribution on or in respect of the [title of Preferred Stock purchasable through exercise of Warrants] in connection with the
dissolution, liquidation or winding up of the Company, or (d)&nbsp;reduce the then current Warrant Price pursuant to Section&nbsp;3.4(d), then the Company shall mail to each holder of Warrants at such holder&#146;s address as it shall appear on the
books of the Warrant Agent, at least ten days prior to the applicable date hereinafter specified, a notice stating (x)&nbsp;the record date for such dividend or distribution, or, if a record is not to be taken, the date as of which the holders of
record of [title of Preferred Stock purchasable through exercise of Warrants] that will be entitled to such dividend or distribution are to be determined, (y)&nbsp;the date on which such Reorganization Event, dissolution, liquidation or winding up
is expected to become effective, and the date as of which it is expected that holders of [title of Preferred Stock purchasable through exercise of Warrants] of record shall be entitled to exchange their shares of [title of Preferred Stock
purchasable through exercise of Warrants] for securities or other property deliverable upon such Reorganization Event, dissolution, liquidation or winding up, or (z)&nbsp;the first date on which the then current Warrant Price shall be reduced
pursuant to Section&nbsp;3.4(d). No failure to mail such notice nor any defect therein or in the mailing thereof shall affect any such transaction or any adjustment in the Warrant Price required by Section&nbsp;3.4. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> [<B><I>If the Warrants are Subject to Acceleration by the Company, Insert</I></B> &#151; Acceleration of Warrants by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) At any time on or after [&#149;], the Company shall have the right to accelerate any or all Warrants at any time by causing them to
expire at the close of business on the day next preceding a specified date (the &#147;<B><I>Acceleration</I></B> <B><I>Date</I></B>&#148;), if the Market Price (as hereinafter defined) of the [title of Preferred Stock purchasable through exercise of
Warrants] equals or exceeds [&#149;] percent ([&#149;]%) of the then effective Warrant Price on any twenty Trading Days (as hereinafter defined) within a period of thirty consecutive Trading Days ending no more than five Trading Days prior to the
date on which the Company gives notice to the Warrant Agent of its election to accelerate the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) (b) &#147;<B><I>Market
Price</I></B>&#148; for each Trading Day shall be, if the [title of Preferred Stock purchasable through exercise of Warrants] is listed or admitted to trading on any registered national securities exchange, the last reported sale price, regular way
(or, if no such price is reported, the average of the reported closing bid and asked prices, regular way) of [title of Preferred Stock purchasable through exercise of Warrants], in either case as reported on the principal registered national
securities exchange on which the [title of Preferred Stock purchasable through exercise of Warrants] is listed or admitted to trading or, if not listed or admitted to trading on any registered national securities exchange, the average of the closing
high bid and low asked prices as reported on the OTC Bulletin Board operated by FINRA, or if not available on the OTC Bulletin Board, then the average of the closing high bid and low asked prices as reported on any other U.S. quotation medium or
inter-dealer quotation system, or if on any such date the shares of [title of Preferred Stock purchasable through exercise of Warrants] are not listed or admitted to trading on a registered national securities exchange, are not included in the OTC
Bulletin Board, and are not quoted on any other U.S. quotation medium or inter-dealer quotation system, the average of the closing bid and asked prices as furnished by any FINRA member firm selected from time to time by the Company for that purpose.
&#147;Trading Day&#148; shall be each Monday through Friday, other than any day on which securities are not traded in the system or on the exchange that is the principal market for the [title of Preferred Stock
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchasable through exercise of Warrants], as determined by the Board of Directors of the Company. In the event of an acceleration of less than all of the Warrants, the Warrant Agent shall select
the Warrants to be accelerated by lot, pro rata or in such other manner as it deems, in its discretion, to be fair and appropriate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)
Notice of an acceleration specifying the Acceleration Date shall be sent by mail first class, postage prepaid, to each registered holder of a Warrant Certificate representing a Warrant accelerated at such holder&#146;s address appearing on the books
of the Warrant Agent not more than sixty days nor less than thirty days before the Acceleration Date. Such notice of an acceleration also shall be given no more than twenty days, and no less than ten days, prior to the mailing of notice to
registered holders of Warrants pursuant to this Section&nbsp;3.6, by publication at least once in a newspaper of general circulation in the City of New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any Warrant accelerated may be exercised until [&#149;] p.m., [City] time, on the business day next preceding the Acceleration Date. The
Warrant Price shall be payable as provided in Section&nbsp;2.] </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AND TRANSFER OF WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Exchange and Transfer of Warrant Certificates</B>. Upon surrender at the corporate trust office of the Warrant Agent, Warrant
Certificates evidencing Warrants may be exchanged for Warrant Certificates in other denominations evidencing such Warrants or the transfer thereof may be registered in whole or in part; provided that such other Warrant Certificates evidence Warrants
for the same aggregate number of Warrant Securities as the Warrant Certificates so surrendered. The Warrant Agent shall keep, at its corporate trust office, books in which, subject to such reasonable regulations as it may prescribe, it shall
register Warrant Certificates and exchanges and transfers of outstanding Warrant Certificates, upon surrender of the Warrant Certificates to the Warrant Agent at its corporate trust office for exchange or registration of transfer, properly endorsed
or accompanied by appropriate instruments of registration of transfer and written instructions for transfer, all in form satisfactory to the Company and the Warrant Agent. No service charge shall be made for any exchange or registration of transfer
of Warrant Certificates, but the Company may require payment of a sum sufficient to cover any stamp or other tax or other governmental charge that may be imposed in connection with any such exchange or registration of transfer. Whenever any Warrant
Certificates are so surrendered for exchange or registration of transfer, an authorized officer of the Warrant Agent shall manually countersign and deliver to the person or persons entitled thereto a Warrant Certificate or Warrant Certificates duly
authorized and executed by the Company, as so requested. The Warrant Agent shall not be required to effect any exchange or registration of transfer which will result in the issuance of a Warrant Certificate evidencing a Warrant for a fraction of a
Warrant Security or a number of Warrants for a whole number of Warrant Securities and a fraction of a Warrant Security. All Warrant Certificates issued upon any exchange or registration of transfer of Warrant Certificates shall be the valid
obligations of the Company, evidencing the same obligations and entitled to the same benefits under this Agreement as the Warrant Certificate surrendered for such exchange or registration of transfer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Treatment of Holders of Warrant Certificates</B>. The Company, the Warrant
Agent and all other persons may treat the registered holder of a Warrant Certificate as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the
contrary notwithstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Cancellation of Warrant Certificates</B>. Any Warrant Certificate surrendered for exchange,
registration of transfer or exercise of the Warrants evidenced thereby shall, if surrendered to the Company, be delivered to the Warrant Agent and all Warrant Certificates surrendered or so delivered to the Warrant Agent shall be promptly canceled
by the Warrant Agent and shall not be reissued and, except as expressly permitted by this Agreement, no Warrant Certificate shall be issued hereunder in exchange therefor or in lieu thereof. The Warrant Agent shall deliver to the Company from time
to time or otherwise dispose of canceled Warrant Certificates in a manner satisfactory to the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING THE WARRANT AGENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B>Warrant Agent.</B> The Company hereby appoints [&#149;] as Warrant Agent of the Company in respect of the Warrants and the
Warrant Certificates upon the terms and subject to the conditions herein set forth, and [&#149;] hereby accepts such appointment. The Warrant Agent shall have the powers and authority granted to and conferred upon it in the Warrant Certificates and
hereby and such further powers and authority to act on behalf of the Company as the Company may hereafter grant to or confer upon it. All of the terms and provisions with respect to such powers and authority contained in the Warrant Certificates are
subject to and governed by the terms and provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B>Conditions of Warrant Agent&#146;s Obligations</B>. The Warrant
Agent accepts its obligations herein set forth upon the terms and conditions hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the holders from time to time of the Warrant Certificates
shall be subject: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Compensation and Indemnification.</B> The Company agrees promptly to pay the Warrant Agent the compensation to be
agreed upon with the Company for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including
reasonable counsel fees) incurred without negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to
hold it harmless against, any loss, liability or expense incurred without negligence, bad faith or willful misconduct on the part of the Warrant Agent, arising out of or in connection with its acting as Warrant Agent hereunder, including the
reasonable costs and expenses of defending against any claim of such liability. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Agent for the Company.</B> In acting under this
Agreement and in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the holders of Warrant Certificates or
beneficial owners of Warrants. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>Counsel</B>. The Warrant Agent may consult with counsel satisfactory to it, which may
include counsel for the Company, and the written advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of
such counsel. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>Documents</B>. The Warrant Agent shall be protected and shall incur no liability for or in respect of any action
taken or omitted by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented or signed by the proper
parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>Certain Transactions</B>. The Warrant Agent, and its officers, directors and employees, may become the owner of, or
acquire any interest in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they may engage or be interested in any financial or other
transaction with the Company and may act on, or as depositary, trustee or agent for, any committee or body of holders of Warrant Securities or other obligations of the Company as freely as if it were not the Warrant Agent hereunder. Nothing in this
Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the Company is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
<B>No Liability for Interest.</B> Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant
Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B>No Liability for Invalidity.</B> The Warrant Agent shall have no liability with respect to any invalidity of this
Agreement or any of the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B>No Responsibility
for Representations</B>. The Warrant Agent shall not be responsible for any of the recitals or representations herein or in the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon), all of which are made solely by
the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <B>No Implied Obligations</B>. The Warrant Agent shall be obligated to perform only such duties as are herein and in the
Warrant Certificates specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action
hereunder which may tend to involve it in any expense or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under any duty or responsibility for
the use by the Company of any of the Warrant Certificates authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrant Certificates. The Warrant
Agent shall have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a holder of a
Warrant Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or, except as provided in
Section&nbsp;6.2 hereof, to make any demand upon the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B>Resignation, Removal and Appointment of Successors</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees, for the benefit of the holders from time to time of the Warrant Certificates, that there shall at all times be a
Warrant Agent hereunder until all the Warrants have been exercised or are no longer exercisable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Warrant Agent may at any time
resign as agent by giving written notice to the Company of such intention on its part, specifying the date on which its desired resignation shall become effective; provided that such date shall not be less than three months after the date on which
such notice is given unless the Company otherwise agrees. The Warrant Agent hereunder may be removed at any time by the filing with it of an instrument in writing signed by or on behalf of the Company and specifying such removal and the intended
date when it shall become effective. Such resignation or removal shall take effect upon the appointment by the Company, as hereinafter provided, of a successor Warrant Agent (which shall be a bank or trust company authorized under the laws of the
jurisdiction of its organization to exercise corporate trust powers) and the acceptance of such appointment by such successor Warrant Agent. The obligation of the Company under Section&nbsp;5.2(a) shall continue to the extent set forth therein
notwithstanding the resignation or removal of the Warrant Agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In case at any time the Warrant Agent shall resign, or shall be
removed, or shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or shall commence a voluntary case under the Federal bankruptcy laws, as now or hereafter constituted, or under any other applicable Federal or state
bankruptcy, insolvency or similar law or shall consent to the appointment of or taking possession by a receiver, custodian, liquidator, assignee, trustee, sequestrator (or other similar official) of the Warrant Agent or its property or affairs, or
shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts generally as they become due, or shall take corporate action in furtherance of any such action, or a decree or order for relief by a
court having jurisdiction in the premises shall have been entered in respect of the Warrant Agent in an involuntary case under the Federal bankruptcy laws, as now or hereafter constituted, or any other applicable Federal or state bankruptcy,
insolvency or similar law, or a decree or order by a court having jurisdiction in the premises shall have been entered for the appointment of a receiver, custodian, liquidator, assignee, trustee, sequestrator (or similar official) of the Warrant
Agent or of its property or affairs, or any public officer shall take charge or control of the Warrant Agent or of its property or affairs for the purpose of rehabilitation, conservation, winding up or liquidation, a successor Warrant Agent,
qualified as aforesaid, shall be appointed by the Company by an instrument in writing, filed with the successor Warrant Agent. Upon the appointment as aforesaid of a successor Warrant Agent and acceptance by the successor Warrant Agent of such
appointment, the Warrant Agent shall cease to be Warrant Agent hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any successor Warrant Agent appointed hereunder shall
execute, acknowledge and deliver to its predecessor and to the Company an instrument accepting such appointment hereunder, and thereupon such successor Warrant Agent, without any further act, deed or conveyance, shall become vested with all the
authority, rights, powers, trusts, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immunities, duties and obligations of such predecessor with like effect as if originally named as Warrant Agent hereunder, and such predecessor, upon payment of its charges and disbursements then
unpaid, shall thereupon become obligated to transfer, deliver and pay over, and such successor Warrant Agent shall be entitled to receive, all monies, securities and other property on deposit with or held by such predecessor, as Warrant Agent
hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any corporation into which the Warrant Agent hereunder may be merged or converted or any corporation with which the Warrant
Agent may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party, or any corporation to which the Warrant Agent shall sell or otherwise transfer all or substantially all
the assets and business of the Warrant Agent, provided that it shall be qualified as aforesaid, shall be the successor Warrant Agent under this Agreement without the execution or filing of any paper or any further act on the part of any of the
parties hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>
<B>Amendment</B>. This Agreement may be amended by the parties hereto, without the consent of the holder of any Warrant Certificate, for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained
herein, or making any other provisions with respect to matters or questions arising under this Agreement as the Company and the Warrant Agent may deem necessary or desirable; provided that such action shall not materially adversely affect the
interests of the holders of the Warrant Certificates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B>Notices and Demands to the Company and Warrant Agent</B>. If the
Warrant Agent shall receive any notice or demand addressed to the Company by the holder of a Warrant Certificate pursuant to the provisions of the Warrant Certificates, the Warrant Agent shall promptly forward such notice or demand to the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B>Addresses</B>. Any communication from the Company to the Warrant Agent with respect to this Agreement shall be addressed to
[&#149;], Attention: [&#149;] and any communication from the Warrant Agent to the Company with respect to this Agreement shall be addressed to Alaunos Therapeutics, Inc. 8030 El Rio Street, Houston, TX 77054, Attention: [&#149;] (or such other
address as shall be specified in writing by the Warrant Agent or by the Company). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> <B>Governing Law</B>. This Agreement and each
Warrant Certificate issued hereunder shall be governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5</B>
<B>Delivery of Prospectus</B>. The Company shall furnish to the Warrant Agent sufficient copies of a prospectus meeting the requirements of the Securities Act of 1933, as amended, relating to the Warrant Securities deliverable upon exercise of the
Warrants (the &#147;Prospectus&#148;), and the Warrant Agent agrees that upon the exercise of any Warrant, the Warrant Agent will deliver to the holder of the Warrant Certificate evidencing such Warrant, prior to or concurrently with the delivery of
the Warrant Securities issued upon such exercise, a Prospectus. The Warrant Agent shall not, by reason of any such delivery, assume any responsibility for the accuracy or adequacy of such Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6</B> <B>Obtaining of Governmental Approvals</B>. The Company will from time to time
take all action which may be necessary to obtain and keep effective any and all permits, consents and approvals of governmental agencies and authorities and securities act filings under United States Federal and state laws (including without
limitation a registration statement in respect of the Warrants and Warrant Securities under the Securities Act of 1933, as amended), which may be or become requisite in connection with the issuance, sale, transfer, and delivery of the Warrant
Securities issued upon exercise of the Warrants, the issuance, sale, transfer and delivery of the Warrants or upon the expiration of the period during which the Warrants are exercisable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7</B> <B>Persons Having Rights Under the Agreement</B>. Nothing in this Agreement shall give to any person other than the Company, the
Warrant Agent and the holders of the Warrant Certificates any right, remedy or claim under or by reason of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8</B>
<B>Headings</B>. The descriptive headings of the several Articles and Sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9</B> <B>Counterparts</B>. This Agreement may be executed in any number of counterparts, each of which as so executed shall be deemed to
be an original, but such counterparts shall together constitute but one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10</B> <B>Inspection of
Agreement</B>. A copy of this Agreement shall be available at all reasonable times at the principal corporate trust office of the Warrant Agent for inspection by the holder of any Warrant Certificate. The Warrant Agent may require such holder to
submit such holder&#146;s Warrant Certificate for inspection by it </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties hereto have caused this Agreement to be duly executed
as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Alaunos Therapeutics, Inc., as Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATTEST</B>:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COUNTERSIGNED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[&#149;], as Warrant Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ATTEST</B>:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGE TO ALAUNOS THERAPEUTICS, INC. PREFERRED STOCK WARRANT AGREEMENT] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WARRANT CERTIFICATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FACE OF WARRANT CERTIFICATE] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[<B><I>Form
of Legend if Warrants are not immediately exercisable</I></B>.] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Prior to [&#149;], Warrants evidenced by this Warrant Certificate cannot be exercised.]
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXERCISABLE ONLY IF COUNTERSIGNED BY THE WARRANT AGENT AS PROVIDED HEREIN </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOID AFTER [&#149;] P.M., [City] time, ON [&#149;]. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATE REPRESENTING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS TO PURCHASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[TITLE OF WARRANT SECURITIES] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. [&#149;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[&#149;] Warrants</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certifies that [&#149;] or registered assigns is the registered owner of the above indicated number of Warrants, each
Warrant entitling such owner to purchase, at any time [after [&#149;] p.m., [City] time, [on [&#149;] and] on or before [&#149;] p.m., [City] time, on [&#149;], [&#149;] shares of [TITLE OF WARRANT SECURITIES], par value $0.001 per share (the
&#147;<B><I>Warrant</I></B> <B><I>Securities</I></B>&#148;), of Alaunos Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;) on the following basis: during the period from [&#149;], through and including [&#149;], the exercise price per
Warrant Security will be $[&#149;], subject to adjustment as provided in the Warrant Agreement (as hereinafter defined) (the &#147;Warrant Price&#148;). The Holder may exercise the Warrants evidenced hereby by providing certain information set forth
on the back hereof and by paying in full, in lawful money of the United States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant
Price for each Warrant Security with respect to which this Warrant is exercised to the Warrant Agent (as hereinafter defined) and by surrendering this Warrant Certificate, with the purchase form on the back hereof duly executed, at the corporate
trust office of [name of Warrant Agent], or its successor as warrant agent (the &#147;<B><I>Warrant</I></B> <B><I>Agent</I></B>&#148;), which is, on the date hereof, at the address specified on the reverse hereof, and upon compliance with and
subject to the conditions set forth herein and in the Warrant Agreement (as hereinafter defined). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>Holder</I></B>&#148; as used
herein shall mean the person in whose name at the time this Warrant Certificate shall be registered upon the books to be maintained by the Warrant Agent for that purpose pursuant to Section&nbsp;4 of the Warrant Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants evidenced by this Warrant Certificate may be exercised to purchase a whole number of Warrant Securities in registered form. Upon any exercise of
fewer than all of the Warrants evidenced by this Warrant Certificate, there shall be issued to the Holder hereof a new Warrant Certificate evidencing Warrants for the number of Warrant Securities remaining unexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate is issued under and in accordance with the Warrant Agreement dated as of [&#149;] (the &#147;<B><I>Warrant</I></B>
<B><I>Agreement</I></B>&#148;), between the Company and the Warrant Agent and is subject to the terms and provisions contained in the Warrant Agreement, to all of which terms and provisions the Holder of this Warrant Certificate consents by
acceptance hereof. Copies of the Warrant Agreement are on file at the above-mentioned office of the Warrant Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfer of this Warrant Certificate
may be registered when this Warrant Certificate is surrendered at the corporate trust office of the Warrant Agent by the registered owner or such owner&#146;s assigns, in the manner and subject to the limitations provided in the Warrant Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After countersignature by the Warrant Agent and prior to the expiration of this Warrant Certificate, this Warrant Certificate may be exchanged at the
corporate trust office of the Warrant Agent for Warrant Certificates representing Warrants for the same aggregate number of Warrant Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not entitle the Holder hereof to any of the rights of a holder of the Warrant
Securities, including, without limitation, the right to receive payments of dividends or distributions, if any, on the Warrant Securities (except to the extent set forth in the Warrant Agreement) or to exercise any voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not be valid or obligatory for any purpose until
countersigned by the Warrant Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be executed in its name and on its behalf by the
facsimile signatures of its duly authorized officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Alaunos Therapeutics, Inc</B>., as Company </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ATTEST:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>COUNTERSIGNED</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">[&#149;], as Warrant Agent</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ATTEST</B>:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REVERSE OF WARRANT CERTIFICATE] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Instructions for Exercise of Warrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To exercise any Warrants evidenced hereby for Warrant Securities (as hereinafter defined), the Holder must pay, in lawful money of the United
States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant Price in full for Warrants exercised, to [&#149;] [address of Warrant
Agent], Attention: [&#149;], which payment must specify the name of the Holder and the number of Warrants exercised by such Holder. In addition, the Holder must complete the information required below and present this Warrant Certificate in person
or by mail (certified or registered mail is recommended) to the Warrant Agent at the appropriate address set forth above. This Warrant Certificate, completed and duly executed, must be received by the Warrant Agent within five business days of the
payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed upon exercise of Warrants) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably elects to exercise Warrants, evidenced by this Warrant Certificate, to purchase shares of the [TITLE OF
WARRANT SECURITIES], par value $0.001 per share (the &#147;<B><I>Warrant</I></B> <B><I>Securities</I></B>&#148;), of Alaunos Therapeutics, Inc. and represents that the undersigned has tendered payment for such Warrant Securities, in lawful money of
the United States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], to the order of Alaunos Therapeutics, Inc., c/o [insert name and address of
Warrant Agent], in the amount of $ in accordance with the terms hereof. The undersigned requests that said Warrant Securities be in fully registered form in the authorized denominations, registered in such names and delivered all as specified in
accordance with the instructions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of Warrants exercised is less than all of the Warrants evidenced hereby,
the undersigned requests that a new Warrant Certificate evidencing the Warrants for the number of Warrant Securities remaining unexercised be issued and delivered to the undersigned unless otherwise specified in the instructions below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</U> Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Please
Print&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Insert Social Security or Other Identifying Number of Holder) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Signature </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must
conform in all respects to name of holder as specified on the face of this Warrant Certificate and must bear a signature guarantee by a FINRA member firm). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant may be exercised at the following addresses: By hand at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By mail at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Instructions as to form and delivery of Warrant Securities and, if applicable, Warrant Certificates evidencing Warrants for the number of Warrant Securities
remaining unexercised&#151;complete as appropriate.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Form of assignment to be executed if Warrant Holder desires to transfer Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Please print name and address
including zip code) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereby sells, assigns and transfers unto:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Please print Social Security or other identifying number </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the right represented by the within Warrant to purchase<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
shares of [Title of Warrant Securities] of Alaunos Therapeutics, Inc. to which the within Warrant relates and appoints
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <U></U>attorney to transfer such right on the books of the Warrant Agent
with full power of substitution in the premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated:
<U></U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Name:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Signature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of holder as specified on the face of the Warrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>7
<FILENAME>d286456dex46.htm
<DESCRIPTION>EX-4.6
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALAUNOS THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>____________, As
Warrant Agent </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form Of Debt Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrant Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated As Of ____________ </B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>LAUNOS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.
F<SMALL>ORM</SMALL> O<SMALL>F</SMALL> D<SMALL>EBT</SMALL> S<SMALL>ECURITIES</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> D<SMALL>EBT</SMALL> S<SMALL>ECURITIES</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (this
&#147;<B><I>Agreement</I></B>&#148;), dated as of [&#149;], between <B>Alaunos Therapeutics, Inc.</B>, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and [&#149;], a [corporation] [national banking association] organized and
existing under the laws of [&#149;] and having a corporate trust office in [&#149;], as warrant agent (the &#147;<B><I>Warrant Agent</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company has entered into an indenture dated as of [&#149;] (the
&#147;<B><I>Indenture</I></B>&#148;), with [&#149;], as trustee (such trustee, and any successors to such trustee, herein called the &#147;<B><I>Trustee</I></B>&#148;), providing for the issuance from time to time of its debt securities, to be
issued in one or more series as provided in the Indenture (the &#147;<B><I>Debt Securities</I></B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company proposes to sell [<B><I>If Warrants are sold with other securities</I></B> &#151;
[title of such other securities being offered] (the &#147;<B><I>Other Securities</I></B>&#148;) with] warrant certificates evidencing one or more warrants (the &#147;<B><I>Warrants</I></B>&#148; or, individually, a &#147;<B><I>Warrant</I></B>&#148;)
representing the right to purchase [title of Debt Securities purchasable through exercise of Warrants] (the &#147;<B><I>Warrant Debt Securities</I></B>&#148;), such warrant certificates and other warrant certificates issued pursuant to this
Agreement being herein called the &#147;Warrant Certificates&#148;; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>HEREAS</SMALL></B><SMALL></SMALL>, the Company desires
the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing so to act, in connection with the issuance, registration, transfer, exchange, exercise and replacement of the Warrant Certificates, and in this Agreement wishes to
set forth, among other things, the form and provisions of the Warrant Certificates and the terms and conditions on which they may be issued, registered, transferred, exchanged, exercised and replaced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>N<SMALL>OW</SMALL> T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in consideration of the premises and of the mutual agreements herein
contained, the parties hereto agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUANCE OF WARRANTS AND EXECUTION AND </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DELIVERY OF WARRANT CERTIFICATES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1 Issuance of Warrants</B>. [<B><I>If Warrants alone</I></B> &#151; Upon issuance, each Warrant Certificate shall evidence one or more
Warrants.] [<B><I>If Other Securities and Warrants</I></B> &#151; Warrant Certificates will be issued in connection with the issuance of the Other Securities but shall be separately transferable and each Warrant Certificate shall evidence one or
more Warrants.] Each Warrant evidenced thereby shall represent the right, subject to the provisions contained herein and therein, to purchase one Warrant Debt Security. [<B><I>If Other Securities and Warrants</I></B> &#151; Warrant Certificates will
be issued with the Other Securities and each Warrant Certificate will evidence [&#149;] Warrants for each [$[&#149;] principal amount] [[&#149;] shares] of Other Securities issued.] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2 Execution and Delivery of Warrant Certificates</B>. Each Warrant Certificate, whenever issued, shall be in registered form
substantially in the form set forth in <B>Exhibit A</B> hereto, shall be dated the date of its countersignature by the Warrant Agent and may have such letters, numbers, or other marks of identification or designation and such legends or endorsements
printed, lithographed or engraved thereon as the officers of the Company </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executing the same may approve (execution thereof to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this Agreement, or as may be required to comply
with any law or with any rule or regulation made pursuant thereto or with any rule or regulation of any securities exchange on which the Warrants may be listed, or to conform to usage. The Warrant Certificates shall be signed on behalf of the
Company by any of its present or future chief executive officers, presidents, senior vice presidents, vice presidents, chief financial officers, chief legal officers, treasurers, assistant treasurers, controllers, assistant controllers, secretaries
or assistant secretaries under its corporate seal reproduced thereon. Such signatures may be manual or facsimile signatures of such authorized officers and may be imprinted or otherwise reproduced on the Warrant Certificates. The seal of the Company
may be in the form of a facsimile thereof and may be impressed, affixed, imprinted or otherwise reproduced on the Warrant Certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Warrant Certificate shall be valid for any purpose, and no Warrant evidenced thereby shall be exercisable, until such Warrant Certificate
has been countersigned by the manual signature of the Warrant Agent. Such signature by the Warrant Agent upon any Warrant Certificate executed by the Company shall be conclusive evidence that the Warrant Certificate so countersigned has been duly
issued hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case any officer of the Company who shall have signed any of the Warrant Certificates either manually or by
facsimile signature shall cease to be such officer before the Warrant Certificates so signed shall have been countersigned and delivered by the Warrant Agent, such Warrant Certificates may be countersigned and delivered notwithstanding that the
person who signed such Warrant Certificates ceased to be such officer of the Company; and any Warrant Certificate may be signed on behalf of the Company by such persons as, at the actual date of the execution of such Warrant Certificate, shall be
the proper officers of the Company, although at the date of the execution of this Agreement any such person was not such officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
term &#147;<B><I>holder</I></B>&#148; or &#147;<B><I>holder of a Warrant Certificate</I></B>&#148; as used herein shall mean any person in whose name at the time any Warrant Certificate shall be registered upon the books to be maintained by the
Warrant Agent for that purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3 Issuance of Warrant Certificates</B>. Warrant Certificates evidencing the right to purchase
Warrant Debt Securities may be executed by the Company and delivered to the Warrant Agent upon the execution of this Agreement or from time to time thereafter. The Warrant Agent shall, upon receipt of Warrant Certificates duly executed on behalf of
the Company, countersign such Warrant Certificates and shall deliver such Warrant Certificates to or upon the order of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">WARRANT PRICE, DURATION AND EXERCISE OF WARRANTS </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1 Warrant Price</B>. During the period specified in Section&nbsp;2.2, each Warrant shall, subject to the terms of this Agreement and the
applicable Warrant Certificate, entitle the holder thereof to purchase the principal amount of Warrant Debt Securities specified in the applicable Warrant Certificate at an exercise price of [&#149;]% of the principal amount thereof [plus accrued
amortization, if any, of the original issue discount of the Warrant Debt Securities] [plus accrued interest, if any, from the most recent date from which interest shall have been paid on the Warrant Debt Securities or, if no interest shall have been
paid on the Warrant Debt Securities, from the date of their initial issuance.] [The original issue discount ($[&#149;] for each $1,000 principal amount of Warrant Debt Securities) will be amortized at a [&#149;]% annual rate, computed on a[n]
[semi-] annual basis [using a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months].] Such purchase price for the Warrant Debt Securities is referred to in this Agreement as
the &#147;<B><I>Warrant Price</I></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2 Duration of Warrants</B>. Each Warrant may be exercised in whole or in part at any time, as
specified herein, on or after [the date thereof] [&#149;] and at or before [&#149;] p.m., [City] time, on [&#149;] or such later date as the Company may designate by notice to the Warrant Agent and the holders of Warrant Certificates mailed to their
addresses as set forth in the record books of the Warrant Agent (the &#147;<B><I>Expiration Date</I></B>&#148;). Each Warrant not exercised at or before [&#149;] p.m., [City] time, on the Expiration Date shall become void, and all rights of the
holder of the Warrant Certificate evidencing such Warrant under this Agreement shall cease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 Exercise of Warrants</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) During the period specified in Section&nbsp;2.2, the Warrants may be exercised to purchase a whole number of Warrant Debt Securities in
registered form by providing certain information as set forth on the reverse side of the Warrant Certificate and by paying in full, in lawful money of the United States of America, [in cash or by certified check or official bank check in New York
Clearing House funds] [by bank wire transfer in immediately available funds] the Warrant Price for each Warrant Debt Security with respect to which a Warrant is being exercised to the Warrant Agent at its corporate trust office, provided that such
exercise is subject to receipt within five business days of such payment by the Warrant Agent of the Warrant Certificate with the form of election to purchase Warrant Debt Securities set forth on the reverse side of the Warrant Certificate properly
completed and duly executed. The date on which payment in full of the Warrant Price is received by the Warrant Agent shall, subject to receipt of the Warrant Certificate as aforesaid, be deemed to be the date on which the Warrant is exercised;
provided, however, that if, at the date of receipt of such Warrant Certificates and payment in full of the Warrant Price, the transfer books for the Warrant Debt Securities purchasable upon the exercise of such Warrants shall be closed, no such
receipt of such Warrant Certificates and no such payment of such Warrant Price shall be effective to constitute the person so designated to be named as the holder of record of such Warrant Debt Securities on such date, but shall be effective to
constitute such person as the holder of record of such Warrant Debt Securities for all purposes at the opening of business on the next succeeding day on which the transfer books for the Warrant Debt Securities purchasable upon the exercise of such
Warrants shall be opened, and the certificates for the Warrant Debt Securities in respect of which such Warrants are then exercised shall be issuable as of the date on such next succeeding day on which the transfer books shall next be opened, and
until such date the Company shall be under no duty to deliver any certificate for such Warrant Debt Securities. The Warrant Agent shall deposit all funds received by it in payment of the Warrant Price in an account of the Company maintained with it
and shall advise the Company by telephone at the end of each day on which a payment for the exercise of Warrants is received of the amount so deposited to its account. The Warrant Agent shall promptly confirm such telephone advice to the Company in
writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Warrant Agent shall, from time to time, as promptly as practicable, advise the
Company of (i)&nbsp;the number of Warrant Debt Securities with respect to which Warrants were exercised, (ii)&nbsp;the instructions of each holder of the Warrant Certificates evidencing such Warrants with respect to delivery of the Warrant Debt
Securities to which such holder is entitled upon such exercise, (iii)&nbsp;delivery of Warrant Certificates evidencing the balance, if any, of the Warrants for the remaining Warrant Debt Securities after such exercise, and (iv)&nbsp;such other
information as the Company or the Trustee shall reasonably require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) As soon as practicable after the exercise of any Warrant, the
Company shall issue pursuant to the Indenture, in authorized denominations, to or upon the order of the holder of the Warrant Certificate evidencing such Warrant the Warrant Debt Securities to which such holder is entitled, in fully registered form,
registered in such name or names as may be directed by such holder. If fewer than all of the Warrants evidenced by such Warrant Certificate are exercised, the Company shall execute, and an authorized officer of the Warrant Agent shall manually
countersign and deliver, a new Warrant Certificate evidencing Warrants for the number of Warrant Debt Securities remaining unexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) The Company shall not be required to pay any stamp or other tax or other governmental charge required to be paid in connection with any
transfer involved in the issue of the Warrant Debt Securities, and in the event that any such transfer is involved, the Company shall not be required to issue or deliver any Warrant Debt Securities until such tax or other charge shall have been paid
or it has been established to the Company&#146;s satisfaction that no such tax or other charge is due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Prior to the issuance of any
Warrants there shall have been reserved, and the Company shall at all times through the Expiration Date keep reserved, out of its authorized but unissued Warrant Debt Securities, a number of shares sufficient to provide for the exercise of the
Warrants. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OTHER PROVISIONS RELATING TO RIGHTS OF HOLDERS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1 No Rights as Holder of Warrant Debt Securities Conferred by Warrants or Warrant Certificates</B>. No Warrant Certificate or Warrant
evidenced thereby shall entitle the holder thereof to any of the rights of a holder of Warrant Debt Securities, including, without limitation, the right to receive the payment of principal of (or premium, if any) or interest, if any, on the Warrant
Debt Securities or to enforce any of the covenants in the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2 Lost, Stolen, Mutilated or Destroyed Warrant
Certificates</B>. Upon receipt by the Warrant Agent of evidence reasonably satisfactory to it and the Company of the ownership of and the loss, theft, destruction or mutilation of any Warrant Certificate and/or indemnity reasonably satisfactory to
the Warrant Agent and the Company and, in the case of mutilation, upon surrender of the mutilated Warrant Certificate to the Warrant Agent for cancellation, then, in the absence of notice to the Company or the Warrant Agent that such Warrant
Certificate has been acquired by a bona fide purchaser, the Company shall execute, and an authorized officer of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Warrant Agent shall manually countersign and deliver, in exchange for or in lieu of the lost, stolen, destroyed or mutilated Warrant Certificate, a new Warrant Certificate of the same tenor
and evidencing Warrants for a like principal amount of Warrant Debt Securities. Upon the issuance of any new Warrant Certificate under this Section&nbsp;3.2, the Company may require the payment of a sum sufficient to cover any tax or other
governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Warrant Agent) in connection therewith. Every substitute Warrant Certificate executed and delivered pursuant to this
Section&nbsp;3.2 in lieu of any lost, stolen or destroyed Warrant Certificate shall represent an additional contractual obligation of the Company, whether or not the lost, stolen or destroyed Warrant Certificate shall be at any time enforceable by
anyone, and shall be entitled to the benefits of this Agreement equally and proportionately with any and all other Warrant Certificates duly executed and delivered hereunder. The provisions of this Section&nbsp;3.2 are exclusive and shall preclude
(to the extent lawful) all other rights and remedies with respect to the replacement of mutilated, lost, stolen or destroyed Warrant Certificates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3 Holder of Warrant Certificate May Enforce Rights</B>. Notwithstanding any of the provisions of this Agreement, any holder of a Warrant
Certificate, without the consent of the Warrant Agent, , the Trustee, the holder of any Warrant Debt Securities or the holder of any other Warrant Certificate, may, in such holder&#146;s own behalf and for such holder&#146;s own benefit, enforce,
and may institute and maintain any suit, action or proceeding against the Company suitable to enforce, or otherwise in respect of, such holder&#146;s right to exercise the Warrants evidenced by such holder&#146;s Warrant Certificate in the manner
provided in such holder&#146;s Warrant Certificates and in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4 Merger, Sale, Conveyance or Lease</B>. In case of
(a)&nbsp;any share exchange, merger or similar transaction of the Company with or into another person or entity (other than a share exchange, merger or similar transaction in which the Company is the acquiring or surviving corporation) or
(b)&nbsp;the sale, exchange, lease, transfer or other disposition of all or substantially all of the properties and assets of the Company as an entirety (in any such case, a &#147;<B><I>Reorganization Event</I></B>&#148;), then, as a condition of
such Reorganization Event, lawful provisions shall be made, and duly executed documents evidencing the same from the Company&#146;s successor shall be delivered to the holders of the Warrants, so that such successor shall succeed to and be
substituted for the Company, and assume all the Company&#146;s obligations under, this Agreement and the Warrants. The Company shall thereupon be relieved of any further obligation hereunder or under the Warrants, and the Company as the predecessor
corporation may thereupon or at any time thereafter be dissolved, wound up or liquidated. Such successor or assuming entity thereupon may cause to be signed, and may issue either in its own name or in the name of the Company, any or all of the
Warrants issuable hereunder which heretofore shall not have been signed by the Company, and may execute and deliver securities in its own name, in fulfillment of its obligations to deliver Warrant Debt Securities upon exercise of the Warrants. All
the Warrants so issued shall in all respects have the same legal rank and benefit under this Agreement as the Warrants theretofore or thereafter issued in accordance with the terms of this Agreement as though all of such Warrants had been issued at
the date of the execution hereof. In any case of any such Reorganization Event, such changes in phraseology and form (but not in substance) may be made in the Warrants thereafter to be issued as may be appropriate. The Warrant Agent may receive a
written opinion of legal counsel as conclusive evidence that any such Reorganization Event complies with the provisions of this Section&nbsp;3.4. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5 Notice to Warrantholders</B>. In case the Company shall (a)&nbsp;effect any
Reorganization Event or (b)&nbsp;make any distribution on or in respect of the [title of Warrant Debt Securities] in connection with the dissolution, liquidation or winding up of the Company, then the Company shall mail to each holder of Warrants at
such holder&#146;s address as it shall appear on the books of the Warrant Agent, at least ten days prior to the applicable date hereinafter specified, a notice stating the date on which such Reorganization Event, dissolution, liquidation or winding
up is expected to become effective, and the date as of which it is expected that holders of [title of Warrant Debt Securities] of record shall be entitled to exchange their shares of [title of Warrant Debt Securities] for securities or other
property deliverable upon such Reorganization Event, dissolution, liquidation or winding up. No failure to mail such notice nor any defect therein or in the mailing thereof shall affect any such transaction. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCHANGE AND
TRANSFER OF WARRANT CERTIFICATES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1 Exchange and Transfer of Warrant Certificates</B>. Upon surrender at the corporate trust
office of the Warrant Agent, Warrant Certificates evidencing Warrants may be exchanged for Warrant Certificates in other denominations evidencing such Warrants or the transfer thereof may be registered in whole or in part; provided that such other
Warrant Certificates evidence Warrants for the same aggregate principal amount of Warrant Debt Securities as the Warrant Certificates so surrendered. The Warrant Agent shall keep, at its corporate trust office, books in which, subject to such
reasonable regulations as it may prescribe, it shall register Warrant Certificates and exchanges and transfers of outstanding Warrant Certificates, upon surrender of the Warrant Certificates to the Warrant Agent at its corporate trust office for
exchange or registration of transfer, properly endorsed or accompanied by appropriate instruments of registration of transfer and written instructions for transfer, all in form satisfactory to the Company and the Warrant Agent. No service charge
shall be made for any exchange or registration of transfer of Warrant Certificates, but the Company may require payment of a sum sufficient to cover any stamp or other tax or other governmental charge that may be imposed in connection with any such
exchange or registration of transfer. Whenever any Warrant Certificates are so surrendered for exchange or registration of transfer, an authorized officer of the Warrant Agent shall manually countersign and deliver to the person or persons entitled
thereto a Warrant Certificate or Warrant Certificates duly authorized and executed by the Company, as so requested. The Warrant Agent shall not be required to effect any exchange or registration of transfer which will result in the issuance of a
Warrant Certificate evidencing a Warrant for a fraction of a Warrant Debt Security or a number of Warrants for a whole number of Warrant Debt Securities and a fraction of a Warrant Debt Security. All Warrant Certificates issued upon any exchange or
registration of transfer of Warrant Certificates shall be the valid obligations of the Company, evidencing the same obligations and entitled to the same benefits under this Agreement as the Warrant Certificate surrendered for such exchange or
registration of transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2 Treatment of Holders of Warrant Certificates</B>. The Company, the Warrant Agent and all other persons
may treat the registered holder of a Warrant Certificate as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the contrary notwithstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3 Cancellation of Warrant Certificates</B>. Any Warrant Certificate surrendered for
exchange, registration of transfer or exercise of the Warrants evidenced thereby shall, if surrendered to the Company, be delivered to the Warrant Agent and all Warrant Certificates surrendered or so delivered to the Warrant Agent shall be promptly
canceled by the Warrant Agent and shall not be reissued and, except as expressly permitted by this Agreement, no Warrant Certificate shall be issued hereunder in exchange therefor or in lieu thereof. The Warrant Agent shall deliver to the Company
from time to time or otherwise dispose of canceled Warrant Certificates in a manner satisfactory to the Company. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONCERNING THE WARRANT AGENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1 Warrant Agen</B>t. The Company hereby appoints [&#149;] as Warrant Agent of the Company in respect of the Warrants and the Warrant
Certificates upon the terms and subject to the conditions herein set forth, and [&#149;] hereby accepts such appointment. The Warrant Agent shall have the powers and authority granted to and conferred upon it in the Warrant Certificates and hereby
and such further powers and authority to act on behalf of the Company as the Company may hereafter grant to or confer upon it. All of the terms and provisions with respect to such powers and authority contained in the Warrant Certificates are
subject to and governed by the terms and provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2 Conditions of Warrant Agent&#146;s Obligations</B>. The Warrant Agent
accepts its obligations herein set forth upon the terms and conditions hereof, including the following to all of which the Company agrees and to all of which the rights hereunder of the holders from time to time of the Warrant Certificates shall be
subject: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <B>Compensation and Indemnification</B>. The Company agrees promptly to pay the Warrant Agent the compensation to be agreed
upon with the Company for all services rendered by the Warrant Agent and to reimburse the Warrant Agent for reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including reasonable
counsel fees) incurred without negligence, bad faith or willful misconduct by the Warrant Agent in connection with the services rendered hereunder by the Warrant Agent. The Company also agrees to indemnify the Warrant Agent for, and to hold it
harmless against, any loss, liability or expense incurred without negligence, bad faith or willful misconduct on the part of the Warrant Agent, arising out of or in connection with its acting as Warrant Agent hereunder, including the reasonable
costs and expenses of defending against any claim of such liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <B>Agent for the Company</B>. In acting under this Agreement and
in connection with the Warrant Certificates, the Warrant Agent is acting solely as agent of the Company and does not assume any obligations or relationship of agency or trust for or with any of the holders of Warrant Certificates or beneficial
owners of Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <B>Counsel</B>. The Warrant Agent may consult with counsel satisfactory to it, which may include counsel for the
Company, and the written advice of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice of such counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <B>Documents</B>. The Warrant Agent shall be protected and shall incur no liability for
or in respect of any action taken or omitted by it in reliance upon any Warrant Certificate, notice, direction, consent, certificate, affidavit, statement or other paper or document reasonably believed by it to be genuine and to have been presented
or signed by the proper parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <B>Certain Transactions</B>. The Warrant Agent, and its officers, directors and employees, may
become the owner of, or acquire any interest in, Warrants, with the same rights that it or they would have if it were not the Warrant Agent hereunder, and, to the extent permitted by applicable law, it or they may engage or be interested in any
financial or other transaction with the Company and may act on, or as depositary, trustee or agent for, any committee or body of holders of Warrant Debt Securities or other obligations of the Company as freely as if it were not the Warrant Agent
hereunder. Nothing in this Agreement shall be deemed to prevent the Warrant Agent from acting as trustee under any indenture to which the Company is a party, including, without limitation, as Trustee under the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <B>No Liability for Interest</B>. Unless otherwise agreed with the Company, the Warrant Agent shall have no liability for interest on any
monies at any time received by it pursuant to any of the provisions of this Agreement or of the Warrant Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <B>No Liability
for Invalidity</B>. The Warrant Agent shall have no liability with respect to any invalidity of this Agreement or any of the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <B>No Responsibility for Representations</B>. The Warrant Agent shall not be responsible for any of the recitals or representations herein
or in the Warrant Certificates (except as to the Warrant Agent&#146;s countersignature thereon), all of which are made solely by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <B>No Implied Obligations</B>. The Warrant Agent shall be obligated to perform only such duties as are herein and in the Warrant
Certificates specifically set forth and no implied duties or obligations shall be read into this Agreement or the Warrant Certificates against the Warrant Agent. The Warrant Agent shall not be under any obligation to take any action hereunder which
may tend to involve it in any expense or liability, the payment of which within a reasonable time is not, in its reasonable opinion, assured to it. The Warrant Agent shall not be accountable or under any duty or responsibility for the use by the
Company of any of the Warrant Certificates authenticated by the Warrant Agent and delivered by it to the Company pursuant to this Agreement or for the application by the Company of the proceeds of the Warrant Certificates. The Warrant Agent shall
have no duty or responsibility in case of any default by the Company in the performance of its covenants or agreements contained herein or in the Warrant Certificates or in the case of the receipt of any written demand from a holder of a Warrant
Certificate with respect to such default, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or, except as provided in Section&nbsp;6.2
hereof, to make any demand upon the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3 Resignation, Removal and Appointment of Successors</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees, for the benefit of the holders from time to time of the Warrant Certificates, that there shall at all times be a
Warrant Agent hereunder until all the Warrants have been exercised or are no longer exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Warrant Agent may at any time
resign as agent by giving written notice to the Company of such intention on its part, specifying the date on which its desired resignation shall become effective; provided that such date shall not be less than three months after the date on which
such notice is given unless the Company otherwise agrees. The Warrant Agent hereunder may be removed at any time by the filing with it of an instrument in writing signed by or on behalf of the Company and specifying such removal and the intended
date when it shall become effective. Such resignation or removal shall take effect upon the appointment by the Company, as hereinafter provided, of a successor Warrant Agent (which shall be a bank or trust company authorized under the laws of the
jurisdiction of its organization to exercise corporate trust powers) and the acceptance of such appointment by such successor Warrant Agent. The obligation of the Company under Section&nbsp;5.2(a) shall continue to the extent set forth therein
notwithstanding the resignation or removal of the Warrant Agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) In case at any time the Warrant Agent shall resign, or shall be
removed, or shall become incapable of acting, or shall be adjudged a bankrupt or insolvent, or shall commence a voluntary case under the Federal bankruptcy laws, as now or hereafter constituted, or under any other applicable Federal or state
bankruptcy, insolvency or similar law or shall consent to the appointment of or taking possession by a receiver, custodian, liquidator, assignee, trustee, sequestrator (or other similar official) of the Warrant Agent or its property or affairs, or
shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts generally as they become due, or shall take corporate action in furtherance of any such action, or a decree or order for relief by a
court having jurisdiction in the premises shall have been entered in respect of the Warrant Agent in an involuntary case under the Federal bankruptcy laws, as now or hereafter constituted, or any other applicable Federal or state bankruptcy,
insolvency or similar law, or a decree or order by a court having jurisdiction in the premises shall have been entered for the appointment of a receiver, custodian, liquidator, assignee, trustee, sequestrator (or similar official) of the Warrant
Agent or of its property or affairs, or any public officer shall take charge or control of the Warrant Agent or of its property or affairs for the purpose of rehabilitation, conservation, winding up or liquidation, a successor Warrant Agent,
qualified as aforesaid, shall be appointed by the Company by an instrument in writing, filed with the successor Warrant Agent. Upon the appointment as aforesaid of a successor Warrant Agent and acceptance by the successor Warrant Agent of such
appointment, the Warrant Agent shall cease to be Warrant Agent hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Any successor Warrant Agent appointed hereunder shall
execute, acknowledge and deliver to its predecessor and to the Company an instrument accepting such appointment hereunder, and thereupon such successor Warrant Agent, without any further act, deed or conveyance, shall become vested with all the
authority, rights, powers, trusts, immunities, duties and obligations of such predecessor with like effect as if originally named as Warrant Agent hereunder, and such predecessor, upon payment of its charges and disbursements then unpaid, shall
thereupon become obligated to transfer, deliver and pay over, and such successor Warrant Agent shall be entitled to receive, all monies, securities and other property on deposit with or held by such predecessor, as Warrant Agent hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any corporation into which the Warrant Agent hereunder may be merged or converted or any
corporation with which the Warrant Agent may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Warrant Agent shall be a party, or any corporation to which the Warrant Agent shall sell or
otherwise transfer all or substantially all the assets and business of the Warrant Agent, provided that it shall be qualified as aforesaid, shall be the successor Warrant Agent under this Agreement without the execution or filing of any paper or any
further act on the part of any of the parties hereto. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1
Amendment</B>. This Agreement may be amended by the parties hereto, without the consent of the holder of any Warrant Certificate, for the purpose of curing any ambiguity, or of curing, correcting or supplementing any defective provision contained
herein, or making any other provisions with respect to matters or questions arising under this Agreement as the Company and the Warrant Agent may deem necessary or desirable; provided that such action shall not materially adversely affect the
interests of the holders of the Warrant Certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2 Notices and Demands to the Company and Warrant Agent</B>. If the Warrant
Agent shall receive any notice or demand addressed to the Company by the holder of a Warrant Certificate pursuant to the provisions of the Warrant Certificates, the Warrant Agent shall promptly forward such notice or demand to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3 Addresses</B>. Any communication from the Company to the Warrant Agent with respect to this Agreement shall be addressed to [&#149;],
Attention: [&#149;] and any communication from the Warrant Agent to the Company with respect to this Agreement shall be addressed to Alaunos Therapeutics, Inc., [&#149;], Attention: [&#149;] (or such other address as shall be specified in writing by
the Warrant Agent or by the Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.4 Governing Law</B>. This Agreement and each Warrant Certificate issued hereunder shall be
governed by and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.5 Delivery of Prospectus.</B> The Company shall
furnish to the Warrant Agent sufficient copies of a prospectus meeting the requirements of the Securities Act of 1933, as amended, relating to the Warrant Debt Securities deliverable upon exercise of the Warrants (the &#147;Prospectus&#148;), and
the Warrant Agent agrees that upon the exercise of any Warrant, the Warrant Agent will deliver to the holder of the Warrant Certificate evidencing such Warrant, prior to or concurrently with the delivery of the Warrant Debt Securities issued upon
such exercise, a Prospectus. The Warrant Agent shall not, by reason of any such delivery, assume any responsibility for the accuracy or adequacy of such Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.6 Obtaining of Governmental Approvals</B>. The Company will from time to time take all action which may be necessary to obtain and keep
effective any and all permits, consents and approvals of governmental agencies and authorities and securities act filings under United States Federal and state laws (including without limitation a registration statement in respect of the Warrants
and Warrant Debt Securities under the Securities Act of 1933, as amended), which may be or become requisite in connection with the issuance, sale, transfer, and delivery of the Warrant Debt Securities issued upon exercise of the Warrants, the
issuance, sale, transfer and delivery of the Warrants or upon the expiration of the period during which the Warrants are exercisable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.7 Persons Having Rights Under the Agreement</B>. Nothing in this Agreement shall give
to any person other than the Company, the Warrant Agent and the holders of the Warrant Certificates any right, remedy or claim under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.8 Headings</B>. The descriptive headings of the several Articles and Sections of this Agreement are inserted for convenience only and
shall not control or affect the meaning or construction of any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.9 Counterparts</B>. This Agreement may be
executed in any number of counterparts, each of which as so executed shall be deemed to be an original, but such counterparts shall together constitute but one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.10 Inspection of Agreement</B>. A copy of this Agreement shall be available at all reasonable times at the principal corporate trust
office of the Warrant Agent for inspection by the holder of any Warrant Certificate. The Warrant Agent may require such holder to submit such holder&#146;s Warrant Certificate for inspection by it. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the
parties hereto have caused this Agreement to be duly executed as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Alaunos Therapeutics, Inc., as Company</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COUNTERSIGNED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[&#149;], as Warrant Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> T<SMALL>O</SMALL> A<SMALL>LAUNOS</SMALL>
T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>. D<SMALL>EBT</SMALL> S<SMALL>ECURITIES</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF WARRANT CERTIFICATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[FACE OF WARRANT CERTIFICATE] </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><I>[Form of Legend if Warrants are not immediately exercisable.]</I></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><I>[Prior to [&#149;], Warrants evidenced by this Warrant Certificate cannot be exercisable.]</I></B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXERCISABLE ONLY IF COUNTERSIGNED BY THE WARRANT AGENT AS PROVIDED HEREIN </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">VOID AFTER [&#149;] P.M., [City] time, ON [&#149;]. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> T<SMALL>O</SMALL> A<SMALL>LAUNOS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.
D<SMALL>EBT</SMALL> S<SMALL>ECURITIES</SMALL> W<SMALL>ARRANT</SMALL> A<SMALL>GREEMENT</SMALL>] </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT CERTIFICATE REPRESENTING </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANTS TO PURCHASE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[TITLE OF WARRANT DEBT SECURITIES] </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">No. [&#149;]</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">[&#149;] Warrants</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certifies that [&#149;] or registered assigns is the registered owner of the above indicated number of Warrants, each
Warrant entitling such owner to purchase, at any time [after [&#149;] p.m., [City] time, [on [&#149;] and] on or before [&#149;] p.m., [City] time, on [&#149;], $[&#149;] principal amount of [TITLE OF WARRANT DEBT SECURITIES] (the
&#147;<B><I>Warrant Debt Securities</I></B>&#148;), of Alaunos Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;) issued or to be issued under the Indenture (as hereinafter defined), on the following basis: during the period from [&#149;],
through and including [&#149;], each Warrant shall entitle the Holder thereof, subject to the provisions of this Agreement, to purchase the principal amount of Warrant Debt Securities stated in the Warrant Certificate at the warrant price (the
&#147;<B><I>Warrant Price</I></B>&#148;) of [&#149;]% of the principal amount thereof [plus accrued amortization, if any, of the original issue discount of the Warrant Debt Securities] [plus accrued interest, if any, from the most recent date from
which interest shall have been paid on the Warrant Debt Securities or, if no interest shall have been paid on the Warrant Debt Securities, from the date of their original issuance]. [The original issue discount ($[&#149;] for each $1,000 principal
amount of Warrant Debt Securities) will be amortized at a [&#149;]% annual rate, computed on a[n] [semi-]annual basis [using a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT>
months]. The Holder may exercise the Warrants evidenced hereby by providing certain information set forth on the back hereof and by paying in full, in lawful money of the United States of America, [in cash or by certified check or official bank
check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant Price for each Warrant Debt Security with respect to which this Warrant is exercised to the Warrant Agent (as hereinafter defined) and by
surrendering this Warrant Certificate, with the purchase form on the back hereof duly executed, at the corporate trust office of [name of Warrant Agent], or its successor as warrant agent (the &#147;<B><I>Warrant Agent</I></B>&#148;), which is, on
the date hereof, at the address specified on the reverse hereof, and upon compliance with and subject to the conditions set forth herein and in the Warrant Agreement (as hereinafter defined). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B><I>Holder</I></B>&#148; as used herein shall mean the person in whose name at the time this Warrant Certificate shall be registered upon the
books to be maintained by the Warrant Agent for that purpose pursuant to Section&nbsp;4 of the Warrant Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants evidenced by this Warrant
Certificate may be exercised to purchase Warrant Debt Securities in the principal amount of $1,000 or any integral multiple thereof in registered form. Upon any exercise of fewer than all of the Warrants evidenced by this Warrant Certificate, there
shall be issued to the Holder hereof a new Warrant Certificate evidencing Warrants for the aggregate principal amount of Warrant Debt Securities remaining unexercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate is issued under and in accordance with the Warrant Agreement dated as of [&#149;] (the &#147;<B><I>Warrant Agreement</I></B>&#148;),
between the Company and the Warrant Agent and is subject to the terms and provisions contained in the Warrant Agreement, to all of which terms and provisions the Holder of this Warrant Certificate consents by acceptance hereof. Copies of the Warrant
Agreement are on file at the above-mentioned office of the Warrant Agent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Debt Securities to be issued and delivered upon the exercise of Warrants evidenced by this
Warrant Certificate will be issued under and in accordance with an Indenture, dated as of [&#149;] (the &#147;<B><I>Indenture</I></B>&#148;), between the Company and [&#149;], as trustee (such trustee, and any successors to such trustee, the
&#147;<B><I>Trustee</I></B>&#148;)] and will be subject to the terms and provisions contained in the Warrant Debt Securities and in the Indenture. Copies of the Indenture, including the form of the Warrant Debt Securities, are on file at the
corporate trust office of the Trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfer of this Warrant Certificate may be registered when this Warrant Certificate is surrendered at the
corporate trust office of the Warrant Agent by the registered owner or such owner&#146;s assigns, in the manner and subject to the limitations provided in the Warrant Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After countersignature by the Warrant Agent and prior to the expiration of this Warrant Certificate, this Warrant Certificate may be exchanged at the
corporate trust office of the Warrant Agent for Warrant Certificates representing Warrants for the same aggregate principal amount of Warrant Debt Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not entitle the Holder hereof to any of the rights of a holder of the Warrant Debt Securities, including, without limitation,
the right to receive payments of principal of (and premium, if any) or interest, if any, on the Warrant Debt Securities or to enforce any of the covenants of the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant Certificate shall not be valid or obligatory for any purpose until
countersigned by the Warrant Agent. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, the Company has
caused this Warrant to be executed in its name and on its behalf by the facsimile signatures of its duly authorized officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Alaunos Therapeutics, Inc., as Company</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COUNTERSIGNED</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">[&#149;], as Warrant Agent</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ATTEST:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[REVERSE OF WARRANT CERTIFICATE] </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Instructions for Exercise of Warrant) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To exercise any Warrants evidenced hereby for Warrant Debt Securities (as hereinafter defined), the Holder must pay, in lawful money of the
United States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], the Warrant Price in full for Warrants exercised, to [&#149;] [address of
Warrant Agent], Attention: [&#149;], which payment must specify the name of the Holder and the number of Warrants exercised by such Holder. In addition, the Holder must complete the information required below and present this Warrant Certificate in
person or by mail (certified or registered mail is recommended) to the Warrant Agent at the appropriate address set forth above. This Warrant Certificate, completed and duly executed, must be received by the Warrant Agent within five business days
of the payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be executed upon exercise of Warrants) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby irrevocably elects to exercise Warrants, evidenced by this Warrant Certificate, to purchase $[&#149;] principal amount
of the [TITLE OF WARRANT DEBT SECURITIES] (the &#147;<B><I>Warrant Debt Securities</I></B>&#148;), of Alaunos Therapeutics, Inc. and represents that the undersigned has tendered payment for such Warrant Debt Securities, in lawful money of the United
States of America, [in cash or by certified check or official bank check in New York Clearing House funds] [by bank wire transfer in immediately available funds], to the order of Alaunos Therapeutics, Inc., c/o [insert name and address of Warrant
Agent], in the amount of $ in accordance with the terms hereof. The undersigned requests that said principal amount of Warrant Debt Securities be in fully registered form in the authorized denominations, registered in such names and delivered all as
specified in accordance with the instructions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of Warrants exercised is less than all of the Warrants
evidenced hereby, the undersigned requests that a new Warrant Certificate evidencing the Warrants for the aggregate principal amount of Warrant Debt Securities remaining unexercised be issued and delivered to the undersigned unless otherwise
specified in the instructions below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Please Print</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Insert Social Security or Other Identifying Number of</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature
Guaranteed:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Signature</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of holder as specified on the face of this Warrant Certificate and must bear a
signature guarantee by a FINRA member firm). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Warrant may be exercised at the following addresses: By hand at: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[&#149;] By mail at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[Instructions as to form and delivery of Warrant Debt Securities and, if applicable, Warrant Certificates evidencing Warrants for the number of Warrant Debt
Securities remaining unexercised&#151;complete as appropriate.] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Form of assignment to be executed if Warrant Holder desires to transfer Warrant] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>OR</SMALL> V<SMALL>ALUE</SMALL> R<SMALL>ECEIVED</SMALL></B><SMALL></SMALL>,</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Please print name and
address including zip code)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hereby sells, assigns and transfers unto:</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Please print Social
Security or other identifying number</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the right represented by the within Warrant to purchase ________ aggregate principal amount of [Title of Warrant Debt
Securities] of Alaunos Therapeutics, Inc. to which the within Warrant relates and appoints ____________ attorney to transfer such right on the books of the Warrant Agent with full power of substitution in the premises. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of holder as specified on the face of the Warrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature Guaranteed <U>________________________</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>8
<FILENAME>d286456dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g286456newimg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:66%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">August&nbsp;12, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8030 El Rio Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, Texas 77054 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Alaunos Therapeutics, Inc., a Delaware corporation (the &#147;<I>Company</I>&#148;), in connection with the
registration by the Company under the Securities Act of 1933 (the &#147;<I>Securities Act</I>&#148;), pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission (the
&#147;<I>Commission</I>&#148;) on or about the date hereof (such registration statement is herein referred to as the &#147;<I>Registration Statement</I>&#148;), of up to $200,000,000 of one or more of the following securities (collectively, the
&#147;<I>Securities</I>&#148;), which the Company may issue from time to time under the Registration Statement: (i)&nbsp;shares of the Company&#146;s common stock, par value $0.001 per share (the &#147;<I>Common Stock</I>&#148;), which may include
shares of Common Stock issuable upon the conversion or exercise of the other Securities included in the Registration Statement, (ii)&nbsp;shares of the Company&#146;s preferred stock, par value $0.001 per share (the &#147;<I>Preferred
Stock</I>&#148;), which may include shares of Preferred Stock issuable upon the conversion or exercise of the Debt Securities and Warrants (as defined herein) included in the Registration Statement, (iii)&nbsp;one or more series of debt securities
(the &#147;<I>Debt Securities</I>&#148;), the terms of which will be determined by the board of directors of the Company prior to the issuance thereof, and (iv)&nbsp;warrants (the &#147;<I>Warrants</I>&#148;) to purchase Common Stock, Preferred
Stock or Debt Securities, the terms of which will be determined by the board of directors of the Company prior to the issuance thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or
appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed further that any Securities that are issued and delivered, and the issuance thereof, will comply with all requirements and
restrictions, if any, applicable to the Company, whether imposed by any agreement or instrument to which the Company is a party or by which it is bound or any court or governmental or regulatory body having jurisdiction over the Company or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources
believed by us to be responsible. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 12, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the qualifications set forth below, we are of the
opinion that when, as and if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the shares of Common Stock: (i)&nbsp;the Registration Statement and any required post-effective
amendments thereto have all become effective under the Securities Act and all prospectus supplements required by applicable law have been delivered and filed as required by such laws, (ii)&nbsp;all necessary corporate action has been taken by the
Company to authorize the issuance and sale of shares of Common Stock and fix or otherwise determine the consideration to be received for such shares and the terms of the offer and sale thereof, (iii)&nbsp;any legally required consents, approvals,
authorizations and other orders of the Commission and other regulatory authorities have been obtained and (iv)&nbsp;the shares of Common Stock with consideration so fixed have been duly issued and delivered by the Company against payment therefor in
accordance with such corporate action and applicable law and as contemplated in the Registration Statement and the related prospectus supplement setting forth the terms of such shares and the plan of distribution, then, upon the happening of such
events, such shares of Common Stock (including any shares of Common Stock to be issued by the Company upon the conversion or exercise of other Securities issued by the Company pursuant to the Registration Statement) will be duly authorized and
validly issued and will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to shares of Preferred Stock: (i)&nbsp;the Registration Statement and any required post-effective
amendments thereto have all become effective under the Securities Act and all prospectus supplements required by applicable law have been delivered and filed as required by such laws, (ii)&nbsp;all necessary corporate action has been taken by the
Company to establish the rights, preferences and privileges of, and limitations on, any series of Preferred Stock and to authorize the issuance and sale of shares of such series of Preferred Stock and fix or otherwise determine the consideration to
be received for such shares and the terms of the offer and sale thereof, (iii)&nbsp;any legally required consents, approvals, authorizations and other orders of the Commission and other regulatory authorities have been obtained, (iv)&nbsp;an
appropriate certificate of designations with respect to such series of Preferred Stock has been duly filed in accordance with applicable law and (v)&nbsp;the shares of Preferred Stock with terms so fixed have been duly issued and delivered by the
Company against payment therefor in accordance with such corporate action and applicable law and as contemplated in the Registration Statement and the related prospectus supplement setting forth the terms of such shares and plan of distribution,
then, upon the happening of such events, such shares of Preferred Stock (including any shares of Preferred Stock to be issued by the Company upon the conversion or exercise of other Securities issued by the Company pursuant to the Registration
Statement) will be duly authorized and validly issued and will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 12, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Debt Securities: (i)&nbsp;the Registration Statement and any required post-effective
amendments thereto have all become effective under the Securities Act and all prospectus supplements required by applicable law have been delivered and filed as required by such laws, (ii)&nbsp;an indenture in the form of Exhibit 4.2 to the
Registration Statement and any necessary indenture supplements have been duly executed and delivered on behalf of the Company and a trustee qualified to act under applicable law and such indenture has been qualified under the Trust Indenture Act of
1939, as amended, (iii)&nbsp;all necessary corporate action has been taken by the Company to authorize, execute and deliver the applicable indenture and any necessary indenture supplement and to authorize the form, terms, execution and delivery of
any Debt Securities, (iv)&nbsp;any legally required consents, approvals, authorizations and other orders of the Commission and other regulatory authorities have been obtained, (v)&nbsp;any shares of Common Stock or Preferred Stock issuable upon the
conversion of such Debt Securities, as applicable, have been duly and validly authorized and reserved for issuance and sale and (vi)&nbsp;such Debt Securities have been duly executed by the Company and authenticated by the trustee in accordance with
the applicable indenture, or any applicable indenture supplement, and have been duly issued and delivered against payment therefor in accordance with such corporate action and applicable law and as contemplated in the Registration Statement and the
related prospectus supplement setting forth the terms of the Debt Securities and plan of distribution, then, upon the happening of such events, such Debt Securities (including any Debt Securities to be issued by the Company upon the conversion or
exercise of other Securities issued by the Company pursuant to the Registration Statement) will constitute the valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to the Warrants: (i)&nbsp;the Registration Statement and any required post-effective amendments
thereto have become effective under the Securities Act and all prospectus supplements required by applicable law have been delivered and filed as required by such laws, (ii)&nbsp;all necessary corporate action has been taken by the Company to
authorize, execute and deliver a warrant agreement and to authorize the form, terms, execution and delivery of any Warrants and to fix or otherwise determine the consideration to be received for such Warrants and the terms of the offer and sale
thereof, (iii)&nbsp;any legally required consents, approvals, authorizations and other orders of the Commission and other regulatory authorities have been obtained, (iv)&nbsp;any shares of Common Stock or Preferred Stock or any Debt Securities
purchasable upon the exercise of such Warrants, as applicable, have been duly and validly authorized and reserved for issuance and sale and (v)&nbsp;such Warrants have been duly executed and delivered by the Company against payment therefor in
accordance with any applicable warrant agreement, in accordance with such corporate action and applicable law and as contemplated in the Registration Statement and the </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 12, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
related prospectus supplement setting forth the terms of such shares and plan of distribution, then, upon the happening of such events, such Warrants (including any Warrants to be issued by the
Company upon the conversion or exercise of other Securities issued by the Company pursuant to the Registration Statement) will constitute the valid and binding obligations of the Company, enforceable against the Company in accordance with their
terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We express no opinion as to: (i)&nbsp;waivers of defenses, subrogation and related rights, rights to trial by jury, rights to object to venue,
or other rights or benefits bestowed by operation of law; (ii)&nbsp;releases or waivers of unmatured claims or rights; (iii)&nbsp;indemnification, contribution, exculpation, or arbitration provisions, or provisions for the <FONT
STYLE="white-space:nowrap">non-survival</FONT> of representations, to the extent they purport to indemnify any party against, or release or limit any party&#146;s liability for, its own breach or failure to comply with statutory obligations, or to
the extent such provisions are contrary to public policy; or (iv)&nbsp;provisions for liquidated damages and penalties, penalty interest and interest on interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the laws of the State of New
York, the Delaware General Corporation Law, and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. We also hereby consent to the reference to our
firm under the heading &#147;Legal Matters&#148; in the prospectus relating to the offer and sale of the Securities constituting part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of
persons whose consent is required under Section&nbsp;7 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">Very truly yours, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
Covington &amp; Burling LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>9
<FILENAME>d286456dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g286456newimg001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:66%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">August&nbsp;12, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8030 El Rio Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston, Texas 77054 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Alaunos Therapeutics, Inc., a Delaware corporation (the &#147;<I>Company</I>&#148;), in connection with the
registration by the Company under the Securities Act of 1933, as amended (the &#147;<I>Securities Act</I>&#148;), of the offer and sale of shares of the Company&#146;s common stock, par value $0.001 per share, having an aggregate offering price of
up to $50,000,000 (the &#147;<I>Shares</I>&#148;), pursuant to the Equity Distribution Agreement, dated August&nbsp;12, 2022, between the Company and Piper Sandler&nbsp;&amp; Co., as sales agent (the &#147;<I>Equity Distribution
Agreement</I>&#148;). The offer and sale of the Shares are being registered under the Securities Act pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the Securities and Exchange Commission on or
about the date hereof (such registration statement is herein referred to as the &#147;<I>Registration Statement</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
reviewed the Equity Distribution Agreement, the Registration Statement and the prospectus included therein with respect to the offer and sale of the Shares, as filed with the Securities and Exchange Commission on August&nbsp;12, 2022. We have also
reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of
documents submitted to us conform to the originals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied as to certain matters on information obtained from public officials,
officers of the Company and other sources believed by us to be responsible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, we are of the opinion that the
Shares have been duly authorized, and when issued and sold by the Company pursuant to the terms of the Equity Distribution Agreement and upon receipt by the Company of full payment therefor in accordance with the Equity Distribution Agreement, will
be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are members of the bar of the State of New
York. We do not express any opinion herein on any laws other than the State of New York, the Delaware General Corporation Law, and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alaunos Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August 12, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as Exhibit 5.2 to the Registration Statement.
We also hereby consent to the reference to our firm under the heading &#147;Legal Matters&#148; in the prospectus relating to the offer and sale of the Shares constituting part of the Registration Statement. In giving such consent, we do not thereby
admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">Very
truly yours, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:56%; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
Covington &amp; Burling LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>d286456dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and related Prospectus of
Alaunos Therapeutics, Inc. of our report dated March&nbsp;30, 2022, relating to the financial statements of Alaunos Therapeutics, Inc. and its subsidiaries appearing in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of
Alaunos Therapeutics, Inc. for the year ended December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to our firm under the heading &#147;Experts&#148;
in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ RSM US LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;12, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>11
<FILENAME>d286456dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form S-3 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alaunos Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact
Name of Registrant as Specified in its Charter) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Type</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Security</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Class</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Title</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Calculation</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rule</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Amount</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Registered</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Proposed<BR>&nbsp;&nbsp;Maximum&nbsp;&nbsp;<BR>Offering<BR>Price Per<BR>Unit</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Maximum</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Aggregate</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Offering</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Price</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Fee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">Rate</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Amount of<BR>Registration<BR>Fee</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="4" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees to be</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Common&nbsp;Stock, par&nbsp;value&nbsp;$0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;Rule&nbsp;457(o)&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Preferred Stock, par value $0.001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Debt</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Debt Securities</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Other</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Warrants</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">(1)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Unallocated (Universal) Shelf</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Rule 457(o)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;$200,000,000&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;$200,000,000&nbsp;(2)&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">&nbsp;&nbsp;0.0000927&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&nbsp;&nbsp;$18,540&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Fees</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;Previously&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Paid</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total&nbsp;Offering&nbsp;Amounts</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">$200,000,000 (2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$18,540</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total&nbsp;Fees&nbsp;Previously&nbsp;Paid</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Total&nbsp;Fee&nbsp;Offsets</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000"><B>Net&nbsp;Fee&nbsp;Due</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$18,540</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An indeterminate number or aggregate principal amount, as applicable, of securities of each identified class is
being registered as may from time to time be offered on a primary basis at indeterminate prices, including an indeterminate number or amount of securities that may be issued upon the exercise, settlement, exchange or conversion of securities offered
hereunder. Separate consideration may or may not be received for securities that are issuable upon conversion of, or in exchange for, or upon exercise of, convertible or exchangeable securities. Pursuant to Rule 416 under the Securities Act of 1933,
as amended, or the Securities Act, this registration statement shall also cover any additional securities of the registrant that become issuable by reason of any splits, dividends or similar transactions or anti-dilution adjustments.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee. Subject to Rule 462(b) under the
Securities Act, the aggregate initial offering price of all securities issued by the registrant pursuant to this registration statement will not exceed $200,000,000. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g286456g01a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g286456g01a03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#Z^8@8X0DE-! 0      !D< 5H  QLE1QP"   "   < E  !41E;'1A
M #A"24T$)0      $)_]]5M,FVC]2'%8$L(%V8@X0DE-!#H      .4    0
M     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT
M965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 6+)-P         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              #C   "<
M   !                          $              G    #C
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   #C     %)G
M:'1L;VYG   "<     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    XP    !29VAT;&]N9P   G     #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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ME5OK
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( -T"7@,!$0 "$0$#$0'_Q  ?   " 00# 0$
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M8G*")28T-6.2HD1&5&1SDS96LE5T@\+CA925EL/$TM/B_]H # ,!  (1 Q$
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M +7 6=1&2Q[,#O?0](W6"H&(JNT$5*9/_"/[JQ:1=GNS'%E7T)^BND03U*R
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M!G2<\HEKLX<N'D8@>8/7S)^N_5@8/^,&[C][?/[8[!N-_P#:#GO]>O+&57O
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M.'\]Q@_L8]$L =5\D&>QZ6B=FSD$GE'%S#',%KRS*UNU7^/UAW:G)PP>OC?
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M?1\._P#\LUQ<SMQPE>A+T8*_]Q^C]U#^_P#25O$9T18Q[IPAS!ZZC?6K5<K
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MZ')N=L5OP@]=L-K7JL P.=1;N<D$ ,U>9O(ALYQW\T^DGK"'=-8'=JM*8_\
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MGC2OTF]-$G+U*E32P*U=I2)2DNULJ%/%@KG+N=.9]!WHM445#U3R%-.7/:*
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M/"IU*"JBE"G3)(8CM':[F\\8EXL^/O4KJ:F[%#<>TO!N".0N^$01CI)R' )
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M/6+TLY?-],KRO2G378T,YZOK3E,O4I)13R-"JHT$#)*4@^L9A6NH3HJ%!"1
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M>J4*;EZY)08,I\WP9F57 \6-[,:O5OJO73IS?1O1>5RB%@5\Q1SZZJJ8"DE
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MLQ3K98K *J2DY,:%4D.I2% Z@4DR&-L2NE=N2VG=RW=6M.=))>^ZE*VG%I5
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MNILC6X,=A+1Z;-3"EJ7'6I24IAH]D+45!*0<J''N]5:'5O,=)989U=0TU5$
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MZHH4U ( 8Z:G>5+H4YT@,'U L\,^._=$L>E>D2,UF,R49"B$TZV5-&D5]JH
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MNC,[F:3@KH=CFE=M/==**&HZ20J&9@=B#)/6[J%J2K^*>JKI!"%?;O1+I#,
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M]8DY.7A)]HQ9B:F9*% @PTA)*HD5:0D $G;@/5+K8Y_N&8V_RJP) BW9.Q+
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M)KT^U57$4OZ(:BY@B 9A5#NI4S$DP3TR418E"Z(W4KK?;H <.QN1T!UP!/\
M=LV7 <E%<J(&IDG[II<3M!?$#TWZ/J83_P!9>J@&HJT_;?1( 6"'4 <VQ4"7
MU!B+R^ :=ZL%*(7T2U*1!0AX<)5$NI2(20[P D2I!2D.P?N=^S^PNN3,,OG
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M*U-2<Q!C)*H,:!,R\E$@QH45(ZH<2'$4B(D**">*/X/ZV.5>H9J8_P *M<L
MS40VXC:V+?X]ZI*MUJZLAY/_ $_T4>?_ ,4T?/<;\CZLM2F<:?7J1AA]%*^S
MCR_:\%C[O,'?B(ZF]:]\CFKC_*K'P$47C<C86X!Z^]4)_P"M?5EGVZ>Z+W@7
MSC$G:'Y,<)&G&H\)7BIL.^9>( "KHM2X$N!Y+-/!#D@)/F7XT#J1UL07&2S"
M2)BG7!D#847;=[VVQ)?7;JBM)2KK5U74]GZ>Z*+CP];(B=B(M@.FVIY$8*L*
M^X:8BTQ%DVU<:8>^%3254\&+%."E8QU ,6;B/\(];*:HRF:<D*/<KGO N'^X
M&H@[RS0<8E];NJ"R >L_5AFTA?VYT2X28,C-0 +:6&_@?5WJG$B]<Q9.H<2-
M"04P%Q+?N<S(AD,4R\<29\%!!+(/M#W<7GJ[UZ*G.4SQ.Q-.O WD4@6-V#<A
MMC)_$'4(!0'6?JMI+E0'3G10!+W_ .UL7/'<N^.4+#U72M$<6KJ2(T9*AXZ*
M'=B8\),$'IA1E"3"E(4Q"B&)'4$OC@_A[KR00O*9W2H:5G17'=(TD%J)<%R_
MD8$8@KISJ$I!0>LG5127A/VYT00Y!DH.;(!!GC#G?%*#I[JI!$0"S-1X*(BB
M8J(5MW)#1&47>+&4F34N.Y)!$8$*R% [<1'57K8F1E\TQDA*:TO#12#@#:SS
MQQ;3ZQ=0Z10H]9NJA[.4 ].]$'207[NK-D N+@!B\XH_5MJ,$E";!O9U*ZO:
MM.OK5$).Q5\W;]SD 'B:.JG6=) 7T=F*J1)1V&86JH)[H2*()?@ #PXX],]?
M>H])"BGK7U<)"2R:'3G12U\]"$YLE2GL "X\V@K3'4@G^YY?"B1_WHW X)W;
M]KR[!R[N"3T]^/-J]4NL';@_PYG0";)R.=('OHV>8&QX XRY?TB]3%U2@=9^
MCE&#I5TAT>! +^SF01-X.VQQL+RQ:?W](:GU.8G[%NN5@JL6L01&J-N5F4EC
M$76K-7#AIC1Y%"#&4B%%4B&%=:DPXZF(AK(^YZ ZO].9<J"^K682#24 OU//
MN3KIL".R9R)+?E&./^DSKAU5SBJ R_67(55C,!11Z]D"E"!2J@MIKD^TH#A)
MLX?YDN8(+_"#YAG<'Z]M<?\ "(W;4Z]V/V@^"'?9VSW_ *=_9JJA&O*]%NP<
ME1 L)#['P?>7&/X\Y3IRKE\FL)"4J8E*2%!1'>L-8O??@V,0/$8EUD@[F8C'
M8N,]7O'GLQXG]E!#'U7HHE-P%R=[-\(># G'G9'K%G>VKA=,I"D*&HBHD/I4
M&!4ICY6<\G"5;Y^ F(VX!_X9P^[C.&XN]7I@M]F]&V_(O=N-C\L5?:N=,!8#
M&.\KWR=N0&YL,)U@,ZL8;QXW<%V/5EG/N?B"LM04DIJ=&]'=FI)"PE*U+*""
M%!*3!47[H,'<X9Z3SI@K]H@-J5O_ ,SR-U68#@T02-_$#ELQXI[AME88=]W9
MCQG/1/0)/_=2)NV52\O;:(\W&V)(Z5SB/Q@M )*CM:"6?C /$V$^H]PO!.#'
MBL?(X/YF=^^!PT]$= N_V6AQ9\JD6M8_J(AC?&E?3^>--:'!U B%J?<;J;PV
MWP\#+K<?\=&/;+.3N=]GR>+OLKH'_P#%=,?_ )A!GBVJ2-N.,GVQG.;F"!J8
MW'YCNU]C :,)SG[0)&#X\5O/<%QY;._W'B*NB^ADC5ENC* K#V.UH)0AR9U*
M!+#2[,Q=GXXDGIC.@@Q!AU'3/$:G$1QOA%2WR3GV?X>-\2Y< .<C.3W<<1&1
MIEVZ.Z-=WM4&F;[1;B +XL'3.>AE(+,&U*=1E_Q1[Y:\P$KV!41G:-&![?\
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M#^"NAR(RHXOV-*W)T3'[MB)ZW9H%NQ6(%D5+D7/WA=^7 W=\,_*4YW8\H5$
MV;ZRXZ=VRQMP-N<LX(?MP#J5T*W_ &)!Y]A2<GQ"!.*U]8<[4)J %(-AWW81
M(U3Q][O@'RE*? ('*%1!ER3J9,YQV_<YM_HSP?P5T*/_ &%'_P!A3_5'SP?;
MV=+L3 #.I<\79=_EN1; /E*,\[_@B40O_-^LR/L&)27MP8\PV&?XV)ZE="$!
MLHD<!V%+?_\ -OO8D'QOC8GIO,Z$/50%,">^078W&OVF9P_F):7ZY4GM_P $
M.AL>IOWS([[]@+=?S#%P0!OMP_X+Z$9_5$#<O0IA^+?=C@>.,J^G,VE2F4"
M3(6H@0X<:S9[>8Q$?*59T?\ :@T8$DECJ3,9;!;]S8P[GX%\#/$#U-Z'!+98
M,'_R*+!HN*=O'A OA#K9G&"3246[NK15VAWUMS<-JOXQF/E)T[-2D:7/*%18
M1FY:=EE1$:E3)9*X9 ZC]&RE/4[.X+X#D<(=3NATDGU6'<@T*8<./_#,&'X.
MQL,'\1YE0<TR(OI6+._X[>/-KQCW2;Y0I4=*-,K&T[3RJTNKHM*WI6A0ZU%U
M&FH:YN'*2\$0)B/"7;84I4(QXD*"I0_&>$H)R">+#U.Z#))&52DACI33HL&$
M, B':6+^ <F/\59I*6*.[L"*C%V)+FI;@1/"<9$'RE.?Q_8D48 %@?K*C$/Y
M_P F\I41C(Q[([#@/4WH-XH#9ON*7!_](VWON2</^+,RS=F>#Z5[R[]J 7-C
MY;XR?HU\HJL6\=2+;M?5S0!&F-CURHJD*O?E-NR-<HMX+6F%+5&)0H].@P_5
M8BU Q^F*HRL+J7$ 2@MES/5?HM%,A&5*R&("Z-( D!@24TPIBWYGW)QMH]9<
MP5I44@N&5W5 :19B*A#< _(OCZ1*'6*%=%$H]Q6S5*77:)7I"5JM$K=+7+35
M/K--G88CRD24BH@Q8,RB) 4(T-<!2PJ$2M)Z<\>+4Z&Z)I*)5T?2B&[))((A
MP0VJS;R9&/3'3M:H&-)P0&9"P 3$G7?WAW88[D)V:'!W#/#A,Y&3_%<[8\MS
MPO4^B"W]Q2TR,OYM"O*Q)VL^&<]6#@M-^\7;:YW#/:XQ+I3D%$N<NX1"[!B[
M2QPH8!\R7;'$3D>B%A2?46!!#G+@"?%3[[C <]6$@I#L"'4XV>[/$L2Q$%GQ
M%02V(<L'88APO>?\W))\S^D8%(Z'Z'@>IH_^Q3Y#@&P#-55DNH!@0^LBTRY8
M%Y(L(\V$)( \*7(+_P"QP')W/^#%G][,^#Q,=%]'4F5E\K1%9)>F5T@E 5LZ
MA(#DN0/,C$DU%I6*G;:0ER]-;K F4 GVV!WY\\"X:.DO EV"27Z4%6!C:7?J
M^XOL/+BTY6H9]7Z-U391/SO\(>UL497I*H,TH5,YTH*9/M*! %]S'B";6QV=
M'1"$=:(:$NF60Z40T.!U) )>6)VP?>2XVXB*>:2HA.6R)B#JJ.P\&N&EY8<,
M3Z4K"I604YSI!2-)A.E0U'27AV+.&):[/+?F$<Q+?A"\P_G]>NN+8;!U.O<^
M7N+AWV\N.H$6E@_-F8!MQ8&[/,8YUJ# 21I<V!?2I^"FVX[WOB%PXP!C9P0[
M.';M@@DD/DMD,I=V8WY$;.;!@X'&9%\0+1;]SMY_RC"_J^_QV_0'VXMD;W\0
M_P"\-?CPG$IXF6<RTVYD>7AA?#^NWYVV^/!X[OX_T)OO&&3:=F! ,DB7)DL[
M&+!@,#N[>?Z-_P F?=[]V/ZV]WE^^^(A]G<@GDP!D/> H<FB;/\ K_7[O+]+
M\-_+=V#QPMN]IVG#@>(9B#$W!8 ^XGQP<+^OZ>7FWRPN=[0Y+#AR]X/+"+8W
M/;!\_-FV\^WYR W9A[O@_'<;VY89DB)+0X >UB!N)N-B<-\9)[/GR[G/P^X]
MAP?J(#&7V\C\MV#@NQ@N Q<-+<V(L'!:8<#!_K[?'^K]^#]AN+^Z;VN/+ Y)
MM=SQN;DD$D"W\\']6_K_ -7!MM'@_P#/W'W8"X#&S P0QX&+_,<L&<CS!&"V
M?B[?T>9XKJMI3=RM+ ;N\0" =[_+%M(,I0$NA8?R'EXS8\6PL$IW<Q(?D #X
MB01@]R1[B06#<3KF*1>0P$07X/<EB=I@WQFI":@9W2JP LP+L[7N!RQL%I@!
M]&D8+"=GG R,Q4DG[8P=AEC[V;CLW51_LY&W=3#-^'@02^^]HQQSK<'SI2SM
M65=R\NZSJ#B(!OY1D1V# A()?L"#[P?('L?)@W'U)!YN2.88;RXAMA,8^1!$
M'2 P)-P0I0:0-!91@:B0TNV C8O@,74 Q8/@##$X<G. >'+/ 8FQD@,S;@O9
MV8.0=\19RQ=F9V@$DERDI+B&)"E N+EV"^,98.=CD]V[;^;%\-NK-P, @AB;
M^R>(9R7/G&"74@Z1ITC5W0X"B  "#8:@U@4\X0+@G8$@C(?SSDD99\8QYG@4
M [&7-P+2SS=F\VD," P5%&I 4&#:G]IP=(LUR7##2Y908$MW/<C).-P&P'=W
M/?=_(< <B&: Q'$1NS 7\#QA.=9)200D$,D$_P"X. DNY$$*EYAL##[0\PX#
MN?>&/9S@L<G ? !YBYX6N)<$PY!=GGC)SO 42S@A0#OI+!X;45$P=A?!DLQ;
MN-Q\79TN['8/D$@@.FEI!)N"[%W+<29:? 2IB;A@ 0P(#,X$A@ MV !LY[Q(
M&$72_F .^&[=@"=_(Y&Y&#40P]YL))<DG;@  .%\)F=E/W4I((EQ(+ $.IW+
MJ)D@@JTLRW?!['L7/=E @'\W8$ \# ,;!VAB2/,NP<1O#-&$2Y41I!!(U$QJ
MC;8-9B0#L^%W8I[?$@!V8N<_<,D<29I!+6(!,N(M WW#;[X;L>\'5I8+*@!8
MD_B!XN5 VN,,Y 8NPW(&Q8'W[@N2&9_@%R(9R\&0VW>9AQ$F;/&%W20Y40P
M21WB[22"SO(+B-V@,$EP<9 PS# +!O+JR.SDA@YXMRQ>LH&&  %RVD.XDDD7
MN 8=B,59A^S<QW@[ "Y! U AQJ4P 8F"Q<M[I>@3/3S&:OA2@!]4JR"3T@)^
MDM'2/\E6X(!=NKJ2DEB!R'TI!J";RK<N_P"QXR1%@<=@]&3G,I>6*0"S$AP&
M-CMXLP<AF^E75*T[BN:9T^JUL1*%&G[$ON4NV8IEPU*KT>2K4I*4NI4Z+2U5
M2GT:XI^2B)34$QH"85,]2F%H*?%)ZFX0@M3 $=V2X-R[\.,D%[&,=WJ_XJV)
M)U^+6;<ORMS&-?*ER\ZD5^Y:1,UFO69+VM2KSF[EC4Q-1N:LS%7I=:U)I%ZU
M.CS7B6W2Y<PY"2EZG09!*I> A5.CH"8"8:RGB6H%Y+D<0_LD,Q4!>S/+EC.*
MRHERSGX@/#&_D>0??%I:<Z(:FVAK]9,_<% ^EMLV0%FW[ABS$>)*T*2C6M>-
M%E:Q*7'-3,I/"A4"7J=)LF!I/!ILU.1(@A7O("+39-,X!2G! [KN8 !YLY8D
MN9(V!B<7)9@7<L(=M)<- B"[,;^['H)U,3UKB+.2I<5E15J<NN+TL"M1!*R
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MBI22E04$Q"004@L%!C[+ACG*2H!P"X/;AI]I+6U#R)(DF//CB%0**5!B.XH
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MZ9X+;M\[,P<=2026+OA@?:U*[K!X&FLG=@)#DL? D"""QZFL7!V[QT\=SH+
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M4^@N;Z6GF1 &SQ81QP_Z_P!?CP A[@_'Y$87LN[3#EXYC;YGE@W;X?#\OO\
MCGB%5F3R6D[<2(O#'GYXG14A2B M+Z%G9S >!8;;F9OA,24[_P *@$'R"T;>
M3E_+ 4279I5@#V478_R#CPW/E.*Z(+U#R4PM+B1S#O&PF,;!:8_R91V/KT]A
M@6_&I9@&V<'.WEL>.T=4RW1Z;N$HL5&"/>]W/Q;'&>MX?-D%O\908@,6)8@
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MB"'2H)#,T@ AB0)DN0\& QG" RS;IR0 &V9WR[@,1M@  .>+<J *JGV2'$"
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M<$E(W ,$'B&N[#O\2#V<Y'P&S!+/G#[<,,&?B&')BXY&"W >(Q)14 [NH@P
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MV_<,C3:=!1(5&WJ)'ILK(UJ<ARXE8<[+1X<2"LDE>RG0"F)=)+EB'8!G!)!
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M2-3M,HE8F: B_K(-6D:;)UJ8EC<M)2E-*J"E(DYZ'-*G1*S,M,+!$.)+QHK
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MN6+2J'/W+4M.:Y2K;A09:$FDR$:X?G*) @2"XM*FJD8Y1$1$5]KCS>D:5:N
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MU"HSDNJD3E>N2I5&4ASGSDM<RJJQZM,J7!_$SDJE24!]O18@J5 (D,"68J4
MX+,\"+L<4E"W)879W<B; L0EX=R0>0Q:=P<ET6LR5>HL#4*GRE,NB?%:K!F+
M+3/3QJ4K2[IHDK!EEKKP0*:NG70I,Q"6GK,Q)HB@ N[]8R[AC(#>RLN2 "3
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MX)0(W_&68.\A]^2/R?;TBC-\R:#;N/WVZ?MW?]I@<!R"'(SGACIS+_ZBH_\
M"J.?+1[P\M;@OLS-G_+!E@Q1#L)919PX!!?8[88^3[>D3=C1=!F8Y^MN0(8]
MF^97]WE@,7SP?;F6#'M%N]NRJ1=S_AL_&[[W)P?9N;OV:2?^)$*FYU<HAQ,D
MDX/UOOZ1/'[2:"]R"-6Z>WP(%&9GQC.SOP?;>6G[Q8+A_NZCF6C[L$QQ9L'V
M=FTQV:7)OJ0!Q$:O<Y'*TK];[^D4[T309L;ZM4XN?A\S,_8G\_ .G,M'WB[?
MDJQX?=>9$0&=\+[-S8LE+@_F0'=[]_<LT>#8#\GU](J3BB:#99A];5.'E@#Y
MFV&SD 9'$D]-Y.=56H_'LZUA80B..S[\,!Z,S<DT4$O?6@$2#Q(<@-O^I8^3
MZ>D6*730]"5-D@:M2& 20X(HV6[MY[ XX?VQD2WWM2'M3JC=_P C;L\!XM.'
M]G9D"::7  /?3>S/J,Z9:.+#%D(]!SSZ'4B+I2*+H\B\(-H_3A4*'J=(>HJM
MSYT@4=4T9U5$$/Q$5"9@03+>(([+$9,%4)*UI?VQDMJR@+L:=5]Q^2;\^(+8
MH7T=F=0(IH!( ?6B;\"""8!L..+W/R?;TBG4&H>A*00^=6Y$G;)/51G<^3!L
MMW9#I?)!@:RN34Z@VA_NY!C^>(?9N9G[M$"!VB1NZB>]!\3^N ?)]O2*!S\R
MZ#]/F=6J>[.R7>BC8_ D>8XB>F\J"PJU"P@]G4.W_!^L"YOB^GT=F0EPA#.7
M[Z=PQ8J+MRB^^ ?)^/2)[FAZ# 9<_6U3AW W%&\W;.?(;\+[;RT?>+,PU.H?
M _X=^6V\QB?V9FY[B>]+%22"2+AE:I+R\NX ).#];[^D35_M+H,0^0=6:?YG
M.*."/(>[<;\+[;RXCM% @;4ZC/Y4]MQX[L"CT;G'<TT\@2@7._?<\OC,X!\G
MV](H' HN@Q?L=6J<-QO_ &E\PS;?T/[;RSN:BV <?=U+V_)?A:'VG!]G9IP"
MA' =Y#&(@J#,YM&V(GY/MZ149-$T&[Y&K5.[!VS10 0!AF^/ .F\OO54W*G4
M=WNP00U]SQW& =&9M3#LTDB6!3$O^8-+.UR&+L<3'R??TBI']I-!B#Y:M4]B
MWVG_ &G#.3DOMOPOMO+6-119Y[.J1R/^&9YR?>XE]FYM(FFD"X=27!423=2;
M.6M=N.(J^3[^D4[T309O_?<IY<O[J+VV9G\GQPQTWEF?M%\/\.J[</\ "CD'
M;F&POLW-/%-,.94AS/)7#A &]L0B_)^O2)08,6/$H>A0@P$+BQ5#5:29,.&A
M411 %$/5[*20$@J/9RPX#TWEX/:*V([E0D\0 *98RTRQ? .CLU+H3<F5)Y M
MWK ?1Q:EA>@NY^-2+-MR_+8H>C:Z#=%.@56C1)_56GR4X9:9"U2TST&C0HT(
M14HZ_!F$0H\,,E<-*BPL^ULG'WBG-R*=4@\A]V1O#1>);&<]'9OO'LT!B6*J
MB%.!&R@  SGX;C%W#Y/OZ19\T/0<=)]H_6W(?F(HQRHCR)<\+[6RD'M*C-_I
M5A\TW@W<>0B)Z,S))&A(;_>AMP&[W!@&^ C&3]'?D\W-U6-2+9D]>*KIE8VE
M:YXQ;OK5H:@RUW78:.A:5)I=$EOH_!A>OS* J#&J$T$$ E28A4 >*,UTSEJR
M5!*U*.WW:DDP6$TP'W9V'/?30Z)SJ%!2Z8"=SVB%%//NJ )9Q8OPQ]>^D6D5
M@:$Z:6EI%IA0(5MZ?V32)>C46B2\1<1X,N $S%2,>(OYUF9F,E<_4)E<:56N
M;BA<* L I'S%:HBK4!2JZGL6<PS$!O&2\\,>_1HA([SA4 23";!Q$[P&MC(@
M3$P,$;[[MMDY;+LZ?M'8N>+<:"2P$->PWO;Y? 8D4K.& 8@?:!8L3EE8;IW#
ME/2/O, _42[,WAL?!^&X,2A1(#[ $J]EW.W\YR[Y(<L1AMS _%C[YGB#/C_+
M 8;@N05#N#ML "Y8-EL?>_!@;F(?X? _6TX82H @!B4J2Q4')(4D;L2"-AL#
MMD\,^)/C_4X&MSWL/EL;_1QW-!9,Y,K4R$^ E.7)ZNM)]ZB" [D-MG(XK()=
M@[D'9F;G\[^0P;%G$CGL;GC_ #Q^8+S$9YA>8?W:ZZX98X_?.O?NWO.<]QOC
MCH)VXWW;9SX3<<2[A\?!!.T@Z2T@%QK (>[PX=H\L8B2@%1 (<=2E%6!AR23
MY;OLW;B*=G<%Y)W?COX/O/ 8K8G^H&_/CO\ SPNG/25)22Y25* "P" Z'^T"
M7 (W(4VW%LC8D2-X(<SX7X>>)E(V,0!/%G(>"[[$#"*5)"E)60I(<&$I(BND
M./#*O8"W'LDLD*8G&>"[#F0VTV/T]AAD,7$!*@'<$AK,PV\]N&(+A)B$IBI3
M$'B0HZE)EX1ZX\-75#C-'!3+QH1Z3XD(9(!2"1B0%BPEP 3:98AR0=A'"Y<N
MQWDAV%S/&TN2P8B3)<G0F&KQ/#@(Z8GCQ$B&H0#.+@O'G H0T3*EQ8I".HJ3
M$A%)5#]C/"@AB;AB3L'L-A9YO$#>0/>!: S@GB.(,3Y@R"V)*0B&I(AK:)ZP
MB(8@A)2(Z@GJ4(241DDH7#ZH2G(6RBLNS</L4_7,[S)_EP;%H$VO(<:9 V;Q
MD-YEIY\A4JK2HDXNCU"K46+4I"<D*BFE5:I4^)5)**I*XE)GXTK%A&=I\^@>
M#-2,_P"/)1H2? CI\-9(@J@BHE2(+CY%RY=[;B]F;$DEE L(+N[R00"^X+D<
M>8<87SG5(4A%HB*G5!19B:@U&-143U1A4>:JB(<:##J,>C(G/FE<Y*2JER\O
M.Q):)-084U%@0%(@E9$4Y-"+@07,[&]S?E XMA5JA8AR01LX=X&Y9@[1XN3'
M!+ 8AJ!+!)P2I3]/2D-[2E'  ^[SXMT@ $,>+<+Q=@'AW$^1Q A2F9[MQ%X%
MX!!MML<-:%()2M*@7(8C=044E*1_.4Z20 Y;.QX7(%A<3NWP,L\ MQQ,I-I@
M/_Q'D.-QO;$00690?^<@_;1G9:=TGR!\WSQ55<!$$_>)F6\MFC@7V#MB=(G4
MH-="N;!GC@YN7\;8,.GN1%1N/9_A!W/8%\ ;<2KDGL0&#D3O.\^/%RS/BFE>
MJWY26V,\1[SX/C8'3)C;"4GJ ]>G5A:?94E:(B8B$AL +6E*5M_-6>^_;^IG
M8^HCM92:*&)<=Z\,Q$&/V...=;J-2OF,P$W2I:B0Q8&"SG_:;W(@C&Q^F-%O
M[4"Y[7TILRX9ZGS->N&!.4&GKJTQ2Z!+7%*2<:9EZPKP 8DK4):'**1#GAT+
MAD0O#7VX]3I-?1J$5*BJ;I2 DA*:BSWU 0 22 3+#FSR?D>A$YZC64$$#VE=
M[0D0-R00\'D\2X;*,I(<Q]<H476VF7G?5>J-IZ@SVDU.FI&YI^>OB%<54IDW
M5YZ%22B'T*@SP\:-,1(<)4G-K6J#43XJR_B4E]%IJKIK2 Z$K2--1B 6'!+Z
M@&#E@Q$"/=RQZ1S-7,%^Y3TI+&G!+DL $K+@OJA))($WXE"M#F;HDOJ+K)1I
MK4JVZQ;=?M6UM0+@E*Q<=)O"X9V^*I$KM&$Q-2L:4K%0@U&K6_0)ZIQHJHJ(
MLQ+R:(BGF !8JIT,54Z)13)4FHM""E3 (":=0ARR2$UM!L=*BGV2<7+RV?TK
M45* 9*2H%,.ZDNSO*"6(9PY+G$:A-<U=>I%U6G7Y75ZX).YOH\+LAUJ!7:A/
MS$K0*A/UFVX25QU3HEY=5?EY^<AE,7QZ@($U+J"E2Q2FRGF^C:&:RS!,E2@^
MON@!@SN1=G!# M:,>95R6>JLY+!TJ4E20"Y@&1J(#$)?O$<&.+4M&S]<:\FR
MZ3;U+OR6HTU>DBBR(\/YTE:#2[NGYN%28%4ID2)!1)PI^)'A*EXLTOIB0%PX
MT-*QTJ'&OI;/=&J(6I*2$#O$ZB2 Q4"#=A+&2-H&'3R>>! 2LR &[H!)W8$$
M$VW' D8R5IEI1S'U?6S4FR]/Z[7+?U=M*V[VN*ZIJ!<<[1ZU<]/M2=EIVX)*
M!4992)RM5&KS$25C2M.BQ3#GUK1X"E1%@<1Z1Z6Z+RN4R:UTTJI5$TA3:DJJ
MD*J=VFHITJ*0WXOP@[#&E'1N=S%0G4U1"%ZB5)0=*2"M+$@D@B ZM3;MBA:U
ME\TU5T>O'5^V[KU#%I5S4F!8=?13:]6#<%[7;5Z)4X<Y.RU+ASBXM57;=($6
MCU"IJCP8\BGJD8DV$4D08.&GTKT9ZTBBI -70:H9*F2@K0""IN[J4Q"2Q5IU
M?A[JK9+/4\N5I6R2K0&*0=24*-B[LP*E!P'2#)!-NZ;6OS%P=.[\O?36HW_;
M%ET2FV]7JZ*)5[@H,A49*H5WZ,TJJTB!)5$F?G9.J17B5:1$O.442U1FQ-14
M+F$)UYO,]$UJB%KT:U)-) 99-JE4I<%PDI!4780E[@#S*">DTND'N346Y2(U
M)2_LV*NZGB\,1'=6M97-%<-T7M=E)CZE4Z[J/94[=%UW+4:K5H%<GK/A1).E
MSDO,5"HHFIBO+F1$E?'1'B*,XJ7C"/"\<NK(OI#HS+I0G0A00M/9H"5:4K'L
M%-PDIG24@-LS3ZE#(9VN5=XC4GO*U)*F>=3D.\@RYYN1CKZ]):_6%=-ZSMM7
ME?U=131("[;UM)-P2%,J,&%)2D[TS\*9@0H"4TB6F050YB13&E A$Q B&$I*
MN-.6S_1^;I)JU:82MR"@E2E=TL.\"Q!N& @D<L55\AG\M7*::^X$AB FY&HL
M#+DQS:SR;5NBC<P=<F:'+7M2M6ZY%J<_6JE1):Z(ERS,:KU"IP8,_<<W(+C1
M4A<S/R<*7J-;C+3#$Q(R<!208,%Q<G,=%)]E--*0$I24Z@-*5*TA+$0%*< ,
M)B2,%2GT@L%.M3,2I/<<DM)=+.S<3#-;%HUVY-0H<]>=(NVXKQ55;AG;?7?\
MC<DW,Q(MRU*V!."F+O*4G(D28FYZ1EX\)%-B*4I<D8_3U)A0PGCT.CLIE:E<
MYB@A*:920E@0!I&E@ZH&I-F )$AAC'7K5:-%&7KJ)J)601W23J[XU,&/=5!(
M=09B-_:WY/[)PIKF1UA@S!B10-(98)45^TL?2FE!2E*_W11<K.REE2@_4XY5
MZ7*RJ67IA-D@%W][06,N9..H>C8"KF26N51 +ID.7' \=R-\?7,+:H81UJ@Q
M!DE0$51Z747)8, '<G8=^/SS1JJ--"GN'VW^OW?'>%)DAS?9N#<_Z\[2%LT+
MI!3"B+!(2 (BE$N0'8AR!U!14, 9)9^+NT7QMY\>+C?$2 9<^1B_(?$XG]&Z
M(& @Q"HA1 $1740AP2&;_)8-@EFW'"[1?YC]?7U&#?VB#Y#C:.4-XX!;=$)(
M\!;]72YB*8D)ZG!."!L^W4%)W!'!VBW?4?KP\O=AMMJ/#;]GPE6]1 5$P(K@
M/[*UD_:" 4[]R!\'.S\1)?Q^O+Z\<)FARPVN_P '(GR\L2-J4<[P8O\ ZTYR
M#G&V&^'"^M_K]/.</S/P_;$OHO2,_B%[,'B'&2?S$_E#\6]LL;CW?7](MA[N
M_&+#@QW^/Z,?1:D."8*E,&#K/O8EFR''Y!P"LL;C@[?5_K?!/'Z_8B&;!]%J
M0-H*P?/Q#VVV;^G@[9?+W8,1-L4I(4M,)84 2"5DY <'[B.&FLL$,SN&Y&)^
MG\#B*@Z5<TD? X\X-&=9-"+ U5YQ;>U*U+L>SJO'YGJE4H-(N.Y*;29Y4E.Z
M.Z1^!-B6FYA$40(IE8H0OHZ"4$/EN)&G4J@LC78#B6\&V'$6-P,8PI"5/J[-
MR9$018R>/ N_,8V*_"3Y/RP.N^DHR K]VU$!(*FR1.LQ.^,CNV\TT,R@,*"F
M((E/+B2\1XVN^+AF:8[HJ"6#.DL\3 VLY(<\<5?PDN3P%OKTTEP-Q?5#"<]\
M3H<,=O)O=Q'L,Q_H'A[)%]I.^)]K3;_$'BX]TAML+\)/D[ '[^NDI.[IOJB=
ML_Y[C<</L<S;L5<?9/EOR\L+MJ<G6 3R3M#P.7A=L/\ "2Y/ P^O324D@[7U
M1.S%\SN/T9X789B_8D7+Z?F7^O?@[5!(^\#OOI+[[?KY8/PD>3PN/KTTEP/:
M_=U1![L_LW!+$?TOP=CF-J*IX)X[W^/OP"J@1V@:TLT \#9[;VXO@/,GR=_[
M^FDA\A].J)[@V)W<,Y\G<\'8Y@QV)._L_&\^.'VM.W:6+;;O=AO[X#@,^ \R
M7)Y@C7724N>U]4,[_&=QO@[??P"CF/\ 14?^7]7\< K4Q98!)X@N?^4_/P$8
M1YDN3PD$:Z:2!G'\NJ'DO_[=[EW)W^_ABAF07[%7_EYO]?S+KM*9M4#VV+,>
M%H8\;W88U8YW-?\ E;K7*IK91[;UGTPJ57J-FS,O+2,A>=&F)F:"9J5CJ@PH
M*)M2EK(A!0"4]1;&2_$D4*ZB :92&NWNWW/EA*JTV=P9]DD39P2) 8F'WLV-
MJ(O,WRA1EGQ==M*.MNHA5\43^>B&00#.;L 6;V7\B.(]AF6/W2B[O!?QV9X_
MJ^*^UH?G2&YP1X:CS%PPY'$1S)\GQ!2==M)2&# WQ0@W9W]=R^<;;\'8YG_1
M5YI)^9GGBQ-2B"X6EPXY>#%V9XMB1YD>3T.VNND@[?RZHAW8X/KNQ _3[AP"
MEF?]%4S*3^ORWOB7:TX^\ +N2Z0[<6FUN#\7P#F2Y/#TGZ]-)0&</?5$8MEG
M,Y[_ +_B_!V.8,=@3_RS'&7+ [V& UD6-4!S#MP@>$P&>[0YPOPD>3QW.NND
MA[?RZHF/(/Z[O^G\_!V&8OV*O'3^KX#507!J#FY2]O..32XVP?A)<GA<_7KI
M*"2,?3JB,-NWKO\ 5]N%V.9_T5'_ )!=[D"#Y[# *M,?C#7N&B )\/>\W& \
MR/)Z#_=UTD_^W-#;.7_CV?<[_>_!V.89NQ4W#2?D^&:J%0%I!D, '?W<L/\
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MN0X,< TN1'[LS3CX=:GMN#<2Y*@SAY!'AN,8@&7QLV^ ,LQ_.XP1C._%Z*P
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M9)<O-S=?FJI5E5#UFKK7)YDY=0(*BGF05<S^4-)MMQ-\>A4S--5@L!R!""!
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M!;R?RR/?WP=@ M/$%R[,&!>S65,LQ!#8@9T)2H$@@D :G8@"7U  [Z0&*MP
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M#CCNSRWQQ']<)<_&!\P\O)VS]6E2?9V+W4WN[/A^_!_#M%QWD ?_ %5@D/+
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M@<O&7?\ >TJ;'!<G]U1.SE]PVX'#_AVC(UI+'_56]_\ @;P\;$V9Z:4![-4
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M?A%A&^)$)'4X5E) ZHA+>R=ST,2=N^1N-P:QL#[AMY_TP!0OOO(?WRQ>.)>
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M+[+6+IEYA^$?X<;R'M&(_K;7F#<?V1FAP&7_ &JN\@=LI^C8?L1OC?W/[8'
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M8CIG9C(#[\W! \0S#X#]18,Y<.5(W8@#<N,AV9CV(QP-']2>,_6QX8>EI@,
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MSJVX^6_B_ WY(>EC]&4&/X36F>-WC53SP6,@,'+[C'Q)#D,\(*2(MJ%N0_;
M,W0,ZEG:YV8<?=RX;:T<XGI-_1XWWRT:NVC9?,5IU5[EKMJ3$G2J7+QZD(T]
M'3'@1_ A]4B$]:TP5=)) *@ ^> ='YUV(*0U]3^$"P+_ *[8/6J+/WCR(\3O
MOL'\'QLQ$]++Z,X1HB8W,QIL%@]2B8U3RHE4-:73(.Z%02[XV()'"^S\[<B1
MQ7X-,@NYM8CPPAF:!,N^P /.[0X;8R^^$/2R^C)=QS-::$@;F-5/RD^H>7OV
MQP_4,\=G?@MOV^%_=AC,T$V!!+@M\B?$0#XB<,>EE]&6& YFM--E8\6IGX_X
M =O?D'[W7V?GK:;M^(<2P_D-F'+!ZU1XJ 9W<O[G_GRX,>EE]&4^.9K3(L.D
M@Q:F1^>0+GMYL6]Q/L_.R-/ PIICAXCE&#UJBTE6SN?U<6N<1_58_1EG_MF]
M- X8CQ:H!\ \AM^?\[GJ&>'X3Y+'Z>-_/;!ZU1);4L!R7M=OJ.&&/2R>C*[<
MS6F?DWBU3R?O(/M]V^,\'V?GORNS3J'-B_G>\X!FJ!_$KA=3OO<B.;^6'^JQ
M^C*_\)K3-MOX:I]L?YCNQ8_Z6X/4,[^5O^8$#P ?<;#F<+UJB78J@D7Y7DG]
MO$87ZK)Z,L$?V36F3 A_QM3RWV?\ ?#Y\RD#;@^S\[;3QC6(AOE\'YXD<S2G
MO*V2+WW/DX>_A?$OU67T9@24_A-:9L=P8M3(<# Q(/VPS'?W\'V?GC^'<F%@
M6WVYS>, S5$?B,/+N7X,_#X^_&M$+TG7H]!S=S=\*YBM/4VBOE]5:Z:R(E3$
MH*XJ_J//(IO4*>YC*DX,6.  60@DMP_4,Z "TDV>1S)MPN''AA>M478F&=R'
M/S)OM-\;))]+%Z,@ !/,[IH0DL"(]3(=V;^(-OW]S@]^#U'/_EX_B#_7+QPO
M6J"I)N!8;OL\^9+1N)Q,>EC]&4Q_LFM-"'42?&J9)+$'>0WW;W@>7"]0SQ+E
M,Q^(#=]N!%MN& 9JBPE0#<2+"S#GON9M@/I9/1E,?[)G3, 9_A:H.S;^HY[8
M\]\G@^S\[?2T-[8\-OF>%XP_6J/%6Q-Q[I^ ^!; /2Q^C)&?PFM,SC_=JF=_
MA(^7EP_L_/?D._X@>9?^?+E@]:HW<^2B?=,O]<P>EC]&2V.9K3-E?\=5>WO]
M1]^S\'J&?'X6;_<!A^M48[RI?<_&1[L+]5C]&2"WX3.F>=GC53R+C^(CM[_T
M<(Y#/-*7Y:P>&WUOMB)S5$$RNQWY><G9S%^& >ED]&4X;F;TSV.\:IGW=Y ]
M\AL8P-F?J&>X?^KD]VY%W\\,9JC =0)XD[%B;R\6N\89]+'Z,HG^^;TS?R$:
MIXSW_8'O?W_EX/4<\;)_]0_5O=MR.'ZU2'XE$L07/ A@?!N7GMU]4]+#Z-"+
M(S\"%S/::!<22FDI C53[4:57 2X$AD@J#L'[_$]0SSV\]0^BV'ZW1N2HV-O
MV+^/QQA+E=]*)Z.JS^7S22U+JYC-.J77K?L^ATVK2,S'J*8DI/)EHZQ B?L'
M[7AP@HM@!:02'/#/1V<'LR ;DD6F 7+/[V&*_6:)N&?ROX!OU:^,^GTL?HR2
M<\S6F;A]XU3=^^#([Y? ;?X%>H9X_AF/Q 'PV=C<<9;?#]8H2)'ZOXPS;\F=
M[Y TJ](AR"ZVWI3-.],M>]/+IO2M*BPZ/0):<FI>=J,2#F)"E?6Y:7@K4D;#
MQ/:?#DOQ75RN<I FH"TNQ>.,3/@_"^&C,T5$:3L&E@3PY\R3P\,;N(DJ'&5T
MII\$A"_"4M+,%@)/264Y8*&0",N">,"EE*@"""5-(%XV\[M?WXT(6"^EV?3<
M&3)EW\><!YQSOF&DN":?*X_X*G8[]^)ZE N\WVQ,N;L7OMXV? *#200?F^6Q
MW93X=LOY'\OW<&I7'X#]L$\GB_+WQ[_/ *%2<O3Y5\,R5>_?/9\-[]N#4KC\
ML$WA_>/E^F 4&DY_:^5<Y^RK?WY\O+@U*XVPKB0/#;Y?IB0H5)!<2$N%8RE)
M!_3Y?Z,<&M7'X#]L!D,;79S?X/RX7WBI"I%-@J6J'*0DE; L^P'QQ[_NX-2N
M/RP-M/O/SO\ ''Y7/,1GF%YAW;^[KK@!_P#>=>^>S=^Q]^3QTTNX(V4#Y6_7
MW8^"F'!+A@U[*;Q''>1L9P^_PP7/F7'<[C\O^J'X@T@D&\W<\#M:>-R,0'UM
M]?6V$?(%ON_J-\\7 &[/YMN//EY\<6 O+/QD/+#9MH',[X?]=W_3PKCZ#$^%
MW ^KX1VEA#1P?XAY'$\&PO?[O+/]?=P-?D;[7;!Y-8/P@ O'+R<X?"P. =C
MN&@!M[.'M,8.'$^$>+C]'P$N7 WE[<O?N^#@V8\FF.+_ %Q.' !LUGX*$^;R
MQV!VPA[OZ_D]W Q):3_,[O:3// !/'8$[,)#3;W.!A\$A]MC^HPGEW9Q)9IC
MAS8GD>.#@V\9^>WZX1)#A]W/%^?ZW\<']=^*ZD:8?OH-I:X\'_5L.X7,:%D
M,)8@/]<)PCGP]Q[:#]W6D!P/O?&X=^)UKHEI21P;O7Y,#\QC1DX15$@L=N*0
M.3&6L9OC8/2\CZ,I9PHSTZ?=B*G)VSEG&Y?WMV7JHK5D*<1V:7$0X!/OCWOC
MAO6UQGEEN\%K8@@#;=6]A$3QMD09[[$$89CW? =_S$G X^J8Q,'P?P(VOP%M
M\?)%DA1,D$  3WG9P6ES+.UN>#;L27=P-F; SW&.Y.??P3O+OSCS;Y/R-\-G
M!,EB#<.HEH%PSBUMI,88;I+'!=L.">ITX;#'(/8=GX3$!,>?C[3^,C>3MANE
M0*G) V/Y@H:64P@%F8  #9HBW;+L _DW88PX?X8/?([$  D!P9-S(/RW\;C"
M&HA0=C! =R " T![;28D88=@"WLGXJQD L-QC\@QD\ $DR'9Q#6'O\1\Q@UJ
M.E]+,7(!<[!,."JQN#>!A,Q!?&1MEU.69G_Z_?PWEH:00]R6-OI_<X0DI8ER
M2#S$.SRQ)[W"\WPW4SDOW<ABS;-[M_/#>_A[,D- @[2')NQ-O/""0" HE04Y
M*F]I@X'$B82=@1O*4I\;NSI)[L#N6)+]Q@N0^W$0XX#@3!%F XAV#O):6DS)
M<N05)+$V DAMW<E),@,+1&)/]Y)R0/<6SD_G[@^7#EMGXCC&TF 1>_(8B $D
M),LHN [2 SW<DO:!X83D!MAG(+,!M@Y)?[CC?@ :YCBSF^_@)W+OAD**0E(%
MX#L"/'8F!</=\0#C .R7"@[LX)9\$OC+.V?+@=R2PV8D,"(8>)<NS2SXAWM+
M:DA4$,7(*B0Q)$NH""&<\+3#;@DAMSW.!W;RW#N=]AQ=E2.TJ<@&O+ [[L6^
M.PQ5F0=")</?R#/XR>+[6Q[Y?)\\<S&L!/\ O22[!_*ZJ6/S[X<]FQQQ+TKE
MZ2&_./-S=_H;[G'9?1A%22[I,6C2!XE_< QQ]&W-Q1Z]4+?T_72)6=G8$KJ9
M3)JLIEZ?4*E+0J2NDUB50:A3Z5-RDU-24.>C2T12D1.J&M(B1'2D#CA-$)*9
MN+3<ZB_P^6.\$AB_^UO=Y<AQM=L:AT.G<S-NFVJM0;1K<.K6];<[(PYZMQ)N
MH08LC5J=I-3YZHU&4,^/G":IT"!=,_295?[*A"5B2ZUJBQ0>-Z!1(E0V86(+
M\/:+LQBX\3BM=F$N6MLQ):;@B/D#C8>^8=QUBU.6:N:ETRKWI39+4.X9N_3;
MM#JM.BS%-F=/=2Y&T9NI4&%.IFH AQXUNPZG#\94$U..(T/V%(0*2D:JH!2"
M6T@@%GO+$-J) WM$XD &'@&#>'NY7_7%B42\.9*Q*#5[=H%L5BH?.=<AU72V
M1GZ5!FXE-M.H:B583%+K<U$CA4M%D+1BTZ-!@S"U1$PH\.$J(J+"62RBD6)L
M/:+D;,+<V)X2+@NV3;:YX>#1>]X=C8G&6=,:IJ55]4;!J5RUZ_IBASVG%7DZ
M]2*Q;M.IM'A7]"JLE.34**F"#'1"I\NN8@TZ:,0HC2\-#]9/5QD4P40+$GG
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MJJAOL3B3S]WP#\':9*9!,'^CQPM; 1F7(D-#!)L1/B7:.1\<(P)B&GQUR<W
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M,WMYRY8>?Y8_:P##L38B%29=_9W)EK<3.))Z,B*I!)22Z($"_P!X_%GAS(+
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M ):P)\O<?#?SQHSR\T:P:OJ5SE52Y+9H%;J$3FEJ,K"G*M;E*J$[#E)+1O2
MPI%,S.2L:)X$)4Q$7#!4GI\1:0!U.9A-5([M0L X )%WD 'E#OBA*T+#!-R'
M<7=B=K%YV#MOC:H6QI$6;3RTCDX^AU R#C ,EMYD8#N^SMLQ_K*'!ZB_D[&U
MMVQ::2/]-$_[0.!N!SP?1?1\N3IU:/F_T.H((V[^I=L;;^0[A.9#?>G@.\J\
M_ [#]6Q$T:6]-'F!]<<'T9T? <Z=6ETD8/T/H!);?'J79L[XV!/ !FH>L8_W
M*#^+/;YX?84R[4T20\"9P&V-($Y.G5I !.'L^@LQ<@_Q'R=SEL,7X7]Y::JK
M_G4"S>/Z\8PQ0IO%-%N ^.T1!F;#<^C.CX /U<VDQV)LZ@[9_P"1;'MW46\C
MP_[RY^^4VW>+?O\ +? :%/\ (@L),0_SF_"-FP?1C1XA_JZM$CS^AU ;?'^!
M? >]ONX#ZU#5B./>)X7_ )?MB/84O]-$Q;WCY?KMB7T6T@<?O=6EG_V'T#+[
M?X%G^C#8/!_>2#]ZKEWE ^/TUIP"C2<-31Y@;^,; 3MRC$?HQH\')TZM)P'S
M9U!&'P6,EYLQ[GW<']ZWJJEF.HBS/9^;^[A@["D"_9HX&WC8.">?'>(U)Y[K
M;TN@<I6N$>F6+;%/GI>S)F)+SDK:M&E9J5B*F):##CP(TO*HB0XB#$"D^TQ&
M#@OQ) S)+=N;&22J )#$AR)<\;<1!=.DD FDERI@$L',\ (@6]T8VT3:FC\!
M2X9T\LTJ"R"F'9]#+!*(>5=4F<DJP0?L]*2'#\)7K2;UC'-5GBQ\SY^)$(HJ
M!4*88SQ^B?C[L5%VSH_TM]7EI$##_0Z@!O(N)(_DQ@9XK0JNHEJRB8?O*#S[
MO CXXGV--0FFD>('PY^6(?1G1T!AIW:+.-[/H'YOV&_^@\2_O7^LH^"B&O\
MUE_?8%&D W9I;P??G;$OHQI Q!T[M#+AQ:% (*<X?U,=)/3[+95EGX/[T_\
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M?/;#G]=C'.[? CD^)H2.I)9*2%)&.LD%QDA2FW\P3Y)+Y;#Q8N'V^O&/<T%
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MZ!5^P;:C2<:8D[@3IY=]1K%;EYR-U"!(I3(JEH+3 =0B*,8J[8JE-2E@@J
M5J+28C8N'XLPMS82D.27)((LT%SS?8-R=R,;YW'KAR):D\VNF'/I6.9C4BTK
M@E[ET;KEP<O:=.9F?G+8K=E3=&E:_ 3=L.LBE_5V)&27,T^3E*<F;"T+(BJZ
M@GC*:)[R'4S*93B2089@(!V-O#%W:AP3IA1!2Q+;AIDP&V<$3#T><'TB'+?J
M]:%J7!8FG&F%<AZ=ZK:S0:ERZWK:M<E=,K^.HMU0Z]2>9:FS%)J4E4Y2[*Q2
MI1%OU^DU&H1H4"8C^NR\M!2PXDBBH+E18Z \.P"0QBVIR[N7LP+I59T[#VB
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MS:+7YP+6WVP>'!?,O <C'XB"0Y41C\7_ #@Q#-Y['B3GB=MSM;Y86A$=T0"
M6XF;W!'A^ZZ8./V-+$#'\7@$[MC\6Y';L[]B_"[VHJU*FX>.5FY[XBJDA0L'
M$ @.0/,6/#A&%TA! AI3#2I1)1#0F&@.<F&E 2(<4[+C)'B$>R5$<)8*PQ49
MON2'>Y^KXOHJ%$@A"2S00P(\!,^.*C!#B&@H0P8*/6'+ ^T<X#OD[ XX$C2
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M#89UN8.U[1PY.\LSB#C'3;4EV]IP)=]1DQXMP#>)V9!!?VD@>8V!8$LY #L
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MI]KP!>8M,_!GE]\4UPX3'XP1<MW5'@]HM^^-N)Y:!'B +ZCXJR_V@D=$(*(
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M>X!F+%1"74YPYW /&*K!$BY:8,@&Y@.9!:^+J9<K+"R?/VI9^?"X@,^%XH#
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MD@FX)C< X^P)-*IZB3ZE*AR7/ADD[^_S\CAF88XX6*J](8GDT ,8M+?1;'<
M&AF&WU_5\5/FBF]Y*7][0P'^.?R>0#?%BI5_-,<;>9^,^>'@^::;_F4OW_V,
M=]_]7D<C.>'K7'>/OYO\[G??!@^:*9_F4#_H?Z^'VB_S'!@^:*9@>HRV-OQ8
M_K\?/OPBM1NHGS^N/E@<BQ; :13#O)2Y_P#@!O+;LPV\NW#[1?YC[\&("D4[
M8R$L ._AL&)5VW)!8EVP=_*L5:W/W&P^4;<>.#Z]^)?-%,&?4H&V6AC] ^&
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M$I39NK3BI27E(!K-7$E*S-7BRTK*RTS.A<Q"E)?K*#Z-:@M*:(!46TAR2]W
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ML:5@)7ZLE!UGI#/)20]()U#4U.>\KN@$/!2^Q;?;&1/1^16=0[4*8@'M" P
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M"9@>M1R'5VB0FB*A<*4-68*EJ (U*8@$AU)<@'O$.0%!\%3-=)5%DU!3"R$
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M%L/]3DY[O_!2UE_^S\IY,W]M-F\^%]K9/_4I<;I+F[MIAOB9.#U.J3[*V,@
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MO+R<>AK@R"U*DUQH46"@*/4'DNA\_1512M6G0**2RP/82!42 " SB&@@.0
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MPRF9AAMA*2$J"(BXJ"M(6I$98(,9*UNH10">B("%PRQ0I)2&J4'.LW#GQN?
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$P8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g286456g01a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g286456g01a04.jpg
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M)#1"45AS=9:7L]08&B4F-39#5E=R=+&RM,73U?_$ !T!  $%  ,!
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M9B%4"Y)V 'MQ_.<:30]?I,!I&8VJ&N]$M399Y7;57W17L/,-6SQS'+KL710
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M&OVBBK5ZP?-%D73-VV540<MU4UD5#IG*8:R""00002""+$$;$$'<$'J,3!!
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MVM)YW,3A&WE,O$S;$+!F]K7<F CN+>52"\1(N!.MC+9%ECFHI/-=69.\7%G
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MB.;%$C9A&1C5)DP9-R"(B5!JU0202*(B)4TRAXCX>/6.2223N2;D]Y.-4
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MCU[18]N-W[YDSDV3R-D&R+QA(-7#)\T<$*JW=,W:1T'+9=,P"51%=%0Z2I#
M)3D,8HAX#UQ>6*.>*2&9%DBFC>*6-P&22.12CHRG8JRDJP.Q!(QR:GGFI9X*
MJFE>"HIIHYZ>:)BDD,T+K)%+&XL5>-U5T8;JP!&XQD6Y><6=!X=Z][^&":0H
MCJ?^.Y-H4>HY3.U]LZ^)1T4XEFXE-'V^M'3(0_F40</2M$IMB0$%Q(A\^?"%
MP)F_@YXAYM-XRN525?C609O"7!CT2<Z&G>=+&+,:(J ;E7E$:U40",0GV?\
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M2.9Q4:V,X64<N!;L6"+=JB*[A55PL*:1156545/YE#F,*))-R22>I)N?J<(
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MJ4JJ1B*$*8!*[+Z'-*6:AS*CIJ^CG73-2U<,=1!(O4:XI59"0;%3:ZL RD,
M<:649SFV09A39MD>9UV49G1OKI<PRVJFHZN!B+$QST[QR*&4E74-I="R.&5B
M#0BP=JWAO.R2DDWI-CKA55!55CJ_=9]&-,<PB8X)MY1S*J-DS"(^"#-=N@D'
M@1!-(@ 4.J*OP$>#BJG,R996489BS0TF9U:P$DW-DG>=HU)Z)&R(HV15  'H
MG+?TO/#?E]*M++G^69H44(E5F60Y:]4%4675)214:RL -Y)XY9'/E2.[$DV-
MQ?B=Q\X_',[RS-86"FE$3H+6=Z=[/VE1)4OE71)8)YS(R3)LY  ]PRCEV;!4
M2E\S7P*4 YEPUP#PCPB3)D62TU)4LI1JZ0RU=<RL+.HJZMYIXT?]N*%XXFVN
MFPMUCQUX8_"3X2%$/%W%-=F% LBR)E,"T^6Y0KH;Q.V6Y=#2TL\L6_*J*J.>
MH2YM-<F]BNN88ZRPNEA89%WS/.--CRQ.D9_2-!BB>?R1EWJD#;(\GJ  *>5E
M/,'[8OG   _@D'F   WCU)69#=693WJ2#]01B+*K"S*K#N8 CZ$'$&QO!7A+
M#2))>(X><7(R434!5*188!E+1ZDJ ^8%$7*%33514 P ('3,0P#\X#U8:BH(
ML9YB.XRN1]-6("" &XAB!O>XC2]^O6V+/,(]A%,FL;%L6<;',4$VS)@P;(LV
M3-LD4"I-VK5N1-!N@F4 *FDDF1,A0 "E /FZJ))-R22>I.Y/XXM  V L.X8]
M?386%TL+ O.5W,_EYQB2L=N'A=GMTR1CH=.H-6NO^ZO0KT_8U-"ND)1*A(OJ
M2&'3:D #V<L$>60:FG9,(QL*RYG*Y4Q 3(*>"8JOC#JY5F9>1<+H4LPU<T7V
M!MY(N<"S33Q780HR:E53S2&.I@HNN@VW.^YL,6\P*\\C[JC:3<A<!IV%+1RD
M.6J)5'<$=H+9DG19,9I1^JCG= ^3IH@[>+*V3,25^*!)+F S/X>(.J)5B73R
MI6DO?5JCY=NEK>6][[]UK=M\71M*;\U%3IITN7OUO>ZK:VW?>^/#I7(4V><D
M>,?'X*B$N'(R,W21-;!G18#3_P"!>KU>R B$'\'>!/\ RD^4?LQ4&7AOA'L_
M< 23]QZ"*6+5%++JMRC&--KZN86'6^UM/<;W[,,TFF6*.U^9S#>_30 >EM[W
M[Q:W;C[MHY &R+4.,&;A4PL <CM2L>;&F1G!BAIP5_+[II'QD(\(B1^/B[&H
M?!OAXO87T/B'Q#WJWM?9.%'%K29]5N2BM:U]6IU2U[BUM5[[]+6WN$\FAXEM
M?FNRWO:UD9[]-_-M;;K>^+&*G]-)13P\WIIG/Y?'P\?(43>'CX#X>/AX>/@/
MA_>'JK%IV!/=@2F&<W>>/(C)*)MF;\ <K<T;1H0E@K2\QS7;14FK'*.7#4IG
ML<IQV5.T6%5LJ I&4.(% H^/S]&R4]-%(T;U3ZD.EK4UQ?V'G8#2:ID176"/
M2PN+S$&U[;CEFV"F5!]9)2IUB3N5?95.WR->A7UJJT;.!9X^M6-W&MEYN 86
M4L=#EL+.'DU'4>VG"Q,6651;D?A',@7]LF&P 8A3J4$@,18D7V)%S:XWM<VZ
M7."Q<@:@ ;"X!N ;;@':X![;"^!XS7,?E18>0'(G&./_  ^HVKPO'6S46JS]
MSM/*!OECR9DKQF57TIN#.KN<9MA6Z;1K9!C!4^/NB+*,P<G%N#@6R!0IX5BB
MDEG9#*K,%6'78*[)NW-7K:_08&YTS22I'$C")E4EI2I.I0VPT$=MNN+)<5N2
MS3DQ3;E)O*)/97H>5:59,<U_,;'(Q4V^I.CU1K$R$E&LK'!J'A[5 /8F=AI>
M!LT:5%I+1\@FH#9LNFN@G3-$8F4!@Z.H>-P" R$D V.ZFX((.X(Q;%+S58E2
MC(Q1T)!*L+7%QL00001U!Q(F];%6./F+:CMUQ,(US+J/8;G(MB+%0<28PL<L
MZ9PC%0Y%"_$YY^5K"Q9!34%61?M4BD.8X%&,:-)(D:]78*/9<]3[ -S[!B4C
MB-'D;HBEC[;"]A[3T'M.(FX:<GG7*K)Y.Y6+.WF.Z32="NF5ZQD<C/DM#_/;
MU3I$H'B5I].'@"2R,I6Y"NV=D]3AF2)V<ZBDB#@B(.UYSPB%PJN)$95=' TA
ME8=;7-K$$=3TQ"&4RIJ*Z&5F1TO?2RGI>PO<$,-NA&) Y-[./'3CUM&\!7 M
MXY%F]KT *L,O\!"P#6(ES*?"1F@C)D8L'OM_0]]\)D?;>?U?9K^7TS1ACYLL
M<5]/,=5U6O:YM>UQ>W=<7[QB4LG*BDDMJT*6M>U[#I?>WTQ2-?GER.S"*H.C
M\G.&,5E^!W6P4"N2>M9UR/@M>7S]?3Y>)KU,FKE2'.;9Y*IU=U8)^%C):4AG
M\J\B#OB'&)>&,FDH1XM$Q=(9R\JAB(WA,>K0"6"L'<:@JD@&P-K XHY\J!6E
MA548J-22:].L@+J4HIM<[D$V[N\I_0>"\"3Q'G!SHY$9C6]BRS@/ETA0;B>=
M&N/ISFBV@I5TV@+),5=TL\B%./+D[$YY&%>"1$SA8?1],X',!PZ-DIZ:)RCU
M+AEM<"GN!<!MCSA?8]V XYJB5 Z01Z6O:\Q!L"1N.7[,%"HTE;9BG5B5OE8C
MZ5=9&#CGEIJ,58RV^-K<ZNV34DH5C:2Q4$6P-8]T91LC+EAHL'Y$P< Q; ?T
MBB,%#$*Q903I8C22.PE;FQ/=<V[S@M2Q4%@%:PU &X![0#87'<;#W8AG*>00
MZ;N_*C%!J80@<:+-D]=+90G1D1NG\)^2U[41>##_  AB%>^"#/? P0"3F_B(
M-?B7K,?7]@E-XM$<,FJ_-5VM:VG1(R6O?>^F_06O;?KBM)-<DR6MRF07O?5J
M17O:VUKV[>E\?51N0PW/E#OO&X:B$:&'T+$[N%Q^.B[&S#L'R]\8P:_\';!#
M?)[Y$!X/ FI3XK\3'Q:QOL_[*=HM,,<NJ_,>1=-NG+T[WOO?5TL+6ZF^$LEY
M9(K>8B-JOUUEA:UNS3UOO?IMCH[Y>.1E*;5A3CW@E/W1U(+RI+2VMVW(XP2M
MMVR; T0NQ<+9Y?\ Y0'E%%I!-PB5*+^&@Q1.*COW@%0:-8FOS96CM;3ICYE^
MM[^6EK;=][X>1I1;E(KWO?4Y2W2UK*U[[]UK=M\4\XN<T.87)4\38D^%.=U'
M+2:G;LRN=R'EFA.SE:6SR[RE%O$K&TT<,AE+&6,E(625C&99N+"9021,1VT!
M<#$OFIX(;CQAV?0KJO(L#K4,H+<TVN"+FQL<40S3RV/)0)K9&/-)(TL58@<L
M7W%QN+CNQ>KD#J@X9@^U;8$$%H'(,GT33PK0R?P4+"-"J,O:0A!F 82HQ02H
MQ7L1D0BY'V7K^Y]B[]+VZ@T:<R2..^G6Z)>U[:F"WM<7M>]KB_>,$2/RXY'M
M?0C/;I?2I:U_;;#GS2X#H><T"_C'?"!O-)JMP&)!W[\(P;-!,)KX<#[VS/WO
MLO>^V]W[-K[CTO6]LAY_2(S#2S+>^EB+]+V-KX=3J56Z:E!M[Q?%.=7Y@:6?
M<[)QKXI8&WW[3<Y@:[8-GLELTAMDV39"G<VJDC3*_.VCY,72;L%VL<0B:;;U
M:OUI4S2#<-)1U)%(+E!M>D"<L2S2\I&)$85#([Z=F(6Z@*#MJ+;FX Q2\S:S
M'#'S'4 N2VA$OT!:S$L1^R =MR1B2^-G(+3=6FM*SW:^/5JP+4LK<UX99 )@
MV@Y1=(2TM';J%L.::TR@:]%V,H^P=)3M>>1,58JRX%LWDF1S*G.E"6)$"M'*
MLJ/>VVEU(-B'0DD>P@D'L.)Q2,Y97C,;I:^^I&!%P5>P![;BP([1OCT<IN3*
MG'B-S:&JV=2NP['MU])FV.Y;%ST94D[)8DH25L\S(V&X3"+N/JE2K%;A)&6G
MIPT=+ND"%;(,XAZJY$45##S=9+!(XUUR.0387"@!1NS$D "X]XPI9>7H 4N\
MC:44$ $V)-V.P 4$DV)VV!.([S/DER70U^FY#R4XFGSA/26%C<TK5,;T=UN>
M9-92L1IIF1KFD.S4&B3>;O'$:4WP*:E8Q[7;#)>$4SD47W\EU-XH=#/%/KT$
M:DD3EN0QL"@U,'WZ@&X&_;M!)9=:I+#IU7TNC<Q+@7(;R5*[="1I/2]\7MZ&
MP1A=+"PNEA872PL#8[KWT2$?M&\1/ZSN5=%T7I__ ,I_Z,F!JOT0^;!_63!)
M^A,$X$7SQSN4U/G/VV:;#ZEI../GT)S6<IWS)GM7C[M'$89YECM1HP=7"JW2
M"(UDB)BRD2N8!RJ=FJJ5LJU7$BY#:=PE/5,423>G&F0,5W:3<A64[=FXWP).
MI>>F4.R&T_E)I#"RK^\K#?MVQ'6N<=;1C/+WMNS4[REY*;TA+<B]$BT8#;9O
M+I2#A5B\;-@=C,0Z5#RG/WZ<J8B)F1E'L@^:>S<+E!F"PD73L2424]6!##%:
M.,WC#@G]<FQU.XM[@#[<0>,I-2DRRR7D86D*$#]4^XTHIO[R1[,&R=?VLX_Q
M"W^K-UG8-;H?<?MC.9VTJUF+7B/Q:M$]W0-7S9TPJT+,26%I[=QE@:1">PL#
MQTK37%>L>7.[PQ@7Z2'HR#-[9_C!FSYQZ$FV.=!5+5JV?GSJ*.-KLP$G+F+'
M:VJX?22.PZ;7[,9].$Y49-4Z[7,>N$*-SY-BFH#_ #7]N-$\+-PUDB8Z>KLO
M&3T%+M$7\3-0K]K*1,FQ<$!1N]CI%BJNS>M%TQ Z+ELLJBJ00,0YBB ]99!!
M((((V((L0>X@],: ((!!!!W!!N".\$=< JC\BY5Z-RX[J\GQ@Y8RW'RRQ%_Q
MA&)J_P#!9D=[JUQN0\4,V<U]Q99J_P!/LUAK[ S@J$4[5KJA"MFBJDB#%XZ1
M*DIHF2%(:(30"4%');7(K*O.>X 5E4GM\H'?;I@ )*TU9RI3&=2V&E&!;E+8
MDL"1OUMV=E\7 [5HT)7C,_?0BEU'8Y/4[R\Y<M]/E6<MIK'E6BK'Q6JLKBM&
ML(F,1*W-&0Z5/0B8F-C!H)*LNW:$57<&/16:N: =/+"*(- (3D]4TW))ZG42
M2=>JYQ?2:>42-6LNQFUD%Q+T8-8 ;6 6PMIM;$<=RF8TO6K[QKX<8E4JQHMK
MLUP9<G-=I=PMKNEU*0Q/C[:*])1E?N5@85RV/(V%ONKOZDQ;&;U^2-(&J\E&
M&(V(X,\0E2A$6:>0LJA3#&RJ&822@@E064$K&&)\H6U [],1J2SM%#& Q+<U
MU9BH*1D$ D*U@SV[#>Q&W7#)P2Q\A,3[BEB+R*S+.,FK?/RCD<5J.S33I;3Z
M\MOW'"N-$WSAY(S%"STU?E;UCSXQE&98YZ::=9NDX3>+N!<)-)2"*2E'*=W-
M,V^M AY4IVL [@A9/:+:_=B,9DCJ3S%1!4+L$<N.9$-^JK8LA&P&^CKBX/<S
M^KVYG?9QU;]TY'JFC]:I_FI]\6U?JT_RV^V(!J/"+;MIHV-17)KF/-ZSB$*7
M+-"7Q*JXAG^41MLDJ4,':Z7"7BX1DE8K'.5:&G(V+?O89B,+\:<QS99VY(=)
M$4;6J(XWD,4 20ETYAD9R UU8A2 NI@2+FX%]AB @D=4$LQ>,:&Y:QJ@)6Q4
M,P)) (&PM>W7!8N@<%XS=]N*JYL;BIB5@G^YWK>-OD)"Z/W^(1FU\:*U4*\#
M+6;D?X'\GKAELM=F,;-H($D)!"0L:CY?XJY79/&J"S4J&K5,_.<"DCD%E D,
M<Q8^0N]U<*2.@LMMMQC-I@O)C)JG0[DQAXE \H[69"P!'\5]]K;8T6P,_ VF
M'C[#6)N(L<!+( ZBYR!DF<O#R34QC$*YCY./6<,GB F(8H+-UU$Q,4Q0-XE$
M RR"I(8$$=0001[P=\:(((!!!!Z$&X/N(P+K&]0S['NXOW"Z;J]QK6<3.MFX
MPZQEY+O-QM8;7ZE0>%0^9V.2JKN9<LFTP>MW"H2<9--F:JKAF)T%3IBEZQT2
MY$:2FIF12XC$L;Z06T,96<!K=-2N"+['?>^V!8V5*FI5B%+F)TN0-2B,(2+]
M;,IOW;8Z'$2WUO7^?7<&U[-YB/N.7M:MQ5QQA?J^[1E:E8+]08+3IV\PU>GF
M1UHV84J*5UKK*<48N5TFD@_*U$XG*;P4X*4U-&X*OJFDTD6(1R@4D'<:M)(]
MF'B(>HJ'4@H%BC# W!90[-8C8VU &QZ[8*9T'@K W.UA]&NZ?:QYC?UD](Z+
MK?2K\BG_ **8%H_1-\Z;^HV)J[@'T$>:7V4.0_W26[JJG]8@^=%^=<65'J\_
MR9?R-B3N-7T<\!_4IE?[BP/4)/22?&WYCB<?HX_@7\HP/OCMHU%XX<U^=V0[
MA:8#.[/N&JU/D7C=CO4LPK47JN=3&95*G2,14IN87:,963S*RU23AI6OIN0E
M&J#Q.1:,EXSUW214JM+3TSQJ66-&BD"B^A];,"P%R X8$$['IUP/&RQSSHY"
MF1UDC)-@ZZ%4@$[$J5((ZBXZ@XNYD?*[(-WU#5,RR.5>WU/'&E9"YZ36DXZ7
MR8MELX2*Q:#"W=A)N6L[=H%@Q1DK3%QS59I MY6,;/)$)11U'-!WA>-$=P%Y
MERJFX?2+>45MLI.RDFYL=K;XO25)&=4NVBUV&Z7-_)#7W86N0.EQOB ^X,'$
MR5B,,IW*BVW3)ALFJ&6QG>J=-S>>KX[JD+79)S&S2NQLB%@,\?3<<X>PD,C;
M%EHJR.UU"#&.B1+A]%6TW/!D:$*]D_61L PD0G<<L[O;J=(NH'47WKJ.21&)
M6*7?R) 2NAP#8ZQLMP3;5L3M8XK)2]7U7 ^6?&G#J?S?;<X\YW:5N<+9\YN3
M#,+#LN15BMTB6L[36QTO)F4%[^LIRD?'P4J2^P!$GYI J%?<.)%PJI&VLD<L
M,TAI_%VB"E64ORW+,!H*N6LUB2"IVMOMBI6>.:*,3\]9"0RL%+H I.O4EO)N
M /*';8&^X-5T!@W"Z6%A=+"PNEA8H9W(?HT(_KUXR?U@\XZ)I/3#X)/Z;8'J
MO1#YD7]1<7SZ&P1BA>]?3M[?_P#D'E_]WN?]$Q>K57O@_.V*)/3P>Z;\JX]'
M*SZ0G;Z^T->OZOFJ=-#Z*I^6O]1<--Z6F^8W]-L7F<?VNO\ XE7_ -!NA\$8
M_,_/_/-_WC?^8]<HQQ?'Z ?;Y^A!Q7_4A0?V&VZX[4>GF^8_YCCD5/Z"'Y:?
ME&&AQA^E;W$_UN8A_5RS[J4WHJ;Y;?U&Q&'TM3\Q?Z:X:?$/Z8/<J_6QB/W.
M,>GF]#2_!)_4.&A]-5?''_3&.[#?6CWS["V=_?K?NF/JB_\ V&_IIAU]:D^3
M'^=\+FW^<O@#]LVM_=7J?2@\RH^3_P"1,*?SZ?YW_C?$B\_OH2<JOU$Z1^[3
M_J-/Z>'YB?F&)5'H)OEO^4XL1F_YNZ%^A=6_8;'JM_/;XF^YQ:O0>X?;#TZC
MA\?FJ6C_ )S6+_+LO^T''7)UZ#W#[8XPW4^\_?&\/MG?0,XP_JU:?M64ZP*O
MUB7XO]ACD%-ZO%\ P&K\)H_,Q@GZ5V?_ %,%T?E/I']P_,N LT]$OQ#_ +L%
M8[1GU?/'G]'I/]O270==ZU+[Q]L%TGJ\?NP27H3!.*']NK\PEK^TERD^_J^=
M$57I1\N+^FN**?T;?-F_JOB5^:GT.N5WV;MP^[.S=0@]/#\V/\ZXE/Z";Y4G
MY&Q(&!_F+Q;]4V<_N?#=1D]))\;?F.)IYB_"OV& 9?A(WT0Z%^L!S_[!KUHY
M5Z=OA'YL 9EZ%?>?MB[/9B^KRP[_ ,--?M%3H:N]:E]X^V+Z+U>/\?N<3!W,
M_H+<B_T(_P#EHWJ%)ZQ%\7^QQ.I]7E^ X 5^#)_\M<CO\FQG[:)UI9MTA_\
5?V1@#+.LGX_FQKBZQ<:V%TL+'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g286456newimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g286456newimg001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC6QD@*XU"5UWOL!!C/!QCT\+_P"#W4>7^S3\"UZ@^)M1//;_ $1!7[%?L[1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJZ?'?36SZI)>6UO<SQ+8K:7$<L5VS*OS7&3^X<@ _2Y;J-L89?FZ#\O\1^=
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M"3XOV7CCP[I>G?"ZUU"T30[CPO/=W.I)?1QQW!^UK?Q)&P6,;#]G8*6)97X
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MR?.JON"GYE -=M10!Q.L? /P=K^@^(=(OO!_A>]TGQ9>F^URSGTN"6WUF?\
M=XGN(V4K-(/*C&]P2!&G]U<&H_ +P;K4>IQ7G@OPG=1ZYJ\&OZDL^E02K?:C
M;B!;:^D#*0]Q$+:WV2,"Z>1%@C8N.VHH \Y\2?LK_#GQA\7+'XA:K\.O NI^
M/=(14T_Q'=Z!9S:O9!0P"QW;QM,@ =A\KC@G&,G-?XC?LA_##XN>$H_#OBSX
M9^ /%GAU=2N-8_LO6/#UG>6:WT\DDL]T(I(V432R2RR/)]YGE<DDL:].HH \
MS^)?[(_PP^-NE:+9>-OAG\/O&%IX=51I<&M^'K/48M,"@!1 LT;"(  #"8P
M .E2?$/]D[X9_%[Q?H_B#Q9\./ GBG7O#:JFDZEK'A^SO;O3,-N'D2RQL\0#
M $!" #S@<5Z110!66!HI 57MD\#KTR??  KFOC%\"_!O[0WA$>'_ !YX/\+>
M-O#_ )R7+:9X@TJWU*T:10=K&*9'3<-QP<9&3SS7744 >0^/OV#_ ((_%C2-
M"T[Q5\%_A3XFT_PK9C3M#MM5\(Z?>Q:/:C'[BW62)EACRH.Q %X''%:GC_\
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M5//(+#H:]*HH X&Q_9M\!Z3IVC6=GX$\&VMKX;-V^D0Q:);+'ICW:NETT"A
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M>^,'QX\!>.M2L]/:]\"WE[=+')I\4IU$7-BUILD<\@)N#CACE%&0.!SGAO\
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M6COX5OO VG^"DM9+RYEU)1:WMY="Y:1P=Y;[4$.YRQVEBV3BO?J* /"_C#\
MO%WCW]KSX3>/M/DT"/0OATFJI<6]S)(+R[^WVT<)*;5*+Y9CW8).[=U%?//P
MU_X)3>+O"GPT^'_P3NM2\-V_P5^%_P 3&^(&F7-D"-3U"SAU"?4[#2&A:/9"
M(KN91),CY>&!54*9&V_?5% 'P1I__!*GQ<OPU\+_  7O-5T&Y^$/A/XDCQ_!
MJ@ED35Y[6/49-3ATMH54)O6Z=5,^_F)?N[R<]+??\$\_&UYH-]\+/[0\/_\
M"G[WXH_\+*^V,S_VM'"=;7Q ^D^3M\HJVIJP$N[BV=05,BEF^TJ* $4DJ,C!
9QR/2EHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
